0001752828 2024-01-01 2024-09-30 0001752828 dei:BusinessContactMember 2024-01-01 2024-09-30 0001752828 2023-12-31 0001752828 2022-12-31 0001752828 2024-09-30 0001752828 srt:ScenarioPreviouslyReportedMember 2023-12-31 0001752828 2023-01-01 2023-12-31 0001752828 2022-01-01 2022-12-31 0001752828 us-gaap:ProductMember 2023-01-01 2023-12-31 0001752828 us-gaap:ProductMember 2022-01-01 2022-12-31 0001752828 us-gaap:ServiceMember 2023-01-01 2023-12-31 0001752828 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001752828 CELU:LicenseRoyaltyAndOtherMember 2023-01-01 2023-12-31 0001752828 CELU:LicenseRoyaltyAndOtherMember 2022-01-01 2022-12-31 0001752828 2024-07-01 2024-09-30 0001752828 2023-07-01 2023-09-30 0001752828 2023-01-01 2023-09-30 0001752828 us-gaap:ProductMember 2024-07-01 2024-09-30 0001752828 us-gaap:ProductMember 2023-07-01 2023-09-30 0001752828 us-gaap:ProductMember 2024-01-01 2024-09-30 0001752828 us-gaap:ProductMember 2023-01-01 2023-09-30 0001752828 us-gaap:ServiceMember 2024-07-01 2024-09-30 0001752828 us-gaap:ServiceMember 2023-07-01 2023-09-30 0001752828 us-gaap:ServiceMember 2024-01-01 2024-09-30 0001752828 us-gaap:ServiceMember 2023-01-01 2023-09-30 0001752828 CELU:LicenseRoyaltyAndOtherMember 2024-07-01 2024-09-30 0001752828 CELU:LicenseRoyaltyAndOtherMember 2023-07-01 2023-09-30 0001752828 CELU:LicenseRoyaltyAndOtherMember 2024-01-01 2024-09-30 0001752828 CELU:LicenseRoyaltyAndOtherMember 2023-01-01 2023-09-30 0001752828 us-gaap:CommonStockMember 2021-12-31 0001752828 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001752828 us-gaap:RetainedEarningsMember 2021-12-31 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001752828 2021-12-31 0001752828 us-gaap:CommonStockMember 2022-12-31 0001752828 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001752828 us-gaap:RetainedEarningsMember 2022-12-31 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2023-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2023-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001752828 us-gaap:CommonStockMember 2023-12-31 0001752828 us-gaap:CommonStockMember 2024-03-31 0001752828 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001752828 us-gaap:RetainedEarningsMember 2024-03-31 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001752828 2024-03-31 0001752828 us-gaap:CommonStockMember 2024-06-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001752828 us-gaap:RetainedEarningsMember 2024-06-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-06-30 0001752828 2024-06-30 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2022-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2022-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001752828 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001752828 us-gaap:CommonStockMember 2023-03-31 0001752828 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001752828 us-gaap:RetainedEarningsMember 2023-03-31 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001752828 2023-03-31 0001752828 us-gaap:CommonStockMember 2023-06-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001752828 us-gaap:RetainedEarningsMember 2023-06-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001752828 2023-06-30 0001752828 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001752828 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001752828 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-12-31 0001752828 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001752828 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001752828 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-12-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001752828 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-03-31 0001752828 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001752828 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001752828 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-04-01 2024-06-30 0001752828 2024-04-01 2024-06-30 0001752828 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001752828 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-07-01 2024-09-30 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001752828 srt:ScenarioPreviouslyReportedMember us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001752828 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-03-31 0001752828 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001752828 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001752828 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0001752828 2023-04-01 2023-06-30 0001752828 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001752828 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-01 2023-09-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001752828 us-gaap:RetainedEarningsMember 2023-12-31 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001752828 us-gaap:CommonStockMember 2024-09-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001752828 us-gaap:RetainedEarningsMember 2024-09-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0001752828 us-gaap:CommonStockMember 2023-09-30 0001752828 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001752828 us-gaap:RetainedEarningsMember 2023-09-30 0001752828 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0001752828 2023-09-30 0001752828 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-02-22 0001752828 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-02-22 2024-02-22 0001752828 srt:ScenarioForecastMember 2024-07-29 0001752828 2024-07-29 0001752828 us-gaap:CommonClassAMember 2024-02-22 0001752828 us-gaap:CommonClassAMember 2024-02-22 2024-02-22 0001752828 CELU:CellTherapyMember 2023-01-01 2023-12-31 0001752828 CELU:DegenerativeDiseaseMember 2022-01-01 2022-12-31 0001752828 CELU:Biovance3LMember 2023-12-31 0001752828 CELU:Biovance3LMember 2022-12-31 0001752828 srt:MinimumMember 2023-01-01 2023-12-31 0001752828 srt:MaximumMember 2023-01-01 2023-12-31 0001752828 CELU:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001752828 CELU:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001752828 CELU:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001752828 CELU:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001752828 CELU:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001752828 CELU:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001752828 CELU:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001752828 CELU:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001752828 CELU:OneCustomerMember 2023-12-31 0001752828 CELU:OneCustomerMember 2022-12-31 0001752828 CELU:CustomerTwoMember srt:MinimumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001752828 CELU:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001752828 CELU:CustomerTwoMember srt:MinimumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001752828 CELU:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001752828 CELU:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001752828 CELU:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001752828 srt:MinimumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001752828 CELU:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001752828 us-gaap:BuildingMember 2023-12-31 0001752828 srt:MinimumMember CELU:OfficeEquipmentAndFurnitureMember 2023-12-31 0001752828 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001752828 us-gaap:EquipmentMember 2023-12-31 0001752828 us-gaap:ComputerEquipmentMember 2023-12-31 0001752828 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001752828 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001752828 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001752828 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001752828 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001752828 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001752828 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-12-31 0001752828 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-12-31 0001752828 CELU:GXSponsorWarrantsMember 2023-01-01 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2023-01-01 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2024-01-01 2024-09-30 0001752828 CELU:GXSponsorWarrantsMember 2024-01-01 2024-09-30 0001752828 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001752828 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001752828 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001752828 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001752828 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001752828 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001752828 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001752828 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001752828 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001752828 srt:MinimumMember CELU:LetterAgreementMember us-gaap:SubsequentEventMember CELU:SanuwaveForbearanceAgreementMember 2024-05-10 2024-05-10 0001752828 srt:MaximumMember CELU:LetterAgreementMember us-gaap:SubsequentEventMember CELU:SanuwaveForbearanceAgreementMember 2024-05-10 2024-05-10 0001752828 srt:MinimumMember CELU:LetterAgreementMember CELU:SanuwaveForbearanceAgreementMember 2024-05-10 2024-05-10 0001752828 srt:MaximumMember CELU:LetterAgreementMember CELU:SanuwaveForbearanceAgreementMember 2024-05-10 2024-05-10 0001752828 srt:MinimumMember CELU:LetterAgreementMember CELU:SanuwaveForbearanceAgreementMember 2024-06-03 2024-06-03 0001752828 CELU:PublicWarrantsMember 2023-01-01 2023-12-31 0001752828 CELU:PublicWarrantsMember 2022-01-01 2022-12-31 0001752828 CELU:SponsorsWarrantsMember 2023-01-01 2023-12-31 0001752828 CELU:SponsorsWarrantsMember 2022-01-01 2022-12-31 0001752828 CELU:TwoThousandTwentyThreeRegisteredDirectWarrantsMember 2023-01-01 2023-12-31 0001752828 CELU:TwoThousandTwentyThreeRegisteredDirectWarrantsMember 2022-01-01 2022-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2023-01-01 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2022-01-01 2022-12-31 0001752828 CELU:SponsorsWarrantsMember 2023-12-31 0001752828 CELU:SponsorsWarrantsMember 2022-12-31 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001752828 CELU:SponsorsWarrantsMember 2024-09-30 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001752828 CELU:SponsorsWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2022-12-31 0001752828 srt:MinimumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2023-12-31 0001752828 srt:MaximumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2024-09-30 0001752828 srt:MinimumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2024-09-30 0001752828 srt:MaximumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember 2024-09-30 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001752828 srt:MinimumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2024-09-30 0001752828 srt:MaximumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2024-09-30 0001752828 srt:MinimumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2023-12-31 0001752828 srt:MaximumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001752828 srt:MinimumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001752828 srt:MaximumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001752828 srt:MinimumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001752828 srt:MaximumMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001752828 srt:MinimumMember 2022-01-01 2022-12-31 0001752828 srt:MaximumMember 2022-01-01 2022-12-31 0001752828 srt:MaximumMember 2023-12-31 0001752828 srt:MaximumMember 2022-12-31 0001752828 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-01-01 2023-12-31 0001752828 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-01 2022-12-31 0001752828 CELU:ContingentStockConsiderationMember 2022-12-31 0001752828 CELU:ContingentStockConsiderationMember 2023-01-01 2023-12-31 0001752828 CELU:ContingentStockConsiderationMember 2023-12-31 0001752828 CELU:ContingentStockConsiderationMember 2024-01-01 2024-09-30 0001752828 CELU:ContingentStockConsiderationMember 2024-09-30 0001752828 CELU:YorkvilleMember 2022-12-31 0001752828 CELU:YorkvilleMember 2023-01-01 2023-12-31 0001752828 CELU:YorkvilleMember 2024-01-01 2024-09-30 0001752828 CELU:YorkvilleMember 2023-12-31 0001752828 CELU:YorkvilleMember 2024-09-30 0001752828 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001752828 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001752828 2024-03-13 0001752828 2024-03-13 2024-03-13 0001752828 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001752828 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-13 0001752828 us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001752828 us-gaap:MeasurementInputPriceVolatilityMember 2024-03-13 0001752828 CELU:DueToLowerOfCostOrMarketAdjustmentsForWorkInProgressGoodsMember 2023-12-31 0001752828 CELU:DueToLowerOfCostOrMarketAdjustmentsForFinishedGoodsMember 2023-12-31 0001752828 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001752828 CELU:LaboratoryAndProductionEquipmentMember 2023-12-31 0001752828 CELU:LaboratoryAndProductionEquipmentMember 2022-12-31 0001752828 CELU:MachineryEquipmentAndFixturesMember 2023-12-31 0001752828 CELU:MachineryEquipmentAndFixturesMember 2022-12-31 0001752828 us-gaap:ConstructionInProgressMember 2023-12-31 0001752828 us-gaap:ConstructionInProgressMember 2022-12-31 0001752828 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001752828 CELU:LaboratoryAndProductionEquipmentMember 2024-09-30 0001752828 CELU:MachineryEquipmentAndFixturesMember 2024-09-30 0001752828 us-gaap:ConstructionInProgressMember 2024-09-30 0001752828 2023-01-01 2023-03-31 0001752828 CELU:OtherMember 2023-07-01 2023-09-30 0001752828 2022-10-01 2022-12-31 0001752828 us-gaap:InProcessResearchAndDevelopmentMember CELU:CellTherapyClinicalTrialUpdateMember 2023-07-01 2023-09-30 0001752828 us-gaap:InProcessResearchAndDevelopmentMember CELU:CellTherapyClinicalTrialUpdateMember 2023-01-01 2023-09-30 0001752828 CELU:CellTherapyMember 2021-12-31 0001752828 CELU:DegenerativeDiseaseMember 2021-12-31 0001752828 CELU:BiobankingMember 2021-12-31 0001752828 CELU:CellTherapyMember 2022-01-01 2022-12-31 0001752828 CELU:BiobankingMember 2022-01-01 2022-12-31 0001752828 CELU:CellTherapyMember 2022-12-31 0001752828 CELU:DegenerativeDiseaseMember 2022-12-31 0001752828 CELU:BiobankingMember 2022-12-31 0001752828 CELU:DegenerativeDiseaseMember 2023-01-01 2023-12-31 0001752828 CELU:BiobankingMember 2023-01-01 2023-12-31 0001752828 CELU:CellTherapyMember 2023-12-31 0001752828 CELU:DegenerativeDiseaseMember 2023-12-31 0001752828 CELU:BiobankingMember 2023-12-31 0001752828 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001752828 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001752828 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001752828 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001752828 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001752828 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001752828 us-gaap:CustomerRelationshipsMember 2023-12-31 0001752828 us-gaap:CustomerRelationshipsMember 2022-12-31 0001752828 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001752828 us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0001752828 srt:MinimumMember us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001752828 srt:MinimumMember us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0001752828 srt:MaximumMember us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001752828 srt:MaximumMember us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0001752828 CELU:ReacquiredRightsMember 2023-12-31 0001752828 CELU:ReacquiredRightsMember 2022-12-31 0001752828 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001752828 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001752828 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001752828 us-gaap:CustomerRelationshipsMember 2024-09-30 0001752828 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001752828 srt:MinimumMember us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001752828 srt:MaximumMember us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001752828 CELU:ReacquiredRightsMember 2024-09-30 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2022-09-15 2022-09-15 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2022-09-15 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-01-01 2023-12-31 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-12-31 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2022-12-31 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-02-21 2023-02-21 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-03-24 2023-03-24 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-04-14 2023-04-14 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-05-14 2023-05-14 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-04-11 2023-04-11 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-06-21 2023-06-21 0001752828 CELU:YorkvilleMember 2023-06-21 2023-06-21 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-08-02 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-09-18 2023-09-18 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-10-05 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-10-31 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2024-02-12 2024-02-12 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2024-01-12 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember us-gaap:SubsequentEventMember 2024-01-12 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2024-03-13 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:LoanAgreementMember 2023-08-21 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:LoanAgreementMember 2023-08-21 2023-08-21 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:CeoPromissoryNoteMember 2023-10-12 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:CeoPromissoryNoteMember 2024-03-13 2024-03-13 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:CeoPromissoryNoteMember 2023-10-12 2023-10-12 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:CeoPromissoryNoteMember 2023-12-31 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2023-03-17 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2023-03-17 2023-03-17 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonClassAMember us-gaap:WarrantMember 2023-03-17 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonClassAMember us-gaap:WarrantMember 2023-12-31 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2023-12-31 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2023-01-01 2023-12-31 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:SubsequentEventMember 2024-01-12 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:SubsequentEventMember 2024-03-13 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:SubsequentEventMember CELU:TrancheTwoWarrantMember 2024-03-13 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:SubsequentEventMember CELU:TrancheTwoWarrantMember 2024-03-13 2024-03-13 0001752828 CELU:InitialLoanMember us-gaap:BridgeLoanMember 2023-05-16 0001752828 CELU:InitialLoanMember us-gaap:BridgeLoanMember 2023-05-16 2023-05-16 0001752828 CELU:AdditionalLoanMember us-gaap:BridgeLoanMember 2023-06-21 0001752828 CELU:AdditionalLoanMember us-gaap:BridgeLoanMember 2023-06-21 2023-06-21 0001752828 2023-05-16 0001752828 us-gaap:BridgeLoanMember 2023-05-16 0001752828 us-gaap:BridgeLoanMember 2023-12-31 0001752828 us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2024-01-12 0001752828 CELU:AdditionalLoanMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2024-01-12 0001752828 CELU:AdditionalLoanMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2024-01-12 2024-01-12 0001752828 us-gaap:BridgeLoanMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember CELU:TrancheOneWarrantMember 2024-01-12 0001752828 us-gaap:BridgeLoanMember us-gaap:CommonClassAMember us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-01-12 0001752828 us-gaap:BridgeLoanMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember CELU:TrancheOneWarrantMember 2024-01-16 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2024-03-13 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2023-06-30 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember us-gaap:CommonClassAMember 2024-09-30 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2022-10-01 2022-12-31 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2024-01-12 2024-01-12 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember 2024-03-13 2024-03-13 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember 2024-03-13 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember 2024-09-13 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember 2024-05-01 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember 2024-01-01 2024-09-30 0001752828 CELU:StandbyEquityPurchaseAgreementMember CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember 2024-09-30 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:CeoPromissoryNoteMember 2023-10-13 2024-10-13 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:CeoPromissoryNoteMember 2024-09-30 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember 2023-12-31 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonClassAMember us-gaap:WarrantMember 2024-09-30 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2024-09-30 0001752828 CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2024-01-12 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2024-03-13 2024-03-13 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2024-03-13 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember CELU:TrancheTwoWarrantMember 2024-03-13 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember CELU:TrancheTwoWarrantMember 2024-03-13 2024-03-13 0001752828 CELU:ForbearanceAgreementMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember 2024-04-15 0001752828 CELU:InitialLoanMember us-gaap:BridgeLoanMember 2023-06-21 0001752828 us-gaap:BridgeLoanMember 2024-09-30 0001752828 us-gaap:BridgeLoanMember 2024-01-12 0001752828 CELU:AdditionalLoanMember us-gaap:BridgeLoanMember 2024-01-12 0001752828 CELU:AdditionalLoanMember us-gaap:BridgeLoanMember 2024-01-12 2024-01-12 0001752828 us-gaap:BridgeLoanMember us-gaap:CommonClassAMember CELU:TrancheOneWarrantMember 2024-01-12 0001752828 us-gaap:BridgeLoanMember us-gaap:CommonClassAMember us-gaap:WarrantMember 2024-01-12 0001752828 us-gaap:BridgeLoanMember us-gaap:CommonClassAMember CELU:TrancheOneWarrantMember 2024-01-16 0001752828 us-gaap:BridgeLoanMember us-gaap:CommonClassAMember CELU:TrancheOneWarrantMember 2024-07-15 0001752828 CELU:InitialAndSecondTrancheMember 2024-01-12 0001752828 srt:MaximumMember CELU:InitialAndSecondTrancheMember 2024-01-12 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember 2024-03-13 2024-03-13 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember us-gaap:WarrantMember 2024-03-13 2024-03-13 0001752828 srt:MaximumMember us-gaap:BridgeLoanMember us-gaap:WarrantMember 2024-03-13 2024-03-13 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember 2024-03-13 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember us-gaap:WarrantMember 2024-03-13 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember us-gaap:WarrantMember 2024-03-13 0001752828 CELU:ForbearanceAgreementMember us-gaap:BridgeLoanMember us-gaap:WarrantMember 2024-08-05 0001752828 CELU:FlorhamParkNewJerseyMember CELU:LegacyCelularityMember CELU:OfficeManufacturingAndLaboratorySpaceMember 2019-03-13 2019-03-13 0001752828 CELU:FlorhamParkNewJerseyMember CELU:LegacyCelularityMember CELU:OfficeManufacturingAndLaboratorySpaceMember 2023-12-31 0001752828 CELU:FlorhamParkNewJerseyMember CELU:LegacyCelularityMember CELU:OfficeManufacturingAndLaboratorySpaceMember 2022-12-31 0001752828 CELU:FlorhamParkNewJerseyMember CELU:LegacyCelularityMember CELU:OfficeManufacturingAndLaboratorySpaceMember 2019-03-13 0001752828 CELU:FlorhamParkNewJerseyMember 2023-09-14 0001752828 CELU:FlorhamParkNewJerseyMember 2023-09-14 2023-09-14 0001752828 CELU:FlorhamParkNewJerseyMember CELU:LegacyCelularityMember CELU:OfficeManufacturingAndLaboratorySpaceMember 2024-09-30 0001752828 CELU:LegacyCelularitysMember CELU:LLCAndAnthrogenesisMember CELU:HLICellularTherapeuticsMember 2023-12-31 0001752828 CELU:LegacyCelularitysMember CELU:LLCAndAnthrogenesisMember CELU:HLICellularTherapeuticsMember 2022-12-31 0001752828 CELU:PalantirTechnologiesIncMember CELU:MasterSubscriptionAgreementMember 2021-05-05 2021-05-05 0001752828 CELU:PalantirTechnologiesIncMember CELU:SoftwareCeaseUseCostsMember 2023-01-01 2023-03-31 0001752828 CELU:PalantirTechnologiesIncMember 2024-05-06 2024-05-06 0001752828 CELU:LicenseAgreementMember 2021-12-01 2021-12-31 0001752828 us-gaap:SubsequentEventMember CELU:SettlementAndReleaseAgreementMember 2023-12-21 2024-06-03 0001752828 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember CELU:SettlementAndReleaseAgreementMember 2023-12-21 2024-06-03 0001752828 CELU:EvolutionMember 2023-04-17 2023-04-17 0001752828 CELU:LegacyCelularitysMember CELU:LLCAndAnthrogenesisMember CELU:HLICellularTherapeuticsMember 2024-09-30 0001752828 CELU:PalantirTechnologiesIncMember CELU:SoftwareCeaseUseCostsMember 2023-01-01 2023-09-30 0001752828 CELU:SettlementAndReleaseAgreementMember 2023-12-21 2024-06-03 0001752828 us-gaap:CommonClassAMember CELU:SettlementAndReleaseAgreementMember 2023-12-21 2024-06-03 0001752828 CELU:EvolutionMember 2024-05-07 2024-05-07 0001752828 us-gaap:CommonClassAMember 2023-12-31 0001752828 us-gaap:CommonClassAMember 2022-12-31 0001752828 srt:MinimumMember CELU:LegacyCelularityMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2022-05-18 2022-05-18 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2022-05-18 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2022-05-18 2022-05-18 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2022-05-18 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2022-05-18 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2023-04-10 2023-04-10 0001752828 2023-04-10 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2023-07-01 2023-07-31 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsModifiedMember 2023-07-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsModifiedMember 2023-07-31 0001752828 CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember 2023-07-31 0001752828 2023-07-31 0001752828 us-gaap:CommonStockMember CELU:AtTheMarketSalesAgreementMember 2022-09-08 2022-09-08 0001752828 CELU:AtTheMarketSalesAgreementMember 2023-01-01 2023-12-31 0001752828 us-gaap:CommonStockMember CELU:AtTheMarketSalesAgreementMember 2023-01-01 2023-12-31 0001752828 us-gaap:CommonStockMember CELU:AtTheMarketSalesAgreementMember 2023-12-31 0001752828 CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-03-20 2023-03-20 0001752828 srt:MaximumMember us-gaap:CommonClassAMember CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2023-03-20 0001752828 srt:MaximumMember 2023-03-20 0001752828 us-gaap:CommonClassAMember CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2023-03-20 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2023-03-20 2023-03-20 0001752828 CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-12-31 0001752828 us-gaap:CommonClassAMember CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-09-14 0001752828 CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-03-14 2023-03-14 0001752828 us-gaap:CommonClassAMember 2023-04-10 2023-04-10 0001752828 us-gaap:CommonClassAMember 2023-04-10 0001752828 2023-04-10 2023-04-10 0001752828 2023-07-31 2023-07-31 0001752828 us-gaap:CommonClassAMember 2023-07-31 0001752828 srt:MinimumMember 2023-07-31 0001752828 srt:MaximumMember 2023-07-31 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-05-18 2023-05-18 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-05-18 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember us-gaap:PrivatePlacementMember 2023-05-18 0001752828 CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-05-18 2023-05-18 0001752828 CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-05-18 0001752828 2023-05-18 0001752828 srt:MaximumMember CELU:LegacyCelularityMember 2022-03-01 0001752828 srt:MinimumMember CELU:LegacyCelularityMember 2022-03-01 0001752828 CELU:LegacyCelularityMember 2022-03-01 0001752828 CELU:LegacyCelularityMember us-gaap:CommonClassAMember 2022-03-01 2022-03-01 0001752828 CELU:LegacyCelularityMember 2022-03-01 2022-03-01 0001752828 CELU:TwoThousandTwentyFourWarrantRepricingMember us-gaap:SubsequentEventMember 2024-01-12 0001752828 CELU:TwoThousandTwentyFourWarrantRepricingMember 2023-12-31 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-01-12 2024-01-12 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-01-12 0001752828 srt:MaximumMember CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-01-12 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:PrivatePlacementMember 2024-01-12 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-01-12 2024-01-12 0001752828 CELU:ChiefAdministrativeOfficerMember CELU:AmendedEmploymentAgreementMember us-gaap:SubsequentEventMember 2024-02-15 2024-02-15 0001752828 CELU:ChiefAdministrativeOfficerMember CELU:AmendedEmploymentAgreementMember us-gaap:SubsequentEventMember 2024-02-16 2024-02-16 0001752828 srt:MaximumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:WarrantMember CELU:RwiForbearanceAgreementMember 2024-03-13 0001752828 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:WarrantMember CELU:RwiForbearanceAgreementMember 2024-03-13 0001752828 CELU:YorkvilleMember us-gaap:CommonClassAMember CELU:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2024-03-13 0001752828 CELU:YorkvilleMember CELU:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2024-03-13 0001752828 CELU:YorkvilleMember CELU:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001752828 CELU:YorkvilleMember us-gaap:CommonClassAMember CELU:StandbyEquityPurchaseAgreementMember us-gaap:SubsequentEventMember 2024-03-13 2024-03-13 0001752828 2021-07-14 0001752828 us-gaap:CommonClassAMember 2024-09-30 0001752828 srt:MinimumMember CELU:LegacyCelularityMember us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001752828 CELU:AtTheMarketSalesAgreementMember 2024-01-01 2024-09-30 0001752828 CELU:AtTheMarketSalesAgreementMember 2023-01-01 2023-09-30 0001752828 us-gaap:CommonStockMember CELU:AtTheMarketSalesAgreementMember 2023-01-01 2023-09-30 0001752828 us-gaap:CommonStockMember CELU:AtTheMarketSalesAgreementMember 2023-09-30 0001752828 us-gaap:CommonClassAMember CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-03-20 2023-03-20 0001752828 2023-03-20 0001752828 srt:MaximumMember us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2022-05-18 0001752828 srt:MinimumMember us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2022-05-18 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember 2023-04-10 2023-04-10 0001752828 us-gaap:CommonClassAMember 2023-07-31 2023-07-31 0001752828 us-gaap:CommonClassAMember CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantMember 2023-05-18 2023-05-18 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2024-01-12 2024-01-12 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2024-01-12 0001752828 srt:MaximumMember CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2024-01-12 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember us-gaap:PrivatePlacementMember 2024-01-12 2024-01-12 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember 2024-01-12 2024-01-12 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember 2024-01-12 0001752828 CELU:TwoThousandTwentyFourWarrantRepricingMember 2024-01-12 0001752828 CELU:DragasacLimitedMember srt:MinimumMember CELU:InvestorRightsAgreementMember 2024-01-12 0001752828 CELU:DragasacLimitedMember srt:MaximumMember CELU:InvestorRightsAgreementMember 2024-01-12 0001752828 2024-01-12 0001752828 CELU:ChiefAdministrativeOfficerMember CELU:AmendedEmploymentAgreementMember 2024-02-16 2024-02-16 0001752828 srt:MinimumMember CELU:ChiefAdministrativeOfficerMember CELU:AmendedEmploymentAgreementMember 2024-02-16 2024-02-16 0001752828 CELU:TwoThousandTwentyFourWarrantRepricingMember 2024-01-12 2024-01-12 0001752828 CELU:TwoThousandTwentyFourWarrantRepricingMember us-gaap:CommonClassAMember 2024-01-12 0001752828 srt:MaximumMember us-gaap:CommonStockMember us-gaap:WarrantMember CELU:RwiForbearanceAgreementMember 2024-03-13 0001752828 us-gaap:CommonStockMember us-gaap:WarrantMember CELU:RwiForbearanceAgreementMember 2024-03-13 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonStockMember us-gaap:WarrantMember CELU:ForbearanceAgreementMember 2024-03-13 2024-03-13 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonStockMember us-gaap:WarrantMember CELU:ForbearanceAgreementMember 2024-03-12 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonStockMember us-gaap:WarrantMember CELU:ForbearanceAgreementMember 2024-03-13 0001752828 CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonStockMember us-gaap:WarrantMember CELU:ForbearanceAgreementMember 2024-03-13 2024-03-13 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonStockMember us-gaap:WarrantMember 2024-03-13 0001752828 CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember CELU:LoanAgreementMember CELU:CVStarrCoIncMember us-gaap:CommonStockMember us-gaap:WarrantMember CELU:ForbearanceAgreementMember 2024-03-13 0001752828 CELU:YorkvilleMember us-gaap:CommonClassAMember CELU:StandbyEquityPurchaseAgreementMember 2024-03-13 0001752828 CELU:YorkvilleMember CELU:StandbyEquityPurchaseAgreementMember 2024-03-13 0001752828 CELU:YorkvilleMember CELU:StandbyEquityPurchaseAgreementMember 2024-03-13 2024-03-13 0001752828 CELU:YorkvilleMember us-gaap:CommonClassAMember CELU:StandbyEquityPurchaseAgreementMember 2024-03-13 2024-03-13 0001752828 CELU:YorkvilleMember CELU:ConvertiblePromissoryNotesMember CELU:StandbyEquityPurchaseAgreementMember 2024-03-13 2024-03-13 0001752828 CELU:DragasacWarrantMember 2023-12-31 0001752828 CELU:PublicWarrantsMember 2023-12-31 0001752828 CELU:SponsorWarrantsMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2023-12-31 0001752828 CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember 2023-12-31 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember 2023-12-31 0001752828 CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2023-12-31 0001752828 CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember 2023-12-31 0001752828 CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2023-12-31 0001752828 CELU:JuneTwoThousandTwentyThreeWarrantsMember 2023-12-31 0001752828 CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember 2023-12-31 0001752828 CELU:JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2023-12-31 0001752828 CELU:DragasacWarrantMember 2024-09-30 0001752828 CELU:PublicWarrantsMember 2024-09-30 0001752828 CELU:SponsorWarrantsMember 2024-09-30 0001752828 CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember 2024-09-30 0001752828 CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2024-09-30 0001752828 CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember 2024-09-30 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember 2024-09-30 0001752828 CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2024-09-30 0001752828 CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember 2024-09-30 0001752828 CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember 2024-09-30 0001752828 CELU:JuneTwoThousandTwentyThreeWarrantsMember 2024-09-30 0001752828 CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember 2024-09-30 0001752828 CELU:JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember 2024-09-30 0001752828 CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember 2024-09-30 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember 2024-09-30 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember 2024-09-30 0001752828 CELU:MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember 2024-09-30 0001752828 us-gaap:CommonClassAMember CELU:DragasacWarrantMember 2023-12-31 0001752828 us-gaap:CommonClassAMember CELU:SponsorWarrantsMember 2023-12-31 0001752828 us-gaap:CommonClassAMember CELU:DragasacWarrantMember 2024-09-30 0001752828 us-gaap:CommonClassAMember CELU:SponsorWarrantsMember 2024-09-30 0001752828 CELU:StarrForbearanceAgreementMember 2024-03-13 0001752828 CELU:CVStarrCoIncMember 2024-03-13 0001752828 CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember us-gaap:CommonClassAMember 2021-07-31 0001752828 CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember us-gaap:CommonClassAMember 2023-12-31 0001752828 CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001752828 CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember 2023-01-01 2023-12-31 0001752828 CELU:TwoThousandAndSeventeenEquityIncentivePlanMember 2023-12-31 0001752828 CELU:TwoThousandAndSeventeenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001752828 srt:MaximumMember CELU:TwoThousandAndSeventeenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001752828 srt:MinimumMember CELU:TwoThousandAndSeventeenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001752828 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001752828 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001752828 us-gaap:EmployeeStockOptionMember 2023-12-31 0001752828 CELU:AwardsWithPerformanceConditionsMember 2022-08-16 2022-08-16 0001752828 CELU:AwardsWithPerformanceConditionsMember CELU:InitialTrancheMember 2022-08-16 2022-08-16 0001752828 CELU:AwardsWithPerformanceConditionsMember 2022-08-16 0001752828 CELU:AwardsWithPerformanceConditionsMember CELU:SecondTrancheMember 2022-11-01 2022-11-01 0001752828 CELU:AwardsWithPerformanceConditionsMember 2022-11-01 2022-11-01 0001752828 CELU:AwardsWithPerformanceConditionsMember 2023-01-01 2023-12-31 0001752828 CELU:AwardsWithPerformanceConditionsMember 2023-08-16 2023-08-16 0001752828 CELU:AwardsWithPerformanceConditionsMember 2022-01-01 2022-12-31 0001752828 CELU:AwardsWithPerformanceConditionsMember 2023-12-31 0001752828 CELU:AwardsWithMarketConditionsMember 2021-09-01 2021-09-30 0001752828 CELU:AwardsWithMarketConditionsMember 2023-01-01 2023-12-31 0001752828 CELU:AwardsWithMarketConditionsMember 2022-01-01 2022-12-31 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001752828 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0001752828 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001752828 us-gaap:PerformanceSharesMember 2023-07-01 2023-07-31 0001752828 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-07-01 2023-07-31 0001752828 srt:MaximumMember us-gaap:PerformanceSharesMember 2023-07-01 2023-07-31 0001752828 us-gaap:PerformanceSharesMember 2023-12-31 0001752828 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001752828 CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember us-gaap:CommonClassAMember 2024-09-30 0001752828 CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember us-gaap:CommonClassAMember 2024-01-01 2024-09-30 0001752828 CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember 2024-01-01 2024-09-30 0001752828 CELU:TwoThousandAndSeventeenEquityIncentivePlanMember 2024-09-30 0001752828 srt:MaximumMember CELU:TwoThousandAndSeventeenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001752828 srt:MinimumMember CELU:TwoThousandAndSeventeenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001752828 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001752828 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001752828 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001752828 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001752828 us-gaap:EmployeeStockOptionMember 2024-09-30 0001752828 CELU:AwardsWithPerformanceConditionsMember 2024-01-01 2024-09-30 0001752828 CELU:AwardsWithMarketConditionsMember 2024-01-01 2024-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001752828 CELU:MarketConditionStockUnitMember 2023-07-01 2023-07-31 0001752828 srt:MinimumMember CELU:MarketConditionStockUnitMember 2023-07-01 2023-07-31 0001752828 srt:MaximumMember CELU:MarketConditionStockUnitMember 2023-07-01 2023-07-31 0001752828 CELU:MarketConditionStockUnitMember 2024-09-30 0001752828 CELU:MarketConditionStockUnitMember 2024-01-01 2024-09-30 0001752828 CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember 2022-12-31 0001752828 CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001752828 CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001752828 CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember 2023-12-31 0001752828 CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001752828 CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember 2024-09-30 0001752828 CELU:TwentyTwentyOneAndTwoThousandSeventeenPlanMember 2024-09-30 0001752828 CELU:TwentyTwentyOneAndTwoThousandSeventeenPlanMember 2023-09-30 0001752828 CELU:TwentyTwentyOnePlanMember 2024-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001752828 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001752828 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001752828 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001752828 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001752828 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001752828 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001752828 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001752828 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001752828 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001752828 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001752828 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001752828 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001752828 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001752828 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001752828 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001752828 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001752828 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001752828 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001752828 CELU:RegeneronResearchCollaborationServicesAgreementMember 2023-08-25 2023-08-25 0001752828 CELU:RegeneronResearchCollaborationServicesAgreementMember 2023-12-31 0001752828 CELU:ArthrexAgreementMember 2021-05-07 2021-05-07 0001752828 CELU:EvolutionAgreementMember 2021-09-01 2021-09-01 0001752828 CELU:EvolutionAgreementMember 2023-04-13 0001752828 CELU:EvolutionAgreementMember 2023-04-13 2023-04-13 0001752828 CELU:PultheraLlcBindingTermSheetMember 2023-01-01 2023-12-31 0001752828 us-gaap:CommonStockMember CELU:PultheraLlcBindingTermSheetMember 2023-01-01 2023-12-31 0001752828 us-gaap:CommonStockMember CELU:PultheraLlcBindingTermSheetMember 2023-03-17 2023-03-17 0001752828 us-gaap:ResearchAndDevelopmentExpenseMember CELU:PultheraLlcBindingTermSheetMember 2023-03-17 2023-03-17 0001752828 CELU:LicenseAgreementWithBiocellgraftIncMember 2023-12-11 2023-12-11 0001752828 CELU:RegeneronResearchCollaborationServicesAgreementMember 2024-09-30 0001752828 CELU:PultheraLlcBindingTermSheetMember 2024-01-01 2024-09-30 0001752828 us-gaap:CommonStockMember CELU:PultheraLlcBindingTermSheetMember 2024-01-01 2024-09-30 0001752828 CELU:UnitedStatesFederalAndStateMember 2023-12-31 0001752828 CELU:UnitedStatesFederalAndStateMember 2022-12-31 0001752828 CELU:UnitedStatesFederalAndStateMember 2023-01-01 2023-12-31 0001752828 CELU:OtherMember 2023-01-01 2023-12-31 0001752828 CELU:OtherMember 2022-01-01 2022-12-31 0001752828 CELU:CellTherapyMember 2024-07-01 2024-09-30 0001752828 CELU:BiobankingMember 2024-07-01 2024-09-30 0001752828 CELU:DegenerativeDiseaseMember 2024-07-01 2024-09-30 0001752828 CELU:OtherMember 2024-07-01 2024-09-30 0001752828 CELU:CellTherapyMember 2023-07-01 2023-09-30 0001752828 CELU:BiobankingMember 2023-07-01 2023-09-30 0001752828 CELU:DegenerativeDiseaseMember 2023-07-01 2023-09-30 0001752828 CELU:CellTherapyMember 2024-01-01 2024-09-30 0001752828 CELU:BiobankingMember 2024-01-01 2024-09-30 0001752828 CELU:DegenerativeDiseaseMember 2024-01-01 2024-09-30 0001752828 CELU:OtherMember 2024-01-01 2024-09-30 0001752828 CELU:CellTherapyMember 2023-01-01 2023-09-30 0001752828 CELU:BiobankingMember 2023-01-01 2023-09-30 0001752828 CELU:DegenerativeDiseaseMember 2023-01-01 2023-09-30 0001752828 CELU:OtherMember 2023-01-01 2023-09-30 0001752828 CELU:DrRobertHaririMember 2023-12-31 0001752828 CELU:DrRobertHaririMember 2023-01-25 2023-01-25 0001752828 CELU:DrRobertHaririMember CELU:SecuritiesPurchaseAgreementMember 2023-01-25 2023-01-25 0001752828 CELU:DrRobertHaririMember CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember CELU:SecuritiesPurchaseAgreementMember 2023-03-20 2023-03-20 0001752828 CELU:DrHaririMember CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember CELU:SecuritiesPurchaseAgreementMember 2023-03-20 2023-03-20 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember CELU:LoanAgreementMember 2003-08-21 0001752828 CELU:ChairmanAndChiefExecutiveOfficerMember 2023-10-12 0001752828 CELU:DrAndrewPecoraMember CELU:ConsultingAgreementMember 2023-01-01 2023-12-31 0001752828 CELU:DrAndrewPecoraMember CELU:ConsultingAgreementMember 2022-09-01 2022-09-21 0001752828 CELU:DrAndrewPecoraMember CELU:ScientificAndClinicalAdvisorAgreementMember 2022-09-01 2022-09-01 0001752828 us-gaap:RestrictedStockUnitsRSUMember CELU:ScientificAndClinicalAdvisorAgreementMember 2022-09-01 0001752828 us-gaap:RestrictedStockUnitsRSUMember CELU:DrAndrewPecoraMember CELU:ScientificAndClinicalAdvisorAgreementMember 2022-09-01 2022-09-01 0001752828 CELU:RobinLSmithMdMember CELU:AdvisoryAgreementMember 2022-08-16 2022-08-16 0001752828 CELU:RobinLSmithMdMember CELU:AdvisoryAgreementMember CELU:InitialTrancheMember 2022-08-16 2022-08-16 0001752828 CELU:RobinLSmithMdMember CELU:AdvisoryAgreementMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-09-01 2022-09-01 0001752828 CELU:RobinLSmithMdMember CELU:AdvisoryAgreementMember 2023-01-01 2023-12-31 0001752828 CELU:RobinLSmithMdMember CELU:AdvisoryAgreementMember 2022-01-01 2022-12-31 0001752828 CELU:COTAIncMember 2023-01-01 2023-12-31 0001752828 CELU:COTAIncMember 2022-01-01 2022-12-31 0001752828 CELU:CryoportSystemsIncMember 2023-01-01 2023-12-31 0001752828 CELU:CryoportSystemsIncMember 2022-01-01 2022-12-31 0001752828 CELU:CVStarLoanMember 2023-03-17 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember CELU:CVStarLoanMember us-gaap:CommonClassAMember 2023-12-31 0001752828 CELU:JuneTwoThousandTwentyThreeWarrantsMember CELU:CVStarLoanMember us-gaap:CommonClassAMember 2023-12-31 0001752828 CELU:CVStarLoanMember us-gaap:CommonClassAMember 2023-12-31 0001752828 CELU:ResortsWorldIncPteLtdMember 2023-06-21 0001752828 CELU:ResortsWorldIncPteLtdMember us-gaap:CommonClassAMember 2023-12-31 0001752828 CELU:SorrentoTherapeuticsIncMember 2023-01-01 2023-12-31 0001752828 CELU:SorrentoTherapeuticsIncMember 2022-01-01 2022-12-31 0001752828 CELU:MsHaririMember CELU:EmploymentOfImmediateFamilyMemberMember 2023-01-01 2023-12-31 0001752828 CELU:MsHaririMember CELU:EmploymentOfImmediateFamilyMemberMember 2022-01-01 2022-12-31 0001752828 CELU:DrRobertHaririMember 2024-09-30 0001752828 CELU:RobinLSmithMdMember CELU:AdvisoryAgreementMember 2024-01-01 2024-09-30 0001752828 CELU:RobinLSmithMdMember CELU:AdvisoryAgreementMember 2023-01-01 2023-09-30 0001752828 CELU:COTAIncMember 2024-01-01 2024-09-30 0001752828 CELU:COTAIncMember 2023-01-01 2023-09-30 0001752828 CELU:CryoportSystemsIncMember 2024-01-01 2024-09-30 0001752828 CELU:CryoportSystemsIncMember 2023-01-01 2023-09-30 0001752828 CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember CELU:CVStarLoanMember us-gaap:CommonClassAMember 2024-09-30 0001752828 CELU:CVStarLoanMember us-gaap:CommonClassAMember 2024-09-30 0001752828 CELU:MsHaririMember CELU:EmploymentOfImmediateFamilyMemberMember 2024-01-01 2024-09-30 0001752828 CELU:MsHaririMember CELU:EmploymentOfImmediateFamilyMemberMember 2023-01-01 2023-09-30 0001752828 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001752828 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001752828 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001752828 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001752828 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001752828 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-09-30 0001752828 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember 2024-07-15 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember 2024-01-16 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-07-15 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-01-16 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-07-15 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-16 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-07-15 0001752828 CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-01-16 0001752828 CELU:PrePaidAdvanceAgreementMember CELU:YorkvilleMember 2024-09-30 0001752828 CELU:ConvertiblePromissoryNotesMember CELU:YorkvilleMember 2024-09-30 0001752828 CELU:ConvertiblePromissoryNotesMember CELU:YorkvilleMember 2023-12-31 0001752828 CELU:CVStarrBridgeLoanNetOfDiscountMember 2024-09-30 0001752828 CELU:CVStarrBridgeLoanNetOfDiscountMember 2023-12-31 0001752828 CELU:RWIBridgeLoanNetOfDiscountMember 2024-09-30 0001752828 CELU:RWIBridgeLoanNetOfDiscountMember 2023-12-31 0001752828 CELU:CeoPromissoryNoteMember 2024-09-30 0001752828 CELU:CeoPromissoryNoteMember 2023-12-31 0001752828 CELU:SequenceLifescienceIncMember us-gaap:SubsequentEventMember 2024-10-09 2024-10-09 0001752828 srt:MaximumMember us-gaap:SubsequentEventMember 2024-11-25 0001752828 us-gaap:SubsequentEventMember 2024-11-25 2024-11-25 0001752828 us-gaap:SubsequentEventMember 2024-11-25 iso4217:USD shares iso4217:USD shares pure CELU:Integer CELU:Segment utr:sqft true 0001752828 S-1/A http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember P1M P24M P24M P5Y P5Y P5Y P5Y P5Y P3Y P2Y P1Y P6Y P2Y P12M P45D P3Y http://fasb.org/us-gaap/2024#AccountingStandardsUpdateExtensibleList P12M P5Y P5Y P5Y P5Y P5Y P3Y P4Y P5Y P2Y P1Y P4Y P2Y Amendment No. 1 CELULARITY INC. DE 83-1702591 170 Park Avenue Florham Park NJ 07932 (908) 768-2170 Robert J. Hariri, 170 Park Avenue Florham Park NJ 07932 (908) 768-2170 Non-accelerated Filer true false 227000 13966000 5837000 1789000 10046000 4452000 2072000 2514000 5753000 5308000 1695000 7262000 19793000 33502000 67828000 75655000 7347000 119694000 11001000 120994000 10990000 13060000 9936000 14836000 16657000 22949000 337000 376000 143889000 401066000 14144000 5810000 7580000 9069000 3500000 7333000 17223000 16623000 37603000 37000000 17223000 37603000 3695000 17223000 19331000 2108000 1419000 18490000 19909000 2834000 2273000 67298000 62088000 3186000 2219000 1606000 105945000 26177000 27985000 4359000 3598000 9000 9000 294000 321000 102929000 202165000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 730000000 19378192 19378192 730000000 14892129 14892129 19000 15000 882732000 844373000 9000 -841791000 -645496000 40960000 198901000 143889000 401066000 13149000 3749000 5441000 5512000 4181000 8714000 22771000 17975000 8628000 2353000 1650000 3536000 5738000 13776000 30465000 78363000 50576000 66021000 -104339000 -126277000 112347000 3610000 107800000 2193000 2193000 215058000 43575000 -192287000 -25600000 320000 365000 3015000 -6164000 -42109000 1177000 2522000 -6290000 -147000 -3998000 39805000 -196285000 14205000 10000 13000 -196295000 14192000 146000 9000 146000 9000 -196149000 14201000 -11.02 1.01 17813044 13990703 -11.02 0.95 17813044 14983002 12430788 12000 763087000 -663681000 99418000 3993000 3993000 13125 441000 441000 171047 948000 948000 -1050 -86000 -86000 1328189 2000 46489000 46491000 262797 1000 4098000 -11000 4088000 23252 0 -7067 132000 132000 15856000 15856000 405406 7651000 7651000 265641 6021000 6021000 20000 20000 14192000 14192000 14892129 15000 844373000 -645496000 9000 198901000 1780220 2000 1320000 1322000 270731 712000 712000 108637 304000 304000 403000 403000 169492 1000000 1000000 2016000 2016000 559481 1000 4598000 -155000 4444000 83759 0 -19130 101000 101000 15017000 15017000 1519579 1000 12680000 12681000 13296 136000 136000 146000 146000 274000 274000 -196295000 -196295000 19378192 19000 882732000 -841791000 40960000 19378192 19000 882732000 -841791000 40960000 -196295000 14192000 9324000 9436000 -13000 -59000 -1000 1233000 1877000 1328000 -6164000 -42109000 5384000 904000 112347000 3610000 107800000 15017000 15856000 -104339000 -126277000 3000000 1000000 712000 2151000 403000 1177000 2522000 -159000 186000 -4157000 37000 6827000 3584000 865000 16891000 -5606000 -49000 8497000 -2948000 -1128000 -2623000 3834000 -7333000 275000 263000 1528000 425000 -38685000 -137876000 1048000 5236000 3000000 -4048000 -5236000 12375000 46491000 16811000 4994000 39200000 136000 6519000 498000 2000000 1000000 12750000 30000000 304000 862000 101000 132000 9000000 1553000 2604000 24094000 119838000 -18639000 -23274000 28802000 52076000 10163000 28802000 1073000 223000 683000 4599000 4099000 2002000 -2083000 -69000 -1770000 441000 <p id="xdx_80E_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zmxbXPs4D6ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_828_z9EwMaTuxID9">Nature of Business</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celularity Inc., (“Celularity” or the “Company”), formerly known as GX Acquisition Corp. (“GX”), was a blank check company incorporated in Delaware on <span id="xdx_908_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20231231_z3ch4stgG8h8" title="Date of incorporation">August 24, 2018</span>. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 16, 2021 (the “Closing Date”), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated January 8, 2021 (the “Merger Agreement”), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of GX (“First Merger Sub”), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary of GX (“Second Merger Sub”), and the entity formerly known as Celularity Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (“Legacy Celularity”). Upon completion of the merger transaction, GX changed its name to Celularity Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the special meeting held on February 22, 2024, the stockholders of Celularity approved an amendment to Celularity’s Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of Celularity’s Class A common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpqkPzMhk65c" title="Common stock, par value">0.0001</span> per share, at a ratio of <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240222__20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrOfI51NxJpc" title="Reverse stock split ratio">1-for-10</span>. Following the reverse stock split, each 10 shares of Celularity’s Class A Common Stock issued and outstanding immediately prior thereto were combined into one new share of Class A Common Stock. Unless specifically provided otherwise herein, all share and per share information has been adjusted to reflect the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Description of Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celularity is a cell therapy and regenerative medicine company focused on addressing aging related diseases including cancer and degenerative diseases. Celularity develops and markets off-the-shelf placental-derived allogeneic advanced biomaterial products including allografts and connective tissue matrices for soft tissue repair and reconstructive procedures in the treatment of degenerative disorders and diseases including those associated with aging. Celularity is developing a pipeline of off-the-shelf placental-derived allogeneic cell therapy product candidates including T cells engineered with a chimeric antigen receptor (“CAR”), natural killer (“NK”) cells, and mesenchymal-like adherent stromal cells (“MLASCs”) and exosomes. These therapeutic candidates may potentially target indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address a significant unmet global need for effective, accessible and affordable therapeutics. Celularity’s biomaterials business today is comprised primarily of the sale of its Biovance 3L products, directly or through its distribution network. Biovance 3L is a tri-layer decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. It is an intact, natural extracellular matrix that provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue. Celularity is developing new placental biomaterial products to deepen the commercial pipeline. The Company also plans to leverage its core expertise in cellular therapeutic development and manufacturing to generate revenues by providing contract manufacturing and development services to third parties. The initial focus of this new service offering will be to assist development stage cell therapy companies with the development and manufacturing of their therapeutic candidates for clinical trials.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celularity is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (“Anthrogenesis”) in August 2017 from Celgene Corporation (“Celgene”), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously, Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene’s cell therapy division.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Celularity IMPACT (<b><i><span style="text-decoration: underline">IM</span></i></b>munomodulatory<b><i><span style="text-decoration: underline">P</span></i></b>lacenta-derived<b><i><span style="text-decoration: underline">A</span></i></b>llogeneic<b><i><span style="text-decoration: underline">Cellular therapy</span></i></b>) platform capitalizes on the benefits of placenta-derived cells to target multiple diseases, and provides seamless integration, from bio sourcing through manufacturing cryopreserved and packaged allogeneic cells at its purpose-built U.S.-based <span id="xdx_907_ecustom--AreaOfBuilding_usqft_c20230101__20231231_zEZsvkLl3mU8" title="Area of building">147,215</span> square foot facility. We believe the use of placental-derived cells, sourced from the placentas of full-term healthy informed consent donors, has potential inherent advantages, from a scientific and an economic perspective. First, relative to adult- derived cells, placental-derived cells demonstrate greater stemness, meaning the ability to expand and persist. Second, placental-derived cells are immunologically naïve, meaning the cells have never been exposed to a specific antigen, and suggesting the potential for less toxicity and for low or no graft-versus-host disease, or GvHD, in transplant. Third, Celularity’s placental-derived cells are allogeneic, meaning they are intended for use in any patient, as compared to autologous cells, which are derived from an individual patient for that patient’s use. We believe this is a key difference that will enable readily available off-the-shelf treatments that can be delivered faster, more reliably, at greater scale and to more patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From a single source material, the postpartum human placenta, the Company derives four allogeneic cell or extracellular vesicle types: T cells, NK cells, MLASCs and exosomes, which have the potential to support multiple therapeutic programs. In 2022, the </span>Company had active and approved clinical trials under development utilizing CYNK-001, a placental derived unmodified NK cell, for the treatment of acute myeloid leukemia, or AML, a blood cancer, and for glioblastoma multiforme, or GBM, a solid tumor cancer. The Company also had an active clinical trial utilizing CYNK-101, a genetically modified NK cell, for the treatment of HER2+ Gastric cancer. Due to a need to prioritize corporate resources, in January 2023 the Company announced its intention to cease recruitment in the GBM and the HER2+ gastric trials. In addition, in April 2023, the Company announced based on the preliminary results of the phase 1 trial data of CYNK-001, the AML trial would be closed to further enrollment and has completed follow up. The Company is currently not actively investigating CYNK-001 for any indication. During the second quarter of 2023, the Company fully impaired the in-process research and development (“IPR&amp;D”) assets associated with CYNK-001. In the first quarter of 2022, the Company submitted an IND to investigate CYCART-19, a placental-derived CAR-T cell therapy targeting the cluster of differentiation 19, for the treatment of B-cell malignancies. In late May 2022, the Company received formal written communication from the U.S. Food and Drug Administration requesting additional information before it can proceed with the planned Phase 1/2 clinical trial. After assessing the status of the IND to determine an optional path forward for the CYCART-19 program, the Company elected to terminate development of CYCART-19 for B-cell malignancies during the third quarter of 2023. The Company may continue pre-clinical development of other T-cell candidates. APPL-001 is a placenta-derived MLASC being developed for the treatment of Crohn’s disease, and other degenerative diseases. Due to an internal alignment of corporate resources, the Company has paused development in exosomes to focus on other priorities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40) (“ASU 205-40”), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an emerging clinical-stage biotechnology company, Celularity is subject to certain inherent risks and uncertainties associated with the development of an enterprise. In this regard, since the Company’s inception, substantially all of management’s efforts have been devoted to making investments in research and development including basic scientific research into placentally-derived allogeneic cells, pre-clinical studies to support its current and future clinical programs in cellular therapeutics, and clinical development of its cell programs as well as facilities and selling, general and administrative expenses that support its core business operations (collectively the “investments”), all at the expense of the Company’s short-term profitability. The Company has historically funded these investments through limited revenues generated from its biobanking and degenerative disease businesses and issuances of equity and debt securities to public and private investors (these issuances are collectively referred to as “outside capital”). Notwithstanding these efforts, management can provide no assurance that the Company’s research and development and commercialization efforts will be successfully completed, or that adequate protection of the Company’s intellectual property will be adequately maintained. Even if these efforts are successful, it is uncertain when, if ever, the Company will generate significant sales or operate in a profitable manner to sustain the Company’s operations without needing to continue to rely on outside capital. Continued decline in the Company’s share price could result in impairment of goodwill or long-lived assets in a future period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date the accompanying consolidated financial statements were issued (the “issuance date”), management evaluated the significance of the following adverse conditions and events in accordance with ASU 205-40:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● </span>Since its inception, the Company has incurred significant operating losses and used net cash outflows from operations. For the year ended December 31, 2023, the Company incurred a net operating loss of $<span id="xdx_909_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20230101__20231231_zMZMefmes7il" title="Net operating loss">192,287</span> and used net cash outflows in operations of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20231231_z2FhH2qXogSd" title="Net cash used in operating activities">38,685</span>. As of December 31, 2023, the Company had an accumulated deficit of $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20231231_z5neRKfUn5Kf" title="Accumulated deficit">841,791</span>. The Company expects to continue to incur significant operating losses and use net cash in operations for the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● As of the issuance date, the Company had approximately $<span id="xdx_90E_ecustom--UnrestrictedCashAndCashEquivalents_iI_pn3n3_c20240729__srt--StatementScenarioAxis__srt--ScenarioForecastMember_ztEK4VRVIdbh" title="Unrestricted cash and cash equivalent">593</span> of unrestricted cash and cash equivalents available to fund the Company’s operations and no available additional sources of outside capital to sustain the Company’s operations for a period of 12 months beyond the issuance date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● The Company expects to incur substantial expenditures to fund its investments for the foreseeable future. In order to fund these investments, the Company will need to secure additional sources of outside capital. While the Company is actively seeking to secure additional outside capital (and has historically been able to successfully secure such capital), as of the issuance date, no additional outside capital has been secured or was deemed probable of being secured. In addition, </span>management can provide no assurance the Company will be able to secure additional outside capital in the future or on terms that are acceptable to the Company. Absent an ability to secure additional outside capital in the very near term, the Company will be unable to meet its obligations as they become due over the next 12 months beyond the issuance date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● As of the issuance date, the Company had approximately $<span id="xdx_908_eus-gaap--DebtCurrent_iI_pn3n3_c20240729_zJGMwS1xyfYd" title="Debt outstanding">42,700</span> of debt outstanding, all of which is currently due or due within one year of the issuance date. As disclosed in Note 9 substantially all of the Company’s outstanding debt is subject to a forbearance agreement. In the event the terms of the forbearance agreements are not met and/or the outstanding borrowings are not repaid, the lenders may, at their discretion, exercise all of their rights and remedies under the loan agreements which may include, among other things, seizing the Company’s assets and/or forcing the Company into liquidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● On April 17, 2024, Nasdaq provided formal notice to the Company that as a result of the Company’s failure to timely file its 2023 Form 10-K, it no longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). The Company was required to submit a plan to Nasdaq to regain compliance within 60 calendar days, or by June 17, 2024. On June 18, 2024, Nasdaq indicated that it had received the Company’s plan and granted the Company an extension to file this annual report on Form 10-K and the Company’s quarterly report on Form 10-Q for the period ended March 31, 2024 on or before August 30, 2024. If the Company is unable to regain compliance, the Company’s securities will be delisted from the Nasdaq, which such delisting would have a materially adverse effect on the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● In the event the Company is unable to secure additional outside capital to fund the Company’s obligations when they become due, including repayment of the Company’s outstanding debt, over the next 12 months beyond the issuance date, management will be required to seek other strategic alternatives, which may include, among others, a significant curtailment of the Company’s operations, a sale of certain of the Company’s assets, a sale of the entire Company to strategic or financial investors, and/or allowing the Company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy Code.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These uncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates that the Company will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 2018-08-24 0.0001 1-for-10 147215 -192287000 -38685000 -841791000 593000 42700000 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z00woBJ4ozcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_820_zAqRzAHn9c6j">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zB0V0AIWdgf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zqxO84m6kuz9">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_846_eus-gaap--UseOfEstimates_zopearkLonQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zOxFTgr4Xux7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible impairment assessment, the valuation of inventory, contingent consideration, short-term debt, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgNUeCK2YUv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zqUuHSqrC9Vg">Fair Value Measurements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value </span>must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmP0uP2PeQu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqo3IgGleZP5">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. At December 31, 2023 and 2022, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_84A_ecustom--RestrictedCashPolicyTextBlock_zXrlhIGfupD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zPMDDNQWREX7">Restricted Cash</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company maintained a letter of credit of $<span id="xdx_905_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231_z3dy3I68Kw8e" title="Restricted cash">9,936</span> and $<span id="xdx_907_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20221231_zq1FQHEE4RW8" title="Restricted cash">14,836</span>, respectively, for the benefit of the landlord of a leased property, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zchqeFnxlPhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zFsjm3Tycspc">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product. The Company continues to expense costs associated with clinical trial supply costs as research and development expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i) expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. Inventory, net of current portion on the Company’s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zJy4fXaykx4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z4e94AB73Phe">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zTAvW9rDieZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zuGSI1Gh9pd2" style="display: none">Schedule of Property and Equipment Estimated Useful Life</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 73%">Building</td><td style="width: 2%"> </td> <td style="width: 25%; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zdgj5mUA2OU7" title="Property and equipment expected useful lives">26</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember__srt--RangeAxis__srt--MinimumMember_zWalL91Kjf0j" title="Property and equipment expected useful lives">5</span> - <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z3y0b1DXrNGh" title="Property and equipment expected useful lives">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYaSeY3dSl" title="Property and equipment expected useful lives">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVEMxyPN4Pq" title="Property and equipment expected useful lives">3</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_z5jGOpdlARTc" title="Property and equipment expected useful lives">3</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1pDZrcuuzJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0840">shorter of the estimated useful life or the lease term</span></span></td></tr> </table> <p id="xdx_8AF_zQVzIugV4Qve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of operations in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ze4kEMBTbq7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zKs0c7GFXcwa">Impairment of Long-Lived Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets consist of property, plant and equipment, operating right-of-use assets, and definite-lived intangible assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the goodwill impairment recognized during the years ended December 31, 2023 and 2022, as discussed below and in Note 7, the Company performed a recoverability test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company did not record any impairment losses on long-lived assets during the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_848_ecustom--AssetAcquisitionsPolicyTextBlock_zAJw6uzP97A3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z14TfSDEFihk">Asset Acquisitions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_841_eus-gaap--InProcessResearchAndDevelopmentPolicy_zCTqFwWFWOn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zPqYBE2qJJ73">In-Process Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset is reclassified to a definite-lived asset and amortized over its estimated useful life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of an IPR&amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite-lived IPR&amp;D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived IPR&amp;D annually for impairment during the fourth quarter. In testing indefinite-lived IPR&amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived IPR&amp;D without performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived IPR&amp;D is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived IPR&amp;D. Under either approach, if the fair value of the indefinite-lived IPR&amp;D is less than its carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the years ended December 31, 2023 and 2022, the Company recognized an impairment charge related to its indefinite-lived IPR&amp;D of $<span id="xdx_905_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_c20230101__20231231_zpr8TadFJLxl" title="Indefinite-lived IPR&amp;D">107,800</span> and $<span id="xdx_905_ecustom--InProcessResearchAndDevelopmentImpairment_dxL_c20220101__20221231_ztAtHKgCVHAd" title="Indefinite-lived IPR&amp;D::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0850">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zAHPxrV3xH9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zWRsirdczOy">Goodwill</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company manages its operations through an evaluation of <span id="xdx_90B_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20230101__20231231_zTlmZYteElNe" title="Operating segments">three</span> different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than its carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances considered in the Company’s qualitative assessment include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, the Company would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, no impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, not to exceed the total amount of goodwill allocated to the reporting unit. During the years ended December 31, 2023 and 2022, the Company recognized goodwill impairment of $<span id="xdx_909_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zQR627Vi1gHk" title="Goodwill impairment">112,347</span> relating to the Cell Therapy reporting unit and $<span id="xdx_908_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_ztWF22v6iSci" title="Goodwill impairment">3,610</span> relating to the Degenerative Disease reporting unit, respectively, (See Note 7) in the Company’s consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_844_ecustom--WarrantsLiabilitiesPolicyTextBlock_zIGRLQ0NWPuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zUu7z5FuLtc3">Warrant Liabilities</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the public warrants, private placement warrants, registered direct warrants, and May 2022 PIPE warrants (collectively, “Liability Warrants”) in accordance with the guidance contained in ASC 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity,” under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other (expense) income in the consolidated statements of operations. The Liability Warrants excluding the public warrants were initially and subsequently valued using a Black-Scholes option pricing model, which is considered to be a Level 3 fair value measurement. The public warrants are valued based on the quoted market price as of each relevant reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zshviWtrTJRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z2irgkkD1pZ1">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02” or “ASC 842”), the Company classifies leases at the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as right-of-use assets (“ROU”), lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU are recorded based on the present values of lease payments over the terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to ROUs may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected the “package of 3” practical expedients permitted under the transition guidance, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer to Note 10 for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_84A_ecustom--ShortTermDebtPolicyTextBlock_zhja7ddxxL1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zDt32UpvwZM5">Short-Term Debt- Yorkville</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company elected the fair value option to account for the financial instrument as per the pre-paid advance agreement with YA II PN, Ltd (“Yorkville”) (see Note 9). As of December 31, 2023, due to the short term nature of the debt, the fair value approximates the settlement amount which was fully paid on January 17, 2024. As of December 31, 2022, the estimate of the fair value was determined using a binomial lattice model. The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing of when and if Yorkville elects to convert amounts into common shares, potential cash repayment by us prior to maturity, and movements in the Company’s common share price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zO2BdeFBTNp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zHtAEn5YGUxc">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance^®, Biovance 3L^®, CentraFlex^®, and Interfyl^®), biobanking services (i.e., the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies), and license, royalty and other revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Product sales and rentals</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biovance^®is a decellularized, dehydrated human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure with its biochemical components, and is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Interfyl^® is an allogeneic decellularized particulate human placental connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied. Sales and other taxes collected on behalf of third parties are excluded from revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company offers volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what levels of incentives will be earned. At December 31, 2023, the Company had reserves totaling $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pn3n3_c20231231__srt--ProductOrServiceAxis__custom--Biovance3LMember_zkAQ9e0AEqca" title="Accounts receivable">3,270</span> included within accounts receivable, net related to direct-customer rebates for Biovance 3L. At December 31, 2022, there were <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_do_c20221231__srt--ProductOrServiceAxis__custom--Biovance3LMember_z1QIDtcDRr72" title="Accounts receivable">no</span> reserves for customer rebates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore does not record a provision for returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Services</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company separately recognizes revenues for services to expectant parents who contract with the Company to collect, process and store umbilical cord blood and placenta derived cells and tissue for private use. The Company recognizes revenue from collection and processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period. Contracted storage periods are generally <span id="xdx_90E_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zBV67ACHO9e7" title="Contracted storage periods">18</span> years and <span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zdcwGLvfNkSd" title="Contracted storage periods">25</span> years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the 18- and the 25-year storage fees that are being recognized over the contractual storage period. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans (annual, lifetime, <span id="xdx_903_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zATWqdkZzAn2" title="Contracted storage periods">18</span> years and <span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zAfThMMW4bc4" title="Contracted storage periods">25</span> years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans for customers to pay over time for a period of <span id="xdx_90F_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dxL_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z7WyMCKoqsj9" title="Pay over time for a period::XDX::P1M"><span style="-sec-ix-hidden: xdx2ixbrl0880">one</span></span> to <span id="xdx_90D_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dxL_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z3fZ9UtWn8x7" title="Pay over time for a period::XDX::P24M"><span style="-sec-ix-hidden: xdx2ixbrl0882">24</span></span> months (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When considered over a <span id="xdx_907_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dxL_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zXdDTApqHYag" title="Pay over time for a period::XDX::P24M"><span style="-sec-ix-hidden: xdx2ixbrl0884">24</span></span>-month period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company offers promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what levels of incentives will be earned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the Company’s processing and storage agreements contain multiple performance obligations, ASC 606 <i>Revenue from Contracts with Customers,</i> requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">License, royalty and other</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under license agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company’s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. See Note 15 for further discussion of the Company’s license agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company’s direct sales of degenerative disease products are included in product sales and rentals, sales through the Company’s network of distribution partners are included in license, royalty and other revenues. For certain distribution agreements as described in Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to invoice so long as the consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_zIawlh3SHgbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z48OKsezV8Z8">Cost of Revenues</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenues consists of labor, material and overhead costs associated with the Company’s two existing commercial business segments, biobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials as well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues. Degenerative disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing the placental tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending on the class of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance, Biovance 3L and Interfyl product lines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf1vxwQ31A38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zVj2etBZBiD7">Research and Development Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expense as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront payments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zf3s8sGMjkH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zAPqUv8xfTDb">Advertising and Marketing Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were $<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20230101__20231231_zLxZcQRnX7gl" title="Marketing and advertising expenses">44</span> and $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20220101__20221231_zf2ITVtec215" title="Marketing and advertising expenses">163</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84F_ecustom--GovernmentGrantsPolicyTextBlock_zQkqRmIdyfja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z32nXixhPG35">Government Grants</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency. The Company did <span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20230101__20231231_zqv0JLw0Xyse" title="Grant monies"><span id="xdx_901_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20220101__20221231_zV0dVD9BCnd" title="Grant monies">no</span></span>t receive grant monies during the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zKLUNCc68lM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zQHoZjUAqlNk">Patent Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zKdDHjUJwwSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zRQF6jppFTbe">Stock-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using a straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s board of directors may also approve and award performance-based stock options. The performance-based stock options are earned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based awards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options granted to employees is determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award or the Company’s estimated term based on the underlying agreement. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. The Company elects to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is generally reversed in the period of the forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z8i4UN5nzFxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zv3nNEerXnRh">Comprehensive Income (Loss)</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive income (loss) refers to revenues, expenses, gains and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net income (loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company’s only component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of indebtedness accounted for under the fair value option that is attributable to changes in instrument-specific credit risk. During the year ended December 31, 2023, the Company recorded instrument-specific credit risk income of $<span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20231231_zC6FrwHZLtwj" title="Instrument-specific credit risk income">146</span> and reclassified $<span id="xdx_904_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20231231_z4ngnobKhpQ7" title="Accumulated other comprehensive income">155</span> from accumulated other comprehensive income to other income (expense) on the consolidated statements of operations upon short-term debt conversions. During the year ended December 31, 2022, the Company recorded instrument-specific credit risk income of $<span id="xdx_907_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20220101__20221231_zkLbo97q7upj" title="Instrument-specific credit risk income">20</span> and reclassified $<span id="xdx_90A_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20220101__20221231_z2YeltExUNp2" title="Accumulated other comprehensive income">11</span> from accumulated other comprehensive income to other income (expense) on the consolidated statements of operations upon short-term debt conversions. These amounts have been recorded as a separate component of stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zA5Q59k3u4W1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zvQwdCDalqOg">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than <span id="xdx_905_ecustom--MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority_pid_dp_c20230101__20231231_zjMTrNIN86M3" title="Tax authority percentage">50</span>% likelihood of being realized upon ultimate settlement with the tax authority. The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note 17).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zzgaTvz1GKki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_za87DH35NYfd">Net Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, stock options, restricted stock units and warrants, which would result in the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For diluted net income (loss) per share, the weighted-average number of shares of common stock is the same for basic net income (loss) per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For the year ended December 31, 2022, the Company was in a net income position and calculated the diluted net income per share by dividing the Company’s net income by the dilutive weighted average number of shares outstanding during the year, determined using the treasury stock method. A reconciliation of the numerators and denominators of the basic and diluted net income (loss) per share calculations are as follows:</span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMAysxwcUqQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zda0TEThjXLl" style="display: none">Schedule of Basic and Diluted Net Income Loss Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zNqghNqlcawc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_z2RmxQ06SDs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_pn3n3_zkZpXvzh7ZI2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net (loss) income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(196,295</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,192</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zD6oLP8WPyK" style="vertical-align: bottom; background-color: White"> <td>Weighted average shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,813,044</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,990,703</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_zanRgpmVnf6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average dilutive stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">958,602</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_zXwptcgTqK38" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Weighted average restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,697</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z0pIyaUf5ip9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Weighted average shares outstanding, diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">17,813,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,983,002</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zrgjEtq3Tra7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net (loss) income, basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareDiluted_pid_zR3yWUfrBdB6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net (loss) income, diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.95</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_z44UTKKBasDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1Bk62aSqYie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, prior to the use of the two-class method, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zknYNFtRttca" style="display: none">Schedule of Potentially Dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zeo2WtyKhvO1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zzJHBMT5zJO5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_ztjwcNvNGorf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2,820,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,239,219</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zikyKlbsUn6d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">823,332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,590</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zctqBw4NxOrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,070,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,345,836</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zePWzqaa9vp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">549,681</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">629,101</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_ztMza1TM1CPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11,263,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,342,746</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zdYJn1YgzKi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zSfDbpiyIuPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zswtER09fFj6">Segment Information</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages its operations through an evaluation of <span id="xdx_90D_ecustom--NumberOfBusinessSegments_dc_uInteger_c20230101__20231231_zKTljy37NaW4" title="Business segments">three</span> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the years ended December 31, 2023 and 2022 in Note 18.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zRN4WDhKSAAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zviAr3mb2ujl">Allowance for Credit Losses and Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the adoption of ASU 2016-13 <i>Financial Instruments — Credit Losses </i>(“ASU 2016-13”)<i>, </i>as noted below, the Company recognizes credit losses based on a forward-looking current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_845_ecustom--ConcentrationsOfCreditRiskAndSignificantCustomersPolicyTextBlock_zvKLMhi0uNEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zThae5ob8uvl">Concentrations of Credit Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of December 31, 2023, one of the Company’s customers comprised <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgnWc38tYtDg" title="Concentration risk, percentage">23</span>% of the Company’s outstanding gross accounts receivable and one other customer (Customer A) comprised <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCDzcTFzoNBl" title="Concentration risk, percentage">18</span>% of the outstanding gross accounts receivable. As of December 31, 2022, Customer A comprised of <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zu43XQl42FS8" title="Concentration risk, percentage">38</span>% of the Company’s outstanding gross accounts receivable, and two other customers comprised <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfs7UtI3Rds7" title="Concentration risk, percentage">33</span>% of the outstanding gross accounts receivable. During the year ended December 31, 2023, the Company had one customer provide for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWb3BQkK9Txj" title="Concentration risk, percentage">14</span>% of revenue and another customer provided for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCZ0jKdpp803" title="Concentration risk, percentage">13</span>% of revenue. During the year ended December 31, 2022, the Company had two customers provide for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKNVy80cfdx9" title="Concentration risk, percentage">37</span>% of revenue and Customer A provided for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4goP8J31683" title="Concentration risk, percentage">11</span>% of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2017, the FDA provided guidance that established an updated framework for regulation of Human Cell &amp; Tissue Products (“HCT/P”). The Company’s Interfyl products meet the criteria for minimal manipulation and homologous use as outlined within the applicable guidance and has an official designation from the FDA as an HCT/P product. As a result, the Company did not stop selling its Interfyl products when the FDA ended its enforcement discretion on May 31, 2021. However, the Center for Medicare and Medicaid Services (“CMS”) began rejecting claims for Interfyl submitted by Customer A. The Company believes that CMS is not distinguishing the Interfyl products from its competitors’ products. While the Company and Customer A continue to work with CMS to resolve the rejected claims, a full reserve of $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231__srt--MajorCustomersAxis__custom--OneCustomerMember_zwkknfOOcYIl" title="Accounts receivable">2,349</span> and $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231__srt--MajorCustomersAxis__custom--OneCustomerMember_zUlZne3YgDp4" title="Accounts receivable">1,762</span> was recorded on Customer A’s accounts receivable balance as of December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84F_ecustom--EmergingGrowthCompanyPolicyTextBlock_zpQysgMiI3qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zcue7Sc2TY45">Emerging Growth Company</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zFqvfC510e45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zphEpkeEA0A8">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform with current year presentation on the consolidated balance sheets and consolidated statements of cash flows between accrued expenses and accrued research and development (“R&amp;D”) software to separately present the Palantir liability recorded during the year ended December 31, 2023 (See Note 11 for further information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_845_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zqvl3mE0m6ge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zQ3i2fRG0MHe">Recently Adopted Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company adopted ASU 2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkOLPBaNC8t8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zt2fhxeFEQW">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i> (“ASU 2023-09”), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p id="xdx_855_z8UX029Y7b58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_84D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zB0V0AIWdgf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zqxO84m6kuz9">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_846_eus-gaap--UseOfEstimates_zopearkLonQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zOxFTgr4Xux7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible impairment assessment, the valuation of inventory, contingent consideration, short-term debt, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgNUeCK2YUv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zqUuHSqrC9Vg">Fair Value Measurements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value </span>must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmP0uP2PeQu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqo3IgGleZP5">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. At December 31, 2023 and 2022, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_84A_ecustom--RestrictedCashPolicyTextBlock_zXrlhIGfupD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zPMDDNQWREX7">Restricted Cash</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company maintained a letter of credit of $<span id="xdx_905_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231_z3dy3I68Kw8e" title="Restricted cash">9,936</span> and $<span id="xdx_907_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20221231_zq1FQHEE4RW8" title="Restricted cash">14,836</span>, respectively, for the benefit of the landlord of a leased property, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> 9936000 14836000 <p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zchqeFnxlPhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zFsjm3Tycspc">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out basis. Prior to initial approval from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product. The Company continues to expense costs associated with clinical trial supply costs as research and development expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i) expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is written-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. Inventory, net of current portion on the Company’s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zJy4fXaykx4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z4e94AB73Phe">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zTAvW9rDieZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zuGSI1Gh9pd2" style="display: none">Schedule of Property and Equipment Estimated Useful Life</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 73%">Building</td><td style="width: 2%"> </td> <td style="width: 25%; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zdgj5mUA2OU7" title="Property and equipment expected useful lives">26</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember__srt--RangeAxis__srt--MinimumMember_zWalL91Kjf0j" title="Property and equipment expected useful lives">5</span> - <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z3y0b1DXrNGh" title="Property and equipment expected useful lives">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYaSeY3dSl" title="Property and equipment expected useful lives">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVEMxyPN4Pq" title="Property and equipment expected useful lives">3</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_z5jGOpdlARTc" title="Property and equipment expected useful lives">3</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1pDZrcuuzJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0840">shorter of the estimated useful life or the lease term</span></span></td></tr> </table> <p id="xdx_8AF_zQVzIugV4Qve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of operations in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zTAvW9rDieZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zuGSI1Gh9pd2" style="display: none">Schedule of Property and Equipment Estimated Useful Life</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 73%">Building</td><td style="width: 2%"> </td> <td style="width: 25%; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zdgj5mUA2OU7" title="Property and equipment expected useful lives">26</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentAndFurnitureMember__srt--RangeAxis__srt--MinimumMember_zWalL91Kjf0j" title="Property and equipment expected useful lives">5</span> - <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z3y0b1DXrNGh" title="Property and equipment expected useful lives">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zYaSeY3dSl" title="Property and equipment expected useful lives">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVEMxyPN4Pq" title="Property and equipment expected useful lives">3</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_z5jGOpdlARTc" title="Property and equipment expected useful lives">3</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z1pDZrcuuzJ8" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0840">shorter of the estimated useful life or the lease term</span></span></td></tr> </table> P26Y P5Y P7Y P5Y P3Y P3Y <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ze4kEMBTbq7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zKs0c7GFXcwa">Impairment of Long-Lived Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets consist of property, plant and equipment, operating right-of-use assets, and definite-lived intangible assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the goodwill impairment recognized during the years ended December 31, 2023 and 2022, as discussed below and in Note 7, the Company performed a recoverability test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company did not record any impairment losses on long-lived assets during the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_848_ecustom--AssetAcquisitionsPolicyTextBlock_zAJw6uzP97A3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z14TfSDEFihk">Asset Acquisitions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_841_eus-gaap--InProcessResearchAndDevelopmentPolicy_zCTqFwWFWOn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zPqYBE2qJJ73">In-Process Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset is reclassified to a definite-lived asset and amortized over its estimated useful life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of an IPR&amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite-lived IPR&amp;D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived IPR&amp;D annually for impairment during the fourth quarter. In testing indefinite-lived IPR&amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived IPR&amp;D without performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived IPR&amp;D is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived IPR&amp;D. Under either approach, if the fair value of the indefinite-lived IPR&amp;D is less than its carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the years ended December 31, 2023 and 2022, the Company recognized an impairment charge related to its indefinite-lived IPR&amp;D of $<span id="xdx_905_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_c20230101__20231231_zpr8TadFJLxl" title="Indefinite-lived IPR&amp;D">107,800</span> and $<span id="xdx_905_ecustom--InProcessResearchAndDevelopmentImpairment_dxL_c20220101__20221231_ztAtHKgCVHAd" title="Indefinite-lived IPR&amp;D::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0850">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 107800000 <p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zAHPxrV3xH9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zWRsirdczOy">Goodwill</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company manages its operations through an evaluation of <span id="xdx_90B_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20230101__20231231_zTlmZYteElNe" title="Operating segments">three</span> different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than its carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances considered in the Company’s qualitative assessment include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, the Company would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, no impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, not to exceed the total amount of goodwill allocated to the reporting unit. During the years ended December 31, 2023 and 2022, the Company recognized goodwill impairment of $<span id="xdx_909_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zQR627Vi1gHk" title="Goodwill impairment">112,347</span> relating to the Cell Therapy reporting unit and $<span id="xdx_908_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_ztWF22v6iSci" title="Goodwill impairment">3,610</span> relating to the Degenerative Disease reporting unit, respectively, (See Note 7) in the Company’s consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 3 112347000 3610000 <p id="xdx_844_ecustom--WarrantsLiabilitiesPolicyTextBlock_zIGRLQ0NWPuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zUu7z5FuLtc3">Warrant Liabilities</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the public warrants, private placement warrants, registered direct warrants, and May 2022 PIPE warrants (collectively, “Liability Warrants”) in accordance with the guidance contained in ASC 815-40, “Derivatives and Hedging—Contracts in Entity’s Own Equity,” under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other (expense) income in the consolidated statements of operations. The Liability Warrants excluding the public warrants were initially and subsequently valued using a Black-Scholes option pricing model, which is considered to be a Level 3 fair value measurement. The public warrants are valued based on the quoted market price as of each relevant reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zshviWtrTJRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z2irgkkD1pZ1">Leases</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02” or “ASC 842”), the Company classifies leases at the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as right-of-use assets (“ROU”), lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU are recorded based on the present values of lease payments over the terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to ROUs may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected the “package of 3” practical expedients permitted under the transition guidance, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 26.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer to Note 10 for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_84A_ecustom--ShortTermDebtPolicyTextBlock_zhja7ddxxL1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zDt32UpvwZM5">Short-Term Debt- Yorkville</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.95pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company elected the fair value option to account for the financial instrument as per the pre-paid advance agreement with YA II PN, Ltd (“Yorkville”) (see Note 9). As of December 31, 2023, due to the short term nature of the debt, the fair value approximates the settlement amount which was fully paid on January 17, 2024. As of December 31, 2022, the estimate of the fair value was determined using a binomial lattice model. The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing of when and if Yorkville elects to convert amounts into common shares, potential cash repayment by us prior to maturity, and movements in the Company’s common share price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zO2BdeFBTNp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zHtAEn5YGUxc">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance^®, Biovance 3L^®, CentraFlex^®, and Interfyl^®), biobanking services (i.e., the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies), and license, royalty and other revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Product sales and rentals</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biovance^®is a decellularized, dehydrated human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure with its biochemical components, and is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Interfyl^® is an allogeneic decellularized particulate human placental connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied. Sales and other taxes collected on behalf of third parties are excluded from revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company offers volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what levels of incentives will be earned. At December 31, 2023, the Company had reserves totaling $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pn3n3_c20231231__srt--ProductOrServiceAxis__custom--Biovance3LMember_zkAQ9e0AEqca" title="Accounts receivable">3,270</span> included within accounts receivable, net related to direct-customer rebates for Biovance 3L. At December 31, 2022, there were <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_do_c20221231__srt--ProductOrServiceAxis__custom--Biovance3LMember_z1QIDtcDRr72" title="Accounts receivable">no</span> reserves for customer rebates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore does not record a provision for returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Services</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company separately recognizes revenues for services to expectant parents who contract with the Company to collect, process and store umbilical cord blood and placenta derived cells and tissue for private use. The Company recognizes revenue from collection and processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period. Contracted storage periods are generally <span id="xdx_90E_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zBV67ACHO9e7" title="Contracted storage periods">18</span> years and <span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zdcwGLvfNkSd" title="Contracted storage periods">25</span> years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the 18- and the 25-year storage fees that are being recognized over the contractual storage period. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans (annual, lifetime, <span id="xdx_903_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zATWqdkZzAn2" title="Contracted storage periods">18</span> years and <span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zAfThMMW4bc4" title="Contracted storage periods">25</span> years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans for customers to pay over time for a period of <span id="xdx_90F_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dxL_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z7WyMCKoqsj9" title="Pay over time for a period::XDX::P1M"><span style="-sec-ix-hidden: xdx2ixbrl0880">one</span></span> to <span id="xdx_90D_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dxL_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z3fZ9UtWn8x7" title="Pay over time for a period::XDX::P24M"><span style="-sec-ix-hidden: xdx2ixbrl0882">24</span></span> months (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When considered over a <span id="xdx_907_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dxL_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zXdDTApqHYag" title="Pay over time for a period::XDX::P24M"><span style="-sec-ix-hidden: xdx2ixbrl0884">24</span></span>-month period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company offers promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what levels of incentives will be earned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the Company’s processing and storage agreements contain multiple performance obligations, ASC 606 <i>Revenue from Contracts with Customers,</i> requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">License, royalty and other</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under license agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company’s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. See Note 15 for further discussion of the Company’s license agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company’s direct sales of degenerative disease products are included in product sales and rentals, sales through the Company’s network of distribution partners are included in license, royalty and other revenues. For certain distribution agreements as described in Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to invoice so long as the consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 3270000 0 P18Y P25Y P18Y P25Y <p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_zIawlh3SHgbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z48OKsezV8Z8">Cost of Revenues</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenues consists of labor, material and overhead costs associated with the Company’s two existing commercial business segments, biobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials as well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues. Degenerative disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing the placental tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending on the class of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance, Biovance 3L and Interfyl product lines.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf1vxwQ31A38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zVj2etBZBiD7">Research and Development Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expense as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront payments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zf3s8sGMjkH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zAPqUv8xfTDb">Advertising and Marketing Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were $<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20230101__20231231_zLxZcQRnX7gl" title="Marketing and advertising expenses">44</span> and $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20220101__20221231_zf2ITVtec215" title="Marketing and advertising expenses">163</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 44000 163000 <p id="xdx_84F_ecustom--GovernmentGrantsPolicyTextBlock_zQkqRmIdyfja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z32nXixhPG35">Government Grants</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency. The Company did <span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20230101__20231231_zqv0JLw0Xyse" title="Grant monies"><span id="xdx_901_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20220101__20221231_zV0dVD9BCnd" title="Grant monies">no</span></span>t receive grant monies during the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 0 0 <p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zKLUNCc68lM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zQHoZjUAqlNk">Patent Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zKdDHjUJwwSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zRQF6jppFTbe">Stock-Based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using a straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s board of directors may also approve and award performance-based stock options. The performance-based stock options are earned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based awards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options granted to employees is determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award or the Company’s estimated term based on the underlying agreement. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. The Company elects to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is generally reversed in the period of the forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z8i4UN5nzFxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zv3nNEerXnRh">Comprehensive Income (Loss)</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive income (loss) refers to revenues, expenses, gains and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net income (loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company’s only component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of indebtedness accounted for under the fair value option that is attributable to changes in instrument-specific credit risk. During the year ended December 31, 2023, the Company recorded instrument-specific credit risk income of $<span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20231231_zC6FrwHZLtwj" title="Instrument-specific credit risk income">146</span> and reclassified $<span id="xdx_904_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20231231_z4ngnobKhpQ7" title="Accumulated other comprehensive income">155</span> from accumulated other comprehensive income to other income (expense) on the consolidated statements of operations upon short-term debt conversions. During the year ended December 31, 2022, the Company recorded instrument-specific credit risk income of $<span id="xdx_907_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20220101__20221231_zkLbo97q7upj" title="Instrument-specific credit risk income">20</span> and reclassified $<span id="xdx_90A_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20220101__20221231_z2YeltExUNp2" title="Accumulated other comprehensive income">11</span> from accumulated other comprehensive income to other income (expense) on the consolidated statements of operations upon short-term debt conversions. These amounts have been recorded as a separate component of stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 146000 155000 20000 11000 <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zA5Q59k3u4W1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zvQwdCDalqOg">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than <span id="xdx_905_ecustom--MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority_pid_dp_c20230101__20231231_zjMTrNIN86M3" title="Tax authority percentage">50</span>% likelihood of being realized upon ultimate settlement with the tax authority. The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note 17).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 0.50 <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zzgaTvz1GKki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_za87DH35NYfd">Net Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, stock options, restricted stock units and warrants, which would result in the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For diluted net income (loss) per share, the weighted-average number of shares of common stock is the same for basic net income (loss) per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For the year ended December 31, 2022, the Company was in a net income position and calculated the diluted net income per share by dividing the Company’s net income by the dilutive weighted average number of shares outstanding during the year, determined using the treasury stock method. A reconciliation of the numerators and denominators of the basic and diluted net income (loss) per share calculations are as follows:</span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMAysxwcUqQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zda0TEThjXLl" style="display: none">Schedule of Basic and Diluted Net Income Loss Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zNqghNqlcawc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_z2RmxQ06SDs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_pn3n3_zkZpXvzh7ZI2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net (loss) income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(196,295</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,192</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zD6oLP8WPyK" style="vertical-align: bottom; background-color: White"> <td>Weighted average shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,813,044</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,990,703</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_zanRgpmVnf6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average dilutive stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">958,602</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_zXwptcgTqK38" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Weighted average restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,697</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z0pIyaUf5ip9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Weighted average shares outstanding, diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">17,813,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,983,002</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zrgjEtq3Tra7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net (loss) income, basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareDiluted_pid_zR3yWUfrBdB6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net (loss) income, diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.95</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_z44UTKKBasDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1Bk62aSqYie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, prior to the use of the two-class method, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zknYNFtRttca" style="display: none">Schedule of Potentially Dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zeo2WtyKhvO1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zzJHBMT5zJO5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_ztjwcNvNGorf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2,820,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,239,219</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zikyKlbsUn6d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">823,332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,590</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zctqBw4NxOrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,070,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,345,836</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zePWzqaa9vp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">549,681</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">629,101</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_ztMza1TM1CPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11,263,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,342,746</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zdYJn1YgzKi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMAysxwcUqQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zda0TEThjXLl" style="display: none">Schedule of Basic and Diluted Net Income Loss Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zNqghNqlcawc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_z2RmxQ06SDs1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_pn3n3_zkZpXvzh7ZI2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net (loss) income</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(196,295</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,192</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zD6oLP8WPyK" style="vertical-align: bottom; background-color: White"> <td>Weighted average shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,813,044</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,990,703</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_zanRgpmVnf6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average dilutive stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">958,602</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_zXwptcgTqK38" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Weighted average restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,697</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z0pIyaUf5ip9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Weighted average shares outstanding, diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">17,813,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,983,002</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zrgjEtq3Tra7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net (loss) income, basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareDiluted_pid_zR3yWUfrBdB6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net (loss) income, diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.95</td><td style="text-align: left"> </td></tr> </table> -196295000 14192000 17813044 13990703 958602 33697 17813044 14983002 -11.02 1.01 -11.02 0.95 <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1Bk62aSqYie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, prior to the use of the two-class method, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zknYNFtRttca" style="display: none">Schedule of Potentially Dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zeo2WtyKhvO1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zzJHBMT5zJO5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_ztjwcNvNGorf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2,820,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,239,219</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zikyKlbsUn6d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">823,332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,590</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zctqBw4NxOrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,070,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,345,836</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zePWzqaa9vp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">549,681</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">629,101</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_ztMza1TM1CPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11,263,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,342,746</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2820187 1239219 823332 128590 7070627 3345836 549681 629101 11263827 5342746 <p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zSfDbpiyIuPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zswtER09fFj6">Segment Information</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages its operations through an evaluation of <span id="xdx_90D_ecustom--NumberOfBusinessSegments_dc_uInteger_c20230101__20231231_zKTljy37NaW4" title="Business segments">three</span> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the years ended December 31, 2023 and 2022 in Note 18.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3 <p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zRN4WDhKSAAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zviAr3mb2ujl">Allowance for Credit Losses and Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the adoption of ASU 2016-13 <i>Financial Instruments — Credit Losses </i>(“ASU 2016-13”)<i>, </i>as noted below, the Company recognizes credit losses based on a forward-looking current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_845_ecustom--ConcentrationsOfCreditRiskAndSignificantCustomersPolicyTextBlock_zvKLMhi0uNEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zThae5ob8uvl">Concentrations of Credit Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of December 31, 2023, one of the Company’s customers comprised <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgnWc38tYtDg" title="Concentration risk, percentage">23</span>% of the Company’s outstanding gross accounts receivable and one other customer (Customer A) comprised <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCDzcTFzoNBl" title="Concentration risk, percentage">18</span>% of the outstanding gross accounts receivable. As of December 31, 2022, Customer A comprised of <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zu43XQl42FS8" title="Concentration risk, percentage">38</span>% of the Company’s outstanding gross accounts receivable, and two other customers comprised <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfs7UtI3Rds7" title="Concentration risk, percentage">33</span>% of the outstanding gross accounts receivable. During the year ended December 31, 2023, the Company had one customer provide for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWb3BQkK9Txj" title="Concentration risk, percentage">14</span>% of revenue and another customer provided for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCZ0jKdpp803" title="Concentration risk, percentage">13</span>% of revenue. During the year ended December 31, 2022, the Company had two customers provide for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKNVy80cfdx9" title="Concentration risk, percentage">37</span>% of revenue and Customer A provided for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4goP8J31683" title="Concentration risk, percentage">11</span>% of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2017, the FDA provided guidance that established an updated framework for regulation of Human Cell &amp; Tissue Products (“HCT/P”). The Company’s Interfyl products meet the criteria for minimal manipulation and homologous use as outlined within the applicable guidance and has an official designation from the FDA as an HCT/P product. As a result, the Company did not stop selling its Interfyl products when the FDA ended its enforcement discretion on May 31, 2021. However, the Center for Medicare and Medicaid Services (“CMS”) began rejecting claims for Interfyl submitted by Customer A. The Company believes that CMS is not distinguishing the Interfyl products from its competitors’ products. While the Company and Customer A continue to work with CMS to resolve the rejected claims, a full reserve of $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231__srt--MajorCustomersAxis__custom--OneCustomerMember_zwkknfOOcYIl" title="Accounts receivable">2,349</span> and $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231__srt--MajorCustomersAxis__custom--OneCustomerMember_zUlZne3YgDp4" title="Accounts receivable">1,762</span> was recorded on Customer A’s accounts receivable balance as of December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 0.23 0.18 0.38 0.33 0.14 0.13 0.37 0.11 2349000 1762000 <p id="xdx_84F_ecustom--EmergingGrowthCompanyPolicyTextBlock_zpQysgMiI3qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zcue7Sc2TY45">Emerging Growth Company</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zFqvfC510e45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zphEpkeEA0A8">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform with current year presentation on the consolidated balance sheets and consolidated statements of cash flows between accrued expenses and accrued research and development (“R&amp;D”) software to separately present the Palantir liability recorded during the year ended December 31, 2023 (See Note 11 for further information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_845_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zqvl3mE0m6ge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zQ3i2fRG0MHe">Recently Adopted Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company adopted ASU 2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkOLPBaNC8t8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zt2fhxeFEQW">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i> (“ASU 2023-09”), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zUKEWyzL9lSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_82A_zdDB3Mu6oqX2">Fair Value of Financial Assets and Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zrFSAAm7jTNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B9_z5hupg2gTAB1" style="display: none">Schedule of Financial Assets and Liabilities Measures at Fair Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zB0NIy7vkBp9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze2uItH9obci" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSUeWyhjpQn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20231231_zADzZSli4NFd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zjv04P4oYJ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_i01I_pn3n3_zb5Y8WpKAAzg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Cash equivalents - money market funds</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ConvertibleNoteReceivable_i01I_pn3n3_zd1XzlNShQRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Convertible note receivable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zTkFnLeBK9Jh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zkHBiSXoypUk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zWJwjfmi7zL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Acquisition-related contingent consideration obligations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zU1Cy24aG9Wd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zl44AXAF9Ln5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Short-term debt - Yorkville</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zIovKamIgAEb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Warrant liability - July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zq5YPfe8vzNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Warrant liability - April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zeuuKikTxyBh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zqzYoIR18Asf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zLotBTLrdii8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zl504nEszAYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,640</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6jfMCtLGkm" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfeAibsZ6Pcg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0EimSm4D1lg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20221231_znW4BdpAsvZ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zkhPTr3UTFVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_i01I_pn3n3_zhijPOveeF1i" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents – money market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,174</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,174</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ConvertibleNoteReceivable_i01I_pn3n3_zMP17PWY0OFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Convertible note receivable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,514</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,514</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zbw5u4KbLsF4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,514</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zXrzcAECCTX4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zJKQsshLVwRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Acquisition-related contingent consideration obligations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">105,945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">105,945</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zqlA9eSsl19f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zQuc169MRFfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Short-term debt - Yorkville</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,603</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,603</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zctqZEQpbGI9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,402</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zZ079aTzjmgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,190</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,190</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zw3sIS1iTF2h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,006</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,006</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zkqEI7bPMdQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146,326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">147,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zKtLymv5DMtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, there were <span id="xdx_905_ecustom--FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod_do_c20230101__20231231_zlzjC30bmMyh"><span id="xdx_901_ecustom--FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod_do_c20230101__20231231_zlgXdGBfoexc"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_do_c20230101__20231231_zaeY6eAG7e8l" title="Fair value, assets, transfers into level 3, amount"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_do_c20230101__20231231_zz9xBSss1Kg3" title="Fair value, assets, transfers out of level 3, amount"><span id="xdx_904_ecustom--FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod_do_c20220101__20221231_zas8FZLS3oO3"><span id="xdx_904_ecustom--FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod_do_c20220101__20221231_zhdG1q9g4zc4"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_do_c20220101__20221231_zGX7MAy2ST7f" title="Fair value, assets, transfers into level 3, amount"><span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_do_c20220101__20221231_zY0gsTo69NQi" title="Fair value, assets, transfers out of level 3, amount">no</span></span></span></span></span></span></span></span> transfers between Level 1, Level 2 and Level 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s cash equivalents consisted of a money market funds. The money market fund was valued using inputs observable in active markets for similar securities, which represents a Level 1 measurement in the fair value hierarchy. The carrying values of accounts receivable, accounts payable, deferred revenue and other current liabilities approximate fair value in the accompanying consolidated financial statements due to the short-term nature of those instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Contingent Consideration</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s own assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zGi1VNuXzkZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BD_zj2gEFH6aHW7" style="display: none">Schedule of Reconciliation of Contingent Consideration Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of)<br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ContingentConsiderationObligation_iS_pn3n3_c20230101__20231231_z7LLQLRBYto8" style="width: 10%; text-align: right" title="Beginning balance">          105,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20230101__20231231_zfxUbthaJkVl" style="width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1148">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_pn3n3_c20230101__20231231_zuWxts7bILe9" style="width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1150">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20230101__20231231_z8EsuIblUsxc" style="width: 10%; text-align: right" title="Fair value adjustments">(104,339</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ContingentConsiderationObligation_iE_pn3n3_c20230101__20231231_z5193L0jTGOh" style="width: 10%; text-align: right" title="Ending balance">1,606</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of)<br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentConsiderationObligation_iS_pn3n3_c20220101__20221231_z25s7ioV5Adj" style="width: 10%; text-align: right" title="Beginning balance">           232,222</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20220101__20221231_zQBFDXdzg8ld" style="width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1158">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_pn3n3_c20220101__20221231_zmlg7Y1Am3kg" style="width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1160">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20220101__20221231_zuzcKmcd2PNb" style="width: 10%; text-align: right" title="Fair value adjustments">(126,277</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentConsiderationObligation_iE_pn3n3_c20220101__20221231_z6THayHe38g9" style="width: 10%; text-align: right" title="Ending balance">           105,945</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_8AB_zywo5o6klJ74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the liability to make potential future milestone and earn-out payments was estimated by the Company at each reporting date based, in part, on the results of a third-party valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving specified events, discount rates, and the period of time until earn-out payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the Company’s consolidated statements of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The Company has classified all of the contingent consideration as a long-term liability in the consolidated balance sheets as of December 31, 2023 and 2022. See Note 11, “Commitment and Contingencies”, for more information on contingent consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Warrant Liability</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant liability at December 31, 2023 is composed of the fair value of warrants to purchase shares of Class A Common Stock. The Liability Warrants were recorded at their respective closing date fair values based on a Black-Scholes option pricing model that utilizes inputs for: (i) value of the underlying asset, (ii) the exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset and (vi) maturity. The Black-Scholes option pricing model’s primary unobservable input utilized in determining the fair value of the Liability Warrants is the expected volatility of the Class A Common Stock. Prior to the Mergers, Legacy Celularity was historically a private company and lacks company-specific historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies. Inputs to the Black-Scholes option pricing model for the warrants are updated each reporting period to reflect fair value. The public warrants (the “Public Warrants”) were recorded at the closing date fair value based on the close price of such warrants. Each subsequent reporting period, the Public Warrants are marked-to-market based on the period-end close price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the fair value of the warrant liabilities was $<span id="xdx_901_ecustom--FairValueNetAssetsLiabilities_iI_pn3n3_c20231231_zAS7D8gMI1K8" title="Fair value of the warrant liabilities">4,359</span> and $<span id="xdx_902_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20221231_z9lF4Bo6y2A6" title="Fair value of the warrant liabilities">3,598</span>, respectively. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated remaining term of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zqWSQ8KXNRd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a roll-forward of the aggregate fair values of the Company’s warrant liabilities for which fair values are determined using Level 3 inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B1_zcx8e3GOpQN2" style="display: none">Schedule of Roll-forward of the Aggregate Fair Values of Company’s Warrant Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueNetAssetsLiability_iS_pn3n3_c20220101__20221231_zgxYmsuaeAUe" style="width: 16%; text-align: right" title="Fair value, Beginning Balance">25,962</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">May 2022 PIPE warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--PrivateInvestmentInPublicEquityWarrantIssuance_pn3n3_c20220101__20221231_zXy1bPK1LpIg" style="text-align: right" title="May 2022 PIPE warrant issuance">19,745</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zdQ7ww5wwHG2" style="text-align: right" title="April 2023 Registered Direct warrant issuance">4,280</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">July 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zlxEnWFcOJGc" style="text-align: right" title="July 2023 Registered Direct warrant issuance">2,645</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Gain recognized in earnings from change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20220101__20221231_zdnmAYa9qPo9" style="border-bottom: Black 1pt solid; text-align: right" title="Gain recognized in earnings from change in fair value">(42,109</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueNetAssetsLiability_iE_pn3n3_c20220101__20221231_zQOepr9xdPx8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">3,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0pt 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueNetAssetLiability_iS_pn3n3_c20230101__20231231_zEX1Jv9bLgBa" style="width: 16%; text-align: right" title="Fair value, Beginning Balance">3,598</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zdLr73xC2ZZ4" style="text-align: right" title="April 2023 Registered Direct warrant issuance">4,280</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">July 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zhcBTS5h3BG4" style="text-align: right" title="July 2023 Registered Direct warrant issuance">2,645</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Gain recognized in earnings from change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20230101__20231231_zgMFzR3VS9kc" style="border-bottom: Black 1pt solid; text-align: right" title="Gain recognized in earnings from change in fair value">(6,164</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iE_pn3n3_c20230101__20231231_zzgM9WEQNpZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">4,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zOm1yq9pWw96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_894_ecustom--ScheduleOfFairValueOfTheLiabilityTableTextBlock_zWm3bam0IWAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Liability Warrants are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zcDnsI900oxf" style="display: none">Schedule of Fair Value of Liability Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zQq0Z8KtVNfl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220101__20221231_zp63g0NEd78a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zD0LDd3xjtka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Public Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">575</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zHaKiMMQAZ14" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,190</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKEnEADPJ3Xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,016</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z01F2qyt7HCf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">May 2022 PIPE Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">708</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--FairValueOfWarrants_pn3n3_zD9MT9Bbx1pe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z18voOEKr6Hg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zbCY3t3nZBCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Sponsor Warrants are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B4_zrReOVAEbMfi" style="display: none">Schedule of Sponsor Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zPa17hPniYgj" style="width: 16%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zYDl3SDmrUQh" style="width: 16%; text-align: right" title="Common share price">12.90</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zvqaCk7P5yld" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_ziAHxzXpqKsg" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1YQuSBZjdTj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zHxw9l6aAmAd" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zpjhcsu69N2g" title="Term (years)">2.5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zyhN3NSbt4me" title="Term (years)">3.5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zAK3XJgBbWDb" style="text-align: right" title="Dividend yield">4.12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zAffkeSU5Sf" style="text-align: right" title="Dividend yield">4.16</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zlaXTCzIyXa3" style="text-align: right" title="Volatility">100.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zamkBUvjFAYg" style="text-align: right" title="Volatility">75.0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A7_zFre1c8U5nZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z5DQQxAPOp22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BA_zMROgVDJCdH6" style="display: none">Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zLsq9m5BnA83" style="width: 16%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zIoV6QwiaRyk" style="width: 16%; text-align: right" title="Common share price">12.90</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zOPpYR08eoif" title="Exercise price">3.50</span> - <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zhFvjwtFo1u5" title="Exercise price">7.50</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zCEjcqDbNeKh" style="text-align: right" title="Exercise price">82.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z2FXzNjfnsZh" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgaqerJWXCoj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zamwSbitgWf5" title="Term (years)">5.03</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_z1vgFIZvdU34" title="Term (years)">5.34</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zP13qgnPyKP7" title="Term (years)">4.4</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5lthOi3L3xd" style="text-align: right" title="Dividend yield">4.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztc4JpvnwbPe" style="text-align: right" title="Dividend yield">3.99</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zVvQVVYlQRdi" style="text-align: right" title="Volatility">97.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zjdugoqX8RJg" style="text-align: right" title="Volatility">81.2</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A7_z5ixE2Yryy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of the Note Receivable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The convertible note receivable was received in connection with the disposition of the UltraMIST/MIST business in 2020. At any time on or after January 1, 2021, at the sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted into Sanuwave common stock at a defined rate. The convertible promissory note was to be paid on or before August 6, 2021, however, remains outstanding in full as of December 31, 2023 and 2022. The fair value of this note was based on a bond valuation which employs a credit default model. The Company utilized Level 3 inputs on a probability weighted model based on outcomes of a default, repayment and conversion of the note. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s own assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89E_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_zk1jUsBnNrE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the convertible note valuation model are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zZv5T36vSRLb" style="display: none">Schedule of Convertible Note Valuation Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid"><p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b> </span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold"><p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">December 31,</p> <p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2022</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Face value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_zmMFjqWyJVW2" style="width: 16%; text-align: right" title="Face value">4,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20221231_zBnNn1cKdbIj" style="width: 16%; text-align: right" title="Face value">4,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Coupon rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--PercentageOfCouponRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zIKZWDuWCO45" title="Coupon rate">12</span>% - <span id="xdx_901_ecustom--PercentageOfCouponRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zRoCdhVyQUV6" title="Coupon rate">17</span>% </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--PercentageOfCouponRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z0fMMQdUw0p8" title="Coupon rate">12</span>% - <span id="xdx_90A_ecustom--PercentageOfCouponRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zj1byholqCud" title="Coupon rate">17</span>%  </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ValuationModelThatRelateToSanuwaveCommonStock_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zDq8WCQhlGq4" style="text-align: right" title="Stock price">0.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--ValuationModelThatRelateToSanuwaveCommonStock_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zSiyDEcFjSmk" style="text-align: right" title="Stock price">0.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zcS0zpfRJghg" title="Term (years)">0.51</span>-<span id="xdx_905_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zoku1YpBLdb8" title="Term (years)">2.45</span> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zEhnY1G2u57b" title="Term (years)">1.01</span> - <span id="xdx_90B_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zzdkVhRWSz9j" title="Term (years)">3.45</span>  </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zpOO6hLUUcfk" title="Risk-free interest rate">5.47</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zmklRoJC9C3i" title="Risk-free interest rate">4.73</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a  </span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A0_z4V9X1el6B2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 18, 2023, the Company entered into a forbearance agreement with Sanuwave (“Sanuwave Forbearance Agreement”). Per the agreement, from the period from December 18, 2023 to the earliest of (i) February 28, 2024, (ii) the commencement of bankruptcy proceeds for Sanuwave pursuant to the U.S. Bankruptcy Code, (iii) the occurrence of an event of default other than payment default, (iv) the failure of Sanuwave to comply with any term, condition or covenant set forth in the agreement, the Company agrees that it will not, exercise any remedy available to it under the Convertible Note Receivable, excluding the right to increase the interest rate. As collateral for payments owed to Palantir, the Company assigned the Sanuwave convertible note in the event of default (see Note 11). On May 10, 2024, the Company entered into a letter agreement with Sanuwave to extend the forbearance period from <span id="xdx_903_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zvkJI1Eui2x4" title="Forbearance extend period">February 28, 2024</span> to <span id="xdx_907_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zneHzpTmsgF2" title="Forbearance extend period">June 3, 2024</span>. The letter agreement increased the total note payments to $<span id="xdx_901_ecustom--IincreasedNotePayments_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_z3fUE5vTxtU6" title="Increased total note payments">2,175</span>. Upon executing the letter agreement, Sanuwave made an initial note payment of $<span id="xdx_90B_ecustom--InitialNotePayment_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zD93heDzMSXb" title="Initial note payment">100</span> and on June 3, 2024 made a second note payment of $<span id="xdx_905_ecustom--SecondNotePayment_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zINjjkOgvJ27" title="Second note payment">2,075</span> fully discharging all outstanding indebtedness under the note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of the Contingent Stock Consideration</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contingent stock consideration liability at December 31, 2023, is comprised of the fair value of potential future issuance of Class A Common Stock to CariCord participating shareholders pursuant to a settlement agreement signed during the year ended December 31, 2021 (see Note 11). The fair value measurement of the contingent stock consideration obligation is determined using Level 3 inputs and is based on a probability-weighted expected return methodology (“PWERM”). The measurement is largely based upon unobservable inputs supported by little or no market activity based on the Company’s own assumptions. As of December 31, 2021, the applicable procurement targets were not probable of being achieved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_897_ecustom--FairValueAssetsOfContingentStockConsiderationMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zBGhebhNa8B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zU5J7lvFCYTg" style="display: none">Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 30%; text-align: left">Contingent stock consideration</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentStockConsiderationObligation_iS_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zDuHd5Aefjx4" style="width: 10%; text-align: right" title="Beginning balance">186</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zD7j66t3GgXf" style="width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1311">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_z5N9y5NJS9w4" style="width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1313">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ChangeInFairValueOfContingentStockConsideration_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zOMJ4ajWBtof" style="width: 10%; text-align: right" title="Fair value adjustments">(159</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentStockConsiderationObligation_iE_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zX9pbuOyXFRg" style="width: 10%; text-align: right" title="Ending balance">27</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p id="xdx_8A1_zm8kIvoEHphh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the liability to issue future shares of Class A Common Stock was estimated by the Company at each reporting date using a PWERM based on various inputs and assumptions, including the Company’s common share price, discount rates, and the probability of achieving specified future operational targets. The actual settlement of contingent stock consideration could differ from current estimates based on the actual achievement of these specified targets and movements in the Company’s common share price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting date, the Company revalues the contingent stock consideration obligation to estimated fair value and records changes in fair value as income or expense in the Company’s consolidated statements of operations. Changes in the fair value of the contingent stock consideration obligation may result from changes in discount rates, changes in the Company’s common share price, and changes in probability assumptions with respect to the likelihood of achieving specified operational targets. The Company has classified all of the contingent stock consideration within accrued expenses and other current liabilities in the consolidated balance sheets as of December 31, 2023. See Note 11, “Commitments and Contingencies”, for more information on contingent stock consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Short-Term Debt - Yorkville</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company elected the fair value option to account for the financial instrument with Yorkville signed on September 15, 2022 (see Note 9). As of December 31, 2023, due to the short term nature of the debt, the fair value approximates the settlement amount which was fully paid on January 17, 2024. As of December 31, 2022, the estimate of the fair value was determined using a binomial lattice model. The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements of operations and comprehensive income (loss) under change in fair value of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive income (loss). The actual settlement of the short-term debt could differ from current estimates based on the timing of when and if Yorkville elects to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and movements in the Company’s common share price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zejhaxd5FGd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the Yorkville debt measured on a recurring basis using Level 3 inputs as of the initial valuation date of September 15, 2022 and as of December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_ztWs2hkkNSbk" style="display: none">Schedule of Reconciliation of Yorkville Debt Measured on a Measured Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%">Balance as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zA2AWsfZFF1a" style="width: 16%; text-align: right" title="Beginning balance">37,603</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of debt into common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zuvwAIx7VdIg" style="text-align: right" title="Conversion of debt into common shares">(4,599</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Principal repayments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zRLCXQa0VrY9" style="text-align: right" title="Principal repayments">(16,811</td><td style="text-align: left">)</td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of convertible promissory note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z6KOxhppQfs6" style="text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value adjustment through earnings</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zGN9mU3swwfh" style="text-align: right" title="Fair value adjustment through earnings">354</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value adjustment through accumulated other comprehensive income</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zQVguPjMEAFf" style="text-align: right" title="Fair value adjustment through accumulated other comprehensive income">(146</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Fair value adjustment through interest accrual</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zCd5GEuPQzR5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment through interest accrual">822</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zHvTLbelU973" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">17,223</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zY0SBks5SyJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Yorkville debt was settled on January 17, 2024, the loan was paid in full. Due to the short term nature, the fair value of the debt as of December 31, 2023 was deemed to be settlement amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_896_ecustom--ScheduleofyorkvilleShortTermDebtValuationModelTableTextBlock_zCrVdBTiKwWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Yorkville short-term debt valuation model as of December 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_zlUEKGWcvmAe" style="display: none">Schedule of Yorkville Short-term Debt Valuation Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ValuationInputForShortTermDebtSharePrice_iI_pid_c20221231_zYoHjuybpks6" style="width: 16%; text-align: right" title="Common share price">12.90</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit spread</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ValuationInputForShortTermDebtCreditSpread_iI_pid_uPure_c20221231_zZE2J2VEzui9" style="text-align: right" title="Credit spread">13.71</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20221231_zB1jfYBvsUv8" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--ValuationInputForShortTermDebtTerm_dtY_c20220101__20221231_zzgELkHMdqj4" title="Term (years)">0.71</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zebob3WUJM79" style="text-align: right" title="Risk-free interest rate">4.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zDFOo7GaDR6f" style="text-align: right" title="Volatility">45.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ValuationInputForShortTermDebtDiscountYield_iI_pid_dp_uPure_c20221231_zLMqVQF8PvJc" style="text-align: right" title="Discount yield">18.46</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A9_zV8AoBJcXJG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zrFSAAm7jTNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8B9_z5hupg2gTAB1" style="display: none">Schedule of Financial Assets and Liabilities Measures at Fair Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zB0NIy7vkBp9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze2uItH9obci" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSUeWyhjpQn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20231231_zADzZSli4NFd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zjv04P4oYJ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_i01I_pn3n3_zb5Y8WpKAAzg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Cash equivalents - money market funds</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ConvertibleNoteReceivable_i01I_pn3n3_zd1XzlNShQRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Convertible note receivable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zTkFnLeBK9Jh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zkHBiSXoypUk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zWJwjfmi7zL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Acquisition-related contingent consideration obligations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zU1Cy24aG9Wd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zl44AXAF9Ln5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Short-term debt - Yorkville</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zIovKamIgAEb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Warrant liability - July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zq5YPfe8vzNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Warrant liability - April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zeuuKikTxyBh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zqzYoIR18Asf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zLotBTLrdii8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zl504nEszAYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,640</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6jfMCtLGkm" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfeAibsZ6Pcg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0EimSm4D1lg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20221231_znW4BdpAsvZ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zkhPTr3UTFVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_i01I_pn3n3_zhijPOveeF1i" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents – money market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,174</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,174</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ConvertibleNoteReceivable_i01I_pn3n3_zMP17PWY0OFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Convertible note receivable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,514</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,514</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zbw5u4KbLsF4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,514</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zXrzcAECCTX4" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zJKQsshLVwRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Acquisition-related contingent consideration obligations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">105,945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">105,945</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zqlA9eSsl19f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zQuc169MRFfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Short-term debt - Yorkville</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,603</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,603</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zctqZEQpbGI9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,402</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zZ079aTzjmgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,190</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,190</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zw3sIS1iTF2h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,006</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,006</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zkqEI7bPMdQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146,326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">147,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2072000 2072000 2072000 2072000 1606000 1606000 27000 27000 17223000 17223000 1529000 1529000 1487000 1487000 708000 708000 60000 60000 575000 575000 575000 22640000 23215000 12174000 12174000 2514000 2514000 12174000 2514000 14688000 105945000 105945000 186000 186000 37603000 37603000 1402000 1402000 1190000 1190000 1006000 1006000 1006000 146326000 147332000 0 0 0 0 0 0 0 0 <p id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zGi1VNuXzkZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_8BD_zj2gEFH6aHW7" style="display: none">Schedule of Reconciliation of Contingent Consideration Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of)<br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ContingentConsiderationObligation_iS_pn3n3_c20230101__20231231_z7LLQLRBYto8" style="width: 10%; text-align: right" title="Beginning balance">          105,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20230101__20231231_zfxUbthaJkVl" style="width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1148">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_pn3n3_c20230101__20231231_zuWxts7bILe9" style="width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1150">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20230101__20231231_z8EsuIblUsxc" style="width: 10%; text-align: right" title="Fair value adjustments">(104,339</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ContingentConsiderationObligation_iE_pn3n3_c20230101__20231231_z5193L0jTGOh" style="width: 10%; text-align: right" title="Ending balance">1,606</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of)<br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentConsiderationObligation_iS_pn3n3_c20220101__20221231_z25s7ioV5Adj" style="width: 10%; text-align: right" title="Beginning balance">           232,222</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20220101__20221231_zQBFDXdzg8ld" style="width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1158">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_pn3n3_c20220101__20221231_zmlg7Y1Am3kg" style="width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1160">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20220101__20221231_zuzcKmcd2PNb" style="width: 10%; text-align: right" title="Fair value adjustments">(126,277</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentConsiderationObligation_iE_pn3n3_c20220101__20221231_z6THayHe38g9" style="width: 10%; text-align: right" title="Ending balance">           105,945</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 105945000 -104339000 1606000 232222000 -126277000 105945000 4359000 3598000 <p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zqWSQ8KXNRd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a roll-forward of the aggregate fair values of the Company’s warrant liabilities for which fair values are determined using Level 3 inputs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B1_zcx8e3GOpQN2" style="display: none">Schedule of Roll-forward of the Aggregate Fair Values of Company’s Warrant Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueNetAssetsLiability_iS_pn3n3_c20220101__20221231_zgxYmsuaeAUe" style="width: 16%; text-align: right" title="Fair value, Beginning Balance">25,962</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">May 2022 PIPE warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--PrivateInvestmentInPublicEquityWarrantIssuance_pn3n3_c20220101__20221231_zXy1bPK1LpIg" style="text-align: right" title="May 2022 PIPE warrant issuance">19,745</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zdQ7ww5wwHG2" style="text-align: right" title="April 2023 Registered Direct warrant issuance">4,280</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">July 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zlxEnWFcOJGc" style="text-align: right" title="July 2023 Registered Direct warrant issuance">2,645</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Gain recognized in earnings from change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20220101__20221231_zdnmAYa9qPo9" style="border-bottom: Black 1pt solid; text-align: right" title="Gain recognized in earnings from change in fair value">(42,109</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueNetAssetsLiability_iE_pn3n3_c20220101__20221231_zQOepr9xdPx8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">3,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0pt 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueNetAssetLiability_iS_pn3n3_c20230101__20231231_zEX1Jv9bLgBa" style="width: 16%; text-align: right" title="Fair value, Beginning Balance">3,598</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zdLr73xC2ZZ4" style="text-align: right" title="April 2023 Registered Direct warrant issuance">4,280</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">July 2023 Registered Direct warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zhcBTS5h3BG4" style="text-align: right" title="July 2023 Registered Direct warrant issuance">2,645</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Gain recognized in earnings from change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20230101__20231231_zgMFzR3VS9kc" style="border-bottom: Black 1pt solid; text-align: right" title="Gain recognized in earnings from change in fair value">(6,164</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iE_pn3n3_c20230101__20231231_zzgM9WEQNpZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">4,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25962000 19745000 4280000 2645000 -42109000 3598000 3598000 4280000 2645000 -6164000 4359000 <p id="xdx_894_ecustom--ScheduleOfFairValueOfTheLiabilityTableTextBlock_zWm3bam0IWAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Liability Warrants are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zcDnsI900oxf" style="display: none">Schedule of Fair Value of Liability Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zQq0Z8KtVNfl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20220101__20221231_zp63g0NEd78a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zD0LDd3xjtka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Public Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">575</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,006</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zHaKiMMQAZ14" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,190</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKEnEADPJ3Xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,016</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FairValueOfWarrants_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z01F2qyt7HCf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">May 2022 PIPE Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">708</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--FairValueOfWarrants_pn3n3_zD9MT9Bbx1pe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 575000 1006000 60000 1190000 3016000 708000 1402000 4359000 3598000 <p id="xdx_89A_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zbCY3t3nZBCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Sponsor Warrants are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B4_zrReOVAEbMfi" style="display: none">Schedule of Sponsor Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zPa17hPniYgj" style="width: 16%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zYDl3SDmrUQh" style="width: 16%; text-align: right" title="Common share price">12.90</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zvqaCk7P5yld" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_ziAHxzXpqKsg" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1YQuSBZjdTj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zHxw9l6aAmAd" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zpjhcsu69N2g" title="Term (years)">2.5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zyhN3NSbt4me" title="Term (years)">3.5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zAK3XJgBbWDb" style="text-align: right" title="Dividend yield">4.12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zAffkeSU5Sf" style="text-align: right" title="Dividend yield">4.16</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zlaXTCzIyXa3" style="text-align: right" title="Volatility">100.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zamkBUvjFAYg" style="text-align: right" title="Volatility">75.0</td><td style="text-align: left">%</td></tr> </table> 2.47 12.90 115.00 115.00 0 0 P2Y6M P3Y6M 4.12 4.16 100.7 75.0 <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z5DQQxAPOp22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BA_zMROgVDJCdH6" style="display: none">Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zLsq9m5BnA83" style="width: 16%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zIoV6QwiaRyk" style="width: 16%; text-align: right" title="Common share price">12.90</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zOPpYR08eoif" title="Exercise price">3.50</span> - <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zhFvjwtFo1u5" title="Exercise price">7.50</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zCEjcqDbNeKh" style="text-align: right" title="Exercise price">82.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z2FXzNjfnsZh" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgaqerJWXCoj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zamwSbitgWf5" title="Term (years)">5.03</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_z1vgFIZvdU34" title="Term (years)">5.34</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zP13qgnPyKP7" title="Term (years)">4.4</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z5lthOi3L3xd" style="text-align: right" title="Dividend yield">4.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztc4JpvnwbPe" style="text-align: right" title="Dividend yield">3.99</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zVvQVVYlQRdi" style="text-align: right" title="Volatility">97.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zjdugoqX8RJg" style="text-align: right" title="Volatility">81.2</td><td style="text-align: left">%</td></tr> </table> 2.47 12.90 3.50 7.50 82.5 0 0 P5Y10D P5Y4M2D P4Y4M24D 4.60 3.99 97.0 81.2 <p id="xdx_89E_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_zk1jUsBnNrE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the convertible note valuation model are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zZv5T36vSRLb" style="display: none">Schedule of Convertible Note Valuation Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid"><p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b> </span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold"><p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">December 31,</p> <p style="margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2022</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Face value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_zmMFjqWyJVW2" style="width: 16%; text-align: right" title="Face value">4,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20221231_zBnNn1cKdbIj" style="width: 16%; text-align: right" title="Face value">4,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Coupon rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--PercentageOfCouponRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zIKZWDuWCO45" title="Coupon rate">12</span>% - <span id="xdx_901_ecustom--PercentageOfCouponRate_pid_dp_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zRoCdhVyQUV6" title="Coupon rate">17</span>% </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--PercentageOfCouponRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z0fMMQdUw0p8" title="Coupon rate">12</span>% - <span id="xdx_90A_ecustom--PercentageOfCouponRate_pid_dp_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zj1byholqCud" title="Coupon rate">17</span>%  </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ValuationModelThatRelateToSanuwaveCommonStock_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zDq8WCQhlGq4" style="text-align: right" title="Stock price">0.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--ValuationModelThatRelateToSanuwaveCommonStock_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zSiyDEcFjSmk" style="text-align: right" title="Stock price">0.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zcS0zpfRJghg" title="Term (years)">0.51</span>-<span id="xdx_905_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zoku1YpBLdb8" title="Term (years)">2.45</span> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zEhnY1G2u57b" title="Term (years)">1.01</span> - <span id="xdx_90B_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zzdkVhRWSz9j" title="Term (years)">3.45</span>  </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zpOO6hLUUcfk" title="Risk-free interest rate">5.47</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_c20220101__20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zmklRoJC9C3i" title="Risk-free interest rate">4.73</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a  </span></td><td style="text-align: left"> </td></tr> </table> 4000000 4000000 0.12 0.17 0.12 0.17 0.2 0.2 P0Y6M3D P2Y5M12D P1Y3D P3Y5M12D 0.0547 0.0473 2024-02-28 2024-06-03 2175000 100000 2075000 <p id="xdx_897_ecustom--FairValueAssetsOfContingentStockConsiderationMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zBGhebhNa8B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs as of December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zU5J7lvFCYTg" style="display: none">Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 30%; text-align: left">Contingent stock consideration</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentStockConsiderationObligation_iS_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zDuHd5Aefjx4" style="width: 10%; text-align: right" title="Beginning balance">186</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zD7j66t3GgXf" style="width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1311">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_z5N9y5NJS9w4" style="width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1313">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ChangeInFairValueOfContingentStockConsideration_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zOMJ4ajWBtof" style="width: 10%; text-align: right" title="Fair value adjustments">(159</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ContingentStockConsiderationObligation_iE_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zX9pbuOyXFRg" style="width: 10%; text-align: right" title="Ending balance">27</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> 186000 -159000 27000 <p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zejhaxd5FGd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the Yorkville debt measured on a recurring basis using Level 3 inputs as of the initial valuation date of September 15, 2022 and as of December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_ztWs2hkkNSbk" style="display: none">Schedule of Reconciliation of Yorkville Debt Measured on a Measured Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%">Balance as of December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zA2AWsfZFF1a" style="width: 16%; text-align: right" title="Beginning balance">37,603</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of debt into common shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zuvwAIx7VdIg" style="text-align: right" title="Conversion of debt into common shares">(4,599</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Principal repayments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zRLCXQa0VrY9" style="text-align: right" title="Principal repayments">(16,811</td><td style="text-align: left">)</td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance of convertible promissory note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z6KOxhppQfs6" style="text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value adjustment through earnings</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zGN9mU3swwfh" style="text-align: right" title="Fair value adjustment through earnings">354</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value adjustment through accumulated other comprehensive income</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zQVguPjMEAFf" style="text-align: right" title="Fair value adjustment through accumulated other comprehensive income">(146</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Fair value adjustment through interest accrual</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zCd5GEuPQzR5" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment through interest accrual">822</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zHvTLbelU973" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">17,223</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 37603000 -4599000 -16811000 3150000 354000 -146000 822000 17223000 <p id="xdx_896_ecustom--ScheduleofyorkvilleShortTermDebtValuationModelTableTextBlock_zCrVdBTiKwWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Yorkville short-term debt valuation model as of December 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_zlUEKGWcvmAe" style="display: none">Schedule of Yorkville Short-term Debt Valuation Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ValuationInputForShortTermDebtSharePrice_iI_pid_c20221231_zYoHjuybpks6" style="width: 16%; text-align: right" title="Common share price">12.90</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit spread</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ValuationInputForShortTermDebtCreditSpread_iI_pid_uPure_c20221231_zZE2J2VEzui9" style="text-align: right" title="Credit spread">13.71</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20221231_zB1jfYBvsUv8" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--ValuationInputForShortTermDebtTerm_dtY_c20220101__20221231_zzgELkHMdqj4" title="Term (years)">0.71</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zebob3WUJM79" style="text-align: right" title="Risk-free interest rate">4.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zDFOo7GaDR6f" style="text-align: right" title="Volatility">45.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Discount yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ValuationInputForShortTermDebtDiscountYield_iI_pid_dp_uPure_c20221231_zLMqVQF8PvJc" style="text-align: right" title="Discount yield">18.46</td><td style="text-align: left">%</td></tr> </table> 12.90 13.71 0 P0Y8M15D 0.0475 0.450 0.1846 <p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zvuBspaT41za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_82F_zGpDyMT7YqF8">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zlJnWuEWlsX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s major classes of inventories were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B6_zzKVVOMjh8s7" style="display: none">Schedule of Major Classes of Inventories</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231_z81dipJEIM43" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zfwHGNs0jyL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zJzxG3SLnv87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,081</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,719</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zUn2aRve3Mhi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zp3cjGCKlZrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,922</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,256</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zVkClcVD4kz6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Inventory, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,699</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,356</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_zISZDFimCLZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: inventory reserves</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,289</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,099</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zqytCzPHvIL3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Inventory, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,257</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance Sheet Classification:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_z1cDiHBlrT3j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,308</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zGjNBNPcujOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Inventory, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,657</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,949</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zFH5RKpWpTo9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,257</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zAHIymZDsXEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net of current portion includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized a $<span id="xdx_902_ecustom--InventoryImpairmentCharge_iI_pn3n3_c20231231_z2JptjW0bvW2" title="Inventory impairment charge">5,384</span> inventory impairment charge during the year ended December 31, 2023 in the consolidated statements of operations due to lower of cost or market adjustments of $<span id="xdx_905_ecustom--InventoryImpairmentCharge_iI_pn3n3_c20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--DueToLowerOfCostOrMarketAdjustmentsForWorkInProgressGoodsMember_zsAU6Lq88sy" title="Inventory impairment charge">2,129</span> for finished goods and $<span id="xdx_908_ecustom--InventoryImpairmentCharge_iI_pn3n3_c20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--DueToLowerOfCostOrMarketAdjustmentsForFinishedGoodsMember_z6R0aFKcUwec" title="Inventory impairment charge">3,255</span> for work in progress. <span id="xdx_90A_ecustom--InventoryImpairmentCharge_iI_pn3n3_do_c20221231_zCAWZAnc0yKa" title="Inventory impairment charge">No</span> inventory impairment was recognized during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfActivityInInventoryReservesTableTextBlock_z7pKwOAKAUc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A schedule of the activity in the inventory reserves is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zolaU8T8cfNd" style="display: none">Schedule of Inventory Reserves</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20220101__20221231_zw1gD6IVui5k" style="width: 16%; text-align: right" title="Beginning balance">48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Additions for obsolete inventory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--InventoryReserveForObsolescenceAdditions_pn3n3_c20220101__20221231_z9n1SsILDdF2" style="border-bottom: Black 1pt solid; text-align: right" title="Additions for obsolete inventory">1,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20230101__20231231_z8AQqplPmr1h" style="text-align: right" title="Beginning balance">1,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions for obsolete inventory</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--InventoryReserveForObsolescenceAdditions_pn3n3_c20230101__20231231_zfM5y5riEiYi" style="text-align: right" title="Additions for obsolete inventory">7,627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Write-offs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_z9gCxk10yQj5" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs">(6,437</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--InventoryReserveCurrentAndNoncurrent_iE_pn3n3_c20230101__20231231_zpsNTYmMd5El" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">2,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zFJNTRH8dIyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zlJnWuEWlsX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s major classes of inventories were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B6_zzKVVOMjh8s7" style="display: none">Schedule of Major Classes of Inventories</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231_z81dipJEIM43" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zfwHGNs0jyL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zJzxG3SLnv87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,081</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,719</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zUn2aRve3Mhi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zp3cjGCKlZrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,922</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,256</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zVkClcVD4kz6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Inventory, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,699</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,356</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_zISZDFimCLZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: inventory reserves</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,289</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,099</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zqytCzPHvIL3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Inventory, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,257</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance Sheet Classification:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_z1cDiHBlrT3j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,308</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zGjNBNPcujOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Inventory, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,657</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,949</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zFH5RKpWpTo9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,257</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3081000 7719000 10696000 12381000 10922000 9256000 24699000 29356000 2289000 1099000 22410000 28257000 5753000 5308000 16657000 22949000 22410000 28257000 5384000 2129000 3255000 0 <p id="xdx_891_ecustom--ScheduleOfActivityInInventoryReservesTableTextBlock_z7pKwOAKAUc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A schedule of the activity in the inventory reserves is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zolaU8T8cfNd" style="display: none">Schedule of Inventory Reserves</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20220101__20221231_zw1gD6IVui5k" style="width: 16%; text-align: right" title="Beginning balance">48</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Additions for obsolete inventory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--InventoryReserveForObsolescenceAdditions_pn3n3_c20220101__20221231_z9n1SsILDdF2" style="border-bottom: Black 1pt solid; text-align: right" title="Additions for obsolete inventory">1,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20230101__20231231_z8AQqplPmr1h" style="text-align: right" title="Beginning balance">1,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions for obsolete inventory</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--InventoryReserveForObsolescenceAdditions_pn3n3_c20230101__20231231_zfM5y5riEiYi" style="text-align: right" title="Additions for obsolete inventory">7,627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Write-offs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_z9gCxk10yQj5" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs">(6,437</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--InventoryReserveCurrentAndNoncurrent_iE_pn3n3_c20230101__20231231_zpsNTYmMd5El" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">2,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 48000 1051000 1099000 7627000 -6437000 2289000 <p id="xdx_80C_ecustom--PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_zan1b01hcb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_820_zU4GjQwwiOVf">Prepaid Expenses and Other Current Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_898_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zDQaRKuPPnUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BD_zFv0BcevbPqj" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zKP00YbNLJUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zrdPZh3lCK7f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--PrepaidClinicalExpense_iI_pn3n3_maPEAOAzmHw_zpj6VGdGMs5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid clinical expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">688</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzmHw_zzPFR8JEMIgc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">678</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzmHw_zvjBHpDXx3Jj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">329</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,049</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzmHw_z9EAXA8ya1Nb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,262</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zwrrFOcteMsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_898_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zDQaRKuPPnUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BD_zFv0BcevbPqj" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zKP00YbNLJUl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zrdPZh3lCK7f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--PrepaidClinicalExpense_iI_pn3n3_maPEAOAzmHw_zpj6VGdGMs5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid clinical expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">688</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzmHw_zzPFR8JEMIgc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">678</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzmHw_zvjBHpDXx3Jj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">329</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,049</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzmHw_z9EAXA8ya1Nb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,262</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 688000 5836000 678000 377000 329000 1049000 1695000 7262000 <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zjeISy77QPB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. </b></span><b><span id="xdx_825_z1iwCS8venvc">Property and Equipment, Net</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9Fx6JWegJDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zWuRtq7TDfo3" style="display: none">Schedule of Property and Equipment, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zi2CVJjvLMDd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zymxkdaU8888" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zcZ1P0bUnZki" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">73,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_zs1175bv1G96" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory and production equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,433</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_zomVRh3iUefg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery, equipment and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,781</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,780</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zoibm5h8jvye" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,660</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_zcd7LmcveVt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,986</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_z6ECDykH4Gw7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,278</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(20,331</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_zfT71MSZtqjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">67,828</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">75,655</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zo8wOQZM1wbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20230101__20231231_zXodPIRp78ze" title="Depreciation expense">7,131</span> and $<span id="xdx_906_eus-gaap--Depreciation_pn3n3_c20220101__20221231_zkvSjPfrGvMc" title="Depreciation expense">7,243</span> for the years ended December 31, 2023 and 2022 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z9Fx6JWegJDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zWuRtq7TDfo3" style="display: none">Schedule of Property and Equipment, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zi2CVJjvLMDd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_zymxkdaU8888" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zcZ1P0bUnZki" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">73,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_zs1175bv1G96" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory and production equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,433</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_zomVRh3iUefg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery, equipment and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,781</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,780</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zoibm5h8jvye" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,660</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_zcd7LmcveVt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,986</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_z6ECDykH4Gw7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,278</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(20,331</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_zfT71MSZtqjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">67,828</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">75,655</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 73211000 70113000 14093000 14433000 7781000 7780000 21000 3660000 95106000 95986000 27278000 20331000 67828000 75655000 7131000 7243000 <p id="xdx_80B_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zP80cIohbx7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. </b></span><b><span id="xdx_827_z0rSWPnmXaY6">Goodwill and Intangible Assets, Net</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company performs its annual goodwill impairment test in the fourth quarter of every year for all of our reporting units, and more frequently if events or circumstances indicate a potential impairment. During the quarter ended December 31, 2023, management identified various qualitative and quantitative factors which collectively indicated a triggering event had occurred and performed an impairment test. Based on the results of the impairment analysis, the Degenerative Disease reporting unit had a carrying amount that exceeded its fair value due to lower forecasted sales and growth and it was determined that all of the goodwill for the Degenerative Disease reporting unit was impaired as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company tests its goodwill for impairment on an annual basis in the fourth quarter of each year for all of its reporting units, or more frequently if events or circumstances indicate a potential impairment. The Company manages its operations through an evaluation of <span id="xdx_90E_eus-gaap--NumberOfReportingUnits_dc_uInteger_c20230101__20231231_z9AbcPbGVZjk" title="Number of reporting units">three</span> different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During annual impairment tests and for any period in which the Company identifies an impairment trigger, the Company’s methodology includes internally generated separate cash flow projections for each reporting unit based on the different drivers that affect each reporting unit. The Company compares the fair values of each of its reporting units to their respective carrying amounts. If the carrying value of the reporting unit exceeds its estimated fair value, a goodwill impairment charge is recorded for the difference, with the impairment loss limited to the total amount of goodwill allocated to that reporting unit. The fair values of each of the Company’s reporting units were derived using the income approach, specifically the discounted cash flow method. The use of a discounted cash flow analysis requires significant judgment to estimate the future cash flows and the period of time over which those cash flows will be realized, as well as to determine the appropriate discount rate. The discounted cash flow model reflects management’s assumptions regarding revenue growth rates, risk-adjusted discount rates, terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of the Company’s reporting units. As part of the goodwill impairment test, the Company also considers its market capitalization in assessing the reasonableness of the combined fair values estimated for its reporting units. Substantial changes in the cash flows assumptions of the different reporting units may lead to a future impairment or may alter the implied distribution of value between the different reporting units. A material decline in the Company’s stock price may affect the imputed discount rate and the distribution of value between the reporting units, which may also lead to a future impairment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, the Company recognized $<span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20231231_zctDXwplivx6" title="Goodwill impairment">112,347</span> goodwill impairment charges.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the first quarter 2023, as a result of a sustained decrease in its stock price and market capitalization, and its decision to cease recruitment in its GBM and HER2+ gastric trials, the Company tested for impairment due to these triggering events. Based on the results of the impairment analysis, the carrying value exceeded the fair value on the Cell Therapy reporting unit. The Company recognized a $<span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20230331_zcLXXn6Cd1el" title="Goodwill impairment">29,633</span> goodwill impairment charge during the first quarter of 2023 in its condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the second quarter of 2023, the Company’s stock price and market capitalization continued to decline, and the Company also determined to cease active recruitment in its AML trial and halted all NK programs. The AML trial was the Company’s most advanced clinical program with a relatively large addressable patient population given the high unmet medical need in relapsed and refractory AML. After the Company ceased recruitment, it removed all associated cash flows relating to that program including all other NK related programs as well. As a result of these triggering events, the Company fully impaired the IPR&amp;D assets associated with these product candidates, and performed a goodwill impairment test on its Cell Therapy reporting unit. At June 30, 2023, the estimated fair value of the Cell Therapy reporting unit was determined to be at breakeven compared to the carrying value using a discount rate commensurate with the risks associated with the cash flows for preclinical product candidates. The Company also performed a reconciliation of the aggregate fair value of each reporting unit to the market capitalization of the Company. The analysis showed the fair value of the reporting units approximated our market capitalization, indicating an insignificant control premium. Based on the results of the impairment analysis, the Company did <span id="xdx_90D_eus-gaap--GoodwillImpairmentLoss_do_c20230401__20230630_zvb04W1V7Aka" title="Goodwill impairment">no</span>t recognize a goodwill impairment charge during the second quarter of 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the third quarter of 2023, the Company’s stock price and market capitalization continued to further decline. The Company also elected to terminate development of CYCART-19 for B-cell malignancies during the quarter, as well as paused development in exosomes. Therefore, the Company tested for impairment due to these triggering events. Based on the results of the impairment analysis, the carrying value exceeded the fair value on the Cell Therapy reporting unit. The Company recognized a goodwill impairment charge for the remaining goodwill balance on the Cell Therapy reporting unit of $<span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zMA6avZS39Nj" title="Goodwill impairment">82,714</span> during the three months ended September 30, 2023 in its condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, the estimated fair value of the Biobanking reporting unit was substantially in excess of its book value. The relative stability of the expected cash flows of the Biobanking reporting unit makes an impairment of goodwill in the future less likely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended December 31, 2022, management identified various qualitative and quantitative factors which collectively indicated a triggering event had occurred and performed an impairment test. Based on the results of the impairment analysis, the Degenerative Disease reporting unit had a carrying amount that exceeded its fair value due to lower forecasted sales and growth and it was determined that all of the goodwill, $<span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20221001__20221231_zilR4D9lfN8k" title="Goodwill impairment">3,610</span>, for the Degenerative Disease reporting unit was impaired as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"> </p> <p id="xdx_899_eus-gaap--ScheduleOfGoodwillTextBlock_zgORUzzzd071" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of goodwill assigned to the Company’s reporting units are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zKZyG0TTGk55" style="display: none">Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Biobanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zptKCsuqP7r2" style="width: 11%; text-align: right" title="Balance at beginning of year">112,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_z7Sp0300O0B" style="width: 11%; text-align: right" title="Balance at beginning of year">3,610</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zZ7WsFq3FSM9" style="width: 11%; text-align: right" title="Balance at beginning of year">7,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231_zarXI9vnIk6j" style="width: 11%; text-align: right" title="Balance at beginning of year">123,304</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--GoodwillImpairment_iN_di_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zuJ0qTEOLQY8" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1475">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--GoodwillImpairment_iN_pn3n3_di_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zFdotWhj3zbi" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(3,610</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--GoodwillImpairment_iN_di_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zb7pguHsDAz1" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment"><span style="-sec-ix-hidden: xdx2ixbrl1479">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--GoodwillImpairment_iN_pn3n3_di_c20220101__20221231_z7zSHcUiF8da" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(3,610</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zzYauuaYMTCe" style="text-align: right" title="Balance at beginning of year">112,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iS_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zQ9nXSuYDSza" style="text-align: right" title="Balance at beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1485">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zOyfgXDpOtn4" style="text-align: right" title="Balance at beginning of year">7,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231_zqZ6TcihzG87" style="text-align: right" title="Balance at beginning of year">119,694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--GoodwillImpairment_iN_pn3n3_di_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_ztmRGBVAhuSl" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment">(112,347</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--GoodwillImpairment_iN_di_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zS2N3lpwJFG6" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment"><span style="-sec-ix-hidden: xdx2ixbrl1493">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--GoodwillImpairment_iN_di_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_z7ACqR1olTbe" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment"><span style="-sec-ix-hidden: xdx2ixbrl1495">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--GoodwillImpairment_iN_pn3n3_di_c20230101__20231231_zarzRD5cnqvi" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(112,347</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iE_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zsTPw3N6pMej" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1499">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iE_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_z22CoUy5FK9l" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1501">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iE_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zfeNp1PeFVEg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year">7,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iE_pn3n3_c20230101__20231231_zABetfJj9cfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year">7,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z8k5OPKYsJ84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible Assets, Net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zdy3BGm0poOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <i> </i><span id="xdx_8BD_zilcUkiQYYQ3" style="display: none">Schedule of Intangible Assets, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful<br/> Lives</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Developed technology</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zmDRVQn9Lb6c" style="width: 15%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgOiUjcMzm1i" style="width: 15%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zL9p1ppYFymd" title="Estimated useful lives"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zVPok3x1lwm9" title="Estimated useful lives">11</span></span> – <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zeFrCJuurXdf" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zOx0dp1u0gL4" title="Estimated useful lives">16</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z701niB1wXGg" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMnVd6ZB8Z78" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpv0tez06JO4" title="Estimated useful lives"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ze7uxqyy5lga" title="Estimated useful lives">10</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z7DGkWnhXlz" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zMZK9jGnfJIe" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z6eJPo5rVZfd" title="Estimated useful lives"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zcLsDuYNTMR7" title="Estimated useful lives">10</span></span> – <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zs3BSOBWQoE3" title="Estimated useful lives"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z6LEYCWoNpd" title="Estimated useful lives">13</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zQlkIHhd2M9a" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zB8y0XGk4uNc" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zjMMcfB21yZg" title="Estimated useful lives"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zRbZ1p4SrsIf" title="Estimated useful lives">6</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.75pt"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zLj9COeSkebd" style="text-align: right" title="Amortizable intangible assets">23,993</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zRbpu6r80Ape" style="text-align: right" title="Amortizable intangible assets">23,993</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Developed technology</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z8qN3pqTjSok" style="text-align: right" title="Less: Accumulated amortization">(7,722</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zTrkF932sEx2" style="text-align: right" title="Less: Accumulated amortization">(6,549</td><td style="text-align: left">)</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSshh3thwnwj" style="text-align: right" title="Less: Accumulated amortization">(1,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOS41OvLjRWj" style="text-align: right" title="Less: Accumulated amortization">(1,435</td><td style="text-align: left">)</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zj6Sf0dYMKZ1" style="text-align: right" title="Less: Accumulated amortization">(330</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zV83Oi4zcc9b" style="text-align: right" title="Less: Accumulated amortization">(275</td><td style="text-align: left">)</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_ztVPPewFXovh" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(3,940</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zrxUCGbHw2T1" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(3,240</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 0.75pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_ziyO1y1adAnf" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(13,692</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zkTEywbjK1eb" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(11,499</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zKsvV4iqQYZ3" style="text-align: right" title="Amortizable intangible assets, net">10,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zfzgSrGg8Uv3" style="text-align: right" title="Amortizable intangible assets, net">12,494</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-amortized intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Acquired IPR&amp;D product rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--AcquiredProductRights_iI_pn3n3_c20231231_zbob2YkPiAMd" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--AcquiredProductRights_iI_pn3n3_c20221231_zokdhq1ZHraf" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">108,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_904_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zupBuTkL5IX" title="Estimated useful lives"><span id="xdx_900_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20221231_zckzfkpdVN0d" title="Estimated useful lives">indefinite</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zUmLlpmRJzt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">11,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_z1oe2zmIE2C9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">120,994</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8A2_zQvkTcGGy8vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense for intangible assets was $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_z5JPpjaIuKSd" title="Amortization of acquired intangible assets">2,193</span> and $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20220101__20221231_zuXn1TBA7jig" title="Amortization of acquired intangible assets">2,193</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_znyzxQDacJFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December 31, 2023 is estimated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_8BC_zrvmufAjRMmk" style="display: none">Schedule of Aggregate Amortization Expense Related to Intangible Assets</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_498_20231231_zsWyN80ucis4" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_z4yZa7lgQNtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,753</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_zAWqBpsG5Vg6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,493</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_zi4oIPJ1WdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,356</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_zij58goaFNeg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,258</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_zlXZ2EhNFJN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,208</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zuKOrEnZDJtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3 112347000 29633000 0 82714000 3610000 <p id="xdx_899_eus-gaap--ScheduleOfGoodwillTextBlock_zgORUzzzd071" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of goodwill assigned to the Company’s reporting units are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zKZyG0TTGk55" style="display: none">Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Biobanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zptKCsuqP7r2" style="width: 11%; text-align: right" title="Balance at beginning of year">112,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_z7Sp0300O0B" style="width: 11%; text-align: right" title="Balance at beginning of year">3,610</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zZ7WsFq3FSM9" style="width: 11%; text-align: right" title="Balance at beginning of year">7,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iS_pn3n3_c20220101__20221231_zarXI9vnIk6j" style="width: 11%; text-align: right" title="Balance at beginning of year">123,304</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--GoodwillImpairment_iN_di_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zuJ0qTEOLQY8" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1475">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--GoodwillImpairment_iN_pn3n3_di_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zFdotWhj3zbi" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(3,610</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--GoodwillImpairment_iN_di_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zb7pguHsDAz1" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment"><span style="-sec-ix-hidden: xdx2ixbrl1479">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--GoodwillImpairment_iN_pn3n3_di_c20220101__20221231_z7zSHcUiF8da" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(3,610</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zzYauuaYMTCe" style="text-align: right" title="Balance at beginning of year">112,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iS_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zQ9nXSuYDSza" style="text-align: right" title="Balance at beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1485">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zOyfgXDpOtn4" style="text-align: right" title="Balance at beginning of year">7,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231_zqZ6TcihzG87" style="text-align: right" title="Balance at beginning of year">119,694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--GoodwillImpairment_iN_pn3n3_di_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_ztmRGBVAhuSl" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment">(112,347</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--GoodwillImpairment_iN_di_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zS2N3lpwJFG6" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment"><span style="-sec-ix-hidden: xdx2ixbrl1493">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--GoodwillImpairment_iN_di_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_z7ACqR1olTbe" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment"><span style="-sec-ix-hidden: xdx2ixbrl1495">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--GoodwillImpairment_iN_pn3n3_di_c20230101__20231231_zarzRD5cnqvi" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill impairment">(112,347</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iE_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zsTPw3N6pMej" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1499">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iE_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_z22CoUy5FK9l" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1501">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iE_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zfeNp1PeFVEg" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year">7,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iE_pn3n3_c20230101__20231231_zABetfJj9cfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at beginning of year">7,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 112347000 3610000 7347000 123304000 3610000 3610000 112347000 7347000 119694000 112347000 112347000 7347000 7347000 <p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zdy3BGm0poOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <i> </i><span id="xdx_8BD_zilcUkiQYYQ3" style="display: none">Schedule of Intangible Assets, Net</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful<br/> Lives</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Developed technology</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zmDRVQn9Lb6c" style="width: 15%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgOiUjcMzm1i" style="width: 15%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zL9p1ppYFymd" title="Estimated useful lives"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zVPok3x1lwm9" title="Estimated useful lives">11</span></span> – <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zeFrCJuurXdf" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zOx0dp1u0gL4" title="Estimated useful lives">16</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z701niB1wXGg" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMnVd6ZB8Z78" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpv0tez06JO4" title="Estimated useful lives"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ze7uxqyy5lga" title="Estimated useful lives">10</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z7DGkWnhXlz" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zMZK9jGnfJIe" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z6eJPo5rVZfd" title="Estimated useful lives"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zcLsDuYNTMR7" title="Estimated useful lives">10</span></span> – <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zs3BSOBWQoE3" title="Estimated useful lives"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z6LEYCWoNpd" title="Estimated useful lives">13</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zQlkIHhd2M9a" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zB8y0XGk4uNc" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zjMMcfB21yZg" title="Estimated useful lives"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zRbZ1p4SrsIf" title="Estimated useful lives">6</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.75pt"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zLj9COeSkebd" style="text-align: right" title="Amortizable intangible assets">23,993</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zRbpu6r80Ape" style="text-align: right" title="Amortizable intangible assets">23,993</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Developed technology</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z8qN3pqTjSok" style="text-align: right" title="Less: Accumulated amortization">(7,722</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zTrkF932sEx2" style="text-align: right" title="Less: Accumulated amortization">(6,549</td><td style="text-align: left">)</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSshh3thwnwj" style="text-align: right" title="Less: Accumulated amortization">(1,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOS41OvLjRWj" style="text-align: right" title="Less: Accumulated amortization">(1,435</td><td style="text-align: left">)</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zj6Sf0dYMKZ1" style="text-align: right" title="Less: Accumulated amortization">(330</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zV83Oi4zcc9b" style="text-align: right" title="Less: Accumulated amortization">(275</td><td style="text-align: left">)</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_ztVPPewFXovh" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(3,940</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zrxUCGbHw2T1" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(3,240</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 0.75pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_ziyO1y1adAnf" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(13,692</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zkTEywbjK1eb" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(11,499</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zKsvV4iqQYZ3" style="text-align: right" title="Amortizable intangible assets, net">10,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zfzgSrGg8Uv3" style="text-align: right" title="Amortizable intangible assets, net">12,494</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-amortized intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Acquired IPR&amp;D product rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--AcquiredProductRights_iI_pn3n3_c20231231_zbob2YkPiAMd" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--AcquiredProductRights_iI_pn3n3_c20221231_zokdhq1ZHraf" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">108,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_904_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zupBuTkL5IX" title="Estimated useful lives"><span id="xdx_900_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20221231_zckzfkpdVN0d" title="Estimated useful lives">indefinite</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zUmLlpmRJzt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">11,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_z1oe2zmIE2C9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">120,994</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td></tr> </table> 16810000 16810000 P11Y P11Y P16Y P16Y 2413000 2413000 P10Y P10Y 570000 570000 P10Y P10Y P13Y P13Y 4200000 4200000 P6Y P6Y 23993000 23993000 -7722000 -6549000 -1700000 -1435000 -330000 -275000 -3940000 -3240000 -13692000 -11499000 10301000 12494000 700000 108500000 indefinite indefinite 11001000 120994000 2193000 2193000 <p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_znyzxQDacJFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December 31, 2023 is estimated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_8BC_zrvmufAjRMmk" style="display: none">Schedule of Aggregate Amortization Expense Related to Intangible Assets</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_498_20231231_zsWyN80ucis4" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_z4yZa7lgQNtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,753</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_zAWqBpsG5Vg6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,493</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_zi4oIPJ1WdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,356</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_zij58goaFNeg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,258</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_zlXZ2EhNFJN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,208</td><td style="text-align: left"> </td></tr> </table> 1753000 1493000 1356000 1258000 1208000 <p id="xdx_803_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zKSexraRP2B9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_82C_zXhdH7jsxgx1">Accrued Expenses and Other Current Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zbEdrypN0HJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_z77Us7rST8oj" style="display: none">Schedule of Accrued Expenses and Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20231231_zhunTNTmPSg9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20221231_zSXO80IEmNwj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--AccruedClinicalTrialExpense_iI_pn3n3_maALCzZ4Y_zxUqFDVpH5qa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued clinical trial expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">189</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,659</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZ4Y_zi1eWCzwvYdk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">573</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">880</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_z0kdaoYCcI7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued wages, bonuses, commissions and vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,011</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,576</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccrualsForConstructionInProgress_iI_pn3n3_maALCzZ4Y_z88rpnPVuRVl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accruals for construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedComplianceFee_iI_pn3n3_maALCzZ4Y_z4DPUnXYH06k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued compliance fee</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,145</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1622">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_zwVZ5BShYsK1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,448</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,632</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZ4Y_z6kryhtyelZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,580</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,069</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zXFLk5MSWTog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zbEdrypN0HJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_z77Us7rST8oj" style="display: none">Schedule of Accrued Expenses and Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20231231_zhunTNTmPSg9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20221231_zSXO80IEmNwj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--AccruedClinicalTrialExpense_iI_pn3n3_maALCzZ4Y_zxUqFDVpH5qa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued clinical trial expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">189</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,659</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZ4Y_zi1eWCzwvYdk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">573</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">880</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_z0kdaoYCcI7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued wages, bonuses, commissions and vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,011</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,576</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccrualsForConstructionInProgress_iI_pn3n3_maALCzZ4Y_z88rpnPVuRVl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accruals for construction in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedComplianceFee_iI_pn3n3_maALCzZ4Y_z4DPUnXYH06k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued compliance fee</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,145</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1622">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_zwVZ5BShYsK1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,448</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,632</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZ4Y_z6kryhtyelZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,580</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,069</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 189000 2659000 573000 880000 3011000 2576000 214000 322000 1145000 2448000 2632000 7580000 9069000 <p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_z9NPU9y0PVOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. </b></span><b><span id="xdx_820_zppxp1cgHlBb">Debt</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Short-Term Debt - Yorkville</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2022, the Company entered into a Pre-Paid Advance Agreement (“PPA”) with Yorkville, pursuant to which the Company may request advances of up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zDCRRj4Hdqm" title="Maximum advance amount">40,000</span> in cash from Yorkville (or such greater amount that the parties may mutually agree) (each, a “Pre-Paid Advance”) over an <span id="xdx_90F_ecustom--PrePaidAdvancePeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zXbYqL7fgPd" title="Pre-paid advance period">18</span>-month period, with an aggregate limitation of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zEIvx89oVl1d" title="Line of credit aggregate limitation amount">150,000</span>. Pre-Paid Advances are issued at a <span id="xdx_906_ecustom--PrePaidAdvanceIssuedDiscountPercentage_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_ztEjYTw0AJ1c" title="Pre-paid advance issued discount percentage">2</span>% discount, bear interest at an annual rate equal to <span id="xdx_90B_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zYGoHmuvSypf" title="Annual interest rate">6</span>% (increased to <span id="xdx_902_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zLwUmmGZLobl" title="Line of credit increase in interest rate during period in event of default">15</span>% in the event of default as described in the PPA) and may be offset by the issuance of shares of common stock, at Yorkville’s option, at a price per share calculated pursuant to the PPA, which in no event will be less than $<span id="xdx_909_ecustom--IssuanceOfCommonStockMinimumOptionPricePerShare_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlUXeEtDzDd1" title="Issuance of common stock minimum option price per share">7.50</span> per share. The issuance of the shares under the PPA is subject to certain limitations, including that the aggregate number of shares of common stock issued pursuant to the PPA cannot exceed <span id="xdx_908_ecustom--MaximumPercentageOfCommonStockIssued_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zWt4ObOjOwIi" title="Maximum percentage of common stock issued">19.9</span>% of the Company’s outstanding stock as of September 15, 2022, as well as a beneficial ownership limitation of <span id="xdx_90B_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zkg7x7aKqMCi" title="Percentage of beneficial ownership limitation">4.99</span>%. Further, Yorkville agreed not to purchase any shares of common stock for 60 days following entry into the PPA, nor may Yorkville purchase more than $<span id="xdx_905_ecustom--MinimumNumberOfSharesOfCommonStockPurchase_pid_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zxJypAKsIXXg" title="Minimum number of shares of common stock purchase">6,000</span> of shares of common stock during a 30-day period, in each case at a price per share less than the Fixed Price, as defined in the PPA. In the event the daily volume weighted average price (“VWAP”) of the Class A common stock is below $<span id="xdx_907_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zmTbcRlBFCof" title="Minimum required daily volume weighted average price">7.50</span> (the “floor price”) for any five of seven consecutive trading days, the Company will pay Yorkville a monthly cash payment of $<span id="xdx_908_ecustom--RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zsEU9DYSgM3" title="Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days">6,000</span>, plus any accrued and unpaid interest along with a <span id="xdx_90A_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zr0AN199Aod6" title="Redemption premium percentage if volume weighted average price is less than $0.75">5.0</span>% redemption premium until such time as the daily VWAP for five consecutive trading days immediately prior to the due date of the next monthly payment is at least <span id="xdx_908_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zj4dMGlw3wbf" title="Redemption premium percentage if volume weighted average price more than $0.75">10</span>% greater than $<span id="xdx_908_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zYkTRhu1Vsta" title="Minimum required daily volume weighted average price">7.50</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the entry into the PPA, the Company received the initial Pre-Paid Advance of $<span id="xdx_902_ecustom--ProceedsFromLinesOfCreditGross_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_znR8CtIlmjk7" title="Proceeds from pre-paid advance gross">40,000</span> gross or $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z7HTOgKI9Nhe" title="Proceeds from pre-paid advance">39,200</span> net of discount. Each Pre-Paid Advance has a maturity of <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zqJltwzmocTf" title="Pre-paid advance maturity period">12</span> months. Further Pre-Paid Advances will be based upon the mutual agreement of the parties. Direct costs and fees related to the PPA were recognized in earnings. At issuance, the Company concluded that certain features of the PPA would be considered a derivative that would require bifurcation. In lieu of bifurcation, the Company elected the fair value option for this financial instrument and will record changes in fair value within the statements of operations and comprehensive income (loss) at the end of each reporting period. Under the fair value option, upon derecognition the Company will include in net income the cumulative amount of the gain or loss on the debt that resulted from changes in instrument-specific credit risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, Yorkville elected to convert $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zLSGYnthUaw6" title="Debt conversion, principal amount">3,889</span> of principal and $<span id="xdx_90A_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zmFhbqLxdshg" title="Debt conversion, accrued interest amount">400</span> of accrued interest into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdyBxL6KMFHg" title="Debt conversion, number of shares issued">559,481</span> shares of common stock and $<span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pid_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z2StFNzfy9pk" title="Instrument-specific credit risk income">155</span> was recognized in earnings from changes in instrument-specific credit risk. As of December 31, 2023, the fair value of the debt was $<span id="xdx_901_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z7niBUMOTwah" title="Fair value of debt">17,223</span> and the principal balance was $<span id="xdx_900_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zkNzoURU9pv8" title="Principal balance">16,623</span>. As of December 31, 2022, the fair value of the debt was $<span id="xdx_906_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zZDOEjtVoaR8" title="Fair value of debt">37,603</span> and the principal balance was $<span id="xdx_90F_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zW3iBxNo8gD1" title="Principal balance">37,000</span>. Refer to Note 3 for additional details regarding the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2023, Yorkville provided notice to the Company that a “triggering event” under the terms of the PPA occurred on February 21, 2023 and approximately $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20230221__20230221__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z5PPLGYIKbKk" title="Amount of monthly repayment">6,500</span> was due to Yorkville consisting of principal, accrued interest, and redemption premium of <span id="xdx_90F_ecustom--PercentageOfPremiumPrincipalAmount_pid_dp_uPure_c20230221__20230221__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zgiGxCvhwKy" title="Percentage of premium principal amount">5</span>% of the principal amount being paid (collectively the “repayment amount”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 24, 2023, the Company paid $<span id="xdx_90C_ecustom--DebtInstrumentPayment_pn3n3_c20230324__20230324__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zEcUxnnvamre" title="Debt instrument payment">1,950</span> of the repayment amount owed to Yorkville towards the first trigger payment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2023, the Company and Yorkville agreed that Yorkville would not accelerate any amounts outstanding under the PPA provided that (i) the Company pays the remaining balance on the first trigger payment of approximately $<span id="xdx_903_ecustom--DebtInstrumentPaymentRemainingBalance_pn3n3_c20230414__20230414__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zLe1DVV0Tx6i" title="Debt instrument payment remaining balance">4,600</span> within <span id="xdx_900_ecustom--BusinessDays_c20230414__20230414__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zfmN8U1Sw4n4" title="Business days">two</span> business days of closing a financing transaction, but in any event no later than April 14, 2023; and (ii) the Company pays in full the payment due on the second trigger payment of approximately $<span id="xdx_909_ecustom--DebtInstrumentPaymentRemainingBalance_pn3n3_c20230514__20230514__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zrkvKTe0wHKf" title="Debt instrument payment remaining balance">6,500</span> within two business days of closing a financing transaction, but in any event no later than May 14, 2023. On April 11, 2023, the Company used the net proceeds of $<span id="xdx_906_ecustom--DebtInstrumentPaymentRemainingBalance_pn3n3_c20230411__20230411__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_znZU8U7p8n9j" title="Debt instrument payment remaining balance">5,500</span> from a registered direct offering to pay in full the remaining balance on the first trigger payment and approximately $<span id="xdx_902_ecustom--DebtInstrumentPaymentPartialPayment_pn3n3_c20230411__20230411__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zbScQidcKZ6f" title="Debt instrument payment partial payment">900</span> was applied towards the second trigger payment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2023, the Company used the net proceeds from the RWI Bridge Loan (as defined below) to repay the remaining balance on the second trigger payment for approximately $<span id="xdx_907_ecustom--DebtInstrumentPayment_pn3n3_c20230411__20230411__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_znftKToQ9rY9" title="Debt instrument payment partial payment">5,600</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, on June 21, 2023, the Company used the net proceeds from the Amended RWI Loan (as defined below) to repay $<span id="xdx_909_ecustom--DebtInstrumentPayment_pn3n3_c20230621__20230621__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zUtGJtB0frye" title="Debt instrument payment">5,700</span> towards the third trigger payment at which point payments due under the triggering event were satisfied. During the year December 31, 2023, total repayments to Yorkville were $<span id="xdx_907_ecustom--DebtInstrumentPayment_pn3n3_c20230621__20230621__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zL1PH8V5fkv9" title="Debt instrument payment">18,724</span> which consisted of (i) $<span id="xdx_90C_eus-gaap--RepaymentsOfShortTermDebt_pn3n3_c20230621__20230621__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z1W1OaBxEIlg" title="Principal payments of debt">16,811</span> applied to the principal amount; (ii) $<span id="xdx_908_ecustom--DebtInstrumentAccruedInterest_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z8V6CHJFjCoh" title="Debt instrument accrued interest">1,073</span> towards accrued interest; and (iii) $<span id="xdx_90C_ecustom--DebtInstrumentRedemptionPremium_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zXORUyE6CEOg" title="Debt instrument redemption premium">840</span> of redemption premium. In connection with the Company’s 2023 annual stockholder meeting held in June 2023, the Company and Yorkville agreed to lower the floor price to $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zCeguwATJAHi" title="Purchase price">0.50</span> (the “amended floor price”). The Company also received stockholder approval of the proposal for the issuance of more than 20% of its pre-transaction Class A common stock outstanding at a price below the minimum price pursuant to the PPA. Further, absent prior written consent from Yorkville, the Company agreed it will not increase the size or amount borrowed under the C.V. Starr loan facility nor will not incur other borrowings or liens of any kind as long as any amounts are due and remain outstanding to Yorkville until paid in full. The Company agreed that all obligations due and owing to Yorkville will become secured obligations upon any violation under the PPA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 2, 2023, Yorkville provided notice to the Company that a “triggering event” under the term of the PPA occurred on August 1, 2023. The Company was not able to make the August trigger payment of $<span id="xdx_906_ecustom--DebtInstrumentAmountRequiredForPaymentOnDue_iI_pn3n3_c20230802__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zcVJR89ZBSKk" title="Payment on due">6,340</span> when due.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 18, 2023, the Company and Yorkville entered into a letter agreement to extend the maturity date of the PPA to December 31, 2023, and Yorkville agreed not to declare an event of default, as defined in the PPA, until January 1, 2024. The Company further agreed to issue <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_pid_c20230918__20230918__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zh2LsWQnsw44" title="Common stock issued pursuant to short-term debt maturity extension, shares">270,730</span> shares of the Company’s Class A common stock to Yorkville, and recognized an expense of $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_pn3n3_c20230918__20230918__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zcHo28pab5na" title="Common stock issued pursuant to short-term debt maturity extension">712</span> within other income (expense) on the consolidated statements of operations. Additionally, the Company was required to pay Yorkville $<span id="xdx_90C_ecustom--DebtInstrumentAmountRequiredForPayment_iI_pn3n3_c20231005__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlKesBzzxJs7" title="Amount required for payment">2,000</span> on or prior to October 5, 2023 and an additional $<span id="xdx_906_ecustom--AdditionalDebtInstrumentAmountRequiredForPayment_iI_pn3n3_c20231031__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zcCUNh9SAYuc" title="Additional amount required for payment">500</span> on or before October 31, 2023. The Company was not able to make the required payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company and Yorkville entered into a forbearance agreement (“Forbearance Agreement”) in which Yorkville agreed to restrain from enforcing its rights and remedies as a result of the event of default during the forbearance period. The forbearance period shall continue until the earliest of the January 19, 2024 or the date the Company fully repaid all amounts outstanding under the PPA (“Forbearance Period”). During the Forbearance Period, interest shall accrue at <span id="xdx_905_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240212__20240212__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_ziCZodChH4vi" title="Annual interest rate">15</span>% per annum. In addition, the Company shall make a cash payment of $<span id="xdx_906_eus-gaap--RepaymentsOfDebt_pn3n3_c20240212__20240212__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z79CRuEiZS83" title="Cash payment">17,348</span> plus per diem interest of $<span id="xdx_90A_ecustom--DebtInstrumentPerDiemInterestAmount_pn3n3_c20240212__20240212__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zQhQqJPbwIu8" title="Diem interest payment for each day">7</span> for each day after January 12, 2024 until payment is made and shall issue Yorkville a total of <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zn8xA2FLdlih" title="Issue of common stock">100,000</span> shares of its common stock. The PPA loan was paid in full on January 17, 2024. On January 12, 2024, the Company issued Yorkville <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoPQZLYPr3K2" title="Issue of common stock">100,000</span> of its common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with Yorkville (Note 12).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon entry into the SEPA, the Company issued Yorkville a $<span id="xdx_90A_eus-gaap--DebtInstrumentIssuedPrincipal_pn4n6_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zxgaZsDEUV3b" title="Issue of Debt">3.15</span> million convertible promissory note for $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn4n6_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zOc0OtmZ0vki" title="Maximum advance amount">2.99</span> million in cash (after a <span id="xdx_900_ecustom--ConvertiblePromissoryNoteDiscountPercentage_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zs30xuIwEhzl" title="Original issue discount">5</span>% original issue discount). The note bears interest at an annual rate equal to <span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zLETTjbnF1ta" title="Annual interest rate">8.0</span>% (increased to <span id="xdx_90C_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_ziwP37rmNu61" title="Line of credit increase in interest rate during period in event of default">18.0</span>% in the event of default as provided in the note), and matures <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_ddp_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zs74NYNVHRIe" title="Maturity date">March 13, 2025</span>. Yorkville may convert the note into common stock at a price per share equal to $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zPHGL2MKPTSi" title="Conversion price per share">6.3171</span>, provided however, on the earlier of (a) the fifth trading day following the effective date of the resale shelf, or (b) August 13, 2024, the conversion price will be the volume weighted average price (“VWAP”) of the common stock on Nasdaq during the five consecutive trading days immediately prior to the conversion price reset date, subject to a floor price of $<span id="xdx_901_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zdhD7waDXmxi" title="Minimum required daily volume weighted average price">2.4898</span> per share. Upon the occurrence and during the continuation of an event of default (as defined in the note), the note (including accrued interest) will become immediately due and payable. The issuance of the common stock upon conversion of the note and otherwise under the SEPA </span>is capped at <span id="xdx_90A_ecustom--PercentageOfConversionOnOutstandingCommonStock_iI_pid_dp_uPure_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zNdzsmVFVan4" title="Percentage of conversion on outstanding common stock">19.9</span>% of the outstanding common stock as of March 13, 2024. Further, the note and SEPA include a beneficial ownership blocker for Yorkville such that Yorkville may not be deemed the beneficial owner of more than <span id="xdx_909_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zLbNf09flkw3" title="Percentage of beneficial ownership limitation">4.99</span>% of the Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Short-Term Debt - Other and Related Party</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2023, the Company entered into a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing for a loan in the aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zyLh9mRiXul7" title="Principal amont">3,000</span> (of which Dr. Hariri contributed $<span id="xdx_901_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zJcJb90wq1Hc" title="Debt instrument contribution amount">1,000</span>), or the “Loan”. The Loan bears interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zWA0MIcgkCH3" title="Loan interest rate">15</span>% per year, with the first year of interest being paid in kind on the last day of each month and matures on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_znlOx5V4nBS3" title="Maturity date">August 21, 2024</span>. Pursuant to the terms of the Loan, the Company is required to apply the net proceeds from a subsequent transaction (as defined) in which the Company receives gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromOtherShortTermDebt_pn3n3_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zOYsOGPu7yO" title="Gross proceeds">4,500</span> or more to repay the Loan. The Company did not repay the Loan upon receipt of the letter of credit funds which was defined as a subsequent transaction in connection with signing the lease amendment (See Note 10). The lenders have not demanded repayment as of the issuance date. The carrying amount of the Loan was deemed to approximate fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 12, 2023, in order to further address the Company’s immediate working capital requirements, Robert Hariri, M.D., Ph.D., the Company’s Chairman and Chief Executive Officer, and the Company signed a promissory note (“CEO Promissory Note”) for $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zP3vPJkFbAGe" title="Principal amont">285</span> which bears interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240313__20240313__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zUCkm7UYx2C9" title="Interest rate">15.0</span>% per year. The CEO Promissory Note matures together with the outstanding principal amount and accrued and unpaid interest upon the earlier of <span id="xdx_90D_eus-gaap--LineOfCreditFacilityExpirationPeriod_dc_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zXut4As61jP8" title="Pre-paid advance maturity period">twelve months</span> from the date of the note or upon a change of control. The carrying amount of the Loan was deemed to approximate fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the carrying value of the Loan and the CEO Promissory Note inclusive of accrued interest is $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zlod82MZIqN8" title="Carrying value of short-term debt">3,527</span> of which $<span id="xdx_90B_ecustom--OtherShortTermDebtDueToRelatedParty_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zliHFpAzX8l5" title="Other short term debt due to related party">1,419</span> is shown as other short-term - related party due to Dr. Hariri and $<span id="xdx_908_ecustom--OtherShortTermDebt_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zM70WJYR4LS2" title="Other short-term debt">2,108</span> shown as other short-term debt on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Short-Term Debt – Related Parties - C.V. Starr and RWI</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C.V. Starr &amp; Co., Inc</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 17, 2023, the Company entered into a loan agreement (the “Starr Bridge Loan”) with C.V. Starr &amp; Co., Inc. (“C.V. Starr”), a stockholder of the Company, for an aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z8KEHvCa9heh" title="Principal amont">5,000</span> net of an original issue discount of $<span id="xdx_90F_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_ztLMbmNirnbl" title="Original issue discount">100</span>. The loan bears interest at a rate equal to <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zHBl9sEiyHLd" title="Loan interest rate">12.0</span>% per year or <span id="xdx_903_ecustom--DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zhybQlVOrndh" title="Debt instrument, interest rate, effective percentage in event of default">15.0</span>% in the event of default, with the first year of interest being paid in kind on the last day of each month, and matures on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20230317__20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zqvl4BFo6oQ3" title="Maturity date">March 17, 2025</span>. In addition, the parties entered into a warrant agreement to acquire up to an aggregate <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dd_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zD8MvbhJWk3e" title="Warrants to purchase Class A common stock">75,000</span> shares of Class A common stock (“Starr Warrant”), at a purchase price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zk0DkdXyI9l5" title="Purchase price of per share">1.25</span> per whole share underlying the Starr Warrant or $<span id="xdx_90A_ecustom--ShareIssuedPurchasedPrice_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z54ybwEm4TZh" title="Share issued purchase price">94</span>. The Starr Warrant has a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zklQQniPSMS7" title="Term (years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1792">five-year</span></span> term and an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zEjcxLaFKit4" title="Exercise per share price (in Dollars per share)">7.10</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, in connection with the Amended RWI Loan (as defined below), the Company granted C.V. Starr additional warrants to acquire up to an aggregate <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zZDkD7uFVnEe" title="Warrants to purchase Class A common stock">50,000</span> shares of its Class A common stock, which additional warrants have a <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zhbQkR3HKZRk" title="Warrants to purchase Class A common stock::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1798">5-year</span></span> term and an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zzOu88d0fLB8" title="Exercise per share price (in Dollars per share)">8.10</span> per share. The Company applied the guidance for this transaction in accordance with <i>ASC 470-20, Debt with Conversion and Other Options </i>and <i>ASC 815, Derivatives and Hedging</i>. The net proceeds of the Starr Bridge Loan and Starr Warrants were recorded at fair value. The fair value of the Starr Warrants was determined using a Black-Scholes option pricing model. The Starr Warrants met the requirements for a derivative scope exception under <i>ASC 815-10-15-74(a) </i>for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. The carrying amount of the Starr Bridge Loan was deemed to approximate fair value. As of December 31, 2023, the carrying value of Starr Bridge Loan inclusive of accrued interest is $<span id="xdx_90A_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_za9EZgcpuoT8" title="Carrying value of short-term debt">5,523</span> on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Starr Bridge Loan, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of the Company’s assets, other than as permitted, or hold cash and cash equivalents less than $<span id="xdx_90A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z4NTePlxztF2" title="Cash and cash equivalents">3,000</span> for more than five consecutive business days. <span id="xdx_905_eus-gaap--DebtInstrumentCovenantCompliance_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zsXX8Xzdt7u6" title="Debt instrument, covenant compliance description">During the year ended December 31, 2023, the Company’s cash and cash equivalents fell below the $<span id="xdx_903_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYIQ582wbDt7" title="Fall in cash and cash equivalents">3,000</span> minimum liquidity covenant, which per the terms of the loan agreement caused an event of default. Therefore, the Company reclassified the loan as a current liability reflected within short-term debt - related parties on the consolidated balance sheets as of December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company entered into an amendment (“Starr Bridge First Amendment”), which terminated the minimum $<span id="xdx_909_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNzzgdkMnqwi" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant requirement. In addition to the negative covenants in the Starr Bridge Loan, the Starr Bridge Loan</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">includes customary events of default and the Company granted C.V. Starr a senior security interest in all of its assets, pari passu with RWI (as defined below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company and C.V. Starr, entered into a forbearance agreement (“Starr Forbearance Agreement”), with respect to the Starr Bridge Loan. Under the Starr Forbearance Agreement, (i) Starr agreed not to exercise its rights and remedies upon the occurrence of any default under the Starr Loan Agreement until the Company’s obligations in respect of the Yorkville convertible note have been indefeasibly paid in full, (ii) Starr consented to the Company’s incurrence of indebtedness under the Yorkville convertible note, (iii) Starr consented to cash payments required to be made under the SEPA and the Yorkville convertible note, (iv) the Company agreed to increase the interest rate on the loan outstanding under the Starr Bridge Loan by <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zRmQjMSWdqK4" title="Increase interest rate on loan outstanding by basis points">100</span> basis points and (v) the Company agreed to amend the exercise price of (x) that certain warrant to acquire <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zUNHRgctqhPi" title="Warrants to purchase Class A common stock">75,000</span> shares of the Company’s common stock for $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zFzHtGaFRDJ6" title="Purchase price of per share">7.10</span> per share, expiring <span id="xdx_906_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z62vGiyh8KOg" title="Warrant expiration date">March 17, 2028</span>, and (y) that certain warrant to acquire <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zrnCL6fwqyFg" title="Warrants to purchase Class A common stock">50,000</span> shares of Common Stock for $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zoJQUq0CDJs" title="Purchase price of per share">8.10</span> per share expiring <span id="xdx_90F_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zrWe90RUaszc" title="Warrant Expiration Date">June 20, 2028</span>, each of which are held by Starr, such that the exercise price of each such warrant in (x) and (y) is $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zwFwTuAJwMc1" title="Warrants to purchase Class A common stock">5.895</span> per share. In addition, the interest rate of the Starr Bridge Loan was increased to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zfTZmpoT8n27" title="Loan interest rate">13</span>% per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Resorts World Inc Pte Ltd</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2023, with written consent provided by Yorkville, the Company entered into a senior secured loan agreement (“RWI Bridge Loan”) with Resorts World Inc Pte Ltd, (“RWI”) providing for an initial loan in the aggregate principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_ze8qn6D8G1xi" title="Principal amont">6,000</span> net of an original issue discount of $<span id="xdx_904_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zOwZ0kNiJJOf" title="Discount">120</span>, which bears interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zE0u0yecr6Sa" title="Interest rate">12.5</span>% per year or <span id="xdx_908_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zfKjlR5aLhpi" title="Interest rate during period in event of default">15.5</span>% in the event of default, with the first year of interest being paid in kind on the last day of each month, and matured on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zFlZ01vuYHFe" title="Maturity date">June 14, 2023</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 21, 2023, the Company closed on an amended and restated senior secured loan agreement (“Amended RWI Loan”), to amend and restate the previous senior secured loan agreement, in its entirety. The Amended RWI Loan provided for an additional loan in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zuaOi1UBay2g" title="Principal amont">6,000</span> net of an original issue discount of $<span id="xdx_90B_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z7fbPxIn99di" title="Discount">678</span>, which bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zIEyKnkNNa63" title="Interest rate">12.5</span>% per year or <span id="xdx_905_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z99kaIaen6Fl" title="Interest rate">15.5</span>% in the event of default, with the first year of interest being paid in kind on the last day of each month, and matures <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_ddp_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zBM35UfMdkTe" title="Maturity date">March 17, 2025</span>. The Amended RWI Loan extended the maturity date of the initial loan to March 17, 2025. In addition, the Amended RWI Loan provided for the issuance of warrants to acquire up to an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zioxL7IoIOZa" title="Warrants to purchase Class A common stock">300,000</span> shares of the Company’s Class A common stock (“RWI Warrants”), at a purchase price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zjNCeFpUM4C6" title="Purchase price of per share">1.25</span> per whole share underlying the RWI Warrant (or an aggregate purchase price of $<span id="xdx_902_ecustom--ShareIssuedPurchasedPrice_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zx9biWBeXs7h" title="Share issued purchase price">375</span>). The RWI Warrant has a <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_ddxL_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zKljzvdiaLLa" title="Term (years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1856">5-year</span></span> term and an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zrALOC4uPLXj" title="Exercise per share price (in Dollars per share)">8.10</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applied the guidance for this transaction in accordance with <i>ASC 470-20, Debt with Conversion and Other Options </i>and <i>ASC 815, Derivatives and Hedging</i>. The net proceeds of the Amended RWI Loan and RWI Warrants were recorded at fair value, which resulted in a total discount of $<span id="xdx_90B_ecustom--DiscountOnWarrantAmount_iI_pn3n3_c20230516_ztxwS2WdM3bl" title="Discount on warrant">2,151</span> based on the difference between the proceeds and fair value which were recorded as a loss within other income (expense) on the consolidated statements of operations. The fair value of the RWI Warrants was determined using a Black-Scholes option pricing model. The RWI Warrants met the requirements for a derivative scope exception under <i>ASC 815-10-15-74(a) </i>for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. The carrying amount of the Amended RWI Loan was deemed to approximate fair value. As of December 31, 2023, the carrying value of Amended RWI Loan inclusive of accrued interest is $<span id="xdx_907_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zJ6m7wy8wXk5" title="Carrying value of short-term debt">12,967</span> on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Amended RWI Loan, the Company was required to apply the net proceeds to the trigger payments due to Yorkville pursuant to the PPA. RWI is affiliated with Lim Kok Thay, a former member of the Company’s board of directors. In addition, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of its assets, other than as permitted, or hold cash and cash equivalents less than $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zQAersAYUfz5" title="Cash and cash equivalents">3,000</span> for more than five consecutive business days, and includes customary events of default. The Company granted RWI a senior security interest in all of its assets, pari passu with C.V. Starr pursuant to the Starr Bridge Loan. The Company and RWI signed a forbearance agreement on September 14, 2023, whereby RWI agreed to forebear any action under the terms of the RWI Bridge Loan in relation to the minimum $<span id="xdx_90E_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zZwokmNB4Dr8" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant and with respect to any potential default in relation to the Company’s outstanding debt owed to Yorkville until December 31, 2023. The Company reclassified the loan as a current liability reflected within short-term debt - related parties - C.V. Starr and RWI on the consolidated balance sheets as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the amendment on January 12, 2024, see below, the amendment terminated the minimum $<span id="xdx_90C_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zv96kXDAU6Hk" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant requirement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company entered into a second amended and restated senior secured loan agreement (“RWI Second Amended Bridge Loan”), to amend and restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023, as amended on June 20, 2023, in its entirety. The RWI Second Amended Bridge Loan provided for an additional loan in the </span>aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z4pvEbg7JG4c" title="Principal amont">15,000</span> net of an original issue discount of $<span id="xdx_90E_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zUSRxm1NNQEc" title="Original issue discount">3,750</span>, which bears interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zBQjz8uFXeV8" title="Interest rate">12.5</span>% per year, with the first year of interest being paid in kind on the last day of each month, and matures <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z6pSxLQsRRrj" title="Maturity date">July 16, 2025</span>. In addition, the RWI Second Amended Bridge Loan provides for the issuance of a <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zzvlwZs7c1Bc" title="Term (years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1878">5-year</span></span> immediately exercisable warrant to acquire up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z0JXfRUu9yA9" title="Warrants to purchase Class A common stock">1,650,000</span> shares of Class A common stock (“Tranche 1 Warrant”), and a warrant to acquire up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCLV7j68wb9i" title="Warrants to purchase Class A common stock">1,350,000</span> shares of Class A common stock, which will only be exercisable upon the later of (x) stockholder approval for Nasdaq purposes of its exercise price, (y) CFIUS clearance and (z) six months from issuance date (“Tranche 2 Warrant”) and will expire <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zn83lj7lTyz9" title="Term (years)">5</span> years after it becomes exercisable. The Tranche 1 Warrant and Tranche 2 Warrant were each issued on January 16, 2024, and the Tranche 1 Warrant has an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240116__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zDWg7OCoqsFg" title="Exercise per share price (in Dollars per share)">2.4898</span> per share, and the Tranche 2 Warrant will have an exercise price equal to “Minimum Price” (as determined pursuant to Nasdaq 5635(d)) on the date it becomes exercisable. The Company closed the RWI Second Amended Bridge Loan and the sale and purchase of the Tranche 1 Warrant and Tranche 2 Warrant on January 16, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the RWI Second Amended Bridge Loan, the Company was required to apply the proceeds of the additional loan (i) to the payment in full of all outstanding amounts owed to Yorkville under the PPA, (ii) to the payment of invoices of certain critical vendors, (iii) to the first settlement payment owed to Palantir Technologies, Inc., and (iv) for working capital and other purposes pre-approved by RWI. Pursuant to the terms of the RWI Second Amended Bridge Loan, the Company agreed to customary negative covenants restricting its ability to pay dividends to stockholders, repay or incur other indebtedness other than as permitted, or grant or suffer to exist a security interest in any of the Company’s assets, other than as permitted. In addition, the Company agreed to apply net revenues received through the sale of our products/provision of services in connection with or related to its distribution and manufacturing agreement with Genting Innovation Pte Ltd (“Genting Innovation”), a related party, as a prepayment towards the loan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company and RWI entered into a second forbearance agreement (“RWI 2nd Forbearance Agreement”). Under the RWI 2nd Forbearance Agreement, (i) RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the RWI Loan Agreement until the Company’s obligations in respect of the Yorkville convertible note have been indefeasibly paid in full or March 13, 2025, whichever occurs first, (ii) RWI consented to the Company’s incurrence of indebtedness under the Yorkville convertible note, (iii) RWI consented to cash payments required to be made under the SEPA and the Yorkville convertible note, (iv) the Company agreed to increase the interest rate on the loan outstanding under the RWI Loan Agreement by <span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zzPEUrlS20Y9" title="Increase interest rate on loan outstanding by basis points">100</span> basis points and (v) the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zBmX9VCQDB26" title="Warrants to purchase Class A common stock">300,000</span> shares of Common Stock (“RWI New Warrant”), which expires <span id="xdx_901_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zkmj9JyapCzi" title="Warrant expiration date">June 20, 2028</span> and has an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zXWAygMeMEVl" title="Exercise per share price (in Dollars per share)">5.895</span> per share.</span></p> <p id="xdx_892_eus-gaap--ScheduleOfDebtTableTextBlock_zj3RF4Wht2Hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zDz6mmr67Tka" style="display: none">Schedule of Debt</span></p> <p id="xdx_8AA_zNQjK2kYZh4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="display: none"> </span></p> 40000000 P18M 150000000 0.02 0.06 0.15 7.50 0.199 0.0499 6000 7.50 6000000 0.050 0.10 7.50 40000000 39200000 P12M 3889000 400000 559481 155 17223000 16623000 37603000 37000000 6500000 0.05 1950000 4600000 two 6500000 5500000 900000 5600000 5700000 18724000 16811000 1073000 840000 0.50 6340000 270730 712000 2000000 500000 0.15 17348000 7000 100000 100000 3150000 2990000 0.05 0.080 0.180 2025-03-13 6.3171 2.4898 0.199 0.0499 3000000 1000000 0.15 2024-08-21 4500000 285000 0.150 P12M 3527000 1419000 2108000 5000000 100000 0.120 0.150 2025-03-17 75000 1.25 94 7.10 50000 8.10 5523000 3000000 During the year ended December 31, 2023, the Company’s cash and cash equivalents fell below the $3,000 minimum liquidity covenant, which per the terms of the loan agreement caused an event of default. Therefore, the Company reclassified the loan as a current liability reflected within short-term debt - related parties on the consolidated balance sheets as of December 31, 2023. 3000000 3000000 1 75000 7.10 2028-03-17 50000 8.10 2028-06-20 5.895 0.13 6000000 120000 0.125 0.155 2023-06-14 6000000 678000 0.125 0.155 2025-03-17 300000 1.25 375 8.10 2151000 12967000 3000000 3000000 3000000 15000000 3750000 0.125 2025-07-16 1650000 1350000 P5Y 2.4898 1 300000 2028-06-20 5.895 <p id="xdx_892_eus-gaap--ScheduleOfDebtTableTextBlock_zj3RF4Wht2Hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zDz6mmr67Tka" style="display: none">Schedule of Debt</span></p> <p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_zLoOjZjSCzz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_82C_zY0hy6xlKpXb">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company’s lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date to determine the appropriate discount rate by multiple asset classes. Variable lease payments that are not based on an index or that result from changes to an index subsequent to the initial measurement of the corresponding lease liability are not included in the measurement of lease ROU assets or liabilities and instead are recognized in earnings in the period in which the obligation for those payments is incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. Lease expense was $<span id="xdx_909_ecustom--OperatingLeasesRentExpense_pn3n3_c20230101__20231231_z7YOwltAhhL" title="Rent expense">3,750</span> and $<span id="xdx_904_ecustom--OperatingLeasesRentExpense_pn3n3_c20220101__20221231_zku6wV7Wm4Dj" title="Rent expense">3,803</span> for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2019, Legacy Celularity entered into a lease agreement for a <span id="xdx_901_ecustom--AreaOfBuilding_usqft_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zbfy8nKEMtW6" title="Area of building">147,215</span> square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in <span id="xdx_904_ecustom--OperatingLeaseExpiryYear_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z7m14FCzU2Xk" title="Area of building">2036</span>. The Company has the option to renew the term of the lease for two additional <span id="xdx_909_ecustom--OptionToRenewLeaseTermPeriod_dxL_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zunsfeK6PBV6" title="Option to renew lease term period.::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1908">five-year</span></span> terms so long as the lease is then in full force and effect. The lease term commenced on <span id="xdx_907_ecustom--OperatingLeaseCommencementDate_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z5O57TaO0lP4" title="Option to renew lease term period.">March 1, 2020</span> subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly base rent is approximately $<span id="xdx_905_ecustom--InitialMonthlyBaseRent_pn3n3_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zKEBf71iiVad" title="Initial monthly base rent.">230</span> and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $<span id="xdx_902_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zcF4ADjLZZz3" title="Restricted cash"><span id="xdx_904_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zvGHfOAGLnAh" title="Restricted cash">14,722</span></span> which is classified as restricted cash (non-current) on the consolidated balance sheets as of December 31, 2023 and 2022. The lease agreement allows for a landlord provided tenant improvement allowance of $<span id="xdx_90E_eus-gaap--TenantImprovements_iI_pn3n3_c20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zkeLIZcjHaq9" title="Tenant improvement allowance">14,722</span> to be applied to the costs of the construction of the leasehold improvements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2023, the Company entered into a lease amendment on the Company’s Florham Park, New Jersey facility to reduce the letter of credit by approximately $<span id="xdx_90F_ecustom--ReductionInLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_znShtoZVRORl" title="Reduction in line of credit">4,900</span> for a new letter of credit in the amount of $<span id="xdx_905_ecustom--NewLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zWdWItyS5B1e" title="New line of credit">9,883</span> in exchange for higher base rental payments of approximately $<span id="xdx_909_ecustom--BaseRentalPayments_pn3n3_c20230914__20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zGnTBuFIyZ7k" title="Base rental payments">400</span> per year, effective October 1, 2023. The new letter of credit account settled on October 17, 2023, and reduced the Company’s restricted cash allowing for funds to be used for general corporate purposes. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. The Company accounted for the lease amendment as a modification since the change in lease payments did not represent additional ROU assets. The Company reassessed the IBR, remeasured the lease liability and ROU asset on the modification date of September 14, 2023. As a result, the Company recorded a decrease to the ROU asset and related lease liability in the amount of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zPDmJBCynzs7" title="Operating lease liability">2,083</span> on the consolidated balance sheets reflecting a higher IBR due to lower Company credit rating.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zmkUUZHEQHF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s lease costs are classified on its consolidated statements of operations as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BA_zbVJF0aE4nIf" style="display: none">Schedule of Lease Costs</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zuYcPGiT9BV5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_z86puRKUba61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseCost_zNwjSNR4txO" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,256</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,038</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--VariableLeaseCost_zJbuEOQabog9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,132</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,598</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_zZ6nXlQbez62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_zlxSoUrRP3Fi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1939">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">126</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zTHC7W7qgHJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zCV43edLRAf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below shows the cash and non-cash activity related to the Company’s lease liabilities during the year ended December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_z6KTd4FC02ya" style="display: none">Schedule of Cash and Non-cash Activity Related to the lease Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zZjJ60VslrLg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zFYStQAKiI4l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash paid related to lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zbC8rCDJ37Lb" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,834</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Non-cash lease liability activity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zlwdX6C4e1K" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhw8D9tG9n2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the maturities of the Company’s operating lease liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_zePuSDy0l4Ff" style="display: none">Schedule of Future Minimum Payments under Non-Cancelable Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20231231_zUHyBvOZMp0k" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zKRYfvUWUfa7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zTXqoZYttbb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,378</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zlf1mHLuCYvd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year one</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,378</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_z8spWkOTkzQ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zXu9cSWCCoMe" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zuBVVG24aEyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zTg5BZzHFBNh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zz8H1BevM8r1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zzZG3B6h1BEg" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_zCjH1364ISx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_zejjSnplYd6h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year five</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_zv8AOu1iXwOh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year four Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_zrhu55YZa4E5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_zAFKiXLxpKx" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Year five Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zrztIuUm7yW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5pt">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102,196</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z1DBQqyeONt3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(76,019</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z4xCDC3s3VR7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,177</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zKMMJvYeFKe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the weighted average remaining lease term of the Company’s operating lease was <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhHvMmU3agXc" title="Weighted average remaining lease term">22.3</span> years, and the weighted average discount rate used to determine the lease liability for the operating lease was <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_zMUE3XFVlZAd" title="Weighted average discount rate">14.24</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> 3750000 3803000 147215 2036 2020-03-01 230000 14722000 14722000 14722000 4900000 9883000 400000 2083000 <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zmkUUZHEQHF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s lease costs are classified on its consolidated statements of operations as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BA_zbVJF0aE4nIf" style="display: none">Schedule of Lease Costs</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zuYcPGiT9BV5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_z86puRKUba61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseCost_zNwjSNR4txO" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,256</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,038</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--VariableLeaseCost_zJbuEOQabog9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,132</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,598</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_zZ6nXlQbez62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_zlxSoUrRP3Fi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1939">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">126</td><td style="text-align: left"> </td></tr> </table> 3256000 3038000 1132000 1598000 4388000 4636000 126000 <p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zCV43edLRAf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below shows the cash and non-cash activity related to the Company’s lease liabilities during the year ended December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_z6KTd4FC02ya" style="display: none">Schedule of Cash and Non-cash Activity Related to the lease Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zZjJ60VslrLg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zFYStQAKiI4l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash paid related to lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zbC8rCDJ37Lb" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,834</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Non-cash lease liability activity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Operating leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> 2995000 2834000 <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zhw8D9tG9n2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the maturities of the Company’s operating lease liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_zePuSDy0l4Ff" style="display: none">Schedule of Future Minimum Payments under Non-Cancelable Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20231231_zUHyBvOZMp0k" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zKRYfvUWUfa7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zTXqoZYttbb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,378</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zlf1mHLuCYvd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year one</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,378</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_z8spWkOTkzQ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zXu9cSWCCoMe" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zuBVVG24aEyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zTg5BZzHFBNh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zz8H1BevM8r1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zzZG3B6h1BEg" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_zCjH1364ISx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_zejjSnplYd6h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year five</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_zv8AOu1iXwOh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year four Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_zrhu55YZa4E5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_zAFKiXLxpKx" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Year five Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zrztIuUm7yW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5pt">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102,196</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z1DBQqyeONt3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(76,019</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z4xCDC3s3VR7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,177</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3378000 3378000 3452000 3452000 3526000 3526000 3599000 3599000 3673000 3673000 84568000 84568000 102196000 76019000 26177000 P22Y3M18D 0.1424 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zBH1KNd1YqD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_822_zEzQn0oV10ic">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingent Consideration Related to Business Combinations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Company’s acquisition of HLI Cellular Therapeutics, LLC and Anthrogenesis, the Company has agreed to pay future consideration to the sellers upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $<span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember__us-gaap--RelatedPartyTransactionAxis__custom--LLCAndAnthrogenesisMember_zslB5oG7Pvuj" title="Contingent consideration">1,606</span> and $<span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember__us-gaap--RelatedPartyTransactionAxis__custom--LLCAndAnthrogenesisMember_zZ2NF4U4ZYN7" title="Contingent consideration">105,945</span> as contingent consideration as of December 31, 2023 and 2022, respectively. During 2023, the Company discontinued its unmodified NK cell and AML Cell Therapy clinical trials subject to the contingent consideration agreement under the Anthrogenesis acquisition, and as a result the fair value of the contingent consideration obligation has decreased significantly as of December 31, 2023. Due to the contingent nature of these milestone and royalty payments, there is a high degree of management estimates that determine the fair value of the contingent consideration. See Note 3 for further discussion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Indemnification Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Agreement with Palantir Technologies Inc.</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2021, Legacy Celularity executed a Master Subscription Agreement (“MSA”) with Palantir under which it will pay $<span id="xdx_90D_ecustom--PaymentsForMasterSubscriptionAgreement_pn3n3_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_z6MeBUPTsMFf" title="Payments for master subscription agreement">40,000</span> over <span id="xdx_90D_ecustom--PaymentSubscriptionPeriod_dt_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zZGyacksMF7l" title="Payment subscription period">five years</span> for access to Palantir’s Foundry platform along with certain professional services. The Company intended to utilize Palantir’s Foundry platform to secure deeper insights into data obtained from the Company’s discovery and process development, as well as manufacturing and biorepository operations. In January 2023, the Company ceased use of the software and provided a notice of dispute to Palantir on the basis that the software had not performed as promised and that Palantir had failed to provide the Company with the professional services necessary to successfully implement, integrate and enable the Foundry platform. As a result, in accordance with ASC 420 Exit or Disposal Costs, during the quarter ended March 31, 2023, the Company recognized the remaining related cease-use costs liability estimated based on the discounted future cash flows of contract payments for $<span id="xdx_906_eus-gaap--BusinessExitCosts1_pn3n3_c20230101__20230331__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--IncomeStatementLocationAxis__custom--SoftwareCeaseUseCostsMember_z5vsWqjiNCNa" title="Exit or disposal costs">24,402</span> which was included as software cease-use costs in the consolidated statements of operations. On May 6, 2024, the Company entered into an amended letter agreement with Palantir such that if the Company paid Palantir the settlement fees of $<span id="xdx_90B_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240506__20240506__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zls3gbr9lTHa" title="Agreed to pay settlement payment">3,500</span>, less any amounts previously paid, no later than June 3, 2024, the parties would cease the arbitration and deem the original MSA terminated. The Company made the required payments prior to June 3, 2024, and on June 4, 2024, the parties dismissed all claims and counterclaims. Accordingly, the Company reversed previously recognized costs in excess of the final settlement amount. The Company has a current liability for accrued R&amp;D software on the consolidated balance sheets of $<span id="xdx_906_ecustom--AccruedResearchAndDevelopmentSoftware_iI_pn3n3_c20231231_z92qk41e1y2b" title="Accrued research and development software">3,500</span> and $<span id="xdx_90A_ecustom--AccruedResearchAndDevelopmentSoftware_iI_pn3n3_c20221231_zVO1J0MkOlrc" title="Accrued research and development software">7,333</span> as of December 31, 2023 and 2022, respectively. For the year ended December 31, 2022, the Company recorded $<span id="xdx_90E_eus-gaap--CostsAndExpensesRelatedParty_pn3n3_c20230101__20231231_zSTYifPI4wbk" title="Costs related to straight line basis agreement">8,000</span>, which was on a straight-line basis, which was included as a component of research and development expense in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sirion License Agreement </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 25.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 25.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, the Company entered into a license agreement (“Sirion License”) with Sirion Biotech GmbH (“Sirion”). Under the Sirion License, Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (“Licensed Product”). As part of the Sirion License, the Company paid Sirion $<span id="xdx_90A_ecustom--UpfrontFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z7pVCUo6evRa" title="Upfront fee">136</span> as an upfront fee, a $<span id="xdx_900_ecustom--AnnualMaintenanceFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zPupzfWJycOe" title="Annual maintenance fee">113</span> annual maintenance fee and may owe up to $<span id="xdx_90B_ecustom--ClinicalAndRegulatoryMilestones_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zsRdvXZMQjC8" title="Clinical and regulatory milestones">5,099</span> million related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration of the last to expire valid claim of the patents covering such Licensed Product, and (ii) <span id="xdx_908_eus-gaap--LongtermPurchaseCommitmentPeriod_dtY_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z8ddVoIcgy4k" title="License agreement period">10 </span>years after first Commercial Sale of a Licensed Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company for convenience upon <span id="xdx_906_ecustom--LicenseAgreementNoticePeriod_dtD_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6uVUDV5v4B" title="License agreement period">30</span> days written notice. During the year ended December 31, 2023, no milestones have been achieved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Proceedings</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Civil Investigative Demand</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received a Civil Investigative Demand (the “Demand”) under the False Claims Act, 31 U.S.C. § 3729, dated August 14, 2022, from the U.S. Attorney’s Office for the Eastern District of Pennsylvania. The Demand requests documents and information relating to claims submitted to Medicare, Medicaid, or other federal insurers for services or procedures involving injectable human tissue therapy products derived from amniotic fluid or birth tissue and includes Interfyl. The Company is cooperating with the request and is engaged in an ongoing dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in preliminary stages and there is uncertainty as to whether the Demand will result in any liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arbitration Demand from Palantir Technologies Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 20, 2023, Palantir Technologies Inc. (“Palantir”), commenced an arbitration with JAMS Arbitration asserting claims for declaratory relief and breach of contract relating to the May 5, 2021 Master Service Agreement (the “Palantir MSA”), seeking damages in an amount equal to the full value of the contract. The Company has responded to the arbitration demand and asserted</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">counterclaims for breach of contract, breach of warranty, fraudulent inducement, violation of California’s Unfair Competition Law, amongst others, in relation to the Palantir MSA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 21, 2023, the Company and Palantir entered into a settlement and release agreement pursuant to the JAMS arbitration proceeding asserting claims for declaratory relief and breach of contract relating to the Palantir MSA. Both parties agreed to dismiss the arbitration proceeding and dispute and provide for mutual releases upon the Company’s satisfaction of a settlement payment obligation. Through June 3, 2024, the Company made total settlement payments of $<span id="xdx_90C_eus-gaap--PaymentsForLegalSettlements_pn5n6_c20231221__20240603__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zZts1Y8vY15" title="Settlement payment">3.5</span> million and issued Palantir an aggregate of <span id="xdx_90E_ecustom--NumberOfSharesIssuedForPiggybackRegistrationRights_pid_c20231221__20240603__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zuBaHr8q9Knh" title="Shares issued for piggyback registration rights">60,584</span> shares of the Company’s Class A common stock as consideration for further amendments to the settlement and release agreement. On June 4, 2024, the parties dismissed all claims and counterclaims. The MSA with Palantir is now fully terminated and neither party has any further rights or obligations thereunder. The shares of the Company’s Class A common stock issued to Palantir were issued with piggyback registration rights. Resale of such shares by Palantir shall be included on any future registration statement filed by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Celularity Inc. v. Evolution Biologyx, LLC, et al.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 17, 2023, the Company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively, “Evolution”) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for the sale of its biomaterial products in the amount of approximately $<span id="xdx_906_ecustom--SaleOfBiomaterialProductsAmount_pn4n6_c20230417__20230417__srt--LitigationCaseAxis__custom--EvolutionMember_z74malwLZhRi" title="Sale of biomaterial products amount">2.35</span> million, plus interest. In September 2021, the Company executed a distribution agreement with Evolution, whereupon Evolution purchased biomaterial products from the Company for sale through Evolution’s distribution channels. The Company fulfilled Evolution’s orders and otherwise performed each of its obligations under the distribution agreement. Despite attempts to recover the outstanding invoices and Evolution’s promise to pay, Evolution has refused to pay any of the invoices and has materially breached its obligations under the distribution agreement. The Company’s complaint asserts claims of breach of contract and fraudulent inducement, amongst others. The Company intends to vigorously pursue the matter to recover the outstanding payments owed by Evolution, as well as interest and reasonable attorney’s fees, but there can be no assurance as to the outcome of the litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> 1606000 105945000 40000000 P5Y 24402000 3500000 3500000 7333000 8000000 136000 113000 5099000 P10Y P30D 3500000 60584 2350000 <p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zjs0pQa2JPy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_823_zI0qquOxb37i">Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zW35q0lXSNOc" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zpA3F6c4c7j6" title="Common stock, shares authorized">730,000,000</span></span> shares of $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHjH3IvDSVle" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp67jHCcyiyd" title="Common stock, par value">0.0001</span></span> par value Class A common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Power</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company’s directors and all other matters requiring stockholder action. Holders of <span id="xdx_905_eus-gaap--CommonStockVotingRights_c20230101__20231231_zvgYXuNHEL2l" title="Common stock, voting rights">common stock are entitled to one vote per share</span> on matters to be voted on by stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of Class A Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company’s board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation, Dissolution and Winding Up</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preemptive or Other Rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Election of Directors</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class serving a three-year term, except with respect to the election of directors at the special meeting held in connection with the merger with GX. Class I directors are elected to an initial one-year term (and three-year terms subsequently), the Class II directors are elected to an initial two-year term (and three-year terms subsequently) and the Class III directors are elected to an initial three-year term (and three-year terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the holders of more than <span id="xdx_908_ecustom--PercentageOfSharesRequiredForVoting_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zd9XrhJrA9Na" title="Percentage of shares required for voting">50</span>% of the shares voted for the election of directors can elect all of the directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Certificate of Incorporation authorized <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zDrdRekRs4ig" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock and provides that shares of preferred stock may be issued from time to time in one or more series. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series of preferred stock. The Company’s board of directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock and could have anti-takeover effects. The ability of the Company’s board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management. As of December 31, 2023 and 2022, the Company does <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zkyfLnfxjo3d" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20221231_zO70dtGOU9H6" title="Preferred stock, shares outstanding">no</span></span>t have any outstanding preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 2022 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2022, the Company entered into a securities purchase agreement with an institutional accredited investor providing for the private placement of (i) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220518__20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxAUjbmuLTwa" title="Purchase and sale of shares">405,405</span> shares of Class A common stock and (ii) accompanying warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq1sWYz5bEXa" title="Warrants to purchase aggregate shares">405,405</span> shares of Class A common stock (the “May 2022 PIPE Warrants”), for $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z0CICuUxsR0h" title="Purchase price of per share">74.0</span> per share and accompanying warrant, or an aggregate purchase price of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20220518__20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgtiU4PxFHV8" title="Proceeds from PIPE financings">30,000</span> gross, or $<span id="xdx_905_ecustom--ProceedsFromIssuanceOfPrivatePlacementNet_pn3n3_c20220518__20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zrW2CFZ8jZVi" title="Net related cost">27,396</span> net of related costs of $<span id="xdx_909_ecustom--ReductionToAdditionalPaidInCapital_pn3n3_c20220518__20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zl4laIz1Bzq8" title="Reduction to additional paid in capital">2,604</span> which were recorded as a reduction to additional paid-in-capital. The net proceeds were allocated to the warrant liability as noted below with the remainder of $<span id="xdx_90D_ecustom--ProceedsFromIssuanceOfPrivatePlacementInAdditionalPaidInCapitalNet_pn3n3_c20220518__20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOTqN92olgXc" title="Proceeds from issuance of private placement in additional paid in capital, net">7,651</span> recorded in additional paid-in capital. Each warrant has an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRN8Ibg5K2wa" title="Exercise price">82.50</span> per share, is immediately exercisable, will expire on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgMpFtIimTJ2" title="Warrants and rights outstanding, expire date">May 20, 2027</span> (<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zakDSTGjvwC7" title="Term (years)">five years</span> from the date of issuance) (the “May 2022 PIPE Financing”). The closing of the May 2022 PIPE Financing occurred on <span id="xdx_90D_ecustom--WarrantsAndRightsIssuedClosingDate_c20220518__20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAxAdbznqah4" title="Warrants and rights issued closing date">May 20, 2022</span>. In the event of certain fundamental transactions involving the Company, the holders of May 2022 PIPE Warrants may require the Company to make a payment based on a Black-Scholes valuation, using specified inputs that are not considered indexed to the Company’s stock in accordance with ASC 815. Therefore, the Company accounted for the May 2022 PIPE Warrants as liabilities and were recorded at the Closing Date fair value $<span id="xdx_90F_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOyLouPVwge9" title="Fair value of the warrant liability">19,745</span> which was based on a Black-Scholes option pricing model. The remainder of the proceeds were allocated to the Class A common stock issued and recorded as a component of equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 10, 2023, upon the closing of a registered direct offering (see further discussion below), the Company amended the existing May 2022 PIPE Warrants, to reduce the exercise price from $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfG0o013WzW5" title="Purchase price of per share">82.50</span> to $<span id="xdx_902_ecustom--ReducedExercisePrice_pid_c20230410__20230410__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z6a6ROeeuup4" title="Reduced exercise price">7.50</span> per share and extended the expiration <span id="xdx_90C_ecustom--AmendedTerminationDateDescription_c20230410__20230410__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zaOo0p3AtyVi" title="Amended termination date description">date to five and one-half years following the closing of the offering</span> or October 10, 2028. The modification resulted in the recognition of additional warrant liability of $<span id="xdx_903_ecustom--AdditionalWarrantLiability_iI_pn3n3_c20230410_zceqmO65pzEc" title="Additional warrant liability">1,389</span> based on the Black-Scholes option pricing model as of the modification date. A further modification occurred in connection with the July 2023 registered direct offering to further reduce the exercise price to $<span id="xdx_908_ecustom--ReducedExercisePrice_pid_c20230701__20230731__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zGjp1i0xwqP6" title="Reduced exercise price">3.50</span> on warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsModifiedMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z4MD4wdWwJhf" title="Warrants to purchase aggregate shares">892,857</span> shares of Class A common stock which included the May 2022 PIPE Warrants of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230731__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsModifiedMember_zOnGryrdqyUa" title="Number of warrants or rights outstanding">405,405</span> and a partial modification on the April 2023 Registered Direct Warrants of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230731__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zqwZBoDbaFDd" title="Number of warrants or rights outstanding">487,451</span>. The modification resulted in an increase to the warrant liability of $<span id="xdx_908_ecustom--WarrantLiability_iI_pn3n3_c20230731_z5nmNcG6nMPe" title="Warrant liabilities">511</span> based on the Black-Scholes option pricing model as of the July 31, 2023 modification date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ATM Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2022, the Company entered into an At-the-Market Sales Agreement (the “ATM Agreement”) with BTIG, LLC, Oppenheimer &amp; Co. Inc. and B. Riley Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, having an aggregate offering price of up to $<span id="xdx_909_ecustom--AggregateOfferingPrice_pn3n3_c20220908__20220908__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z9KMhslHUyOb" title="Aggregate offering price">150,000</span>, subject to certain limitations as set forth in the ATM Agreement. The Company is not obligated to make any sales of shares under the ATM Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any shares offered and sold in the at-the-market offering will be issued pursuant to the Company’s effective shelf registration statement on Form S-3 and the related prospectus supplement. Under the ATM Agreement, the sales agents may sell shares of common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act. The Company will pay the sales agents a commission rate of up to <span id="xdx_90D_ecustom--MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z5X04PPOZvI4" title="Sales agents commission rate">3</span>% of the gross sales proceeds of any shares sold and has agreed to provide the sales agents with customary indemnification, contribution and reimbursement rights. The ATM Agreement contains customary representations and warranties and conditions to the placements of the shares pursuant thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company received gross and net proceeds of $<span id="xdx_908_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_zfcmIuEGtHU4" title="Gross proceeds from issuance of common stock">141</span> and $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z6Re5vTHU8p3" title="Net proceeds from sale of common stock">136</span> respectively, from the sale of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zpvLayFkML51" title="Purchase and sale of shares">13,296</span> shares of its common stock at an average price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zqwXNZpv4st4" title="Average price per share">10.60</span> per share under the ATM Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>March 2023 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert Hariri, providing for the private placement of (i) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z8j8Teuhaci8" title="Purchase and sale of shares">938,183</span> shares of its Class A common stock, and (ii) accompanying warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8yPUf6E5jbb" title="Warrants to purchase aggregate shares">938,183</span> shares of Class A common stock (the “March 2023 PIPE Warrants”), for $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__srt--RangeAxis__srt--MaximumMember_zViCfAtV2Iq7" title="Purchase price of per share">83.43</span> per share and $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYDT0dXSQR07" title="Purchase price of per share">1.25</span> per accompanying March 2023 PIPE Warrant, for an aggregate purchase price of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z46ccdX3ogX1" title="Proceeds from PIPE financings">9,000</span> (of which Dr. Hariri subscribed for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2lgdwMqrQx9" title="Proceeds from PIPE financings">2,000</span>). The closing of the private placement occurred on March 27, 2023. Each March 2023 PIPE Warrant has an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zfwzZM8mvjLa" title="Exercise price">30.00</span> per share, is immediately exercisable, will expire on <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zQdWDpGJltAi" title="Expiration dateity">March 27, 2028</span> (<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zpAko5Uw6BFi" title="Term (years)">five years</span> from the date of issuance), and is subject to customary adjustments for certain transactions affecting the Company’s capitalization. The March 2023 PIPE Warrants may not be exercised if the aggregate number of shares of Class A common stock beneficially owned by the holder thereof (together with its affiliates) would exceed the specified percentage cap provided therein (which may be adjusted upon <span id="xdx_900_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zmkxNAqhBEnj" title="Adjusted advance notice period">61</span> days advance notice) immediately after exercise thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the March 2023 PIPE Warrants and common stock as a single non-arm’s length transaction. The Company applied the guidance for this transaction in accordance with ASU 2020-06, (Subtopic 470-20): <i>Debt - Debt with Conversion and Other Options, ASC 815 Derivatives and Hedging, </i>and <i>ASC 480 Distinguishing Liabilities from Equity</i>. Accordingly, the net proceeds were allocated between common stock and the March 2023 PIPE warrants at their respective fair value, which resulted in a net premium of $<span id="xdx_90E_ecustom--PremiumPaidForPrivatePlacementPurchase_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zBHbQjQ3CJNl" title="Premium paid for private placement purchase">1,650</span> based on the difference between the proceeds and fair value of the common stock and March 2023 PIPE warrants, which was recorded as additional paid-in capital within stockholders’ equity on the consolidated balance sheets. The fair value of the March 2023 PIPE Warrants was determined using a Black-Scholes option pricing model and the common stock based on closing date share price. The Company evaluated the March 2023 PIPE warrants under ASC 815 and determined that they did not require liability classification and met the requirements for a derivative scope exception under <i>ASC 815-10-15-74(a) </i>for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. The warrants were recorded in additional paid-in capital within stockholders’ equity on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2023, the Company entered into a warrant amendment on the March 2023 PIPE Warrants with the unaffiliated investor to reduce the exercise price from $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_ze95mG5QtFNj" title="Purchase price of per share">30.00</span> per share to $<span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230314__20230314__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zX40WW66Y5L8" title="Reduced exercise price">10.00</span> per share for warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zAiINrBxpZQ4" title="Warrants to purchase aggregate shares">729,698</span> shares of Class A common stock. The warrant amendment was executed as consideration for professional services rendered to the Company. As a result, the Company accounted for the transaction in accordance with <i>ASC 718 Stock-Based Compensation </i>based on the calculated incremental fair value attributable to the modified warrant compared to the original warrant immediately prior to the modification and recognized an expense of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn3n3_c20230101__20231231_z82szbxxqzC9" title="Fair value of modified warrant, incremental expense">402</span> within selling, general and administrative on the consolidated statements of operations for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Registered Direct Offerings</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 10, 2023, the Company closed on a registered direct offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230410__20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zPKzvL1vgHL2" title="Purchase and sale of shares">923,076</span> shares of its Class A common stock together with warrants (“April 2023 Registered Direct Warrants”) to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zbHoVtGlUvgf" title="Warrants to purchase aggregate shares">923,076</span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z4fMJyeWHWKe" title="Purchase price of per share">6.50</span> per share and accompanying warrant, resulting in total gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230410__20230410_z4chmlNzykc4" title="Proceeds from the exercise of warrants">6,000</span> before deducting placement agent commissions and other estimated offering expenses. The April 2023 Registered Direct Warrants have an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230410_zGRTW4L620V3" title="Exercise price">7.50</span>, became exercisable beginning six months after the date of issuance and will expire <span id="xdx_90C_ecustom--WarrantExpirationTerm_pid_c20230410__20230410_zRUO19D9O512" title="Warrant term">five years</span> thereafter. The Company used the $<span id="xdx_901_ecustom--DebtInstrumentPayment_pn3n3_c20230410__20230410_z4QdZPsAHp73" title="Debt instrument payment">5,505</span> net proceeds from the offering to repay its obligations to Yorkville under the PPA. The Company considered the appropriate accounting guidance and concluded that the April 2023 Registered Direct Warrants qualified for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_907_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230410_zxNPQUGZiSwa" title="Fair value of the warrant liability">4,280</span> which was based on a Black-Scholes option pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded as a component of equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2023, the Company closed on a registered direct offering of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230731__20230731_z2J2ygx2qiGk" title="Purchase and sale of shares">857,142</span> shares of its Class A common stock together with warrants (“July 2023 Registered Direct Warrants”) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxfomlxpNTr9" title="Warrants to purchase aggregate shares">857,142</span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zLh50mIPE4Zf" title="Purchase price of per share">3.50</span> per share and accompanying warrant, resulting in total gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230731__20230731_zOMOk5lk91o4" title="Proceeds from the exercise of warrants">3,000</span> before deducting placement agent commissions and other estimated offering expenses. The July 2023 Registered Direct Warrants have an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731__srt--RangeAxis__srt--MinimumMember_zcomIOzIuhk3" title="Exercise price">3.50</span>, became exercisable beginning six months after the date of issuance and will expire <span id="xdx_903_ecustom--WarrantExpirationTerm_c20230731__20230731_zZe3StgTveue" title="Warrant term">five years</span> thereafter. The Company used the $<span id="xdx_90F_ecustom--DebtInstrumentPayment_pn3n3_c20230731__20230731_zv63gmNbaFwj" title="Debt instrument payment">2,740</span> net proceeds for working capital and general corporate purposes. The Company considered the appropriate accounting guidance and concluded that the July 2023 Registered Direct Warrants qualified for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_90B_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230731_zX30Jx4grKlb" title="Fair value of the warrant liability">2,645</span> which was based on a Black-Scholes option pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded as a component of equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the July 31, 2023 registered direct offering described above, the Company also entered into an amendment to certain existing warrants to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731_zjKCylQTiqyi" title="Warrants to purchase Class A common stock">892,856</span> shares at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731__srt--RangeAxis__srt--MaximumMember_zJmf5cb3lu1j" title="Exercise price">7.50</span> (consisting of all of the warrants originally issued in May 2022 and a portion of which were issued in April 2023), and such amended warrants have a reduced exercise price of $<span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230731__20230731_zmbjJTq0qYz" title="Reduced exercise price">3.50</span> per share. As noted above, the modification resulted in an increase to the warrant liability of $<span id="xdx_90A_ecustom--WarrantLiability_iI_pn3n3_c20230731_zddxwweHMaP1" title="Warrant liabilities">511</span> based on the Black-Scholes option pricing model as of the July 31, 2023 modification date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 2023 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2023, the Company closed on a securities purchase agreement with a group of accredited investors, providing for the private placement of an aggregate (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230518__20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z4Yv2zmw2FJl" title="Purchase and sale of shares">581,394</span> shares of its Class A common stock and (ii) accompanying warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zfrpU9jMvMCh" title="Warrants to purchase aggregate shares">581,394</span> shares of Class A common stock (the “May 2023 PIPE Warrants”), for $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zAcCyY4dTTHl" title="Purchase price of per share">5.20</span> per share and $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxInrfKNGjFf" title="Purchase price of per share">1.25</span> per accompanying May 2023 PIPE Warrant, for an aggregate gross purchase price of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zSRR7COsn3za" title="Proceeds from PIPE financings">3,750</span>. Each May 2023 PIPE Warrant has an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zA7J9gVMdqPc" title="Exercise price">10.00</span> per share, is immediately exercisable, will expire on <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20230518_zzsGeTxdBwmg" title="Warrants and rights outstanding, expire date">May 18, 2028</span> (<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zVARuqDRXyB9" title="Term (years)">five years</span> from the date of issuance), and is subject to customary adjustments for certain transactions affecting the Company’s capitalization. The May 2023 PIPE Warrants may not be exercised if the aggregate number of shares of Class A common stock beneficially owned by the holder thereof (together with its affiliates) would exceed the specified percentage cap provided therein (which may be adjusted upon <span id="xdx_904_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zYaIkg8qpKNg" title="Adjusted advance notice period">61</span> days advance notice) immediately after exercise thereof. The Company evaluated the May 2023 PIPE Warrants under ASC 815 and determined that they did not require liability classification and met the requirements for a derivative scope exception under <i>ASC 815-10-15-74(a) </i>for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. Accordingly, the proceeds were allocated between common stock and the May 2023 PIPE Warrants at their respective relative fair value basis to stockholders’ equity on the consolidated balance sheets. The fair value of the May 2023 PIPE Warrants was determined using a Black-Scholes option pricing model and the common stock based on the closing date share price and were recorded in additional paid-in capital within stockholders’ equity on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2022, Celularity and certain of the related party investors amended and restated the investors’ respective Legacy Celularity Warrants to (i) reduce the exercise price per share from $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220301__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zIaaay5XZJS3" title="Exercise price">75.30</span> per share to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220301__srt--RangeAxis__srt--MinimumMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z6Ymr9A5L64d" title="Exercise price">35.00</span> per share, subject to adjustment as set forth in the A&amp;R Warrants, (ii) remove the transfer restrictions set forth in the A&amp;R Warrants, and (iii) make other changes reflecting the impact of the business combination. In conjunction with the amendment, those investors exercised <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220301__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zMJrbWxMbOrl" title="Warrants to purchase aggregate shares">1,328,138</span> of the A&amp;R Warrants in exchange for <span id="xdx_90A_eus-gaap--SharesIssued_iI_pid_c20220301__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zKqixHWst43i" title="Number of shares issued">1,328,138</span> shares of Class A Common Stock for gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20220301__20220301__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zI7Zv91hNMQ3" title="Proceeds from the exercise of warrants">46,485</span>. The Company accounted for the amendment as a cost to issue equity with the incremental fair value of $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20220301__20220301__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_ziDYeh0zmN15" title="Issuance cost of equity">15,985</span> related to the amendment recognized as an offset to the proceeds received. However, because these were equity classified warrants, the net impact to the consolidated statements of convertible preferred stock and stockholders’ equity (deficit) was zero.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had outstanding warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zyMICj6JPa69" title="Warrants to purchase aggregate shares">7,070,627</span> shares of Class A common stock. A summary of the warrants is as follows:</span></p> <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8hUp0a8Hv47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zI2BgyOjUbke" style="display: none">Summary of the Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration<br/> date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Dragasac Warrant(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zTOfdy1FXxx2" style="width: 15%; text-align: right" title="Number of shares">652,981</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zq8SLZrG7Mx2" style="width: 15%; text-align: right" title="Exercise price">67.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 20%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zFCFZKIpk97d" title="Expiration date">March 16, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Public Warrants(2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zCJYSQAZTtj4" style="text-align: right" title="Number of shares">1,437,447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zUIoPdEJ7pX5" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zl2mzXYoXjdc" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Sponsor Warrants(2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zjCXKtjfrgH6" style="text-align: right" title="Number of shares">849,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zNcPwSZfgzO8" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zWWxkf0PeAYg" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zuaqtJOVbS74" style="text-align: right" title="Number of shares">405,405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zU4LQe0KgHCc" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zIhqFsv3Zefc" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zijbl9Yb0vHi" style="text-align: right" title="Number of shares">208,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_ziykuMDYT0d7" style="text-align: right" title="Exercise price">30.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zz78Bb0PgjAf" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">March 2023 PIPE Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_ztw2AlkiyvGb" style="text-align: right" title="Number of shares">729,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zuaCo9zAypH3" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zKx8aBG2Taj6" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 Loan Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_z7jAukxG3PCd" style="text-align: right" title="Number of shares">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zMa7IgUmqHgb" style="text-align: right" title="Exercise price">7.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zKZOoWgWfHOh" title="Expiration date">March 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zpqNZ9A93Phd" style="text-align: right" title="Number of shares">435,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zmVKBncm2Lll" style="text-align: right" title="Exercise price">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zEl0nfruZadi" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2023 Registered Direct Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zntp83GCXvad" style="text-align: right" title="Number of shares">487,451</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zXzhIOxaeCGa" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_z4HXVdH6ajmh" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zPecD4hEXAM6" style="text-align: right" title="Number of shares">581,394</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zBcbAipxk9j8" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zFWE1cTqU1ul" title="Expiration date">May 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 2023 Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zEVwIdRhdP2h" style="text-align: right" title="Number of shares">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zhTBRJ91jV26" style="text-align: right" title="Exercise price">8.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_z7udC12PwMp4" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>June 2023 Loan Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zjYRAXHVgrTk" style="text-align: right" title="Number of shares">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zV6mLoBLv6Y8" style="text-align: right" title="Exercise price">8.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z1GtcOltSBC9" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">July 2023 Registered Direct Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zst6Msv1njff" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares">857,142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_znDLKcDTg3g7" style="padding-bottom: 1pt; text-align: right" title="Exercise price">3.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_ze6uSq6hDUPg" title="Expiration date">January 31, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zXEJOGHYeqee" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares">7,070,627</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F05_zSYyRRTaV3Hb">(1)</i></span></td><td style="text-align: justify"><i id="xdx_F10_z4hq4nkbL9ig">The exercise price is the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zslHPaZ3UN8d" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> per share or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--WarrantsPerSharePercentage_iI_pid_dp_uPure_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zZX3xAkKodR9" title="Warrants per share, percentage">80</span>% of either (i) the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii) the price at which one share of common stock is sold to the public market in an initial public offering.</i></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F06_zqp2ODGI1yl">(2)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1E_zHitPizwtIt">The number of Public Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_ecustom--WarrantsOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_z9j83frqagE4" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--WarrantsOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zrZWZtrChyq" title="Warrants outstanding">8,499,999</span> Sponsor Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zPO5YB7fAHpi" title="Exercise per share price (in Dollars per share)">115.00</span> as a result of the split.</i></span></td> </tr></table> <p id="xdx_8AE_zSBa4eLOmSuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">2024 Warrant Repricing</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the execution of the private placement on January 12, 2024 described below, the Company agreed to reprice <span id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbbN2BsnXwpf" title="Number of warrants repriced">652,981</span> legacy warrants held by Dragasac with a previous exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zGt5VdIa1Zoi" title="Exercise price">67.70</span> to a new exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2haAjnpVlRc" title="Exercise price">2.4898</span>. The term of the warrant was unchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">January 2024 PIPE Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company entered into a securities purchase agreement with an existing investor, Dragasac Limited, providing for the private placement of (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zNhalMKeWof2" title="Purchase and sale of shares">2,141,098</span> shares of its Class A common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zOGmYjBvE0Wg" title="Common stock, par value">0.0001</span> per share, or the Class A common stock, and (ii) accompanying warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zPcWgJTwWTql" title="Warrants to purchase aggregate shares">535,274</span> shares of Class A common stock (“January 2024 PIPE Warrants”), for $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zZBuCrnUwVkb" title="Exercise price">2.4898</span> per share and $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zWR7yktmMGR9" title="Purchase price of per share">1.25</span> per accompanying January 2024 PIPE Warrant, for an aggregate purchase price of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240112__20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlFwP9KnbCb1" title="Aggregate purchase price">6,000</span>. The closing of the private placement occurred on <span id="xdx_900_ecustom--WarrantsAndRightsIssuedClosingDate_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zksgByZ1Aeba" title="Warrants and rights issued closing date">January 16, 2024</span>. The securities were issued pursuant to an exemption from registration provided for under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The offer and sale of the shares and January 2024 PIPE Warrants (including the shares underlying the January 2024 PIPE Warrants) has not been registered under the Act or any state securities laws. The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Each 2024 PIPE Warrant has an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zGe4CPaEyPMj" title="Exercise price">2.4898</span> per share, is immediately exercisable, and will expire on <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_ze5OhNBdlzL9" title="Warrants and rights outstanding, expire date">January 16, 2029</span> (<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z4KRV541gCWd" title="Term (years)">five years</span> from the date of issuance).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective February 16, 2024, in order to comply with Section 4.15(a) of the securities purchase agreement, the Company entered into an amended employment agreement with its Chief Administrative Officer (“CAO”), whereby the CAO agreed to decrease his base salary from $<span id="xdx_901_ecustom--RelatedPartyBaseSalary_pn3n3_c20240215__20240215__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9G8PfAknJil" title="Base salary">500</span> to $<span id="xdx_906_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zo8Kklz6dMQ1" title="Base salary">425</span> per year through December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Warrant Modifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, in connection with the RWI Forbearance Agreement (See Note 10), the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zYg4hPluxcMa" title="Number of warrants repriced">300,000</span> shares of Common Stock, which expires <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240313__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNiWyzMhAfV" title="Warrants and rights outstanding, expire date">June 20, 2028</span> and has an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYV8VzXA0Pm" title="Exercise price">5.895</span> per share. Additionally, on March 13, 2024, in connection with the Starr Forbearance Agreement (See Note 10), the Company agreed to amend the exercise price of the <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_z2aJnDEIltYk" title="Warrants to purchase aggregate shares">75,000</span> March 2023 Loan Warrants expiring <span id="xdx_90C_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zKbdrUUdcnL6" title="Warrant expiration date">March 17, 2028</span> from $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240312__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zy7fau48wBC2" title="Exercise price">7.10</span> per share to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zxQkjvhAJCc2" title="Exercise price">5.895</span> per share (the “Minimum Price” as determined pursuant to Nasdaq 5635(d) on March 13, 2024) and the <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zt60p8cadome" title="Warrants to purchase aggregate shares">50,000</span> June 2023 Warrants expiring <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zTqSj9D6Slll" title="Warrant expiration date">June 20, 2028</span> from $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_z0UC6jrkdPB8" title="Exercise price">8.10</span> per share to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zssYnbCpUdp2" title="Exercise price">5.895</span> per share, each of which are held by C.V. Starr.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standby Equity Purchase Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company and Yorkville entered into a SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $<span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zISC1erJqgPf" title="Common stock, shares authorized">10,000,000</span> of its Class A common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zLV3pCESadSb" title="Common stock, par value">0.0001</span> per share subject to certain limitations and conditions set forth in the SEPA, from time to time, over a 36-month period. Sales of the common stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company’s option, and the Company is under no obligation to sell any shares of common stock to Yorkville under the SEPA except in connection with notices that may be submitted by Yorkville, in certain circumstances as described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the satisfaction of the conditions precedent in the SEPA, which include having a resale shelf for shares of common stock issued to Yorkville declared effective, the Company has the right to direct Yorkville to purchase a specified number of shares of common stock by delivering written notice (“Advance”). An Advance may not exceed <span id="xdx_90C_ecustom--SaleOfStockMaximumAverageDailyTradedAmountPercentage_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zQYDPCDAmt67" title="Sale of stock, maximum average daily traded amount (in percent)">100</span>% of the average of the daily trading volume of the common stock on Nasdaq, during the <span id="xdx_908_ecustom--SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_pid_dc_uInteger_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zRQFPRsxBZYg" title="Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days">five</span> consecutive trading days immediately preceding the written notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yorkville will generally purchase shares pursuant to an Advance at a price per share equal to <span id="xdx_90B_ecustom--SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zGeMLDWZZ3U6" title="Sale of stock, percentage based on volume weighted average price">97</span>% of the VWAP, on Nasdaq during the <span id="xdx_904_ecustom--SaleOfStockLowestDailyVolumeWeightedAveragePriceThresholdConsecutiveTradingDays_pid_dc_uInteger_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zU0Bkba2J5G8" title="Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days">three</span> consecutive trading days commencing on the date of the delivery of the written notice (unless the Company specifies a minimum acceptable price or there is no VWAP on the subject trading day).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The SEPA will automatically terminate on the earliest to occur of (i) the first day of the month next following the 36-month anniversary of the date of the SEPA or (ii) the date on which Yorkville shall have made payment of for shares of common stock equal to $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zH64dqnLhGF" title="Consideration shares of common stock">10.0</span> million. The Company has the right to terminate the SEPA at no cost or penalty upon five trading days’ prior written notice to Yorkville, provided that there are no outstanding advances for which shares of Common Stock need to be issued and the convertible </span>note (Initial Advance) has been paid in full. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As consideration for Yorkville’s commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville a $<span id="xdx_900_ecustom--SaleOfStockConsiderationCashDueDiligenceFee_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zR8n2V3WP9dl" title="Cash due diligence fee">25</span> cash due diligence fee and a commitment fee equal to <span id="xdx_909_ecustom--SaleOfStockConsiderationCommitmentFeeInShares_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_z3wk76Kxtuka" title="Commitment fee in shares">16,964</span> shares of common stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the entry into the SEPA, on March 13, 2024, the Company entered into a registration rights agreement with Yorkville, pursuant to which the Company agreed to file with the Securities and Exchange Commission (“SEC”) no later than May 3, 2024, a registration statement for the resale by Yorkville of the shares of Common Stock issued under the SEPA (including the commitment fee shares). The Company agreed to use commercially reasonable efforts to have such registration statement declared effective within 45 days of such filing and to maintain the effectiveness of such registration statement during the 36-month commitment period. The Company will not have the ability to request any Advances under the SEPA (nor may Yorkville convert the Initial Advance into Common Stock) until such resale registration statement is declared effective by the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delaware Section 205 Proceeding </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2021, Celularity, then operating as GX Acquisition Corp. (“Pre-Merger Company”), held a special meeting of stockholders (the “Special Meeting”) to approve certain matters related to the business combination between the Pre-Merger Company and Celularity Operations, Inc. (“Legacy Celularity”), including a proposal to adopt a certificate of amendment to the Pre-Merger Company’s amended and restated certificate of incorporation (the “Pre-Merger Charter”) to increase the number of authorized shares of its common stock from <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210714_zoBOf0K5U5X7" title="Common stock, shares authorized">110,000,000</span> to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zykKw1MXd9E" title="Common stock, shares authorized">730,000,000</span> (the “Increase Amendment”). The Increase Amendment received approval from the holders of a majority of the Pre-Merger Company’s outstanding shares of Class A common stock and Class B common stock, voting together as a single class, that were outstanding as of the record date for such Special Meeting. Following the Special Meeting, the business combination closed, the Pre-Merger Company changed its name to “Celularity Inc.” and the Pre-Merger Charter, as amended to give effect to the Authorized Share Amendment (the “New Charter”), became effective.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A recent decision by the Court of Chancery of the State of Delaware (the “Court”) <i>in Garfield v. Boxed, Inc.</i>, 2022 WL 17959766 (Del. Ch. Dec. 27, 2022), created uncertainty as to whether Section 242(b)(2) of the Delaware General Corporation Law (“DGCL”) would have required the Celularity to seek and obtain a vote of a majority of the shares of Class A common stock to approve the Increase Amendment to the Pre-Merger Charter. Thus, to resolve any potential uncertainty, on March 14, 2023, Celularity filed a petition (the “Petition”) in the Court under Section 205 of the DGCL seeking validation and a declaration of effectiveness of the New Charter and actions taken in reliance thereon, including the Increase Amendment and the shares issued pursuant thereto, captioned <i>In re Celularity, Inc.</i>, C.A. No. 2023-0317-LWW (Del. Ch.) (the “Section 205 Action”). Section 205 of the DGCL permits the Court, in its discretion, to ratify and validate potentially validate corporate acts and stock after considering a variety of factors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 29, 2023, the Court of Chancery held a hearing in the Section 205 Action and orally granted the Petition, and, later that same day, the Court issued an order in the Section 205 Action, in which it validated and declared effective the Increase Amendment and the Certificate of Incorporation as of 10:00 a.m. (EDT) on July 16, 2021, and all shares of capital stock of the Company issued in reliance on the effectiveness of the Increase Amendment and the Certificate of Incorporation as of the date and time of the original issuance of such shares. The Courts order has addressed and eliminated the uncertainty created by the <i>Garfield </i>Court’s decision.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> 730000000 730000000 0.0001 0.0001 common stock are entitled to one vote per share 0.50 10000000 0 0 405405 405405 74.0 30000000 27396000 2604000 7651000 82.50 2027-05-20 P5Y 2022-05-20 19745000 82.50 7.50 date to five and one-half years following the closing of the offering 1389000 3.50 892857 405405 487451 511000 150000000 0.03 141000 136000 13296 10.60 938183 938183 83.43 1.25 9000000 2000000 30.00 2028-03-27 P5Y P61D 1650000 30.00 10.00 729698 402000 923076 923076 6.50 6000000 7.50 P5Y 5505000 4280000 857142 857142 3.50 3000000 3.50 P5Y 2740000 2645000 892856 7.50 3.50 511000 581394 581394 5.20 1.25 3750000 10.00 2028-05-18 P5Y P61D 75.30 35.00 1328138 1328138 46485000 15985000 7070627 <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8hUp0a8Hv47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zI2BgyOjUbke" style="display: none">Summary of the Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration<br/> date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Dragasac Warrant(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zTOfdy1FXxx2" style="width: 15%; text-align: right" title="Number of shares">652,981</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zq8SLZrG7Mx2" style="width: 15%; text-align: right" title="Exercise price">67.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 20%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zFCFZKIpk97d" title="Expiration date">March 16, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Public Warrants(2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zCJYSQAZTtj4" style="text-align: right" title="Number of shares">1,437,447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zUIoPdEJ7pX5" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zl2mzXYoXjdc" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Sponsor Warrants(2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zjCXKtjfrgH6" style="text-align: right" title="Number of shares">849,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zNcPwSZfgzO8" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zWWxkf0PeAYg" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zuaqtJOVbS74" style="text-align: right" title="Number of shares">405,405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zU4LQe0KgHCc" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zIhqFsv3Zefc" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zijbl9Yb0vHi" style="text-align: right" title="Number of shares">208,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_ziykuMDYT0d7" style="text-align: right" title="Exercise price">30.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zz78Bb0PgjAf" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">March 2023 PIPE Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_ztw2AlkiyvGb" style="text-align: right" title="Number of shares">729,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zuaCo9zAypH3" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zKx8aBG2Taj6" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 Loan Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_z7jAukxG3PCd" style="text-align: right" title="Number of shares">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zMa7IgUmqHgb" style="text-align: right" title="Exercise price">7.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zKZOoWgWfHOh" title="Expiration date">March 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zpqNZ9A93Phd" style="text-align: right" title="Number of shares">435,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zmVKBncm2Lll" style="text-align: right" title="Exercise price">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zEl0nfruZadi" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2023 Registered Direct Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zntp83GCXvad" style="text-align: right" title="Number of shares">487,451</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zXzhIOxaeCGa" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_z4HXVdH6ajmh" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zPecD4hEXAM6" style="text-align: right" title="Number of shares">581,394</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zBcbAipxk9j8" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zFWE1cTqU1ul" title="Expiration date">May 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 2023 Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zEVwIdRhdP2h" style="text-align: right" title="Number of shares">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zhTBRJ91jV26" style="text-align: right" title="Exercise price">8.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_z7udC12PwMp4" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>June 2023 Loan Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zjYRAXHVgrTk" style="text-align: right" title="Number of shares">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zV6mLoBLv6Y8" style="text-align: right" title="Exercise price">8.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z1GtcOltSBC9" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">July 2023 Registered Direct Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zst6Msv1njff" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares">857,142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_znDLKcDTg3g7" style="padding-bottom: 1pt; text-align: right" title="Exercise price">3.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_ze6uSq6hDUPg" title="Expiration date">January 31, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zXEJOGHYeqee" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares">7,070,627</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F05_zSYyRRTaV3Hb">(1)</i></span></td><td style="text-align: justify"><i id="xdx_F10_z4hq4nkbL9ig">The exercise price is the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zslHPaZ3UN8d" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> per share or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--WarrantsPerSharePercentage_iI_pid_dp_uPure_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zZX3xAkKodR9" title="Warrants per share, percentage">80</span>% of either (i) the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii) the price at which one share of common stock is sold to the public market in an initial public offering.</i></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F06_zqp2ODGI1yl">(2)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1E_zHitPizwtIt">The number of Public Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_ecustom--WarrantsOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_z9j83frqagE4" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--WarrantsOutstanding_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zrZWZtrChyq" title="Warrants outstanding">8,499,999</span> Sponsor Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zPO5YB7fAHpi" title="Exercise per share price (in Dollars per share)">115.00</span> as a result of the split.</i></span></td> </tr></table> 652981 67.70 2025-03-16 1437447 115.00 2026-07-16 849999 115.00 2026-07-16 405405 3.50 2028-10-10 208485 30.00 2028-03-27 729698 10.00 2028-03-27 75000 7.10 2028-03-17 435625 7.50 2028-10-10 487451 3.50 2028-10-10 581394 10.00 2028-05-17 50000 8.10 2028-06-20 300000 8.10 2028-06-20 857142 3.50 2029-01-31 7070627 67.70 0.80 14374478 8499999 115.00 652981 67.70 2.4898 2141098 0.0001 535274 2.4898 1.25 6000000 2024-01-16 2.4898 2029-01-16 P5Y 500000 425000 300000 2028-06-20 5.895 10000000 0.0001 1 5 0.97 3 10000000.0 25000 16964 110000000 730000000 <p id="xdx_80A_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zKcex2Ye9Lce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_824_z9BBsswIJkUf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021 Equity Incentive Plan</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, the Company’s board of directors adopted and the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares of Class A Common Stock initially reserved for issuance under the 2021 Plan is <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20210731__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zWvzBMTfC4w7" title="Number of shares reserved for issuance">2,091,528</span>. As of December 31, 2023, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zw0W1AqvDxZ5" title="Number of shares remaining available for future grant">821,789</span> shares remain available for future grant under the 2021 Plan. The number of shares reserved for issuance will automatically increase on January 1 of each year, for a period of <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zraAPwjW2gq9" title="Number of shares issued for future issuance automatic increase period">10</span> years, from January 1, 2022 through January 1, 2031, by <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zAJSf3pXV4wh" title="Percentage of shares issued from outstanding capital stock, maximum">4</span>% of the total number of shares of Celularity capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company’s board of directors. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021 Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2021 Plan is administered by the Company’s board of directors. The Company’s board of directors, or a duly authorized committee thereof, may delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of the Company’s stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2017 Equity Incentive Plan</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2017 Equity Incentive Plan (the “2017 Plan”) adopted by Legacy Celularity’s board of directors and approved by Legacy Celularity’s stockholders provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with the closing of the Business Combination and effectiveness of the 2021 Plan, no further grants will be made under the 2017 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of stock options that could have been issued under the 2017 Plan was <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_z2U317JUnD0e" title="Number of shares remaining available for future grant">3,234,204</span>. Shares that expired, forfeited, canceled or otherwise terminated without having been fully exercised were available for future grant under the 2017 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2017 Plan is administered by the Company’s board of directors or, at the discretion of the Company’s board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy Celularity’s board of directors, or its committee if so delegated, except that the exercise price per share of stock options could not be less than <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_zYtWWfK1yMOk" title="Percentage of fair market value">100</span>% of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zgyNc4GlZfZe" title="Stock option, expiration period">ten years</span>. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over a <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zAFFdG2hxguf" title="Options vesting period::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2367">three</span></span> or <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_z1R1jBooRul3" title="Options vesting period">four year</span> period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Option Valuation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Awards with Service Conditions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span> The expected term of employee stock options with service-based vesting is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term or its estimated term based on the underlying agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● </span>The expected stock price volatility is based on historical volatilities of comparable public entities within the Company’s industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the respective expected term or contractual term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">● <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected dividend yield is <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dpxL_uPure_c20230101__20231231_zpwST8hD4dJ6" title="Expected dividend yield::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2371">0</span></span>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zpnQPZEzNo91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_8B1_zipwfOK8eTya">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zUeB3aeIXUQj" title="Risk-free interest rate">4.1</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zejmqaZQky15" title="Risk-free interest rate">2.7</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231_zz3xrrCQaKE7" title="Expected term (in years)">5.6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231_z9oMWsgpDVBj" title="Expected term (in years)">5.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zjkqdCsdE9Ce" title="Expected volatility">86.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zuEKEpEZBYtc" title="Expected volatility">77.1</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_z3uR9nEideV8" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2387">—</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zge285NjNwtd" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2389">—</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A1_zTfvfT1E3HD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant-date fair value per share of stock options granted during the years ended December 31, 2023 and 2022 was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_zT2XpNCqK3j9" title="Weighted average grant-date fair value of stock options granted">5.35</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_z3KKRXc53gh6" title="Weighted average grant-date fair value of stock options granted">5.43</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgTBt1s1dwf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zGIVuF0o3CA7">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Contract Term<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_znTmYKuxhLR9" style="width: 11%; text-align: right" title="Options beginning balance">2,514,452</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zyTsR1zro0O3" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, beginning balance">49.08</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z6EB76WTkj0a" style="width: 11%; text-align: right" title="Weighted Average Contract Term">6.1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zOXdcUMfpsc6" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value">7,851</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z0y9tfE0GUl6" style="text-align: right" title="Options Granted">741,634</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zoU70mlVkEia" style="text-align: right" title="Weighted Average Exercise Price, Granted">5.35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zxP3cNBvLWj" style="text-align: right" title="Options Exercised">(108,637</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zex19g5ERtC8" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Forfeited/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zTPhdQivmys4" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited/Expired">(327,262</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z2vC55IszP3e" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired">42.23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zq4FwXPrTSm9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options ending balance">2,820,187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zPixP1loiWCi" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance">40.16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_znq8GvUKGgOa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term">5.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zVh6PnhL6Jol" style="text-align: right" title="Options Vested and expected to vest">2,820,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4ba3yyr6JGa" style="text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest">40.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zv7OYnurtqtf" style="text-align: right" title="Weighted Average Contract Term, Vested and expected to vest">5.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_ztpA7mJCL3Rg" style="text-align: right" title="Options Exercisable">2,025,287</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4IEoDGQ5gxj" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">46.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zb8rpyf8VRDe" style="text-align: right" title="Weighted Average Contract Term Exercisable">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_z55KnKqXCkDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A Common Stock for those options that had exercise prices lower than the fair value of the Company’s Class A Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense relating to awards with service conditions of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNVQ69KjumJk" title="Stock-based compensation expense">9,293</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuOLvKxos3Pg" title="Stock-based compensation expense">10,702</span> during the years ended December 31, 2023 and 2022, respectively. During the years ended December 31, 2023 and 2022, the aggregate intrinsic value was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20230101__20231231_zvFRQVq3Ivmi" title="Aggregate intrinsic value, stock option exercised">0</span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20220101__20221231_zBLRtEXCSff9" title="Aggregate intrinsic value, stock option exercised">7,997</span> for the stock options exercised, respectively. As of December 31, 2023, unrecognized compensation cost for options issued with service conditions was $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOz512MgVDZb" title="Unrecognized compensation cost for options issued">13,449</span> and will be recognized over an estimated weighted-average amortization period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwO42SacmdU9" title="Estimated weighted-average amortization period">2.59</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Awards with Performance Conditions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the advisory agreement signed with Robin L. Smith, MD (see Note 19), the Company awarded options to acquire a total of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zooyJMFZaqMj" title="Vested options to acquire shares">105,000</span> shares with an exercise price of $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zUweftpcktCf" title="Vested options to acquire shares">29.90</span> to Dr. Smith, a former member of the Company’s board of directors. The initial tranche of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--InitialTrancheMember_zypx2j9kvr6a" title="Vested options to acquire shares">25,000</span> stock options vested upon execution of the advisory agreement on August 16, 2022. The remaining <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_z2ZqNcMeqqt4" title="Stock option vesting">80,000</span> stock options are subject to vesting upon achievement of certain predefined milestones in relation to the expansion of the degenerative disease business. On November 1, 2022, the second tranche of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--SecondTrancheMember_zhaD4DRvHMl4" title="Stock option vesting">20,000</span> stock options vested upon achievement of the first milestone. The fair value of the award was determined based on a Black-Scholes option-pricing model. The Company’s grant date fair value assumptions were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zuYbZYDlNEp6" title="Expected volatility">79.9</span>% expected volatility, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zPlAoDyhkq4c" title="Risk-free interest rate">2.95</span>% risk-free interest rate, <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zsK378ibneK2" title="Expected term (in years)">5</span> year expected term, and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zq3EaaLfJGFj" title="Expected dividend yield">0</span>% expected dividend yield. There were no milestones achieved and accordingly there was no stock-based compensation recorded during the year ended December 31, 2023. The remaining <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230816__20230816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zy24KFDjFOFj" title="Number of shares remaining stock options forfeited">60,000</span> stock options were forfeited on August 16, 2023 upon termination of the advisory agreement. The Company recorded stock-based compensation expense of $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zgkIzHH25Y9c" title="Stock-based compensation expense recognized">0</span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zudhmWLVPAuh" title="Stock-based compensation expense recognized">881</span> for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the remaining unrecognized compensation cost was $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20231231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zh80BgqullW8" title="Unrecognized compensation cost for options issued">1,175</span>, and will be recognized upon probable achievement of the milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Awards with Market Conditions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, the Company awarded options to acquire a total of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210901__20210930__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_zU8mIy8ipEia" title="Vested options to acquire shares">246,928</span> shares with an exercise price of $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210901__20210930__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_zKIZWbU5Pm5k" title="Vested options to acquire per share">63.20</span> to the Company’s former President in connection with the commencement of his employment. The grant was comprised of four equal tranches, and would <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230101__20231231__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_zcoP1bnkbh3h" title="Vesting description">vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date</span>, subject to his continued employment with the Company. The Company recognized stock-based compensation expense of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20221231__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_zoxwxU0iTqfl" title="Stock-based compensation">1,167</span> in 2022 and after the Company’s President resigned effective August 31, 2022, and the President’s award was terminated at such time, all previously recognized stock-based compensation expense of $<span id="xdx_908_ecustom--ReversedStockBasedCompensationExpenses_pn3n3_c20220101__20221231__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_zETItzmwnmxg" title="Reversed stock based compensation expenses">1,681 </span>was reversed in 2022, and a consulting agreement was signed thereafter, refer to Note 19 for further details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issues RSUs to employees that generally vest over a <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zisIr99nlTk" title="Options vesting period::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl2483">two-year</span></span> period with <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zSk2VfMKuS8l" title="Vesting percentage">50</span>% of awards vesting after 1 year and then the remaining <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zF1sg3TnSri1" title="Vesting percentage">50</span>% vesting after 2 years. Any unvested shares will generally be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company’s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 29.5pt"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zsMbSdxoxit2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 29.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activity related to RSU stock-based payment awards:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 29.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 29.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_ztkTbSKs9dQ4">Schedule of Activity Related to RSU Stock-Based Payment Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3cc87juZ0U9" style="width: 16%; text-align: right" title="Number of Shares opening balance">227,013</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqY0JbE7wuHb" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, beginning balance">73.35</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo7l6BpJiWei" style="text-align: right" title="Number of Shares Granted">954,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zek9PobeXCch" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">6.29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Released</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKudkW8682Gb" style="text-align: right" title="Number of Shares Released">(83,759</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zY14d0jLdz2f" style="text-align: right" title="Weighted Average Grant Date Fair Value, Released">65.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdOGg8XUVwj8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Forfeited">(274,853</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0WLDAzRCEii" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">21.37</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC80cjXRzOGd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares ending balance">823,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVtar4F95Sd7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance">13.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zvGBGdQZmrJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.75pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq3TMuhZQaJ7" title="Stock-based compensation expense">5,724</span> and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWc4BfGhrarj" title="Stock-based compensation expense">4,787</span> for the years ended December 31, 2023 and 2022, related to RSUs. As of December 31, 2023, the total unrecognized expense related to all RSUs was $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxwYhNWIsprj" title="Stock-based compensation expense">7,732</span>, which the Company expects to recognize over a weighted-average period of <span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zG5Z5pwSkSS9" title="Estimated weighted-average amortization period">2.06</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2023, the Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230701__20230731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzrenN3gFnmf" title="Number of shares granted">174,500</span> performance stock unit awards (“PSUs”) to certain members of management, with a grant date fair value of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230701__20230731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7ThUa1toe0j" title="Weighted average grant date fair value, granted">5.00</span> per unit based on the market closing share price on the date of grant. The awards are scheduled to vest over a period of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20230701__20230731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MinimumMember_zZF0uQotEDq8" title="Options vesting period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl2523">one</span></span> to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230701__20230731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--RangeAxis__srt--MaximumMember_z1L7wHs2sED8" title="Options vesting period">three years</span> from the grant date based on continuous employment and if a specified market performance is achieved. As of December 31, 2023, all of the PSUs were unvested and total unrecognized stock-based compensation expense was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJDvF529vcHg" title="Estimated weighted-average amortization period">871</span>, which is expected to be recognized over a weighted average period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2XAL6jlYygh" title="Estimated weighted-average amortization period">1.79</span> years if the underlying awards are deemed probably of being earned. As of December 31, 2023, the specified market based performance metric was deemed not probable of achievement, therefore <span id="xdx_900_eus-gaap--ShareBasedCompensation_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKhGj9w7CoM9" title="Stock based compensation">no</span> stock-based compensation was recognized during the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation Expense</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zdw3Zs970VZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zev3jYa8raD5">Schedule of Stock-based Compensation Expense </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zp5drBmMIof1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zELQXCQdw6og" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zUlNiPUxPofi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cost of revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">580</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">410</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI4M3FktvZ5e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,118</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zrCjpG79Wxw5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,605</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,328</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zFZLKZYkTLS7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,017</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,856</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_ziBttnZ1bVM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2091528 821789 P10Y 0.04 3234204 1 P10Y P4Y <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zpnQPZEzNo91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_8B1_zipwfOK8eTya">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zUeB3aeIXUQj" title="Risk-free interest rate">4.1</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zejmqaZQky15" title="Risk-free interest rate">2.7</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231_zz3xrrCQaKE7" title="Expected term (in years)">5.6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231_z9oMWsgpDVBj" title="Expected term (in years)">5.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zjkqdCsdE9Ce" title="Expected volatility">86.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zuEKEpEZBYtc" title="Expected volatility">77.1</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_z3uR9nEideV8" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2387">—</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zge285NjNwtd" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2389">—</span></span></td><td style="text-align: left">%</td></tr> </table> 0.041 0.027 P5Y7M6D P5Y10M24D 0.865 0.771 5.35 5.43 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgTBt1s1dwf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zGIVuF0o3CA7">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Contract Term<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_znTmYKuxhLR9" style="width: 11%; text-align: right" title="Options beginning balance">2,514,452</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zyTsR1zro0O3" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, beginning balance">49.08</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z6EB76WTkj0a" style="width: 11%; text-align: right" title="Weighted Average Contract Term">6.1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zOXdcUMfpsc6" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value">7,851</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z0y9tfE0GUl6" style="text-align: right" title="Options Granted">741,634</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zoU70mlVkEia" style="text-align: right" title="Weighted Average Exercise Price, Granted">5.35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zxP3cNBvLWj" style="text-align: right" title="Options Exercised">(108,637</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zex19g5ERtC8" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Forfeited/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zTPhdQivmys4" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited/Expired">(327,262</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z2vC55IszP3e" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired">42.23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zq4FwXPrTSm9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options ending balance">2,820,187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zPixP1loiWCi" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance">40.16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_znq8GvUKGgOa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term">5.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zVh6PnhL6Jol" style="text-align: right" title="Options Vested and expected to vest">2,820,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4ba3yyr6JGa" style="text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest">40.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zv7OYnurtqtf" style="text-align: right" title="Weighted Average Contract Term, Vested and expected to vest">5.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_ztpA7mJCL3Rg" style="text-align: right" title="Options Exercisable">2,025,287</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4IEoDGQ5gxj" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">46.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zb8rpyf8VRDe" style="text-align: right" title="Weighted Average Contract Term Exercisable">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table> 2514452000 49.08 P6Y1M6D 7851000 741634000 5.35 108637000 2.80 327262000 42.23 2820187 40.16 P5Y7M6D 2820187000 40.16 P5Y7M6D 2025287000 46.01 P4Y6M 9293000 10702000 0 7997000 13449000 P2Y7M2D 105000 29.90 25000 80000 20000 0.799 0.0295 P5Y 0 60000 0 881000 1175000 246928 63.20 vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date 1167000 1681000 0.50 0.50 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zsMbSdxoxit2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 29.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activity related to RSU stock-based payment awards:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 29.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 29.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_ztkTbSKs9dQ4">Schedule of Activity Related to RSU Stock-Based Payment Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3cc87juZ0U9" style="width: 16%; text-align: right" title="Number of Shares opening balance">227,013</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqY0JbE7wuHb" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, beginning balance">73.35</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zo7l6BpJiWei" style="text-align: right" title="Number of Shares Granted">954,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zek9PobeXCch" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">6.29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Released</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKudkW8682Gb" style="text-align: right" title="Number of Shares Released">(83,759</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zY14d0jLdz2f" style="text-align: right" title="Weighted Average Grant Date Fair Value, Released">65.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdOGg8XUVwj8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Forfeited">(274,853</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0WLDAzRCEii" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">21.37</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC80cjXRzOGd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares ending balance">823,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVtar4F95Sd7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance">13.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 227013000 73.35 954931000 6.29 83759000 65.05 274853000 21.37 823332 13.77 5724000 4787000 7732000 P2Y21D 174500 5.00 P3Y 871000 P1Y9M14D 0 <p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zdw3Zs970VZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zev3jYa8raD5">Schedule of Stock-based Compensation Expense </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zp5drBmMIof1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zELQXCQdw6og" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zUlNiPUxPofi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cost of revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">580</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">410</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI4M3FktvZ5e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,118</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zrCjpG79Wxw5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,605</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,328</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zFZLKZYkTLS7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,017</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,856</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 580000 410000 1832000 2118000 12605000 13328000 15017000 15856000 <p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_zJl7EEJHLIb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14. <span id="xdx_822_zm6sqHquJSe8">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zweGiO1dwhik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides information about disaggregated revenue by product and services:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zpQTJa7MdV0l">Schedule of Disaggregated Revenue by Product And Services</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_z45rTrd9Svnl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zwaWsD8yfVde" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_z85eMknAWCSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Product sales and rentals</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,149</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,749</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zpGitGj6AVh3" style="vertical-align: bottom; background-color: White"> <td>Services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,512</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zscTermJ8Jmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,181</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,714</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqzQorWgWIx9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,975</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zcuMd6kMiS0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zp9fRqU9C0gi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides changes in deferred revenue from contract liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zg5AS2jnuZcf">Schedule of Changes in Deferred Revenue from Contract Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zFmBvw8n1gll" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zdsL1XofstFf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_z2nuVk8YeqKh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,492</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,067</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_zjlcIhPd51Sh" style="vertical-align: bottom; background-color: White"> <td>Deferral of revenue<span id="xdx_F4F_zlTTwrkvRXBe">*</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,266</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,004</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_zv8yIFA7YlHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Recognition of unearned revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,738</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,579</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_z2B2ScxFEla6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,020</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F07_zRPq2Te57bNd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F12_zBBnPgnhVRg2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed. Also includes up-front payment incurred in connection with signing of the Regeneron Services Agreement in August 2023 (see Note 15 below).</span></td> </tr></table> <p id="xdx_8A4_zEsusl8DsImf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zweGiO1dwhik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides information about disaggregated revenue by product and services:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zpQTJa7MdV0l">Schedule of Disaggregated Revenue by Product And Services</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_z45rTrd9Svnl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zwaWsD8yfVde" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_z85eMknAWCSe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Product sales and rentals</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,149</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,749</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zpGitGj6AVh3" style="vertical-align: bottom; background-color: White"> <td>Services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,512</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zscTermJ8Jmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,181</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,714</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqzQorWgWIx9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,975</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 13149000 3749000 5441000 5512000 4181000 8714000 22771000 17975000 <p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zp9fRqU9C0gi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides changes in deferred revenue from contract liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zg5AS2jnuZcf">Schedule of Changes in Deferred Revenue from Contract Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zFmBvw8n1gll" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zdsL1XofstFf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_z2nuVk8YeqKh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,492</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,067</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_zjlcIhPd51Sh" style="vertical-align: bottom; background-color: White"> <td>Deferral of revenue<span id="xdx_F4F_zlTTwrkvRXBe">*</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,266</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,004</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_zv8yIFA7YlHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Recognition of unearned revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,738</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,579</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_z2B2ScxFEla6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,020</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,492</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F07_zRPq2Te57bNd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F12_zBBnPgnhVRg2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed. Also includes up-front payment incurred in connection with signing of the Regeneron Services Agreement in August 2023 (see Note 15 below).</span></td> </tr></table> 4492000 4067000 6266000 5004000 -4738000 -4579000 6020000 4492000 <p id="xdx_806_ecustom--LicenseAndDistributionAgreementsTextBlock_zmmtVhzNpSy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15. <span id="xdx_821_ztppciyad2d7">License and Distribution Agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regeneron Research Collaboration Services Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 25, 2023, the Company entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”), pursuant to which the Company will support the research effort of Regeneron’s allogeneic cell therapy candidates (the “Regeneron Services Agreement”). The Regeneron Services Agreement’s initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. Payments to the Company under the Regeneron Services Agreement included a nonrefundable up-front payment and payments based upon the achievement of defined milestones according to written statements of work. The Regeneron Services Agreement will expire <span id="xdx_904_ecustom--ServiceAgreementTerm_dc_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zxfZwG0ZFtEc" title="Service agreement term">five years</span> from the effective date and may be terminated immediately by either party for the uncured material breach, bankruptcy, or insolvency of the other party. Regeneron may also terminate for convenience upon <span id="xdx_901_ecustom--LicenseAgreementNoticePeriod_dtD_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zWyk4ZRo0ZC4" title="License agreement notice period">30 </span>days’ written notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Regeneron Services Agreement grants Regeneron a royalty-free, fully-paid up, worldwide, non-exclusive license, with the right to grant sublicenses, to the Company’s intellectual property (“IP”) to the extent that any such license is necessary for Regeneron to fully use the Company’s research services. The Company determined that the (1) research licenses and (2) the research activities performed by the Company represent a single combined performance obligation under the Regeneron Services Agreement. The Company determined that Regeneron cannot benefit from the licenses separately from the research activities because these services are specialized and rely on the Company’s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The upfront payment of $<span id="xdx_909_eus-gaap--DeferredRevenue_iI_pn3n3_c20231231__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_z7gnwxRQsX59" title="Deferred Revenue">750</span> was recorded as deferred revenue and within accounts receivable as of December 31, 2023, and will be recognized as revenue as the combined performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December 31, 2023, the potential research milestone payments that the Company is eligible to receive and have not been achieved, and were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sorrento Therapeutics, Inc. License and Transfer Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and Sorrento Therapeutics, Inc. (“Sorrento”), a related party through September 30, 2023, are party to a License and Transfer Agreement for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder (the “2020 Sorrento License Agreement”). The Company retains the right to sublicense the rights granted under the agreement with Sorrento’s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until terminated by either the Company or Sorrento for uncured material breach upon 90 days written notice or, after the first anniversary of the effective date of the 2020 Sorrento License Agreement, by the Company for convenience upon six months’ written notice to Sorrento. On October 19, 2023, Sorrento filed a Plan of Reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas which plan contemplates a liquidation of the debtor. If the Plan is confirmed by the Bankruptcy Court, the Company believes that Sorrento will not be able to perform under the license and that any rights the Company might have under the license would be unenforceable. After assessing the status of the IND to determine an optional path forward for the program, the Company has elected to terminate development of CYCART-19 for B-cell malignancies during the third quarter of 2023. The Company may continue pre-clinical development of other T-cell candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Genting Innovation PTE LTD Distribution Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 4, 2018, concurrently with Dragasac’s equity investment in Legacy Celularity, Legacy Celularity entered into a distribution agreement with Genting Innovation pursuant to which Genting Innovation was granted supply and distribution rights to certain Company products in select Asia markets (the “Genting Agreement”). The Genting Agreement grants Genting Innovation limited distribution rights to the Company’s then-current portfolio of degenerative disease products and provides for the automatic rights to future products developed by or on behalf of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of the Genting Agreement was renewed on January 31, 2023, and automatically renews for successive twelve month terms unless: Genting provides written notice of its intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party for cause.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genting Innovation and Dragasac are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 14, 2023, the Genting Agreement was amended and restated to include manufacturing rights in the territories covered under the agreement, expanded to include two new countries, and a commitment by the Company to provide technology transfer pursuant to the plan established by a Joint Steering Committee. On January 17, 2024, the Company further amended the Genting Agreement to distribution and manufacturing rights to certain of the Company’s cell therapy products, including PSC-100, PDA-001, PDA-002, pEXO-001, APPL-001 and CYNK-001.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Celgene Corporation License Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is party to a license agreement with Celgene (the “Celgene Agreement”) pursuant to which the Company granted Celgene two separate licenses to certain intellectual property. The Celgene Agreement grants Celgene a royalty-free, fully-paid up, worldwide, non-exclusive license to the certain intellectual property (“IP”) for pre-clinical research purposes in all fields and a royalty-free, fully-paid up, worldwide license, with the right to grant sublicenses, for the development, manufacture, commercialization and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte or NK cell to express such a CAR, and/or the use of such CARs or T-lymphocytes or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic uses thereof. The Celgene Agreement will remain in effect until its termination by either party for cause.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive Supply and Distribution Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, the Company entered into a <span id="xdx_901_ecustom--SupplyAndDistributionAgreementPeriod_dxH_c20210507__20210507__us-gaap--TypeOfArrangementAxis__custom--ArthrexAgreementMember_zZ10ryIyAlDb" title="Supply and distribution agreement period::XDX::P6Y">six-year</span> supply and distribution agreement with Arthrex, Inc. (“Arthrex”) that includes (i) an exclusive Biovance, Interfyl, and Centaflex license for distribution and commercialization within the United States for the orthopedic surgery and (ii) an exclusive Interfyl and Centaflex license for commercialization and distribution within the United States for the acute and chronic non-healing wound market (the “Arthrex Supply and Distribution Agreement”). The Arthrex Supply and Distribution Agreement will automatically renew for terms of <span id="xdx_907_ecustom--SupplyAndDistributionAgreementRenewalTerm_dxL_c20210507__20210507__us-gaap--TypeOfArrangementAxis__custom--ArthrexAgreementMember_zBdZ0ISzS4J2" title="Supply and distribution agreement renewal term::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl2588">two-year</span></span> periods unless either party gives notice of non-renewal at least <span id="xdx_908_ecustom--SupplyAndDistributionAgreementNonRenewalNoticePeriod_dxL_c20210507__20210507__us-gaap--TypeOfArrangementAxis__custom--ArthrexAgreementMember_zpJtFJHeObl5" title="Supply and distribution agreement non-renewal notice period::XDX::P12M"><span style="-sec-ix-hidden: xdx2ixbrl2590">twelve months</span></span> advance of the end of the then current term. At least ninety days prior to the start of each calendar quarter, the Company and Arthrex will agree in good faith to a minimum binding forecast based upon projected sales volume by Arthrex for said upcoming calendar quarter for each of the products. Upon agreement, Arthrex shall submit to the Company a purchase order to purchase products for the minimum forecasted quantities. The Company shall invoice Arthrex after the product has been issued and payments for such invoices will be <span id="xdx_90A_ecustom--DiscountPercentagePaymentForInvoicesWithinTenDays_dp_uPure_c20210507__20210507__us-gaap--TypeOfArrangementAxis__custom--ArthrexAgreementMember_z7NxaptJSPA2" title="Discount percentage payment for invoices within ten days">2</span>%, ten net <span id="xdx_900_ecustom--PaymentTermNet_dxL_c20210507__20210507__us-gaap--TypeOfArrangementAxis__custom--ArthrexAgreementMember_z71TTZMME4ff" title="Payment term net::XDX::P45D"><span style="-sec-ix-hidden: xdx2ixbrl2594">forty-five days</span></span> from the date of the invoice. Upon material breach of the Arthrex Supply and Distribution Agreement either party may deliver such breach to the other party and the notified party will have<span id="xdx_90F_ecustom--MaterialBreachContractTerminatedTerm_dp_uPure_c20210507__20210507__us-gaap--TypeOfArrangementAxis__custom--ArthrexAgreementMember_zNQ9FfKz5PO2" title="Material breach contract terminated term"> thirty days</span> to cure such breach. If the notified party fails to cure the material breach of the Arthrex Supply and Distribution Agreement the non-breaching party may terminate the respective agreement. Under the Arthrex Supply and Distribution Agreement, the Company and Arthrex will establish a joint steering committee to oversee commercialization activities of the products. Membership of the joint steering committee will be comprised of an equal number of employees of each respective party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2021, the Company entered into a <span id="xdx_90D_ecustom--SupplyAndDistributionAgreementPeriod_dxL_c20210901__20210901__us-gaap--TypeOfArrangementAxis__custom--EvolutionAgreementMember_zn8vvZlseahg" title="Supply and distribution agreement period::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2598">three-year</span></span> supply and distribution agreement with Evolution Biologyx, LLC (“Evolution”) that includes an exclusive Interfyl license for the distribution and commercialization within the United States within any medical specialty where Interfyl is administered in an in-office or in-patient setting and is reimbursed through Medicare Part B or any successor, equivalent or similar category established by the Center for Medicare Services or other Government Authority, except in the medical specialty of orthopedic surgery excluding trauma or spine applications in the medical specialty or orthopedic or neurologic surgery (the “Evolution Supply and Distribution Agreement”). On <span id="xdx_900_ecustom--AgreementTerminationDate_iI_c20230413__us-gaap--TypeOfArrangementAxis__custom--EvolutionAgreementMember_zdqIgHMG9Szg" title="Supply and distribution agreement period">April 13, 2023</span>, the Company terminated the Evolution Supply and Distribution Agreement for uncured material breach resulting from Evolution’s refusal to pay outstanding invoices in the amount of approximately $<span id="xdx_90A_ecustom--OutstandingInvoiceAmountRefused_pn4n6_c20230413__20230413__us-gaap--TypeOfArrangementAxis__custom--EvolutionAgreementMember_zvdXnXIPlmzd" title="Outstanding invoice amount refused">2.35 </span>million. On April 17, 2023, we filed a complaint against Evolution in the U.S. District Court for the District of New Jersey to recover unpaid invoice amounts, plus interest (See Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pulthera, LLC Binding Term Sheet</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with the entry into the securities purchase agreement for the private placement described in Note 9 above, the Company executed a binding term sheet to negotiate and enter into a sublicense agreement of certain assets from an affiliate of Pulthera, LLC (the “sublicensor”). Pursuant to the binding term sheet, the Company paid sublicensor $<span id="xdx_90B_ecustom--PaymentOfOptionFeeInCash_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember_zeJHWxayMppc" title="Payment of option fee in cash">3,000</span> option fee in cash and issued $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5n5UrYLxF1e" title="Issuance of common stock">1,000</span> of shares of its Class A common stock (<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlUHuZYcQyh" title="Purchase and sale of shares">169,492</span> shares based on the closing price on March 17, 2023) as consideration for stem-cells inventory to be used in research and development. The option fee paid by the Company will be applied towards an initial license fee as outlined in the sublicense agreement. The Company is required to use diligent and reasonable efforts to develop and obtain regulatory approval to market at least one licensed product contingent upon a firm written commitment to provide further financing to the Company. The $<span id="xdx_90F_ecustom--OptionFeeExpense_pn3n3_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zK9UVSi4teh3" title="Option fee expense">3,000</span> option fee was recorded as acquired IPR&amp;D expense included in research and development expense on the consolidated statements of operations for the year ended December 31, 2023, as the acquired IPR&amp;D had no alternative future use.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License Agreement with BioCellgraft, Inc.</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2023, the Company and BioCellgraft, Inc. (“BioCellgraft”) entered into a license agreement whereby the Company granted an exclusive license to BioCellgraft, with the right to sublicense, to develop and commercialize certain licensed products to the dental market in the United States over an initial <span id="xdx_901_ecustom--CommercialLicenseToDentalProductsAgreementPeriod_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zX3MiBNOfydk" title="Option fee expense">four year</span> term and will automatically renew for an additional <span id="xdx_905_ecustom--CommercialLicenseToDentalProductsAgreementRenewalTerm_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zK1LWLVx9oO3" title="Commercial license to dental products agreement renewal term">two years</span> unless either party provides written notice of termination. BioCellgraft will pay to the Company total license fees of $<span id="xdx_90F_ecustom--LicenseFeeExpense_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z2ItiLzxWWZ4" title="License fee expense">5,000</span> over a <span id="xdx_909_ecustom--LicenseFeesPaymentPeriod_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zGle4KSoaav5" title="License fees payment period">two year</span> period, as defined. Upon execution of the agreement, the Company received a $<span id="xdx_902_ecustom--LicenseFeePayment_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zognGgnoiHk" title="License fee payment">300</span> payment towards the first year payment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> P5Y P30D 750000 0.02 P30D 2023-04-13 2350000 3000000 1000000 169492 3000000 P4Y P2Y 5000000 P2Y 300000 <p id="xdx_80A_eus-gaap--DefinedBenefitPlanTextBlock_ziI4zqus1qgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. <span id="xdx_822_zLmTh7xf7Sdd">Benefit Plan</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company’s board of directors. During the year ended December 31, 2023, the Company made contributions of $<span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20230101__20231231_zqEkTQDjKo6i" title="Contributions made to the plan">198</span>. During the year ended December 31, 2022, the Company accrued $<span id="xdx_904_ecustom--DefinedContributionPlanAccruedAmountMatchingContributionNotMade_pn3n3_c20220101__20221231_zVk4QFfAtlg" title="Accrued amount but not made matching contribution to the plan">1,159</span>, but has not made the matching contribution to the plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> 198000 1159000 <p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zxuN7GYWjL6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17. <span id="xdx_82A_zuAj10OescA">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zVBfqzJEbq29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s current and deferred tax provision is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zOnm3cZHziK6">Schedule of Current and Deferred Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20230101__20231231_z0nEtSpNzym5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220101__20221231_zpxWe4y0D8a3" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current income tax expense:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_z3cKm6EZnVjf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2632">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2633">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zcAyLDv44evh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; padding-bottom: 1pt; padding-left: 10pt">State</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">13</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_zIh69wfKmu63" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Total current income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income tax expense (benefit):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_zTytLmpdWIH5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_zjgoTWBkaYIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_pn3n3_z324nxNjnKib" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total deferred tax expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2647">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2648">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_zurbiIoAR1Yi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total expense from income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zagICJuu9Sl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWNIcwnnTKYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_z4R8PbONznp5">Schedule of Reconciliation of the U.S  federal statutory income tax</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230101__20231231_zhUWhzhRgml1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220101__20221231_zrzX2qcF1GD7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zoawRfcv9bok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zXcZDLVE3Pad" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">State income taxes, net of federal benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(38.9</td><td style="text-align: left">)%</td></tr> <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_pid_dp_uPure_zr9Kx9vqASRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest accretion expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(186.9</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zKypbB3cpXu1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20.0</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">269.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_pid_dp_uPure_zQhoUSYuTYZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Mark to market warrant</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(58.5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueUp_pid_dp_uPure_ziy1kqGoyuS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Deferred true-up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.4</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_zcbwICHnyJE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.0</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.2</td><td style="text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_zDCpNrCBMKXb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12.0</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.3</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_zkJoz8Qd6Fh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other permanent items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.5</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3.1</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_znxtE0GfY24f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.0</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.0</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table> <p id="xdx_8A7_zfoz9OinGzP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z5DDByszlsea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax liabilities as of December 31, 2023 and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zQAAg3aJOxX7">Schedule of Deferred tax assets and liabilities</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231_zyKPyWRFSDc9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20221231_z4ODNtCiHVPl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zWefgLmpWQth" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">109,544</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">102,723</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_iI_pn3n3_zPTkwBFjqFej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Research and development tax credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zH5pvw1pGxYd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,539</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,321</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsStartupCosts_iI_pn3n3_zZAJ5Y7iVTB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Startup costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_zXLQ5TjQjGL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,442</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,905</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_zhtqAIEmpScb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,135</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsUnicap_iI_pn3n3_zxRRXyhCaP58" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Unicap</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsImputedInterestOnContingentPayments_iI_pn3n3_z3VkeeQYnEde" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Imputed interest on contingent payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,654</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_iI_pn3n3_zUETjColI6t4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Legal fee capitalization and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,171</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_zhn66h0NCv9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,318</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_zofVyYNg2t4d" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,751</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,121</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_zBwTPOcQuuT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 20pt">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,787</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesInProcessResearchAndDevelopment_iNI_pn3n3_di_zG00dQI8ghdi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">In-process research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2723">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,271</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zCwmztLMpYM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2726">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,271</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zcTAeFiu1Bek" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(169,797</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(130,525</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_zRpj0lnAaBEi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AC_zOyN1CbRjjD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zwll1KOgX7Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zkpgu4p8d78j">Schedule of Unrecognized Tax Benefits</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrecognized<br/> Tax Benefits</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20220101__20221231_zx0WCBSBuUY5" style="width: 16%; text-align: right" title="Balance beginning">1,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Decrease related to current year tax provisions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_iN_pn3n3_di_c20220101__20221231_zmYUdTeOmTy3" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions">(242</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20230101__20231231_zdxMpUnjzB7e" style="text-align: right" title="Balance beginning">1,028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Decrease related to current year tax provisions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_pn3n3_c20230101__20231231_ztS2j6rZKgr8" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"><span style="-sec-ix-hidden: xdx2ixbrl2743">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20230101__20231231_zEayPCJhcR0d" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">1,028</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zNQH68z8cGpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company had U.S. federal and state net operating loss carryforwards of $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zOUANFQgO4Sb" title="Net operating loss carryforwards">109,544</span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zY0YeA6BOdya" title="Net operating loss carryforwards">102,723</span>, respectively, which may be available to offset future taxable income and begin to expire in<span id="xdx_905_ecustom--OperatingLossCarryforwardsExpirationYear_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zNfm2HO1d6l1" title="Operating loss carryforwards expiration year"> 2040</span>. As of December 31, 2023 and 2022, the Company also had U.S. federal and state research and development tax credit carryforwards of $<span id="xdx_90E_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zltoUANkIWK7" title="Tax credit carryforwards"><span id="xdx_907_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20221231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zlqTwSF8Ec7k" title="Tax credit carryforwards">5,674</span></span>, which may be available to offset future tax liabilities and begin to expire in <span id="xdx_902_ecustom--TaxCreditCarryforwardsExpirationYear_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zke6ddtHAgmd" title="Tax credit carryforwards expiration year">2032</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. A corporation that experiences an ownership change is subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate subject to additional adjustments, as required. The Company experienced an ownership change on August 15, 2017. The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development credits before utilization.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The realization of deferred tax assets is dependent upon the Company’s ability to generate taxable income in future years. ASC 740-10, <i>Income Taxes,</i> requires a valuation allowance to be applied against deferred tax assets when it is considered “more likely than not” that some or all of the gross deferred tax assets will not be realized. The Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded valuation allowance against its federal and state gross deferred tax assets. The valuation allowance increased by $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zhcLFFfrE0c4" title="Valuation allowance increased amount">39,272</span> during the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact of an uncertain income tax position is recognized at the largest amount that is “more likely than not” to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the Company had gross unrecognized tax benefits of $<span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20231231_zgTMxFtak7T1" title="Unrecognized tax benefits"><span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20221231_zZiWhGVapoG9" title="Unrecognized tax benefits">1,028</span></span>. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next 12 months. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s consolidated statements of operations. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2017 to the present; however, carryforward attributes that were acquired may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zVBfqzJEbq29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s current and deferred tax provision is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zOnm3cZHziK6">Schedule of Current and Deferred Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20230101__20231231_z0nEtSpNzym5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220101__20221231_zpxWe4y0D8a3" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current income tax expense:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_z3cKm6EZnVjf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2632">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2633">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zcAyLDv44evh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; padding-bottom: 1pt; padding-left: 10pt">State</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">13</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_zIh69wfKmu63" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Total current income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income tax expense (benefit):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_zTytLmpdWIH5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_zjgoTWBkaYIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_pn3n3_z324nxNjnKib" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total deferred tax expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2647">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2648">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_zurbiIoAR1Yi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total expense from income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10000 13000 10000 13000 1000 1000 -1000 -1000 10000 13000 <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWNIcwnnTKYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_z4R8PbONznp5">Schedule of Reconciliation of the U.S  federal statutory income tax</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230101__20231231_zhUWhzhRgml1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220101__20221231_zrzX2qcF1GD7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zoawRfcv9bok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zXcZDLVE3Pad" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">State income taxes, net of federal benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(38.9</td><td style="text-align: left">)%</td></tr> <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_pid_dp_uPure_zr9Kx9vqASRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest accretion expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(186.9</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zKypbB3cpXu1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(20.0</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">269.1</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_pid_dp_uPure_zQhoUSYuTYZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Mark to market warrant</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(58.5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueUp_pid_dp_uPure_ziy1kqGoyuS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Deferred true-up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.4</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_zcbwICHnyJE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.0</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.2</td><td style="text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_zDCpNrCBMKXb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12.0</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.3</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_zkJoz8Qd6Fh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other permanent items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.5</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3.1</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_znxtE0GfY24f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.0</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.0</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table> 0.210 0.210 0.014 -0.389 0.110 -1.869 -0.200 2.691 0.005 -0.585 -0.024 0.002 -0.000 -0.082 -0.120 0.053 0.005 -0.031 -0.000 -0.000 <p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z5DDByszlsea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax liabilities as of December 31, 2023 and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zQAAg3aJOxX7">Schedule of Deferred tax assets and liabilities</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231_zyKPyWRFSDc9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20221231_z4ODNtCiHVPl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zWefgLmpWQth" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">109,544</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">102,723</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_iI_pn3n3_zPTkwBFjqFej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Research and development tax credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_zH5pvw1pGxYd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,539</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,321</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsStartupCosts_iI_pn3n3_zZAJ5Y7iVTB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Startup costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">588</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_zXLQ5TjQjGL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,442</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,905</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_zhtqAIEmpScb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,135</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetsUnicap_iI_pn3n3_zxRRXyhCaP58" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Unicap</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsImputedInterestOnContingentPayments_iI_pn3n3_z3VkeeQYnEde" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Imputed interest on contingent payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,654</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_iI_pn3n3_zUETjColI6t4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Legal fee capitalization and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,171</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_zhn66h0NCv9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,318</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_zofVyYNg2t4d" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,751</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,121</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_zBwTPOcQuuT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 20pt">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169,788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,787</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesInProcessResearchAndDevelopment_iNI_pn3n3_di_zG00dQI8ghdi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">In-process research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2723">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,271</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zCwmztLMpYM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2726">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,271</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zcTAeFiu1Bek" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(169,797</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(130,525</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_zRpj0lnAaBEi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 109544000 102723000 5674000 5674000 16539000 14321000 498000 588000 3442000 3905000 1441000 1135000 5000 6000 110000 5654000 1171000 1342000 26613000 19318000 4751000 3121000 169788000 157787000 27271000 27271000 169797000 130525000 9000 9000 <p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zwll1KOgX7Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zkpgu4p8d78j">Schedule of Unrecognized Tax Benefits</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrecognized<br/> Tax Benefits</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20220101__20221231_zx0WCBSBuUY5" style="width: 16%; text-align: right" title="Balance beginning">1,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Decrease related to current year tax provisions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_iN_pn3n3_di_c20220101__20221231_zmYUdTeOmTy3" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions">(242</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20230101__20231231_zdxMpUnjzB7e" style="text-align: right" title="Balance beginning">1,028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Decrease related to current year tax provisions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_pn3n3_c20230101__20231231_ztS2j6rZKgr8" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"><span style="-sec-ix-hidden: xdx2ixbrl2743">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20230101__20231231_zEayPCJhcR0d" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">1,028</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1270000 242000 1028000 1028000 109544000 102723000 2040 5674000 5674000 2032 39272000 1028000 1028000 <p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zrQezyNdXqOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. <span id="xdx_820_zLwrldliHNFe">Segment Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. Prior to the third quarter of 2020, Legacy Celularity managed operations as <span id="xdx_903_eus-gaap--NumberOfOperatingSegments_uSegment_c20200101__20200630_zfyok7wNilBb" title="Number of operating segments">one</span> segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of <span id="xdx_903_eus-gaap--NumberOfOperatingSegments_uSegment_c20200101__20200930_zi6UZHC3uCBb" title="Number of operating segments">three</span> distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. This change was prompted by certain organizational and personnel changes. The chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation among these segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. Biobanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were approximately $<span id="xdx_900_eus-gaap--Assets_iI_pn3n3_c20231231_zsO24nBZcIb6" title="Total assets">143,889</span> and $<span id="xdx_908_eus-gaap--Assets_iI_pn3n3_c20221231_zNWwqYe5mOtf" title="Total assets">401,066</span> as of December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zowSrpOfYeAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial information by segment is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zC2TYuleT7lg">Schedule of Financial Information by Segment </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_z20UR8LNqYL2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zmnG36tFzEf1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zBj8Ia0Vcpi3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zkLoidr5C1uj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zdpJNotPTCVi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zMDPmhEIcVCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2777">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,441</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2780">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,771</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--GrossProfit_pn3n3_zf2mjnIOqH9b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2783">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,964</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2786">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,755</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zVRrv0BpnEA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,694</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,752</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,876</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">81,041</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zplYfAStpdoj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,694</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,756</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,876</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(74,286</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zNjHgcjLCkod" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">118,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt">(a)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">118,001</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zkmcdTuxOS18" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(192,287</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">(a) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of contingent consideration liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zLqk5Cd294b5" style="text-align: right" title="Change in fair value of contingent consideration liability">(104,339</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_znUaP7YQyE8b" style="text-align: right" title="Goodwill impairment">112,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">IPR&amp;D impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zHEMyFIVutMi" style="text-align: right" title="IPR&amp;D impairment">107,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AdjustmentForAmortization_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zi867L721X98" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">2,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zwsuOrLVHTul" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">118,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zPj77XuXWKl8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zzMLKTXfNJRi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zdviAYmUVC39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zgY4Y2VwCJ4g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zjB2ixVr1ZH1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zUd0PQzYy3Dj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2823">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,512</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,463</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2826">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,975</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--GrossProfit_pn3n3_z35ZiTTW1lr2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2829">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,976</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,666</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2832">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,690</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zH4YpMRyu69h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,379</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,699</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,859</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">56,261</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144,198</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zFpafQoEmVG8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(75,379</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">277</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,525</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(56,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(145,888</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zgysSTn0asm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(120,288</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">(b)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(120,288</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z9itVm2Lxkz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(25,600</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">(b) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of contingent consideration liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zZTkiC2dZnV5" style="text-align: right" title="Change in fair value of contingent consideration liability">(126,277</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ChangeInFairValueOfContingentStockConsideration_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zH9csQ87Nxo7" style="text-align: right" title="Change in fair value of contingent stock consideration">186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zK8CmCR1N495" style="text-align: right" title="Goodwill impairment">3,610</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AdjustmentForAmortization_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zhEmcN7iau83" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">2,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zOc32ZEd0Rdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">(120,288</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zRn6wASCAqHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 143889000 401066000 <p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zowSrpOfYeAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial information by segment is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zC2TYuleT7lg">Schedule of Financial Information by Segment </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_z20UR8LNqYL2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zmnG36tFzEf1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zBj8Ia0Vcpi3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zkLoidr5C1uj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zdpJNotPTCVi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zMDPmhEIcVCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2777">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,441</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2780">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,771</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--GrossProfit_pn3n3_zf2mjnIOqH9b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2783">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,964</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2786">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,755</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zVRrv0BpnEA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,694</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,752</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,876</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">81,041</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zplYfAStpdoj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,694</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,756</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,876</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(74,286</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zNjHgcjLCkod" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">118,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt">(a)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">118,001</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zkmcdTuxOS18" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(192,287</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">(a) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of contingent consideration liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zLqk5Cd294b5" style="text-align: right" title="Change in fair value of contingent consideration liability">(104,339</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_znUaP7YQyE8b" style="text-align: right" title="Goodwill impairment">112,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">IPR&amp;D impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zHEMyFIVutMi" style="text-align: right" title="IPR&amp;D impairment">107,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AdjustmentForAmortization_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zi867L721X98" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">2,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zwsuOrLVHTul" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">118,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zPj77XuXWKl8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zzMLKTXfNJRi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zdviAYmUVC39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zgY4Y2VwCJ4g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zjB2ixVr1ZH1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zUd0PQzYy3Dj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2823">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,512</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,463</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2826">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,975</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--GrossProfit_pn3n3_z35ZiTTW1lr2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2829">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,976</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,666</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2832">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,690</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zH4YpMRyu69h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">75,379</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,699</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,859</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">56,261</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144,198</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zFpafQoEmVG8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(75,379</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">277</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,525</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(56,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(145,888</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zgysSTn0asm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(120,288</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">(b)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(120,288</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z9itVm2Lxkz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(25,600</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">(b) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of contingent consideration liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zZTkiC2dZnV5" style="text-align: right" title="Change in fair value of contingent consideration liability">(126,277</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ChangeInFairValueOfContingentStockConsideration_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zH9csQ87Nxo7" style="text-align: right" title="Change in fair value of contingent stock consideration">186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zK8CmCR1N495" style="text-align: right" title="Goodwill impairment">3,610</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AdjustmentForAmortization_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zhEmcN7iau83" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">2,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zOc32ZEd0Rdk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">(120,288</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5441000 17330000 22771000 3791000 2964000 6755000 28694000 1752000 9720000 40876000 81041000 -28694000 2039000 -6756000 -40876000 -74286000 118001000 118001000 -192287000 -104339000 112347000 107800000 2193000 118001000 5512000 12463000 17975000 1976000 -3666000 -1690000 75379000 1699000 10859000 56261000 144198000 -75379000 277000 -14525000 -56261000 -145888000 -120288000 -120288000 -25600000 -126277000 186000 3610000 2193000 -120288000 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z41nkIFBkdp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19. <span id="xdx_827_zp8OapshOxbj">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The related party transactions described below do not have any associated balances on the consolidated balance sheets as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amended and Restated Employment Agreement with Dr. Robert Hariri</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 25, 2023, in order to address the Company’s current working capital requirements, Dr. Robert Hariri, M.D., Ph.D., the Company’s Chairman and Chief Executive Officer, agreed to temporarily reduce payment of his salary pursuant to his employment agreement to minimum wage level with the remaining salary deferred until December 31, 2023. As of December 31, 2023, $<span id="xdx_901_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zLKrnPkAGx6f" title="Accrued expenses">1,088</span> was recorded to accrued expenses on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to comply with the Securities Purchase Agreement dated <span id="xdx_907_ecustom--SecuritiesPurchaseAgreementDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zVyU9PrUiJt7" title="Securities purchase agreement date">January 12, 2024</span> with Dragasac Limited that Dr. Hariri not be paid the $<span id="xdx_901_ecustom--UnpaidBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPUo65Rvnktb" title="Unpaid base salary">1,088</span> in base salary that was otherwise due to him for the 2023 calendar year unless the Company raises additional cash through offerings of equity securities with aggregate net proceeds equal or greater to $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVTUAud8qVD" title="Net proceeds from offerings of equity securities">21.0</span> million at a valuation at least equal to the valuation, cost per security or exercise/conversion price, as applicable, of the Class A common stock and PIPE Warrant purchased by Dragasac Limited in January 2024. In compliance with the requirements of Internal Revenue Code Section 409A, the compensation committee of the Company’s board of directors approved a cash bonus program, or bonus program, effective February 16, 2024, pursuant to which Dr. Hariri will be paid <span id="xdx_90B_ecustom--PercentageOfUnpaidBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPXBLM7qCb64" title="Percentage of unpaid base salary">125</span>% of his unpaid base salary upon the satisfaction of the foregoing performance conditions. Accordingly, the Company entered into a second amendment to Dr. Hariri’s employment agreement implementing the <span id="xdx_903_ecustom--PercentageOfBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zoshfZVou3ha" title="Percentage of base salary">85</span>% base salary reduction effective as of <span id="xdx_90F_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDWATN0ksNtc" title="Bonus program effective date">February 16, 2024</span> and documenting the bonus program. As a result of the reduction, Dr. Hariri’s annual rate of base salary for the 2024 year will be $<span id="xdx_90C_ecustom--AnnualRateOfBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zr8HD3gBKdSa" title="Annual rate of base salary">180</span>. Payment of Dr. Hariri’s base salary at the rate in effect prior to the reduction will resume on <span id="xdx_90D_ecustom--BaseSalaryEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zoHS8fIQeYwi" title="Bonus program effective date">January 1, 2025</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>March 2023 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert Hariri, for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DrRobertHaririMember_zbi9NRjgnmG9" title="Proceeds from PIPE financings">9,000</span> (of which Dr. Hariri subscribed for $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--DrHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z0JrlVS9NOzl" title="Proceeds from PIPE financings">2,000</span>). See Note 12, Equity under March 2023 PIPE caption for further details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan Agreement with Dr. Robert Hariri</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2023, the Company entered into a $<span id="xdx_90A_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z0EvshMk5xv3" title="Debt instrument contribution amount">1,000</span> loan agreement with Dr. Robert Hariri, M.D., Ph.D., the Company’s Chairman and Chief Executive Officer, which bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zxNQtT23HRt5" title="Loan interest rate">15</span>% per year, with the first year of interest being paid in kind on the last day of each month and matures on August 21, 2024 (Note 9).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 12, 2023, in order to further address the Company’s immediate working capital requirements, Robert Hariri, M.D., Ph.D., the Company’s Chairman and Chief Executive Officer, and the Company signed a promissory note (“CEO Promissory Note”) for $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zs0QEDI8Ynvc" title="Principal amont">285</span> which bears interest at a rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zMXsmH2TCif3" title="Interest rate">15.0</span>% per year (Note 9).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting &amp; Advisory Agreements with Dr. Andrew Pecora</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--RelatedPartyTransactionTermsAndMannerOfSettlement_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zdTPGTKsu1q2" title="Related party description">On August 31, 2022, Dr. Pecora resigned as the Company’s President, and subsequently entered into a consulting agreement with the Company dated September 21, 2022, to receive a $<span id="xdx_905_ecustom--ReceiveForMonth_pn3n3_c20220901__20220921__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zZydY2me4vqh" title="Receive for month">10</span> monthly fee for an initial six-month term and will be automatically renewed for one additional six- month term if either party does not provide notice of non-renewal.</span> Simultaneously, the Company entered into a scientific and clinical advisor agreement (the “SAB Agreement”), effective as of September 1, 2022, whereby Dr. Pecora agreed to serve as co-chair of the Company’s scientific and clinical advisory board for a $<span id="xdx_908_ecustom--ReceiveForMonth_pn3n3_c20220901__20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zmistqJXGzeb" title="Receive for month">10</span> monthly fee and a one-time grant of RSUs having a value of $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmMfUMxlgq26" title="RSUs one-time grant value">125</span> on the grant date and will vest equally over <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220901__20220901__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zzdr70FAflSf" title="Options vesting period">four years</span>. The SAB Agreement has a one-year term and may be renewed for successive one-year terms upon mutual agreement of both parties. The consulting agreement was early terminated effective January 14, 2023. Dr. Pecora continues to serve on the Company’s scientific and clinical advisory board.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advisory Agreement with Robin L. Smith MD</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 16, 2022, the Company entered into an advisory agreement with Robin L. Smith, MD, a then member of the Company’s board of directors, to receive $<span id="xdx_90D_ecustom--ReceiveForMonth_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zzKBifed2R0a" title="Receive for month">20 </span>per month for advisory fees, an equity grant for a total amount of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_z3ARbEqRA2og" title="Vested options to acquire shares">105,000</span> stock options with the initial tranche of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__custom--InitialTrancheMember_zOO9EPbPl39" title="Vested options to acquire shares">25,000</span> stock options vesting upon execution of the advisory agreement and the remaining shares subject to vesting upon achievement of certain predefined milestones. On November 1, 2022, the second tranche of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zSQF8xpT4pM7" title="Vested options to acquire shares">20,000</span> stock options vested upon achievement of the milestone. The agreement also provides for a one-time cash bonus of $<span id="xdx_901_ecustom--RelatedPartyCashBonus_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zpMCgm8dNCni" title="One-time cash bonus">1,500</span> upon the successful achievement of the trigger event, as defined in the agreement. The Company paid advisory fees of $<span id="xdx_908_ecustom--PaymentsToRelatedParty_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zg5UL5mKsMEe" title="Amount paid">20</span> and $<span id="xdx_903_ecustom--PaymentsToRelatedParty_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zIFRkOYZ7Ia2" title="Amount paid">80</span> for the years ended December 31, 2023 and 2022, respectively. The advisory agreement expired pursuant to the terms of the agreement on August 16, 2023 and was not renewed for an additional term. Dr. Smith resigned from the Company’s board effective December 24, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COTA, Inc</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2020, Legacy Celularity and COTA, Inc. (“COTA”) entered into an Order Schedule (the “Order Schedule No. 2”), to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide the licensed data in connection with AML patients. The COTA Order Schedule No. 2 will terminate on the one-year anniversary following the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity’s former President, is the Founder and Chairman of the Board of COTA and Dr. Robin L. Smith, a former member of the Company’s board of directors, is an investor in COTA. The Company did <span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zgz4WbhLxGdh" title="Contribution made">no</span>t make any payments to COTA during the year ended December 31, 2023, and made payments of $<span id="xdx_906_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zOtCYWo1KZyd" title="Contribution made">86</span> during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cryoport Systems, Inc</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company made payments totaling $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_zf979WcPGWEd" title="Contribution made">33</span> and $<span id="xdx_906_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_z1CVXKNjg6cc" title="Contribution made">70</span> to Cryoport Systems, Inc (“Cryoport”) for transportation of cryopreserved materials during the years ended December 31, 2023 and 2022, respectively. The Company’s Chief Executive Officer and director, Dr. Robert Hariri, M.D, Ph.D., has served on Cryoport’s board of directors since September 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>C.V. Starr Loan</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 17, 2023, the Company entered into a $<span id="xdx_909_ecustom--LoanAgreement_iI_pn3n3_c20230317__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember_zfH4EOBIWHdb" title="Loan agreement">5,000</span> loan agreement with C.V. Starr. C.V. Starr is a significant stockholder of the Company, holding <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__custom--StatementEquityComponentsAxis.Axis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zB1OaR7BpCEi" title="Warrants to purchase Class A common stock">75,000</span> warrants issued in March 2023 and another <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__custom--StatementEquityComponentsAxis.Axis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zmCxF8UPyZ5f" title="Warrants to purchase Class A common stock">50,000</span> issued in June 2023, for a total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zoH9Ati0Be5" title="Warrants to purchase Class A common stock">125,000</span> warrants to purchase Class A common stock and<span id="xdx_90C_ecustom--NumberOfSharesHolding_iI_pid_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zC1hJ1AxCxo9" title="Number of shares holding"> 764,069</span> shares of Class A common stock as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Resorts World Inc Pte Ltd</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2023, the Company entered into a $<span id="xdx_90A_ecustom--LoanAgreement_iI_pn3n3_c20230621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember_zpgO0CRMmGXf" title="Loan agreement">12,000</span> loan agreement, as amended on June 21, 2023, with RWI. RWI is affiliated with Lim Kok Thay, a significant stockholder and former member of the Company’s board of directors, holding <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z0JVcZenTmsf" title="Warrants to purchase Class A common stock">300,000</span> warrants to purchase Class A common stock as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sorrento Therapeutics, Inc.</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2020, the Company entered into the 2020 Sorrento Agreement, with Sorrento. Henry Ji, Ph.D., a former member of Legacy Celularity’s board of directors, previously served as President and Chief Executive Officer of Sorrento. Sorrento was also a significant stockholder and invested in the July 2021 PIPE Financing. During the year ended December 31, 2023, the Company did <span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SorrentoTherapeuticsIncMember_znkQLUsYWhQ2" title="Contribution made">no</span>t make any payments to Sorrento. During the year ended December 31, 2022, the Company made payments totaling $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SorrentoTherapeuticsIncMember_zI0XVf1SK2u2" title="Contribution made">1,821</span>, to Sorrento for supply of products pursuant to the supply agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment of an Immediate Family Member </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and Chief Executive Officer, is employed by Celularity as an Executive Director, Corporate Strategy &amp; Business Development. For each of the years ended December 31, 2023 and 2022, Ms. Hariri’s base salary was $<span id="xdx_90B_ecustom--RelatedPartyBaseSalary_pn3n3_c20230101__20231231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_zyyWtS9Vb8Vk" title="Base salary">265</span> and $<span id="xdx_90B_ecustom--RelatedPartyBaseSalary_pn3n3_c20220101__20221231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_zIsMiu1TCdWe" title="Base salary">216</span> per year, respectively. Ms. Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and conditions as applicable to unrelated employees in similar positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> 1088 2024-01-12 1088000 21000000.0 1.25 0.85 2024-02-16 180000 2025-01-01 9000000 2000000 1000000 0.15 285000 0.150 On August 31, 2022, Dr. Pecora resigned as the Company’s President, and subsequently entered into a consulting agreement with the Company dated September 21, 2022, to receive a $10 monthly fee for an initial six-month term and will be automatically renewed for one additional six- month term if either party does not provide notice of non-renewal. 10000 10000 125000 P4Y 20000 105000 25000 20000 1500000 20000 80000 0 86000 33000 70000 5000000 75000 50000 125000 764069 12000000 300000 0 1821000 265000 216000 <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zjwyv9NbrvDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20. <span id="xdx_826_zwEZfXTCU4B">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date of issuance and there are no additional items that have not previously been mentioned elsewhere requiring disclosure (see Notes 1, 2, 3, 9, 11, 12, 15, and 19).</span></p> 133000 227000 6059000 5837000 8770000 10046000 8770000 10046000 2072000 3963000 5753000 1636000 1695000 14502000 19793000 63208000 67828000 7347000 7347000 9624000 11001000 10865000 10990000 10163000 9936000 12844000 16657000 287000 337000 128840000 143889000 15400000 14144000 14466000 7580000 3500000 3695000 17223000 3695000 19331000 38915000 19909000 3693000 2834000 76169000 67298000 2639000 3186000 1606000 1606000 26451000 26177000 4403000 4359000 9000 9000 283000 294000 111560000 102929000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 730000000 730000000 21984614 21984614 19378192 19378192 2000 2000 2000 2000 903670000 882749000 -2000 -886390000 -841791000 17280000 40960000 128840000 143889000 3393000 1684000 26199000 3633000 1292000 1427000 3857000 4062000 4611000 675000 6032000 2964000 9296000 3786000 36088000 10659000 547000 557000 2888000 1486000 238000 398000 952000 1355000 3098000 2647000 3806000 3566000 3098000 2647000 3806000 3566000 3915000 5182000 13558000 30737000 243000 24161000 12650000 10748000 42585000 37508000 -104339000 82714000 112347000 107800000 375000 553000 1377000 1640000 20823000 103042000 65166000 216261000 -11527000 -99256000 -29078000 -205602000 77000 23000 254000 205000 1752000 971000 4452000 2352000 -714000 -5187000 1156000 -6788000 708000 -2003000 694000 354000 -3908000 -2902000 -862000 -5565000 -4527000 -4571000 5380000 -15521000 -240000 -16098000 -93876000 -44599000 -205842000 -16098000 -93876000 -44599000 -205842000 -2000 -2000 2541000 -2000 -2000 2541000 -16100000 -93876000 -44601000 -203301000 -0.73 -0.73 -4.98 -4.98 -2.05 -2.05 -11.86 -11.86 21976339 21976339 18831713 18831713 21756498 21756498 17353605 17353605 19378192 2000 882749000 -841791000 40960000 116964 317000 317000 3322000 3322000 2141098 6000000 6000000 233361 -80672 357000 357000 20000 50000 50000 -191 2966000 2966000 -22013000 -22013000 21808752 2000 895047000 -863804000 31245000 40584 125000 125000 -61000 -61000 87180 -2655 2990000 2990000 -6488000 -6488000 21933861 2000 898101000 -870292000 27811000 75472 -24719 73000 73000 -2000 -2000 2970000 2970000 2672000 2672000 -16098000 -16098000 21984614 2000 903670000 -886390000 -2000 17280000 14892129 1000 844387000 -645496000 9000 198901000 107100 300000 300000 365612 3510000 -152000 3358000 938183 8931000 8931000 169492 1000000 1000000 25339 -8110 53000 53000 13296 136000 136000 274000 274000 3988000 3988000 2810000 2810000 -64017000 -64017000 16503041 1000 862473000 -709513000 2667000 155628000 1537 4000 4000 38085 282000 -10000 272000 581395 3750000 3750000 923077 1000 1225000 1226000 39178 -4589 33000 33000 2016000 2016000 3856000 3856000 -269000 -269000 -47949000 -47949000 18081724 2000 873573000 -757462000 2388000 118501000 18081724 2000 873573000 -757462000 2388000 118501000 155785 807000 7000 814000 270731 712000 712000 857143 96000 96000 805 -275 1000 1000 403000 403000 3598000 3598000 -93876000 -93876000 -93876000 -93876000 19365913 2000 879188000 -851338000 2395000 30247000 19365913 2000 879188000 -851338000 2395000 30247000 -44599000 -205842000 6046000 7028000 125000 -62000 222000 456000 -50000 1156000 -6788000 112347000 107800000 8628000 11442000 -104339000 3000000 1000000 175000 317000 712000 2151000 403000 -159000 -3908000 694000 354000 3217000 285000 -2012000 -1054000 118000 -5653000 1605000 -109000 -2179000 1312000 6754000 7237000 1533000 3500000 -24161000 274000 172000 312000 1065000 -7995000 -34344000 105000 468000 -2175000 3000000 2070000 -3468000 15000000 18369000 9000000 304000 17374000 16811000 2993000 2000000 25000 106000 6000000 12750000 136000 1553000 430000 87000 6058000 24108000 133000 -13704000 10163000 28802000 10296000 15098000 144000 1073000 56000 752000 51000 -2083000 1162000 2002000 2970000 -69000 4599000 -1229000 <p id="xdx_80E_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z87CeOJqdlFi" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_ztuBNsCYWE71">Nature of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celularity Inc., (“Celularity” or the “Company”), formerly known as GX Acquisition Corp. (“GX”), was a blank check company incorporated in Delaware on <span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20240101__20240930_zMjR1WU9VvDk" title="Date of incorporation">August 24, 2018</span>. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 16, 2021 (the “Closing Date”), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated January 8, 2021 (the “Merger Agreement”), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of GX (“First Merger Sub”), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary of GX (“Second Merger Sub”), and the entity formerly known as Celularity Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (“Legacy Celularity”). Upon completion of the merger transaction, GX changed its name to Celularity Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the special meeting held on February 22, 2024, the stockholders of Celularity approved an amendment to Celularity’s Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of Celularity’s Class A common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zYH0CWao68Dk" title="Common stock, par value">0.0001</span> per share, at a ratio of <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240222__20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQ2Xnl7d9v37" title="Reverse stock split ratio">1-for-10</span>. Following the reverse stock split, each 10 shares of Celularity’s Class A Common Stock issued and outstanding immediately prior thereto were combined into one new share of Class A Common Stock. Unless specifically provided otherwise herein, all share and per share information has been adjusted to reflect the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Description of Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celularity is a cell therapy and regenerative medicine company focused on addressing aging related diseases including cancer and degenerative diseases. Celularity is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (“Anthrogenesis”) in August 2017 from Celgene Corporation (“Celgene”), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously, Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene’s cell therapy division.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from cellular therapy product sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an emerging clinical-stage biotechnology company, Celularity is subject to certain inherent risks and uncertainties associated with the development of an enterprise. In this regard, since the Company’s inception, substantially all of management’s efforts have been devoted to making investments in research and development including basic scientific research into placentally-derived allogeneic cells, pre-clinical studies to support its current and future clinical programs in cellular therapeutics, and clinical development of its cell programs as well as facilities and selling, general and administrative expenses that support its core business operations (collectively, the “investments”), all at the expense of the Company’s short-term profitability. The Company has historically funded these investments through limited revenues generated from its biobanking and degenerative disease businesses and issuances of equity and debt securities to public and private investors (these issuances are collectively referred to as “outside capital”). Notwithstanding these efforts, management can provide no assurance that the Company’s research and development and commercialization efforts will be successfully completed, or that adequate protection of the Company’s intellectual property will be adequately maintained. Even if these efforts are successful, it is uncertain when, if ever, the Company will generate significant sales or operate in a profitable manner to sustain the Company’s operations without needing to continue to rely on outside capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date the accompanying condensed consolidated financial statements were issued, or the issuance date, management evaluated the significance of the following adverse conditions and events in considering its ability to continue as a going concern:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since its inception, the Company has incurred significant operating losses and net cash used in operating activities. For the nine months ended September 30, 2024, the Company incurred an operating loss of $<span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20240101__20240930_zSvhmg2yTkm1" title="Net operating loss">29,078</span> and net cash used in operating activities of $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20240930_zBhU3oD68kk7" title="Net cash used in operating activities">7,995</span>. As of September 30, 2024, the Company had an accumulated deficit of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240930_zNm7T46aY0m6" title="Accumulated deficit">886,390</span>. The Company expects to continue to incur significant operating losses and use net cash for operations for the foreseeable future.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expects to incur substantial expenditures to fund its investments for the foreseeable future. In order to fund these investments, the Company will need to secure additional sources of outside capital. While the Company is actively seeking to secure additional outside capital (and has historically been able to successfully secure such capital), as of the issuance date, additional outside capital sufficient to fund operations for the next 12 months has not been secured or was deemed probable of being secured. In addition, management can provide no assurance that the Company will be able to secure additional outside capital in the future or on terms that are acceptable to the Company. Absent an ability to secure additional outside capital in the very near term, the Company will be unable to meet its obligations as they become due over the next 12 months beyond the issuance date.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the issuance date, the Company had approximately $<span id="xdx_904_ecustom--Debt_iI_pn3n3_c20240930_zpTq4kCqxPyf" title="Debt outstanding">46,050</span> of debt outstanding, all of which is currently due or due within one year of the issuance date. As disclosed in Note 7, a substantial portion of the Company’s outstanding debt is subject to forbearance agreements. In the event the terms of the forbearance agreements are not met and/or the outstanding borrowings are not repaid, the lenders may, at their discretion, exercise all of their rights and remedies under the loan agreements which may include, among other things, seizing the Company’s assets and/or forcing the Company into liquidation.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the Company’s failure to timely file its quarterly reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024, it no longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). The Company had regained compliance with the Nasdaq listing requirements upon filing its Form 10-Q for the period ended June 30, 2024 on November 7, 2024. On November 21, 2024, Nasdaq provided formal notice to the Company that as a result of Company’s failure to timely file its quarterly report on Form 10-Q for the period ended September 30, 2024, the Company was not in compliance with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Company has 60 days to submit a plan to Nasdaq to regain compliance with the continued listing requirements. If Nasdaq accepts the Company’s plan, it may grant an exception of up to 180 days from the filing’s due date, or May 13, 2025, to regain compliance. There can be no assurance that Nasdaq will grant the Company an extension or that the Company will maintain compliance with the Nasdaq listing requirements. If the Company is unable to regain compliance, the Company’s securities will be delisted from the Nasdaq, which such delisting could have a materially adverse effect on the Company’s ability to continue as a going concern.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the Company is unable to secure additional outside capital to fund the Company’s obligations when they become due over the next 12 months beyond the issuance date, which includes the funds needed to repay the Company’s outstanding debt, management will be required to seek other strategic alternatives, which may include, among others, a significant curtailment of the Company’s operations, a sale of certain of the Company’s assets, a sale of the entire Company to strategic or financial investors, and/or allowing the Company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy Code.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These uncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates that the Company will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> 2018-08-24 0.0001 1-for-10 -29078000 -7995000 -886390000 46050000 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zlUKngzL65Wl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_820_zl5eXKc6hfGi">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"> </p> <p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zo0nJERW7ih3" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z4GWuLZEVMic">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The unaudited condensed consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The unaudited condensed consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of consolidated financial position, results of operations and cash flows for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s condensed consolidated financial statements are prepared in accordance with the U.S. Securities and Exchange Commission’s (“SEC”) rules for the presentation of interim financial statements, which permit certain disclosures to be condensed or omitted. These financial statements should be read in conjunction with the Company’s annual financial statements as of and for the year ended December 31, 2023 included in the Annual Report on Form 10-K filed with the SEC on July 30, 2024, (the “2023 Form 10-K”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s consolidated financial position as of September 30, 2024, and its consolidated results of operations and cash flows for the nine months ended September 30, 2024 and 2023. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--UseOfEstimates_z8eN0DgH6Ha5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zahsPnBUJY2k">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of inventory, contingent consideration, short-term debt, stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zwMJfmd4LAHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zWQNrzFsdJs7">Fair Value Measurements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zRfY4O0ZcUR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zCb4sg5yPraf">Comprehensive Income (Loss)</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive income (loss) refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded from net income (loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company’s only component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of indebtedness accounted for under the fair value option that is attributable to changes in instrument-specific credit risk. During the nine months ended September 30, 2024, the Company recorded instrument-specific credit risk loss of $<span id="xdx_90C_ecustom--InstrumentSpecificCreditRiskLoss_pn3n3_c20230101__20231231_zmC4fsOO6ADi" title="Instrument-specific credit risk income">2</span>. During the nine months ended September 30, 2023, the Company recorded instrument-specific credit risk income of $<span id="xdx_90A_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20230930_z94ws00kDJQc" title="Instrument-specific credit risk income">2,541</span> and reclassified $<span id="xdx_902_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20230930_zRFZPbvRExN9" title="Accumulated other comprehensive income">155</span> from accumulated other comprehensive income to other expense, net on the condensed consolidated statements of operations and comprehensive loss upon short-term debt conversion. These amounts have been recorded as a separate component of stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zkuQSFBDQgf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_ziKRjByd3nh2">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. No income tax expense was incurred during the nine months ended September 30, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z7ZJxYtCM1aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zQRwxdLjdhxa">Net Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible debt, stock options, restricted stock units and warrants, which would result in the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For diluted net loss per share when the Company has a net loss, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis with Class A common stock in the distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing earnings per share, the warrants are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company computes earnings per share using the two-class method, an earnings allocation method that determines net income (loss) per share (when there are earnings) for common stock and participating securities. <span id="xdx_907_ecustom--IncomeLossFromAllocatedToWarrants_pn3n3_do_c20240101__20240930_zryR9lMO8rpc" title="Income (loss) from allocated to warrants"><span id="xdx_908_ecustom--IncomeLossFromAllocatedToWarrants_pn3n3_do_c20230101__20230930_zUiXSaKMkAWl" title="Income (loss) from allocated to warrants">No</span></span> income was allocated to the warrants for the nine months ended September 30, 2024 and 2023, as results of operations were a loss for both periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBvQWVenox3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior to the use of the two-class method, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zFwa9yY9Jec7" style="display: none">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20240930_z6ojh0kbmQug" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20230930_zv25W6yWhNi1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zR4cSf4uEGic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">3,455,049</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">2,961,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzF0nEKvEQ8g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">327,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">878,555</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo8HdW18mKbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,905,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,070,627</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zyqEa4jp9cea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,241,291</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,830,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z8nZnm8KyCN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">15,929,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,740,797</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zWr6SQXISBd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zDr4WkaWArv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_ztAQpEOaeM5b">Segment Information</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages its operations through an evaluation of <span id="xdx_908_ecustom--NumberOfBusinessSegments_dc_uInteger_c20240101__20240930_z9hT5x3xRfcl" title="Business segments">three</span> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the three and nine months ended September 30, 2024 and 2023 in Note 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z4OYNqNihXld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z2n825BYXiX3">Allowance for Credit Losses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the adoption of ASU 2016-13 <i>Financial Instruments — Credit Losses,</i> as noted below, the Company recognizes credit losses based on forward-looking current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_840_ecustom--ConcentrationsOfCreditRiskAndSignificantCustomersPolicyTextBlock_zbbOzllKjJbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zu8QF2yOJKKc">Concentrations of Credit Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash, and accounts receivable. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of September 30, 2024, two of the Company’s customers, each of which individually comprised at least <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zOmuWpRi7ZQb" title="Concentration percentage">10</span>%, represented an aggregate <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z7ytZHJwV761" title="Concentration percentage">33</span>% of the Company’s outstanding gross accounts receivable. As of December 31, 2023, two of the Company’s customers, each of which individually comprised at least <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zsiRPxIWb1m7" title="Concentration percentage">10</span>%, represented an aggregate <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zx8gHZGdFoel" title="Concentration percentage">63</span>% of the Company’s outstanding gross accounts receivable. During the nine months ended September 30, 2024 and 2023, the Company had one customer that provided for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdNlGHg91rW2" title="Concentration percentage">15</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOyooRhTY442" title="Concentration percentage">21</span>% of revenue, respectively. The Company had no customers that individual comprised at least <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--RangeAxis__srt--MinimumMember_zf8bprYb9ny7" title="Concentration percentage">10</span>% of revenue and one customer that provided for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zzeDXkaWfr21" title="Concentration percentage">15</span>% of revenue during the three months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_848_ecustom--EmergingGrowthCompanyPolicyTextBlock_zewaIOlOWns3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z5gcOYweb9bk">Emerging Growth Company</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which expires December 31, 2026 unless the Company is otherwise disqualified. Accordingly, when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This may make comparison of the Company’s condensed consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z16iXp6AIxnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z7piQgR0VnJ2">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform with current year presentation. On the condensed consolidated balance sheets, short-term debt - Yorkville and other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 7 for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_840_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_z1ivUn5UXPL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zNAQ5Lzb2gY9">Recently Adopted Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, <i>Financial Instruments — Credit Losses</i> (“ASU 2016-13”), which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company <span id="xdx_901_eus-gaap--ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_iI_dbT_c20240930_zIYuoXJuRJ1i" title="Change In Accounting Principle Accounting Standards Update Adopted">adopted</span> <span id="xdx_905_eus-gaap--AccountingStandardsUpdateExtensibleList_dxL_c20240101__20240930_zzAKoGIGPNqi" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23AccountingStandardsUpdateExtensibleList"><span style="-sec-ix-hidden: xdx2ixbrl4062">ASU 2016-13</span></span> effective <span id="xdx_901_eus-gaap--ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_iI_dd_c20240930_zbyCSkgs1jii" title="Change In Accounting Principle Accounting Standards Update Adoption Date">January 1, 2023</span>. The standard did <span id="xdx_905_eus-gaap--ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_iI_dbTo_c20240930_zGIwzwML1HK9" title="Change In Accounting Principle Accounting Standards Update Immaterial Effect">no</span>t have a material impact on the condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqLRI0Z3Aqtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zheTE70FTDC4">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i> (“ASU 2023-09”), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the effect of this pronouncement on its condensed consolidated financial statements and footnote disclosures.</span></p> <p id="xdx_85F_zp0rshMVpMXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zo0nJERW7ih3" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z4GWuLZEVMic">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The unaudited condensed consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The unaudited condensed consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of consolidated financial position, results of operations and cash flows for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s condensed consolidated financial statements are prepared in accordance with the U.S. Securities and Exchange Commission’s (“SEC”) rules for the presentation of interim financial statements, which permit certain disclosures to be condensed or omitted. These financial statements should be read in conjunction with the Company’s annual financial statements as of and for the year ended December 31, 2023 included in the Annual Report on Form 10-K filed with the SEC on July 30, 2024, (the “2023 Form 10-K”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s consolidated financial position as of September 30, 2024, and its consolidated results of operations and cash flows for the nine months ended September 30, 2024 and 2023. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--UseOfEstimates_z8eN0DgH6Ha5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zahsPnBUJY2k">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of inventory, contingent consideration, short-term debt, stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zwMJfmd4LAHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zWQNrzFsdJs7">Fair Value Measurements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: -28.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zRfY4O0ZcUR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zCb4sg5yPraf">Comprehensive Income (Loss)</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive income (loss) refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded from net income (loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company’s only component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of indebtedness accounted for under the fair value option that is attributable to changes in instrument-specific credit risk. During the nine months ended September 30, 2024, the Company recorded instrument-specific credit risk loss of $<span id="xdx_90C_ecustom--InstrumentSpecificCreditRiskLoss_pn3n3_c20230101__20231231_zmC4fsOO6ADi" title="Instrument-specific credit risk income">2</span>. During the nine months ended September 30, 2023, the Company recorded instrument-specific credit risk income of $<span id="xdx_90A_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20230930_z94ws00kDJQc" title="Instrument-specific credit risk income">2,541</span> and reclassified $<span id="xdx_902_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20230930_zRFZPbvRExN9" title="Accumulated other comprehensive income">155</span> from accumulated other comprehensive income to other expense, net on the condensed consolidated statements of operations and comprehensive loss upon short-term debt conversion. These amounts have been recorded as a separate component of stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> 2000 2541000 155000 <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zkuQSFBDQgf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_ziKRjByd3nh2">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. No income tax expense was incurred during the nine months ended September 30, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z7ZJxYtCM1aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zQRwxdLjdhxa">Net Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible debt, stock options, restricted stock units and warrants, which would result in the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For diluted net loss per share when the Company has a net loss, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis with Class A common stock in the distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing earnings per share, the warrants are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company computes earnings per share using the two-class method, an earnings allocation method that determines net income (loss) per share (when there are earnings) for common stock and participating securities. <span id="xdx_907_ecustom--IncomeLossFromAllocatedToWarrants_pn3n3_do_c20240101__20240930_zryR9lMO8rpc" title="Income (loss) from allocated to warrants"><span id="xdx_908_ecustom--IncomeLossFromAllocatedToWarrants_pn3n3_do_c20230101__20230930_zUiXSaKMkAWl" title="Income (loss) from allocated to warrants">No</span></span> income was allocated to the warrants for the nine months ended September 30, 2024 and 2023, as results of operations were a loss for both periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBvQWVenox3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior to the use of the two-class method, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zFwa9yY9Jec7" style="display: none">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20240930_z6ojh0kbmQug" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20230930_zv25W6yWhNi1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zR4cSf4uEGic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">3,455,049</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">2,961,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzF0nEKvEQ8g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">327,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">878,555</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo8HdW18mKbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,905,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,070,627</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zyqEa4jp9cea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,241,291</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,830,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z8nZnm8KyCN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">15,929,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,740,797</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zWr6SQXISBd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 0 0 <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBvQWVenox3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior to the use of the two-class method, as they would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zFwa9yY9Jec7" style="display: none">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20240930_z6ojh0kbmQug" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20230930_zv25W6yWhNi1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zR4cSf4uEGic" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">3,455,049</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">2,961,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzF0nEKvEQ8g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">327,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">878,555</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zo8HdW18mKbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,905,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,070,627</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zyqEa4jp9cea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,241,291</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,830,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z8nZnm8KyCN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">15,929,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,740,797</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3455049 2961438 327359 878555 10905901 7070627 1241291 2830177 15929600 13740797 <p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zDr4WkaWArv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_ztAQpEOaeM5b">Segment Information</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages its operations through an evaluation of <span id="xdx_908_ecustom--NumberOfBusinessSegments_dc_uInteger_c20240101__20240930_z9hT5x3xRfcl" title="Business segments">three</span> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the three and nine months ended September 30, 2024 and 2023 in Note 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> 3 <p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z4OYNqNihXld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z2n825BYXiX3">Allowance for Credit Losses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the adoption of ASU 2016-13 <i>Financial Instruments — Credit Losses,</i> as noted below, the Company recognizes credit losses based on forward-looking current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_840_ecustom--ConcentrationsOfCreditRiskAndSignificantCustomersPolicyTextBlock_zbbOzllKjJbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zu8QF2yOJKKc">Concentrations of Credit Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash, and accounts receivable. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of September 30, 2024, two of the Company’s customers, each of which individually comprised at least <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zOmuWpRi7ZQb" title="Concentration percentage">10</span>%, represented an aggregate <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z7ytZHJwV761" title="Concentration percentage">33</span>% of the Company’s outstanding gross accounts receivable. As of December 31, 2023, two of the Company’s customers, each of which individually comprised at least <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zsiRPxIWb1m7" title="Concentration percentage">10</span>%, represented an aggregate <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zx8gHZGdFoel" title="Concentration percentage">63</span>% of the Company’s outstanding gross accounts receivable. During the nine months ended September 30, 2024 and 2023, the Company had one customer that provided for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdNlGHg91rW2" title="Concentration percentage">15</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOyooRhTY442" title="Concentration percentage">21</span>% of revenue, respectively. The Company had no customers that individual comprised at least <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--RangeAxis__srt--MinimumMember_zf8bprYb9ny7" title="Concentration percentage">10</span>% of revenue and one customer that provided for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zzeDXkaWfr21" title="Concentration percentage">15</span>% of revenue during the three months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> 0.10 0.33 0.10 0.63 0.15 0.21 0.10 0.15 <p id="xdx_848_ecustom--EmergingGrowthCompanyPolicyTextBlock_zewaIOlOWns3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z5gcOYweb9bk">Emerging Growth Company</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which expires December 31, 2026 unless the Company is otherwise disqualified. Accordingly, when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This may make comparison of the Company’s condensed consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z16iXp6AIxnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z7piQgR0VnJ2">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform with current year presentation. On the condensed consolidated balance sheets, short-term debt - Yorkville and other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 7 for further information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_840_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_z1ivUn5UXPL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zNAQ5Lzb2gY9">Recently Adopted Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, <i>Financial Instruments — Credit Losses</i> (“ASU 2016-13”), which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company <span id="xdx_901_eus-gaap--ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_iI_dbT_c20240930_zIYuoXJuRJ1i" title="Change In Accounting Principle Accounting Standards Update Adopted">adopted</span> <span id="xdx_905_eus-gaap--AccountingStandardsUpdateExtensibleList_dxL_c20240101__20240930_zzAKoGIGPNqi" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23AccountingStandardsUpdateExtensibleList"><span style="-sec-ix-hidden: xdx2ixbrl4062">ASU 2016-13</span></span> effective <span id="xdx_901_eus-gaap--ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_iI_dd_c20240930_zbyCSkgs1jii" title="Change In Accounting Principle Accounting Standards Update Adoption Date">January 1, 2023</span>. The standard did <span id="xdx_905_eus-gaap--ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_iI_dbTo_c20240930_zGIwzwML1HK9" title="Change In Accounting Principle Accounting Standards Update Immaterial Effect">no</span>t have a material impact on the condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> true 2023-01-01 true <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqLRI0Z3Aqtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zheTE70FTDC4">Recently Issued Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i> (“ASU 2023-09”), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the effect of this pronouncement on its condensed consolidated financial statements and footnote disclosures.</span></p> <p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zSXMVwnyxei8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zZydBODqjLie">Fair Value of Financial Assets and Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zkjhZPY5kMQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zRPrnIlABUek" style="display: none">Schedule of Financial Assets and Liabilities Measures at Fair Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zBh7ABIGchVl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zU9dKOhLx6ui" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRAU7TuBcybd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240930_zJRS7IxqHos2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zpbt2Ws6Xsm5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zvk3LX7zIEbh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4079">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4080">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,606</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,606</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zAEZBd9QKN7j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4084">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4085">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zujspXNgPJH7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Short-term debt - Yorkville convertible note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4089">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4090">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,695</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zMnq1wzLQKD2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4094">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4095">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,748</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,748</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zq8whLWE06qh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4099">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4100">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,670</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zdcguvmemkF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4104">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4105">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">809</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_z5c81lRiR2Of" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4109">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4110">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zgA8JDQ2KpLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4115">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4116">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zwutvjQrkIrb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4120">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,731</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgLwEbSGmpph" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zte2eGk8yj98" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZXw5QKN9lJi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20231231_zyh8O7PR0Og7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zAQrO6ToYITa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ConvertibleNoteReceivable_i01I_pn3n3_z71dgfLulFl9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt">Convertible note receivable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4129">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4130">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_z0HrdnMQEu89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4134">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4135">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zeiJMLjdTLU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_z75r0xlyLiE8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Acquisition-related contingent consideration obligations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4144">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4145">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zdA0uEQBbHsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4149">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4150">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_z67joWHR8iMa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4154">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4155">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zqvW9RJWvQGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4159">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4160">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zpA2YFJ3oK31" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4164">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4165">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zFHQXnxYbefh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4169">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4170">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zLDQd2OndATi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4174">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4175">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zNvPBsdPX425" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4180">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4181">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zy6OtJnH0K37" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4185">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,640</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zLJ2Z5AunuNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3. The carrying values of other current liabilities approximate fair value in the accompanying condensed consolidated financial statements due to the short-term nature of those instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Convertible Note Receivable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The convertible note receivable was received in connection with the disposition of the UltraMIST/MIST business in 2020. At any time on or after January 1, 2021, at the sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted into Sanuwave common stock at a defined rate. The convertible note receivable was to be paid on or before August 6, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 18, 2023, the Company entered into a forbearance agreement with Sanuwave (“Sanuwave Forbearance Agreement”). Per the Sanuwave Forbearance Agreement, from the period from December 18, 2023 to the earliest of (i) February 28, 2024, (ii) the commencement of bankruptcy proceedings for Sanuwave pursuant to the U.S. Bankruptcy Code, (iii) the occurrence of an event of default other than payment default, or (iv) the failure of Sanuwave to comply with any term, condition or covenant set forth in the forbearance agreement, the Company agrees that it will not exercise any remedy available to it under the convertible note receivable, excluding the right to increase the interest rate. As collateral for payments owed to Palantir Technologies, Inc. (“Palantir”), the Company assigned to Palantir the Sanuwave convertible note receivable in the event of default (see Note 9). On May 10, 2024, the Company entered into a letter agreement with Sanuwave to extend the forbearance period from <span id="xdx_902_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_z3jnDNCrpTNe" title="Forbearance extend period">February 28, 2024</span> to <span id="xdx_90C_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_z4Q6C4SZM4Sh" title="Forbearance extend period">June 3, 2024</span>. The letter agreement increased the total note payments to $<span id="xdx_90E_ecustom--IincreasedNotePayments_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zQqmXkghzW9f" title="Increased total note payments">2,175</span>. Upon executing the letter agreement, Sanuwave made an initial note payment of $<span id="xdx_907_ecustom--InitialNotePayment_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zJ6hNBEf42t7" title="Initial note payment">100</span> and on June 3, 2024, made a second note payment of $<span id="xdx_904_ecustom--SecondNotePayment_pn3n3_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zSBEdBv76079" title="Second note payment">2,075</span>, fully discharging all outstanding indebtedness under the note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zF8Z8EoqT1of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zQIgIv1qnLE3" style="display: none">Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> January 1,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 35%; text-align: left">Convertible note receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ConvertibleNoteReceivable_iS_pn3n3_c20240101__20240930_zyYPaHg0Wbaf" style="width: 9%; text-align: right" title="Beginning balance">2,072</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20240101__20240930_znTud5VFbfqc" style="width: 9%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl4203">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20240930_zADHafmrn0m4" style="width: 9%; text-align: right" title="Purchases settlements and other net">(2,072</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20240101__20240930_zrKzAv9bDpmi" style="width: 9%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl4207">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ConvertibleNoteReceivable_iE_pn3n3_c20240101__20240930_z2aAB6K6GXre" style="width: 9%; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl4209">—</span></td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zWsBX5o2U6w7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, the fair value of this note was based on a bond valuation which employs a credit default model. The Company utilized Level 3 inputs on a probability weighted model based on outcomes of a default, repayment and conversion of the note. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s own assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_zxpM1ORtTZX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the convertible note valuation model were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zwpxdPGcdeW8" style="display: none">Schedule of Convertible Note Valuation Model</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%">Face value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_z1yEYH7gBWw3" style="width: 14%; text-align: right" title="Face value">4,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Coupon rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zX8wXDxVatyg" title="Coupon rate">12</span>% - <span id="xdx_90B_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zgR37oe4w6v2" title="Coupon rate">17</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ValuationModelThatRelateToSanuwaveCommonStock_iI_pid_c20231231_z3V3MCqyhTNh" style="text-align: right" title="Stock price">0.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zrjaTernRzri" title="Term (years)">0.51</span>-<span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zWyaGafooYHe" title="Term (years)">2.45</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zoHntARd43vb" title="Risk-free interest rate">5.47</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zGZ3DiVYnnMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Contingent Consideration</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s own assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zRELJ9D7n6L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zIG52EDSEUv" style="display: none">Schedule of Reconciliation of Contingent Consideration Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> January 1, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 35%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ContingentConsiderationObligation_iS_pn3n3_c20240101__20240930_z5YVBOXB5O92" style="width: 9%; text-align: right" title="Beginning balance">1,606</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20240101__20240930_z7pyAlGLefDf" style="width: 9%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl4231">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_pn3n3_c20240101__20240930_zCo9xZTD0lx2" style="width: 9%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl4233">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20240101__20240930_z8Jr0jLNJ5f4" style="width: 9%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl4235">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ContingentConsiderationObligation_iE_pn3n3_c20240101__20240930_zN7G4rYY1K0a" style="width: 9%; text-align: right" title="Ending balance">1,606</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zHx70GhMO5Xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the liability to make potential future milestone and earn-out payments was estimated by the Company at each reporting date based, in part, on the results of a third-party valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving specified events, discount rates, and the period of time until earn-out payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the Company’s condensed consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The change in the fair value of the contingent consideration obligations during the nine months ended September 30, 2024 was de minimus. The Company has classified all of the contingent consideration as a long-term liability in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023. See Note 9 for more information on contingent consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Contingent Stock Consideration</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contingent stock consideration liability at September 30, 2024, is comprised of the fair value of potential future issuance of Class A common stock to CariCord participating shareholders pursuant to a settlement agreement signed during the year ended December 31, 2021. The fair value measurement of the contingent stock consideration obligation is determined using Level 3 inputs and is based on a probability weighted expected return methodology (“PWERM”). The measurement is largely based upon unobservable inputs supported by little or no market activity based on the Company’s own assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_897_ecustom--FairValueAssetsOfContingentStockConsiderationMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zsyJ7YbW9Yq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zmJHL0gojGcf" style="display: none">Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> January 1, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 35%; text-align: left">Contingent stock consideration</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ContingentStockConsiderationObligation_iS_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zxzvM7WJXLAj" style="width: 9%; text-align: right" title="Beginning balance">27</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zedWUunZUjHl" style="width: 9%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl4243">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zpcz5uy2ix4c" style="width: 9%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl4245">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ChangeInFairValueOfContingentStockConsideration_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zwPPY8YmcyS1" style="width: 9%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl4247">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ContingentStockConsiderationObligation_iE_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zLwPjPgryIsg" style="width: 9%; text-align: right" title="Ending balance">27</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zii610nTzmx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the liability to issue future shares of Class A common stock was estimated by the Company at each reporting date using a PWERM based on various inputs and assumptions, including the Company’s common share price, discount rates, and the probability of achieving specified future operational targets. The actual settlement of contingent stock consideration could differ from current estimates based on the actual achievement of these specified targets and movements in the Company’s common share price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting date, the Company revalues the contingent stock consideration obligation to estimated fair value and records changes in fair value as income or expense in the Company’s condensed consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent stock consideration obligation may result from changes in discount rates, changes in the Company’s common share price, and changes in probability assumptions with respect to the likelihood of achieving specified operational targets. The change in the fair value of the contingent stock consideration obligation during the nine months ended September 30, 2024 was de minimus. The Company has classified all of the contingent stock consideration as a current liability in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Short-Term Debt - Yorkville</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company elected the fair value option to account for the Yorkville PPA signed on September 15, 2022 (see Note 7). As of December 31, 2023, due to the short-term nature of the debt, the fair value of the Yorkville PPA approximated the settlement amount, which was fully paid on January 17, 2024. The Company also elected the fair value option to account for the Yorkville convertible promissory note signed on March 13, 2024 (see Note 7). The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying condensed consolidated statements of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive loss in the accompanying condensed consolidated statements of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing of when and if Yorkville elects to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and movements in the Company’s common share price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zqhzYhIuZQY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3O1oNvTnWhh" style="display: none">Schedule of Reconciliation of Yorkville Debt Measured on a Measured Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 62%">Balance as of January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z36LLJfjlq6" style="width: 14%; text-align: right" title="Balance">17,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Principal repayments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zuRzGWFYGbp6" style="text-align: right" title="Principal repayments">(17,374</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Issuance of convertible promissory note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4imlbPNZYjh" style="text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Fair value adjustment through earnings</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zjSsGlnrFHdl" style="text-align: right" title="Fair value adjustment through earnings">694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through accumulated other comprehensive income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zP0r1mmVT9W1" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment through accumulated other comprehensive income">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zCENZTEKxJY6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">3,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zq4uOYrGcmSc" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Yorkville convertible promissory note is based on a valuation which employs a Monte Carlo model and a credit default model. The Company utilized Level 3 inputs in a probability weighted model based on outcomes of a default, repayment and conversion of the note. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s own assumptions. The fair value of the Yorkville convertible promissory note on March 13, 2024, the date of issuance, was $2,993.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_896_ecustom--ScheduleofyorkvilleShortTermDebtValuationModelTableTextBlock_zb4DLwTv5vkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Yorkville convertible promissory note valuation model were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zyKLoy90qUo" style="display: none">Schedule of Yorkville Short-term Debt Valuation Model</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">March 13,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(issuance)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ValuationInputForShortTermDebtSharePrice_iI_pid_c20240930_z6GTKjcDHT3e" style="width: 14%; text-align: right" title="Common share price">2.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ValuationInputForShortTermDebtSharePrice_iI_pid_c20240313_zPtvoyjHqWc4" style="width: 14%; text-align: right" title="Common share price">5.79</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit spread</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ValuationInputForShortTermDebtCreditSpread_iI_pid_uPure_c20240930_zFkSHW5Btbh3" style="text-align: right" title="Credit spread">8.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ValuationInputForShortTermDebtCreditSpread_iI_pid_uPure_c20240313_zECyT4SwVPkh" style="text-align: right" title="Credit spread">8.50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240930_zVCfPygk8nIj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240313_zuCrN73m5653" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ValuationInputForShortTermDebtTerm_dtY_c20240101__20240930_zIESYSh5mRsb" title="Term (years)">0.45</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--ValuationInputForShortTermDebtTerm_dtY_c20240313__20240313_z920BKYImxU1" title="Term (years)">1.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zyQGSAX9f44" style="text-align: right" title="Risk-free interest rate">4.30</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2XS5A7kgBB7" style="text-align: right" title="Risk-free interest rate">4.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zGxkTLLnxGrj" style="text-align: right" title="Volatility">50.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbfZe2FFRNH7" style="text-align: right" title="Volatility">50.0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_zBxa57Uqodll" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation of Warrant Liability</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant liability at September 30, 2024 is comprised of the fair value of warrants to purchase shares of Class A common stock. The Public Warrants are recorded at fair value based on the period-end publicly stated close price, which is a Level 1 input. The January 2024 Bridge Loan - Tranche #2 Warrants were recorded at fair value based on a Monte Carlo simulation model and the Registered Direct, PIPE and Sponsor Warrants are recorded at their respective closing date fair values based on a Black-Scholes option pricing model that utilizes inputs for: (i) value of the underlying asset, (ii) the exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset and (vi) maturity, which are Level 3 inputs. The Black-Scholes option pricing model’s primary unobservable input utilized in determining the fair values of the warrant liabilities is the expected volatility of the Class A common stock. Prior to the merger, Legacy Celularity was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the Company estimates its expected stock price volatility using its volatility since the merger and the historical volatility of publicly traded peer companies. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated remaining term of the warrants. Inputs to the Monte Carlo and Black-Scholes option pricing models for the warrants are updated each reporting period to reflect fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zwlL9t1xTSPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zQz486LjKRAe">Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance as of January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueNetAssetsLiability_iS_pn3n3_c20240101__20240930_zlXVLBRgYK27" style="width: 14%; text-align: right" title="Fair value, Beginning Balance">3,784</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20240930_zgpxW0Uf1SHi" style="text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance">1,858</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gain recognized in earnings from change in fair value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20240101__20240930_ziugY3ke5K6h" style="text-align: right" title="Gain recognized in earnings from change in fair value">1,587</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_pn3n3_c20240101__20240930_zT87KrYVEcNe" style="border-bottom: Black 1pt solid; text-align: right" title="Reclassification of warrants from liability classified to equity classified">(2,970</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--FairValueNetAssetsLiability_iE_pn3n3_c20240101__20240930_zH3g1oxVzu16" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">4,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zY4tbvgpeSQb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zrxDG2OX19id" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zEPl1YrwehR1" style="display: none">Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">December 31,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2023</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zVJPawovs1G" style="width: 14%; text-align: right" title="Common share price">2.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zN7S0bEzQvp1" style="width: 14%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zJr4aRg9O6Bh" title="Exercise price">3.50</span> - <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zuQtLtlpJo18" title="Exercise price">7.50</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zFJv1WolFjEe" title="Exercise price">3.50</span> - <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zI46RsiCeyIg" title="Exercise price">7.50</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zit0QfAZeH6" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zscEInsJiHLh" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MinimumMember_zRwp2LSwd0La" title="Term (years)">4.03</span> - <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MaximumMember_zljqNOyZF1c9" title="Term (years)">4.34</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MinimumMember_z681CEnDm4bb" title="Term (years)">4.78</span> - <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MaximumMember_zA1oWOXVIJUf" title="Term (years)">5.09</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zHoaDukmrez2" style="text-align: right" title="Dividend yield">3.58</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zNnX5uNLnEpc" style="text-align: right" title="Dividend yield">3.84</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z8MtvoHex733" title="Warrant and right outstanding measurement input">97.1</span>% - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxX9glQRXI26" title="Warrant and right outstanding measurement input">98.1</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY1O4qEB4p64" title="Warrant and right outstanding measurement input">100.1</span>% - <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zVbgOWQGGFli" title="Warrant and right outstanding measurement input">100.7</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A9_zxXrV8Sj0Tf2" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_zV2WGPfLSa2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the January 2024 Bridge Loan - Tranche #2 Warrants were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_ziYDZcyw6EU8" style="display: none">Schedule of January 20224 Bridge Loan</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">July 15,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">January 16,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(reclassification)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(issuance)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zwQoS4qcs3I2" style="width: 14%; text-align: right" title="Common share price">3.19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_ziEXGOAp6SV2" style="width: 14%; text-align: right" title="Common share price">2.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term to initial exercise date (years)⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingTermToInitialExerciseDate_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_fKDEp_zIMCfL9Xebbe" title="Term to initial exercise date (years)">0.50</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1GkAzmd1ZIj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMhRDIzip3hj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zUlXpoE12QU9" title="Term (years)">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_z3TPl0J0oZKj" title="Term (years)">5.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znJI5ihj7kZ4" style="text-align: right" title="Risk-free interest rate">4.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zj4bmUQ87FI5" style="text-align: right" title="Dividend yield">3.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zw3boyLWFnw8" style="text-align: right" title="Warrant and right outstanding measurement input">112.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKOV8a09cjo" style="text-align: right" title="Warrant and right outstanding measurement input">107.5</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F09_z7QbFmk4YLX7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_zJGUetJaSfPh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed further in Note 7, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July 15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the Company’s own stock. As such, the warrants were marked to fair value as of the initial exercise date and then reclassified from liability classified to equity classified.</span></td> </tr></table> <p id="xdx_8AA_zyyvd5ttmHy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89A_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zCk7rXgCTBe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Sponsor Warrants were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zjSnFYJ6f9w2" style="display: none">Schedule of Sponsor Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">December 31,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2023</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zOcuTutu7w84" style="width: 14%; text-align: right" title="Common share price">2.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_z806lXiCsmal" style="width: 14%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zBWEoQnX1XQd" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zRCBarGYsYqj" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zu1RRErB1po3" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzXMYj5kgQQe" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zerjcaDiaJCa" title="Term (years)">1.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_z0dvRI8BJ3kh" title="Term (years)">2.5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRMT0gHMfwg1" style="text-align: right" title="Dividend yield">3.66</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zM9p0wpm1h2k" style="text-align: right" title="Dividend yield">4.12</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zP2luCDC7xRa" style="text-align: right" title="Warrant and right outstanding measurement input">105.9</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zHqu1jtpuE02" style="text-align: right" title="Warrant and right outstanding measurement input">100.7</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A3_zaejsA9gxWfa" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zkjhZPY5kMQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zRPrnIlABUek" style="display: none">Schedule of Financial Assets and Liabilities Measures at Fair Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zBh7ABIGchVl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zU9dKOhLx6ui" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRAU7TuBcybd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240930_zJRS7IxqHos2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zpbt2Ws6Xsm5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zvk3LX7zIEbh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4079">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4080">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,606</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,606</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zAEZBd9QKN7j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4084">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4085">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zujspXNgPJH7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Short-term debt - Yorkville convertible note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4089">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4090">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,695</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zMnq1wzLQKD2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4094">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4095">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,748</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,748</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zq8whLWE06qh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4099">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4100">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,670</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zdcguvmemkF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4104">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4105">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">809</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_z5c81lRiR2Of" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4109">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4110">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zgA8JDQ2KpLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4115">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4116">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zwutvjQrkIrb" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4120">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,731</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgLwEbSGmpph" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zte2eGk8yj98" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZXw5QKN9lJi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20231231_zyh8O7PR0Og7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zAQrO6ToYITa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ConvertibleNoteReceivable_i01I_pn3n3_z71dgfLulFl9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt">Convertible note receivable</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4129">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4130">—</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">2,072</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_z0HrdnMQEu89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4134">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4135">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zeiJMLjdTLU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_z75r0xlyLiE8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Acquisition-related contingent consideration obligations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4144">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4145">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,606</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zdA0uEQBbHsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4149">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4150">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_z67joWHR8iMa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4154">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4155">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,223</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zqvW9RJWvQGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4159">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4160">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,529</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zpA2YFJ3oK31" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4164">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4165">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,487</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zFHQXnxYbefh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4169">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4170">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zLDQd2OndATi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4174">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4175">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zNvPBsdPX425" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability - Public Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4180">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4181">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">575</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zy6OtJnH0K37" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fair value liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4185">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,640</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1606000 1606000 27000 27000 3695000 3695000 1748000 1748000 1670000 1670000 809000 809000 32000 32000 144000 144000 144000 9587000 9731000 2072000 2072000 2072000 2072000 1606000 1606000 27000 27000 17223000 17223000 1529000 1529000 1487000 1487000 708000 708000 60000 60000 575000 575000 575000 22640000 23215000 2024-02-28 2024-06-03 2175000 100000 2075000 <p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zF8Z8EoqT1of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zQIgIv1qnLE3" style="display: none">Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> January 1,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 35%; text-align: left">Convertible note receivable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ConvertibleNoteReceivable_iS_pn3n3_c20240101__20240930_zyYPaHg0Wbaf" style="width: 9%; text-align: right" title="Beginning balance">2,072</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20240101__20240930_znTud5VFbfqc" style="width: 9%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl4203">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20240930_zADHafmrn0m4" style="width: 9%; text-align: right" title="Purchases settlements and other net">(2,072</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20240101__20240930_zrKzAv9bDpmi" style="width: 9%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl4207">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ConvertibleNoteReceivable_iE_pn3n3_c20240101__20240930_z2aAB6K6GXre" style="width: 9%; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl4209">—</span></td><td style="width: 1%; text-align: left"> </td></tr> </table> 2072000 -2072000 <p id="xdx_89B_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_zxpM1ORtTZX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the convertible note valuation model were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zwpxdPGcdeW8" style="display: none">Schedule of Convertible Note Valuation Model</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%">Face value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_z1yEYH7gBWw3" style="width: 14%; text-align: right" title="Face value">4,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Coupon rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zX8wXDxVatyg" title="Coupon rate">12</span>% - <span id="xdx_90B_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zgR37oe4w6v2" title="Coupon rate">17</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ValuationModelThatRelateToSanuwaveCommonStock_iI_pid_c20231231_z3V3MCqyhTNh" style="text-align: right" title="Stock price">0.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zrjaTernRzri" title="Term (years)">0.51</span>-<span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zWyaGafooYHe" title="Term (years)">2.45</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zoHntARd43vb" title="Risk-free interest rate">5.47</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td></tr> </table> 4000000 0.12 0.17 0.23 P0Y6M3D P2Y5M12D 0.0547 <p id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zRELJ9D7n6L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zIG52EDSEUv" style="display: none">Schedule of Reconciliation of Contingent Consideration Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> January 1, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 35%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ContingentConsiderationObligation_iS_pn3n3_c20240101__20240930_z5YVBOXB5O92" style="width: 9%; text-align: right" title="Beginning balance">1,606</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_pn3n3_c20240101__20240930_z7pyAlGLefDf" style="width: 9%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl4231">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_pn3n3_c20240101__20240930_zCo9xZTD0lx2" style="width: 9%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl4233">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueAdjustment_pn3n3_c20240101__20240930_z8Jr0jLNJ5f4" style="width: 9%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl4235">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ContingentConsiderationObligation_iE_pn3n3_c20240101__20240930_zN7G4rYY1K0a" style="width: 9%; text-align: right" title="Ending balance">1,606</td><td style="width: 1%; text-align: left"> </td></tr> </table> 1606000 1606000 <p id="xdx_897_ecustom--FairValueAssetsOfContingentStockConsiderationMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zsyJ7YbW9Yq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zmJHL0gojGcf" style="display: none">Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> January 1, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> transfers<br/> in to (out of) <br/> Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Purchases,<br/> settlements<br/> and other<br/> net</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value<br/> adjustments</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance as of<br/> September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 35%; text-align: left">Contingent stock consideration</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ContingentStockConsiderationObligation_iS_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zxzvM7WJXLAj" style="width: 9%; text-align: right" title="Beginning balance">27</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--LiabilitiesFairValueNetTransfersIntoLevelThree_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zedWUunZUjHl" style="width: 9%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl4243">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--LiabilitiesPurchasesSettlementsAndOtherNet_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zpcz5uy2ix4c" style="width: 9%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl4245">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ChangeInFairValueOfContingentStockConsideration_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zwPPY8YmcyS1" style="width: 9%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl4247">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ContingentStockConsiderationObligation_iE_c20240101__20240930__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zLwPjPgryIsg" style="width: 9%; text-align: right" title="Ending balance">27</td><td style="width: 1%; text-align: left"> </td></tr> </table> 27000 27000 <p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zqhzYhIuZQY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3O1oNvTnWhh" style="display: none">Schedule of Reconciliation of Yorkville Debt Measured on a Measured Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 62%">Balance as of January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z36LLJfjlq6" style="width: 14%; text-align: right" title="Balance">17,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Principal repayments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zuRzGWFYGbp6" style="text-align: right" title="Principal repayments">(17,374</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Issuance of convertible promissory note</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4imlbPNZYjh" style="text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Fair value adjustment through earnings</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zjSsGlnrFHdl" style="text-align: right" title="Fair value adjustment through earnings">694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through accumulated other comprehensive income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zP0r1mmVT9W1" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value adjustment through accumulated other comprehensive income">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zCENZTEKxJY6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">3,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 17223000 -17374000 3150000 694000 2000 3695000 <p id="xdx_896_ecustom--ScheduleofyorkvilleShortTermDebtValuationModelTableTextBlock_zb4DLwTv5vkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Yorkville convertible promissory note valuation model were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zyKLoy90qUo" style="display: none">Schedule of Yorkville Short-term Debt Valuation Model</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">March 13,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(issuance)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ValuationInputForShortTermDebtSharePrice_iI_pid_c20240930_z6GTKjcDHT3e" style="width: 14%; text-align: right" title="Common share price">2.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ValuationInputForShortTermDebtSharePrice_iI_pid_c20240313_zPtvoyjHqWc4" style="width: 14%; text-align: right" title="Common share price">5.79</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit spread</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ValuationInputForShortTermDebtCreditSpread_iI_pid_uPure_c20240930_zFkSHW5Btbh3" style="text-align: right" title="Credit spread">8.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ValuationInputForShortTermDebtCreditSpread_iI_pid_uPure_c20240313_zECyT4SwVPkh" style="text-align: right" title="Credit spread">8.50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240930_zVCfPygk8nIj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240313_zuCrN73m5653" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ValuationInputForShortTermDebtTerm_dtY_c20240101__20240930_zIESYSh5mRsb" title="Term (years)">0.45</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--ValuationInputForShortTermDebtTerm_dtY_c20240313__20240313_z920BKYImxU1" title="Term (years)">1.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zyQGSAX9f44" style="text-align: right" title="Risk-free interest rate">4.30</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2XS5A7kgBB7" style="text-align: right" title="Risk-free interest rate">4.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zGxkTLLnxGrj" style="text-align: right" title="Volatility">50.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ValuationInputForShortTermDebtDividendYield_iI_pid_dp_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbfZe2FFRNH7" style="text-align: right" title="Volatility">50.0</td><td style="text-align: left">%</td></tr> </table> 2.97 5.79 8.00 8.50 0 0 P0Y5M12D P1Y 0.0430 0.0490 0.500 0.500 <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zwlL9t1xTSPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the nine months ended September 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zQz486LjKRAe">Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Balance as of January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueNetAssetsLiability_iS_pn3n3_c20240101__20240930_zlXVLBRgYK27" style="width: 14%; text-align: right" title="Fair value, Beginning Balance">3,784</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20240930_zgpxW0Uf1SHi" style="text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance">1,858</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gain recognized in earnings from change in fair value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20240101__20240930_ziugY3ke5K6h" style="text-align: right" title="Gain recognized in earnings from change in fair value">1,587</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_pn3n3_c20240101__20240930_zT87KrYVEcNe" style="border-bottom: Black 1pt solid; text-align: right" title="Reclassification of warrants from liability classified to equity classified">(2,970</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--FairValueNetAssetsLiability_iE_pn3n3_c20240101__20240930_zH3g1oxVzu16" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">4,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3784000 1858000 1587000 -2970000 4259000 <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zrxDG2OX19id" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zEPl1YrwehR1" style="display: none">Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">December 31,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2023</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zVJPawovs1G" style="width: 14%; text-align: right" title="Common share price">2.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zN7S0bEzQvp1" style="width: 14%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zJr4aRg9O6Bh" title="Exercise price">3.50</span> - <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zuQtLtlpJo18" title="Exercise price">7.50</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zFJv1WolFjEe" title="Exercise price">3.50</span> - <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zI46RsiCeyIg" title="Exercise price">7.50</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zit0QfAZeH6" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zscEInsJiHLh" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MinimumMember_zRwp2LSwd0La" title="Term (years)">4.03</span> - <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MaximumMember_zljqNOyZF1c9" title="Term (years)">4.34</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MinimumMember_z681CEnDm4bb" title="Term (years)">4.78</span> - <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__srt--RangeAxis__srt--MaximumMember_zA1oWOXVIJUf" title="Term (years)">5.09</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zHoaDukmrez2" style="text-align: right" title="Dividend yield">3.58</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zNnX5uNLnEpc" style="text-align: right" title="Dividend yield">3.84</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z8MtvoHex733" title="Warrant and right outstanding measurement input">97.1</span>% - <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxX9glQRXI26" title="Warrant and right outstanding measurement input">98.1</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY1O4qEB4p64" title="Warrant and right outstanding measurement input">100.1</span>% - <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zVbgOWQGGFli" title="Warrant and right outstanding measurement input">100.7</span></span></td><td style="text-align: left">%</td></tr> </table> 2.97 2.47 3.50 7.50 3.50 7.50 0 0 P4Y10D P4Y4M2D P4Y9M10D P5Y1M2D 3.58 3.84 97.1 98.1 100.1 100.7 <p id="xdx_899_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_zV2WGPfLSa2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the January 2024 Bridge Loan - Tranche #2 Warrants were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_ziYDZcyw6EU8" style="display: none">Schedule of January 20224 Bridge Loan</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">July 15,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">January 16,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(reclassification)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(issuance)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zwQoS4qcs3I2" style="width: 14%; text-align: right" title="Common share price">3.19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_ziEXGOAp6SV2" style="width: 14%; text-align: right" title="Common share price">2.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term to initial exercise date (years)⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--WarrantsAndRightsOutstandingTermToInitialExerciseDate_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_fKDEp_zIMCfL9Xebbe" title="Term to initial exercise date (years)">0.50</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1GkAzmd1ZIj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMhRDIzip3hj" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zUlXpoE12QU9" title="Term (years)">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_z3TPl0J0oZKj" title="Term (years)">5.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znJI5ihj7kZ4" style="text-align: right" title="Risk-free interest rate">4.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zj4bmUQ87FI5" style="text-align: right" title="Dividend yield">3.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zw3boyLWFnw8" style="text-align: right" title="Warrant and right outstanding measurement input">112.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zKOV8a09cjo" style="text-align: right" title="Warrant and right outstanding measurement input">107.5</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F09_z7QbFmk4YLX7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_zJGUetJaSfPh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed further in Note 7, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July 15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the Company’s own stock. As such, the warrants were marked to fair value as of the initial exercise date and then reclassified from liability classified to equity classified.</span></td> </tr></table> 3.19 2.00 P0Y6M 0 0 P5Y P5Y 4.00 3.90 112.5 107.5 <p id="xdx_89A_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zCk7rXgCTBe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant inputs for the Sponsor Warrants were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zjSnFYJ6f9w2" style="display: none">Schedule of Sponsor Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">December 31,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2023</p></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Common share price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zOcuTutu7w84" style="width: 14%; text-align: right" title="Common share price">2.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_z806lXiCsmal" style="width: 14%; text-align: right" title="Common share price">2.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zBWEoQnX1XQd" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zRCBarGYsYqj" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zu1RRErB1po3" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzXMYj5kgQQe" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zerjcaDiaJCa" title="Term (years)">1.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_z0dvRI8BJ3kh" title="Term (years)">2.5</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRMT0gHMfwg1" style="text-align: right" title="Dividend yield">3.66</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zM9p0wpm1h2k" style="text-align: right" title="Dividend yield">4.12</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zP2luCDC7xRa" style="text-align: right" title="Warrant and right outstanding measurement input">105.9</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zHqu1jtpuE02" style="text-align: right" title="Warrant and right outstanding measurement input">100.7</td><td style="text-align: left">%</td></tr> </table> 2.97 2.47 115.00 115.00 0 0 P1Y9M18D P2Y6M 3.66 4.12 105.9 100.7 <p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zZWeWaUfshj9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zuyIemnAJGMc">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zHVmEZv8rzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s major classes of inventory were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zSAVLoqHicMg" style="display: none">Schedule of Major Classes of Inventories</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240930_zRatreEZ1a8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231_zNKgxAJclfG2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_z4SEubSVv5Z1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,081</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_z76a1tQLLQBa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,696</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zVFISjHSOOI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,922</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zNK4IRwIu9r9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Inventory, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,046</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,699</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_z1eqxmfglpik" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: inventory reserves</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,239</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,289</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zC7AeLWkVoc5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Inventory, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,807</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance Sheet Classification:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_zbuPL7HZmHnb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,963</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zswyzFHOosK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Inventory, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,844</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,657</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zL0fkEfjEWyk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,807</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zRU5m080h72" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net of current portion includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zHVmEZv8rzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s major classes of inventory were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zSAVLoqHicMg" style="display: none">Schedule of Major Classes of Inventories</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240930_zRatreEZ1a8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231_zNKgxAJclfG2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_z4SEubSVv5Z1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,081</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_z76a1tQLLQBa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,696</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zVFISjHSOOI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,922</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zNK4IRwIu9r9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Inventory, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,046</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,699</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_z1eqxmfglpik" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: inventory reserves</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,239</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,289</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zC7AeLWkVoc5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Inventory, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,807</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance Sheet Classification:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_zbuPL7HZmHnb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,963</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zswyzFHOosK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Inventory, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,844</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,657</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zL0fkEfjEWyk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,807</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 42000 3081000 10284000 10696000 8720000 10922000 19046000 24699000 2239000 2289000 16807000 22410000 3963000 5753000 12844000 16657000 16807000 22410000 <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zIRBVIpOzAgd" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zzlivMQvCpOl">Property and Equipment, Net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> </p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6VMJ4vqBrdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zVsQ4lrCqhm8" style="display: none">Schedule of Property and Equipment, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930_zd39s0G7RVee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zY4XMVOR9Qgk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zi7l8pCRk0Xc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">73,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">73,211</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_z6eVedogtFXk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory and production equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,093</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_z7gcxdUG55xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery, equipment and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,781</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,781</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zc3u1P0F6Lof" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_z0VjY9c8RiAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_zyMhScdX6cSf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(31,947</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,278</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_zpITNISPNl74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">67,828</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z6VgTD3g146d" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization expense was $<span id="xdx_90B_eus-gaap--DepreciationAndAmortization_pn3n3_c20240701__20240930_zHKIInU5FzC6" title="Depreciation and amortization expense">1,519</span> and $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn3n3_c20230701__20230930_zGR7sbTxdDx8" title="Depreciation and amortization expense">1,790</span> for the three months ended September 30, 2024 and 2023, respectively. Depreciation and amortization expense was $<span id="xdx_909_eus-gaap--DepreciationAndAmortization_pn3n3_c20240101__20240930_zEy1R4S5hpD4" title="Depreciation and amortization expense">4,669</span> and $<span id="xdx_90B_eus-gaap--DepreciationAndAmortization_pn3n3_c20230101__20230930_zOyruOzpERj9" title="Depreciation and amortization expense">5,388</span> for the nine months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6VMJ4vqBrdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zVsQ4lrCqhm8" style="display: none">Schedule of Property and Equipment, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930_zd39s0G7RVee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zY4XMVOR9Qgk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zi7l8pCRk0Xc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">73,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">73,211</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_z6eVedogtFXk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory and production equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,093</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_z7gcxdUG55xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery, equipment and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,781</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,781</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zc3u1P0F6Lof" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_z0VjY9c8RiAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_zyMhScdX6cSf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(31,947</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,278</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_zpITNISPNl74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">67,828</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 73211000 73211000 14093000 14093000 7781000 7781000 70000 21000 95155000 95106000 31947000 27278000 63208000 67828000 1519000 1790000 4669000 5388000 <p id="xdx_80B_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z4tGJnlQ1hWg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zwGKUJM343j4">Goodwill and Intangible Assets, Net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Goodwill</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company experienced a sustained decline in its stock price resulting in its market capitalization being less than the carrying value of its combined reporting units. The Company concluded the sustained decline in its stock price combined with the decision to discontinue certain Cell Therapy clinical trials and development were triggering events and performed a quantitative impairment test on goodwill and acquired IPR&amp;D assets. Based on the results of the impairment analysis, the Company recognized an $<span id="xdx_907_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230701__20230930_zsFmyQcbDvh2" title="Goodwill, impairment loss">82,714</span> and $<span id="xdx_909_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20230930_zZb5qgbbcGk3" title="Goodwill, impairment loss">112,347</span> goodwill impairment charge for the three and nine months ended September 30, 2023, respectively, relating to the Cell Therapy reporting unit in its condensed consolidated statements of operations and comprehensive loss. There was <span id="xdx_907_eus-gaap--GoodwillImpairmentLoss_dxL_c20240701__20240930_zfmgrIl5gYo2" title="Goodwill, impairment loss::XDX::-"><span id="xdx_90F_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20240930_zQncsjwWIk0f" title="Goodwill, impairment loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl4462"><span style="-sec-ix-hidden: xdx2ixbrl4464">no</span></span></span></span> goodwill impairment recognized during the three and nine months ended September 30, 2024. The carrying value of goodwill, all of which is assigned to the Company’s BioBanking reporting unit, was $<span id="xdx_902_eus-gaap--Goodwill_iI_pn3n3_c20240930_zQf4AP9Nw7h3" title="Goodwill"><span id="xdx_90E_eus-gaap--Goodwill_iI_pn3n3_c20231231_zjx6s0kszs64" title="Goodwill">7,347</span></span> at both September 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible Assets, Net</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zL1D8K0EPA32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <i> </i><span id="xdx_8B5_z8sO5wRjy6je" style="display: none">Schedule of Intangible Assets, Net</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Lives</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Developed technology</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zmU2Xl82xGn9" style="width: 14%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_ziolwEUaPgq1" style="width: 14%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgRhimXgQ2Pa" title="Estimated useful lives"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zhJulJP2O3l8" title="Estimated useful lives">11</span></span> – <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zUOQAi4Uncc5" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z0356nKdzQG8" title="Estimated useful lives">16</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zAIUn9zpmIV8" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zvgCDhpOMGy2" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zvSExvtQFtN2" title="Estimated useful lives"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zYQ8iAaWhJ8g" title="Estimated useful lives">10</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zTq4gaK3RQW1" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zY6MnHxYqXr2" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zhxDVFqKhW07" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zu5Rtw2eDtZ8" title="Estimated useful lives">10</span></span> – <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_znXGgcv9tWig" title="Estimated useful lives"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z9QI0IHPHoAj" title="Estimated useful lives">13</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zPucW2iiTdSk" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zYo0Z0uxQmZh" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zGHENRYhxlOb" title="Estimated useful lives"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z51vVB2Sqnnc" title="Estimated useful lives">6</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zfvkmvOVsaJd" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">23,993</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zKuslK8Ns9E4" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">23,993</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less accumulated amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Developed technology</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z1Ub2YyeXdBb" style="text-align: right" title="Less: Accumulated amortization">(8,600</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zfPUKUlTux1l" style="text-align: right" title="Less: Accumulated amortization">(7,722</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zcJzsbZKcSj" style="text-align: right" title="Less: Accumulated amortization">(1,898</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoQ7tMbbezbl" style="text-align: right" title="Less: Accumulated amortization">(1,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zU3Wokff6kkg" style="text-align: right" title="Less: Accumulated amortization">(371</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zldkVfLoBtb8" style="text-align: right" title="Less: Accumulated amortization">(330</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zaZff4o1RQd7" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(4,200</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_ztswVRx6B8bi" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(3,940</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zsoGq90tKnLb" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(15,069</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zWGGDCkpy74f" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(13,692</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zDphuHHDY0zb" style="text-align: right" title="Amortizable intangible assets, net">8,924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zuIsRALiswog" style="text-align: right" title="Amortizable intangible assets, net">10,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-amortized intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Acquired IPR&amp;D product rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--AcquiredProductRights_iI_pn3n3_c20240930_z5qOcrl25Uw4" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--AcquiredProductRights_iI_pn3n3_c20231231_ziAoWcCFE286" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20240930_zUHqgh7M8MP1" title="Estimated useful lives"><span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zjo8sGu0kWw" title="Estimated useful lives">indefinite</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20240930_z5LpXTKFnCzk" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">9,624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zrx0nSaNy5Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">11,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8A1_zmkYltOVNhxc" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended September 30, 2024 and 2023, amortization expense for intangible assets was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240701__20240930_zdiZpr5xpUfg" title="Amortization of acquired intangible assets">375</span> and $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230701__20230930_zC452GkrwTA5" title="Amortization of acquired intangible assets">553</span>, respectively. For the nine months ended September 30, 2024 and 2023, amortization expense for the intangible assets was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20240930_z2uUGAsadPt7" title="Amortization of acquired intangible assets">1,377</span> and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20230930_zXdebR75O0uk" title="Amortization of acquired intangible assets">1,640</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_do_c20240701__20240930_zOyHiTu3VGD6" title="Impairment of intangible assets"><span id="xdx_90A_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_do_c20240101__20240930_zI4rZvdsGKd4" title="Impairment of intangible assets">No</span></span> impairment charges were recorded on intangible assets for the three and nine months ended September 30, 2024. During the three and nine months ended September 30, 2023, the Company discontinued its unmodified NK cell and AML Cell Therapy clinical trials and as a result recorded an IPR&amp;D impairment of $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pn3n3_c20230701__20230930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyClinicalTrialUpdateMember_zWCVvjBBezVb" title="Impairment of intangible assets"><span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pn3n3_c20230101__20230930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyClinicalTrialUpdateMember_zve4hkMi5Fj" title="Impairment of intangible assets">107,800</span></span> on its CYNK-001 and GMNK intangible assets acquired from the Anthrogenesis acquisition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> 82714000 112347000 7347000 7347000 <p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zL1D8K0EPA32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <i> </i><span id="xdx_8B5_z8sO5wRjy6je" style="display: none">Schedule of Intangible Assets, Net</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Lives</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Developed technology</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zmU2Xl82xGn9" style="width: 14%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_ziolwEUaPgq1" style="width: 14%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgRhimXgQ2Pa" title="Estimated useful lives"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zhJulJP2O3l8" title="Estimated useful lives">11</span></span> – <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zUOQAi4Uncc5" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z0356nKdzQG8" title="Estimated useful lives">16</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zAIUn9zpmIV8" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zvgCDhpOMGy2" style="text-align: right" title="Amortizable intangible assets">2,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zvSExvtQFtN2" title="Estimated useful lives"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zYQ8iAaWhJ8g" title="Estimated useful lives">10</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zTq4gaK3RQW1" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zY6MnHxYqXr2" style="text-align: right" title="Amortizable intangible assets">570</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zhxDVFqKhW07" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zu5Rtw2eDtZ8" title="Estimated useful lives">10</span></span> – <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_znXGgcv9tWig" title="Estimated useful lives"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z9QI0IHPHoAj" title="Estimated useful lives">13</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zPucW2iiTdSk" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zYo0Z0uxQmZh" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">4,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zGHENRYhxlOb" title="Estimated useful lives"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z51vVB2Sqnnc" title="Estimated useful lives">6</span></span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zfvkmvOVsaJd" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">23,993</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zKuslK8Ns9E4" style="border-bottom: Black 1pt solid; text-align: right" title="Amortizable intangible assets">23,993</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less accumulated amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Developed technology</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z1Ub2YyeXdBb" style="text-align: right" title="Less: Accumulated amortization">(8,600</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zfPUKUlTux1l" style="text-align: right" title="Less: Accumulated amortization">(7,722</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zcJzsbZKcSj" style="text-align: right" title="Less: Accumulated amortization">(1,898</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoQ7tMbbezbl" style="text-align: right" title="Less: Accumulated amortization">(1,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zU3Wokff6kkg" style="text-align: right" title="Less: Accumulated amortization">(371</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zldkVfLoBtb8" style="text-align: right" title="Less: Accumulated amortization">(330</td><td style="text-align: left">)</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zaZff4o1RQd7" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(4,200</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_ztswVRx6B8bi" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(3,940</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zsoGq90tKnLb" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(15,069</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zWGGDCkpy74f" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated amortization">(13,692</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amortizable intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zDphuHHDY0zb" style="text-align: right" title="Amortizable intangible assets, net">8,924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zuIsRALiswog" style="text-align: right" title="Amortizable intangible assets, net">10,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-amortized intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Acquired IPR&amp;D product rights</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--AcquiredProductRights_iI_pn3n3_c20240930_z5qOcrl25Uw4" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--AcquiredProductRights_iI_pn3n3_c20231231_ziAoWcCFE286" style="border-bottom: Black 1pt solid; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20240930_zUHqgh7M8MP1" title="Estimated useful lives"><span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zjo8sGu0kWw" title="Estimated useful lives">indefinite</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20240930_z5LpXTKFnCzk" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">9,624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zrx0nSaNy5Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">11,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> 16810000 16810000 P11Y P11Y P16Y P16Y 2413000 2413000 P10Y P10Y 570000 570000 P10Y P10Y P13Y P13Y 4200000 4200000 P6Y P6Y 23993000 23993000 -8600000 -7722000 -1898000 -1700000 -371000 -330000 -4200000 -3940000 -15069000 -13692000 8924000 10301000 700000 700000 indefinite indefinite 9624000 11001000 375000 553000 1377000 1640000 0 0 107800000 107800000 <p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_z9nowtZNHnNc" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zJZxy0aTEA3g">Debt</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zIhfj90vUsEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zrG7m8Q5vZK6" style="display: none">Schedule of Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240930_zBkQeC30RGEk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_zT0C1GDor8H5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term debt - unaffiliated:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zNmcSXoHgfZh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Yorkville - PPA (measured at fair value)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4572">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--ConvertiblePromissoryNotesMember_z9UmXO3aajBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Yorkville - convertible promissory note (measured at fair value)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4576">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OtherShortTermDebt_iI_pn3n3_zg99wFIi8jwe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Short-term debt - other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4578">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,108</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_zUmgoOXqk1B5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total short-term debt - unaffiliated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,695</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,331</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term debt - related parties:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CVStarrBridgeLoanNetOfDiscountMember_zyNwxifzXhKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">C.V. Starr Bridge Loan, net of discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,640</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--RWIBridgeLoanNetOfDiscountMember_z8HBjf6tt5Fb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">RWI Bridge Loan, net of discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,967</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zZksNSpB68ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">CEO promissory note</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,793</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,419</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_zMx8paYsE4w4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total short-term debt - related parties</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38,915</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,909</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtCurrent_iI_pn3n3_zUwgwz1W7IOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,610</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,240</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zHKkGPSrJ225" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Yorkville PPA</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2022, the Company entered into a Pre-Paid Advance Agreement (“PPA”) with YA II PN, Ltd. (“Yorkville”), pursuant to which the Company could request advances of up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlFhZeNjkkQl" title="Maximum advance amount">40,000</span> in cash from Yorkville (or such greater amount that the parties may mutually agree) (each, a “Pre-Paid Advance”) over an <span id="xdx_90F_ecustom--PrePaidAdvancePeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zQCkfKBZHAVb" title="Pre-paid advance period">18</span>-month period, with an aggregate limitation of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zkJBt1787kx2" title="Line of credit aggregate limitation amount">150,000</span>. Pre-Paid Advances were issued at a <span id="xdx_906_ecustom--PrePaidAdvanceIssuedDiscountPercentage_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zzsW7S4O1LS1" title="Pre-paid advance issued discount percentage">2.0</span>% discount, bore interest at an annual rate equal to <span id="xdx_90B_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z5olmVFTSsWg" title="Annual interest rate">6.0</span>% (increased to <span id="xdx_902_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdRp6ckIt70c" title="Line of credit increase in interest rate during period in event of default">15.0</span>% in the event of default as described in the PPA) and may be offset by the issuance of shares of common stock, at Yorkville’s option, at a price per share calculated pursuant to the PPA, which in no event will be less than $<span id="xdx_909_ecustom--IssuanceOfCommonStockMinimumOptionPricePerShare_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyWWFxEkOfba" title="Issuance of common stock minimum option price per share">7.50</span> per share. The issuance of the shares under the PPA was subject to certain limitations, including that the aggregate number of shares of common stock issued pursuant to the PPA cannot exceed <span id="xdx_908_ecustom--MaximumPercentageOfCommonStockIssued_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zcaUR9Wgxugg" title="Maximum percentage of common stock issued">19.9</span>% of the Company’s outstanding stock as of September 15, 2022, as well as a beneficial ownership limitation of <span id="xdx_90B_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zDglYJXMZ8q1" title="Percentage of beneficial ownership limitation">4.99</span>%. Further, Yorkville agreed not to purchase any shares of common stock for 60 days following entry into the PPA, nor could Yorkville purchase more than $<span id="xdx_905_ecustom--MinimumNumberOfSharesOfCommonStockPurchase_pid_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zee7FGbjiG0i" title="Minimum number of shares of common stock purchase">6,000</span> of shares of common stock during a 30-day period, in each case at a price per share less than the Fixed Price, as defined in the PPA. In the event the daily volume weighted average price (“VWAP”) of the Class A common stock is below $<span id="xdx_907_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zGqB9Po9eGs7" title="Minimum required daily volume weighted average price">7.50</span> (the “floor price”) for any five of seven consecutive trading days, the Company would pay Yorkville a monthly cash payment of $<span id="xdx_908_ecustom--RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z81K2VgjUHjl" title="Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days">6,000</span>, plus any accrued and unpaid interest along with a <span id="xdx_90A_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zNpmRtOt0hyg" title="Redemption premium percentage if volume weighted average price is less than $0.75">5.0</span>% redemption premium until such time as the daily VWAP for five consecutive trading days immediately prior to the due date of the next monthly payment was at least <span id="xdx_908_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zxZaxvd1K3yi" title="Redemption premium percentage if volume weighted average price more than $0.75">10.0</span>% greater than $<span id="xdx_908_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z6zyf1dHAOTa" title="Minimum required daily volume weighted average price">7.50</span>. In connection with the Company’s 2023 annual stockholder meeting held in June 2023, the Company and Yorkville agreed to lower the floor price to $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230630__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zgMT9YwJFbBb" title="Share price per share">0.50</span> (the “amended floor price”). The Company also received stockholder approval of the proposal for the issuance of more than <span id="xdx_90A_ecustom--IssuancePricePercentage_iI_pid_dp_uPure_c20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zbOkYCO8tx3i" title="Issuance price percentage">20.0</span>% of its pre-transaction Class A common stock outstanding at a price below the minimum price pursuant to the PPA. Further, absent prior written consent from Yorkville, the Company agreed it would not increase the size or amount borrowed under the C.V. Starr loan facility nor would it incur other borrowings or liens of any kind as long as any amounts were due and remained outstanding to Yorkville until paid in full. The Company agreed that all obligations due and owing to Yorkville would become secured obligations upon any violation under the PPA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the entry into the PPA, the Company received the initial Pre-Paid Advance of $<span id="xdx_902_ecustom--ProceedsFromLinesOfCreditGross_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zf7D4FzjJ7J7" title="Proceeds from pre-paid advance gross">40,000</span> gross or $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zbrE7E38HUW7" title="Proceeds from pre-paid advance">39,200</span> net of discount. Each Pre-Paid Advance had a maturity of <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z8KGRmPBtpw8" title="Pre-paid advance maturity period">12</span> months. Further Pre-Paid Advances would be based upon the mutual agreement of the parties. Direct costs and fees related to the PPA were recognized in earnings. At issuance, the Company concluded that certain features of the PPA would be considered a derivative that would require bifurcation. In lieu of bifurcation, the Company elected the fair value option for this financial instrument and records changes in fair value within the condensed consolidated statements of operations and comprehensive loss at the end of each reporting period. Under the fair value option, upon derecognition the Company will include in net loss the cumulative amount of the gain or loss on the debt that resulted from changes in instrument-specific credit risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2022, Yorkville elected to convert $<span id="xdx_904_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20221001__20221231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zkXEe3Bh3W5h" title="Debt conversion, principal amount">3,000</span> of principal and $<span id="xdx_905_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20221001__20221231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zquYdFWL7xJa" title="Accrued interest">694</span> of accrued interest into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20221001__20221231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zevMtCwiJaT8" title="Debt conversion, number of shares issued">262,797</span> shares of common stock, and during the year ended December 31, 2023, Yorkville elected to convert $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zunRL2kzuQI" title="Debt conversion, principal amount">3,889 </span>of principal and $<span id="xdx_90A_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zXozCkiEf6q2" title="Debt conversion, accrued interest amount">400</span> of accrued interest into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zoQQmFd5XJ03" title="Debt conversion, number of shares issued">559,481</span> shares of common stock. Further, during the year December 31, 2023, total repayments to Yorkville were $<span id="xdx_907_ecustom--DebtInstrumentPayment_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zANd7AXXDO83" title="Debt instrument payment">18,724</span> which consisted of (i) $<span id="xdx_901_eus-gaap--RepaymentsOfShortTermDebt_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z3lVuatDw7R7" title="Repayments of short-term debt">16,811</span> applied to the principal amount; (ii) $<span id="xdx_902_ecustom--DebtInstrumentAccruedInterest_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zCW1OZNMZg2j" title="Accrued interest">1,073</span> towards accrued interest; and (iii) $<span id="xdx_903_ecustom--DebtInstrumentRedemptionPremium_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zm72tygctG05" title="Debt instrument redemption premium">840</span> of redemption premium. As of December 31, 2023, the fair value of the debt was $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zno8QJ6AnMfh" title="Debt instrument, fair value disclosure">17,223</span> and the principal balance was $<span id="xdx_90E_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zg0DreY0pqCj" title="Principal balance">16,623</span>. Refer to Note 3 for additional details regarding the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company and Yorkville entered into a forbearance agreement (“Forbearance Agreement”), pursuant to which Yorkville agreed to restrain from enforcing its rights and remedies as a result of the event of default during the forbearance period. The forbearance period was to continue until the earlier of January 19, 2024 or the date the Company fully repaid all amounts outstanding under the PPA (“Forbearance Period”). During the Forbearance Period, interest accrued at <span id="xdx_907_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zpUN7qUYs86h" title="Annual interest rate">15.0</span>% per annum. In addition, the Company was to make a cash payment of $<span id="xdx_90D_eus-gaap--RepaymentsOfDebt_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zgVdfkjsql1l" title="Cash payment">17,348</span> plus per diem interest of $<span id="xdx_909_ecustom--DebtInstrumentPerDiemInterestAmount_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zodv5y9DTGha" title="Diem interest payment for each day">7</span> for each day after January 12, 2024 until payment was made and was required to issue Yorkville a total of <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlXGP7hWY11i" title="Issue of common stock">100,000</span> shares of its common stock. On January 12, 2024, the Company issued Yorkville <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zkr8xeb1GRUg" title="Issue of common stock">100,000</span> of its common stock in connection with the extension of the maturity date of the PPA. The PPA was repaid in full on January 17, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with Yorkville (see Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Yorkville Convertible Promissory Note</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon entry into the SEPA, the Company issued Yorkville a $<span id="xdx_90E_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zX24voeBWwoa" title="Issue of Debt">3,150</span> convertible promissory note for $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zvIsSVfCGp1h" title="Maximum advance amount">2,993</span> in cash (after a <span id="xdx_90E_ecustom--ConvertiblePromissoryNoteDiscountPercentage_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zJhEs5H3eXf6" title="Original issue discount">5</span>% original issue discount). The note bears interest at an annual rate equal to <span id="xdx_905_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zSCS5nipqV9b" title="Annual interest rate">8.0</span>% (increased to <span id="xdx_90A_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zRY4X05Owzgb" title="Line of credit increase in interest rate during period in event of default">18.0</span>% in the event of default as provided in the note) and matures on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_ddp_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_ziHQiEcq881l" title="Maturity date">March 13, 2025</span>. The note was initially convertible into common stock at a price per share equal to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z1i6Gf6m1wM4" title="Conversion price per share">6.3171</span>, provided however, the conversion price was subject to reset on the earlier of (a) the fifth trading day following the effective date of the resale shelf, or (b) the six-month anniversary of the issuance date of the convertible note (i.e., September 13, 2024). The conversion price was reset to $<span id="xdx_90E_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20240913__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zDopXD3pD0wl" title="Minimum required daily volume weighted average price">2.7546</span> on September 13, 2024. Upon the occurrence and during the continuation of an event of default (as defined in the note), the note (including accrued interest) may become immediately due and payable. The issuance of the common stock upon conversion of the note and otherwise under the SEPA is capped at <span id="xdx_90F_ecustom--PercentageOfConversionOnOutstandingCommonStock_iI_pid_dp_uPure_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zplR2eylGKs" title="Percentage of conversion on outstanding common stock">19.9</span>% of the outstanding common stock as of March 13, 2024. Further, the note and SEPA include a beneficial ownership blocker for Yorkville such that Yorkville may not be deemed the beneficial owner of more than <span id="xdx_909_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z9hIrSDNG1R6" title="Percentage of beneficial ownership limitation">4.99</span>% of the Company’s common stock. As a result of the Company’s failure to file its 2023 Form 10-K by April 30, 2024 (i.e., a deemed Event of Default under the convertible promissory note), the Company began accruing interest at the default rate of <span id="xdx_901_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240501__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zatrW5FZKrYk" title="Debt instrument default interest rate">18.0</span>% as of May 1, 2024. A further event of default occurred as a result of the Company’s failure to file a registration statement with the SEC for the resale by Yorkville of the shares of common stock issuable under the SEPA by May 3, 2024 (see Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the convertible note included embedded derivatives that would otherwise require bifurcation as derivative liabilities, and neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at inception, the Company elected to carry the convertible promissory note comprised of the debt host and the embedded derivative liabilities at fair value on a recurring basis as permitted under ASC 825, <i>Financial Instruments</i>. Changes in fair value caused by changes in the instrument-specific credit risk are reported in other comprehensive income, and the remaining change in fair value is reported in earnings (i.e., as a component of other income/expense). Interest expense is a component of the change in fair value of the notes and, therefore, is not separately recorded. As a result of the fair value election, the original issue discount of $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_ztdfyVb30Pmf" title="Amortization of debt discount (Premium)">157</span> was recorded to other expense in the consolidated statements of operations and comprehensive loss. As of September 30, 2024, the fair value of the debt was $<span id="xdx_90F_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zfv2JaquKlFc" title="Fair value of debt">3,695</span> and the principal balance was $<span id="xdx_90A_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20240930__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zZuXYSIWlzKd" title="Short-term debt, unpaid principal balance">3,150</span>. Refer to Note 3 for additional details regarding the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Short-Term Debt - Other and CEO Promissory Note</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2023, the Company entered into a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing for a loan in the aggregate principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zfsgTGSY8ONc" title="Principal amont">3,000</span> (of which Dr. Hariri contributed $<span id="xdx_901_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_ziJb9LgHTHJ6" title="Debt instrument contribution amount">1,000</span>), or the “Loan.” The Loan bears interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zX0yDDsIJ9G5" title="Loan interest rate">15.0</span>% per year, with the first year of interest being paid in kind on the last day of each month and matured on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z4ay3yGxi9te" title="Maturity date">August 21, 2024</span>. Pursuant to the terms of the Loan, the Company is required to apply the net proceeds from a subsequent transaction (as defined) in which the Company receives gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromOtherShortTermDebt_pn3n3_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z8KWTcIQpXDl" title="Gross proceeds">4,500</span> or more to repay the Loan. The Company did not repay the Loan upon receipt of the letter of credit funds in connection with signing the lease amendment (see Note 8) or the January 2024 PIPE (see Note 10), both of which were defined as subsequent transactions. The lenders agreed to a loan amendment whereby the loan maturity date was extended to December 31, 2024. Subsequently, on September 30, 2024, Dr. Hariri and the two unaffiliated lenders entered into an assignment agreement whereby Dr. Hariri assumed the full loan in exchange for repayment of the other lenders’ respective principal loan amount, plus accrued interest. As of September 30, 2024, the loan was reclassified from short-term debt - unaffiliated to short-term debt - related parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 12, 2023, in order to further address the Company’s immediate working capital requirements, Dr. Robert Hariri and the Company signed a promissory note for $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zjwfGrYearJl" title="Principal amont">285</span> which bears interest at a rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231013__20241013__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_z7NyQs0pW5j7" title="Interest rate">15.0</span>% per year. The note matures together with the outstanding principal amount and accrued and unpaid interest upon the earlier of <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationPeriod_dxL_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zQ9g6bQvQpVj" title="Pre-paid advance maturity period::XDX::P12M"><span style="-sec-ix-hidden: xdx2ixbrl4715">12</span></span> months from the date of the note or upon a change of control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, there was no other short-term debt and the carrying value of the CEO promissory note inclusive of accrued interest was $<span id="xdx_908_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240930__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zwrIjHZjKPa" title="Carrying value of short-term debt">3,793</span>. As of December 31, 2023, the carrying value of the other short-term debt and the CEO promissory note inclusive of accrued interest was $<span id="xdx_902_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zV0y2oZIii01" title="Carrying value of short-term debt">2,108</span> and $<span id="xdx_90F_ecustom--OtherShortTermDebtDueToRelatedParty_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zvdPxIv25KE" title="Other short term debt due to related party">1,419</span>, respectively. At September 30, 2024 and December 31, 2023, the carrying amounts of the loans were deemed to approximate fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Short-Term Debt – Related Parties - C.V. Starr and RWI</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C.V. Starr &amp; Co., Inc</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 17, 2023, the Company entered into a loan agreement (the “Starr Bridge Loan”) with C.V. Starr &amp; Co., Inc. (“C.V. Starr”), a stockholder of the Company, for an aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zC3yxczkmjT4" title="Principal amont">5,000</span> net of an original issue discount of $<span id="xdx_90A_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zFreFjGxsvZi" title="Original issue discount">100</span>. The loan bears interest at a rate equal to <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zFbSV3XXJjWh" title="Loan interest rate">12.0</span>% per year or <span id="xdx_903_ecustom--DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zXltW8Q9ZtNc" title="Debt instrument, interest rate, effective percentage in event of default">15.0</span>% in the event of default, with the first year of interest being paid in kind on the last day of each month, and matures on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230317__20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zkNkQVsBVVH6" title="Maturity date">March 17, 2025</span>. In addition, the parties entered into a warrant agreement to acquire up to an aggregate <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dd_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z8avfKEbIxN8" title="Warrants to purchase Class A common stock">75,000</span> shares of Class A common stock (“Starr Warrant”), at a purchase price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zVWT9p3I53gc" title="Purchase price of per share">1.25</span> per whole share underlying the Starr Warrant or $<span id="xdx_909_ecustom--ShareIssuedPurchasedPrice_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcJZATo9sGqd" title="Share issued purchase price">94</span>. The Starr Warrant has a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsme22JwrPo2" title="Term (years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl4739">five-year</span></span> term and had an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zxQ378PF7SLc" title="Exercise per share price (in Dollars per share)">7.10</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, in connection with the Amended RWI Loan (as defined below), the Company granted C.V. Starr additional warrants to acquire up to an aggregate <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z0GUmzbRXBh8" title="Warrants to purchase Class A common stock">50,000</span> shares of its Class A common stock (“Starr Additional Warrant” and in combination with Starr Warrant, “Starr Warrants”), which additional warrants have a <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zLq1SNlW1dg3" title="Warrants to purchase Class A common stock::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl4745">5-year</span></span> term and had an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z5LId5ewIAXi" title="Exercise per share price (in Dollars per share)">8.10</span> per share. The Company applied the guidance for this transaction in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i> and ASC 815, <i>Derivatives and Hedging</i>. The net proceeds of the Starr Bridge Loan and Starr Additional Warrant were recorded at fair value. The fair value of the Starr Additional Warrant was determined using a Black-Scholes option pricing model. The Starr Warrants met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Starr Bridge Loan, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of the Company’s assets, other than as permitted, or hold cash and cash equivalents less than $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zDzDJSQF0nC3" title="Cash and cash equivalents">3,000</span> for more than five consecutive business days. During the year ended December 31, 2023, the Company’s cash and cash equivalents fell below the $<span id="xdx_904_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zuQfpny64dtb" title="Fall in cash and cash equivalents">3,000</span> minimum liquidity covenant, which per the terms of the loan agreement caused an event of default. Therefore, the Company reclassified the loan as a current liability reflected within short-term debt - related parties on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company entered into an amendment which terminated the minimum $<span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zTCVoS7Y3Cnj" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant requirement. In addition to the negative covenants in the Starr Bridge Loan, the Starr Bridge Loan includes customary events of default and the Company granted C.V. Starr a senior security interest in all of its assets, pari passu with RWI (as defined below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company and C.V. Starr entered into a forbearance agreement (“Starr Forbearance Agreement”) with respect to the Starr Bridge Loan. Under the Starr Forbearance Agreement, (i) C.V. Starr agreed not to exercise its rights and remedies upon the occurrence of any default under the Starr Bridge Loan until the Company’s obligations in respect of the Yorkville convertible promissory note have been indefeasibly paid in full, (ii) C.V. Starr consented to the Company’s incurrence of indebtedness under the Yorkville convertible promissory note, (iii) C.V. Starr consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the Company agreed to increase the interest rate on the loan outstanding under the Starr Bridge Loan by <span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zq7Fu7QPQKXl" title="Increase interest rate on loan outstanding by basis points">100</span> basis points and (v) the Company agreed to amend the exercise price of (x) that certain warrant to acquire <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z8guKWWnfTf1" title="Warrants to purchase Class A common stock">75,000</span> shares of the Company’s common stock for $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zcK6mlHvoqj3" title="Purchase price of per share">7.10</span> per share, expiring <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zzgdOx432IGe" title="Warrant expiration date">March 17, 2028</span>, and (y) that certain warrant to acquire <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zPzlKhRO5Dtc" title="Warrants to purchase Class A common stock">50,000</span> shares of common stock for $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zkqEnyPA8quc" title="Purchase price of per share">8.10</span> per share expiring <span id="xdx_907_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_z7TGdUUH1tB2" title="Warrant expiration date">June 20, 2028</span>, each of which are held by C.V. Starr, such that the exercise price of each such warrant in (x) and (y) is $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zNNpP37A8bC2" title="Warrants to purchase Class A common stock">5.895</span> per share. In addition, the interest rate of the Starr Bridge Loan was increased to <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zmkx3YF6XCe" title="Loan interest rate">13.0</span>% per annum. The Starr Forbearance Agreement resulted in a modification of the Starr Bridge Loan, since the change in cash flows was determined to be less than <span id="xdx_90E_ecustom--PercentageOfChangesInCashFlow_pid_dp_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zRv6t9njBQ19" title="Percentage of changes in cash flow">10</span>%. Accordingly, no gain or loss was recorded and the change in fair value of the Starr Warrants of $51 was recorded as debt discount and will be amortized based on the new effective interest rate over the term of the Starr Bridge Loan. Due to the Company’s failure to make certain interest payments when due, the Company began accruing interest at the default rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240415__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zhVOjVz9KZc2" title="Default rate">16.0</span>% as of April 5, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024 and December 31, 2023, the carrying value of Starr Bridge Loan, inclusive of accrued interest and net of discount, was $<span id="xdx_909_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zMg5zGq2Og4l" title="Short-term debt - related parties">5,640</span> and $<span id="xdx_904_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zyLVlPDDx6f1" title="Short-term debt - related parties">5,523</span>, respectively. The carrying amount of the Starr Bridge Loan was deemed to approximate fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Resorts World Inc Pte Ltd</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2023, with written consent provided by Yorkville, the Company entered into a senior secured loan agreement (“RWI Bridge Loan”) with Resorts World Inc Pte Ltd, (“RWI”) providing for an initial loan in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zeT4UfGFt5O4" title="Principal amont">6,000</span> net of an original issue discount of $<span id="xdx_90E_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_z6LtqPJUkFvc" title="Discount">120</span>, which bears interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zxstPHsmezfe" title="Interest rate">12.5</span>% per year or <span id="xdx_908_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zx3eOJhDxphf" title="Interest rate during period in event of default">15.5</span>% in the event of default, with the first year of interest being paid in kind on the last day of each month, and matured on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_z2kGbYHpb7y1" title="Maturity date">June 14, 2023</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 21, 2023, the Company closed on an amended and restated senior secured loan agreement (“Amended RWI Loan”), to amend and restate the previous senior secured loan agreement, in its entirety. The Amended RWI Loan provided for an additional loan in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zwUWWvqnrPnc" title="Principal amont">6,000</span> net of an original issue discount of $<span id="xdx_90F_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230621__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zcOVAGUeM6Z4" title="Discount">678</span>, which bears interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zgf67bxd3VQk" title="Interest rate">12.5</span>% per year or <span id="xdx_90A_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z6NBrDFYKRN" title="Interest rate">15.5</span>% in the event of default, with the first year of interest being paid in kind on the last day of each month, and matures <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_ddp_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zYpFdwtAAwhi" title="Maturity date">March 17, 2025</span>. The Amended RWI Loan extended the maturity date of the initial loan to March 17, 2025. In addition, the Amended RWI Loan provided for the issuance of warrants to acquire up to an aggregate <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zHJpIHuZzh0c" title="Warrants to purchase Class A common stock">300,000</span> shares of the Company’s Class A common stock (“RWI Warrant”), at a purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zEZHf4uRgsJ1" title="Purchase price of per share">1.25</span> per whole share underlying the RWI Warrant (or an aggregate purchase price of $<span id="xdx_909_ecustom--ShareIssuedPurchasedPrice_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zd8oXGdQiJA4" title="Share issued purchase price">375</span>). The RWI Warrant has a <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z1g1gSO33K2j" title="Term (years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl4807">five-year</span></span> term and an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z2qPXshRnnpl" title="Exercise per share price (in Dollars per share)">8.10</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Amended RWI Loan, the Company was required to apply the net proceeds to the trigger payments due to Yorkville pursuant to the PPA. In addition, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of its assets, other than as permitted, or hold cash and cash equivalents less than $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240930__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zXgGY02bG6Z4" title="Cash and cash equivalents">3,000</span> for more than five consecutive business days, and includes customary events of default. The Company granted RWI a senior security interest in all of its assets, pari passu with C.V. Starr pursuant to the Starr Bridge Loan. The Company and RWI signed a forbearance agreement on September 14, 2023, whereby RWI agreed to forebear any action under the terms of the Amended RWI Loan in relation to the minimum $<span id="xdx_903_ecustom--FallInCashAndCashEquivalents_iI_c20240930__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zffMYYNWBl8c" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant and with respect to any potential default in relation to the Company’s outstanding debt owed to Yorkville until December 31, 2023. The Company reclassified the loan as a current liability reflected within short-term debt - related parties on the condensed consolidated balance sheets. Pursuant to the amendment on January 12, 2024, see below, the minimum $<span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zUmglTHBxiz2" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant requirement was terminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the Amended RWI Loan in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i> and ASC 815, <i>Derivatives and Hedging</i>. The net proceeds of the Amended RWI Loan and RWI Warrant were recorded at fair value, which resulted in a total discount of $<span id="xdx_908_ecustom--DiscountOnWarrantAmount_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z2CgjXHxqVJ2" title="Discount on warrant amount">2,151</span> based on the difference between the proceeds and fair value which were recorded as a loss within other income (expense) on the condensed consolidated statements of operations and comprehensive loss. The fair value of the RWI Warrant was determined using a Black-Scholes option pricing model. The RWI Warrant met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company entered into a second amended and restated senior secured loan agreement (“RWI Second Amended Bridge Loan”), to amend and restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023, as amended on June 20, 2023, in its entirety. The RWI Second Amended Bridge Loan provided for an additional loan in the aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zb5zb0tjQhpb" title="Principal amont">15,000</span> net of an original issue discount of $<span id="xdx_90D_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zyVNumTqSkB1" title="Original issue discount">3,750</span>, which bears interest at a rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zgOw5ZNYeSn7" title="Interest rate">12.5</span>% per year, with the first year of interest being paid in kind on the last day of each month, and matures on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z3gv59glT0qc" title="Maturity date">July 16, 2025</span>. In addition, the RWI Second Amended Bridge Loan provides for the issuance of a <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zMbrIIYllBJa" title="Term (years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl4827">5-year</span></span> immediately exercisable warrant to acquire up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zJY4zUhydM25" title="Warrants to purchase Class A common stock">1,650,000</span> shares of Class A common stock (“Tranche #1 Warrant”), and a warrant to acquire up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxx9uzgVizLl" title="Warrants to purchase Class A common stock">1,350,000</span> shares of Class A common stock, which will only be exercisable upon the later of (x) stockholder approval for Nasdaq purposes of its exercise price, (y) CFIUS clearance and (z) six months from issuance date (“Tranche #2 Warrant”) and will expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zYxzrUFtqFDd" title="Term (years)">5</span> years after it becomes exercisable. The Tranche #1 Warrant and Tranche #2 Warrant were each issued on January 16, 2024 in conjunction with the close of the RWI Second Amended Bridge Loan. The Tranche #1 Warrant has an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240116__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zL0O0BI584s6" title="Exercise per share price (in Dollars per share)">2.4898</span> per share. The Tranche #2 Warrant became exercisable on July 15, 2024 and has an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240715__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zJuoLuykNxpb" title="Exercise per share price (in Dollars per share)">2.988</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the RWI Second Amended Bridge Loan, the Company was required to apply the proceeds of the additional loan (i) to the payment in full of all outstanding amounts owed to Yorkville under the PPA, (ii) to the payment of invoices of certain critical vendors, (iii) to the first settlement payment owed to Palantir (see Note 9), and (iv) for working capital and other purposes pre-approved by RWI. Pursuant to the terms of the RWI Second Amended Bridge Loan, the Company agreed to customary negative covenants restricting its ability to pay dividends to stockholders, repay or incur other indebtedness other than as permitted, or grant or suffer to exist a security interest in any of the Company’s assets, other than as permitted. In addition, the Company agreed to apply net revenues received through the sale of its products/provision of services in connection with or related to its distribution and manufacturing agreement with Genting Innovation Pte Ltd (“Genting Innovation”), a related party, as a prepayment towards the loan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The RWI Second Amended Bridge Loan resulted in an extinguishment of the Amended RWI Loan, since the change in cash flows exceeds 10%. As a result, the Company record a loss on extinguishment equal to the difference between (i) the fair values of the new loan and Tranche #1 and Tranche #2 Warrants and (ii) the previous carrying amount of the Amended RWI Loan, or $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zO6jRgLtAAFg" title="Short-term debt">3,908</span>. The Company has not elected to carry the RWI Second Amended Bridge Loan at fair value, as permitted under ASC 815, <i>Derivatives and Hedging</i> and ASC 825, <i>Fair Value Option for Financial Instruments</i>. The Tranche #1 Warrant has been classified in stockholders’ equity, since it is exercisable into a fixed number of the Company’s own shares at a known exercise price, and therefore is not required to be classified as a liability under ASC 480, <i>Distinguishing Liabilities from Equity</i>. The Tranche #2 Warrant was initially classified as a liability, since the exercise price (i.e., Minimum Price) was not determined at issuance and may be subsequently adjusted. As of July 15, 2024, the Tranche #2 Warrant became exercisable and no longer contains adjustment provisions to the exercise price that are not indexed to the Company’s own stock, resulting in the reclassification from liability to equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and RWI also entered into an investor rights agreement dated as of January 12, 2024. The investor rights agreement provides RWI certain information and audit rights, as well as registration rights with respect to the shares underlying the Tranche #1 Warrant and Tranche #2 Warrant, including both the undertaking to file a registration statement within 45 days of filing of the 2023 Form 10-K, “piggyback” registration rights, as well as the right to request up to three demand rights for underwritten offerings per year; in each case subject to customary “underwriter cutback” language as well as any objections raised by the Securities and Exchange Commission to inclusion of securities. If the initial registration statement was not filed on or prior to May 15, 2024, the investor rights agreement provided for partial liquidating damages equal to <span id="xdx_90F_ecustom--PercentageOfPartialLiquidatingDamagesOnPurchasePrice_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_z67EV0Mkc3el" title="Percentage of partial liquidating damages on purchase price">1.0</span>% of the purchase price of the Tranche #1 and Tranche #2 Warrants amount each month, up to a maximum of <span id="xdx_905_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember__srt--RangeAxis__srt--MaximumMember_zgsDAvpVF9R5" title="Percentage of partial liquidating damages on subscription amount">6.0</span>%, plus interest thereon accruing daily at a rate of <span id="xdx_908_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_zbG37K12vpM2" title="Daily interest accruing rate">18.0</span>% per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company and RWI entered into a second forbearance agreement (“RWI 2nd Forbearance Agreement”). Under the RWI 2nd Forbearance Agreement, (i) RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the RWI Second Amended Bridge Loan until the Company’s obligations in respect of the Yorkville convertible promissory note have been indefeasibly paid in full or March 13, 2025, whichever occurs first, (ii) RWI consented to the Company’s incurrence of indebtedness under the Yorkville convertible promissory note, (iii) RWI consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the Company agreed to increase the interest rate on the loan outstanding under the RWI Loan Agreement by <span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zUw16mxpE8Qc" title="Increase interest rate on loan outstanding by basis points">100</span> basis points, or from <span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZasnfBKiHV8" title="Variable interest rate">12.5</span>% to <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zPlxVi6hjvo4" title="Variable interest rate">13.5</span>% per annum, and (v) the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zergTh9UYihe" title="Warrants to purchase Class A common stock">300,000</span> shares of common stock (“RWI New Warrant”), which expires June 20, 2028 and has an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zxF6NaXQJXI" title="Exercise per share price (in Dollars per share)">5.895</span> per share. The RWI 2nd Forbearance Agreement resulted in a modification of the RWI Second Amended Bridge Loan, since the change in cash flows is less than <span id="xdx_904_ecustom--PercentageOfChangesInCashFlow_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjgWDLdON5q5" title="Percentage of changes in cash flow">10</span>%. Accordingly, no gain or loss was recorded, and the fair value of the RWI New Warrant of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJKBqQGAWiph" title="Debt instrument, unamortized discount">1,162</span> was recorded as debt discount and will be amortized based on the new effective interest rate over the term of the RWI Second Amended Bridge Loan. Due to the Company’s failure to make certain interest payments when due, the Company began accruing interest on the Amended RWI Loan balance of approximately $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240805__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmIsDvL2xl1f" title="Short-term debt">13,700</span> at the default rate of <span id="xdx_90C_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240805__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember_z4sCgYoMi1La" title="Debt instrument default interest rate">16.5</span>% as of August 5, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024 and December 31, 2023, the carrying value of the RWI Second Amended Bridge Loan and Amended RWI Loan, inclusive of interest and net of discount was $<span id="xdx_908_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20240930__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zj5v9h6qhLVj" title="Short-term debt - related parties">29,482</span> and $<span id="xdx_902_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zKil21zvaYW8" title="Short-term debt - related parties">12,967</span>, respectively. The carrying amount of the RWI Second Amended Bridge Loan was deemed to approximate fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zIhfj90vUsEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zrG7m8Q5vZK6" style="display: none">Schedule of Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240930_zBkQeC30RGEk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_zT0C1GDor8H5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term debt - unaffiliated:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zNmcSXoHgfZh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Yorkville - PPA (measured at fair value)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4572">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--ConvertiblePromissoryNotesMember_z9UmXO3aajBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Yorkville - convertible promissory note (measured at fair value)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4576">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OtherShortTermDebt_iI_pn3n3_zg99wFIi8jwe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Short-term debt - other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl4578">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,108</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_zUmgoOXqk1B5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total short-term debt - unaffiliated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,695</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,331</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term debt - related parties:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CVStarrBridgeLoanNetOfDiscountMember_zyNwxifzXhKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">C.V. Starr Bridge Loan, net of discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,640</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,523</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--RWIBridgeLoanNetOfDiscountMember_z8HBjf6tt5Fb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">RWI Bridge Loan, net of discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,967</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zZksNSpB68ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">CEO promissory note</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,793</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,419</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_zMx8paYsE4w4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total short-term debt - related parties</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38,915</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,909</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtCurrent_iI_pn3n3_zUwgwz1W7IOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,610</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,240</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 17223000 3695000 2108000 3695000 19331000 5640000 5523000 29482000 12967000 3793000 1419000 38915000 19909000 42610000 39240000 40000000 P18M 150000000 0.020 0.060 0.150 7.50 0.199 0.0499 6000 7.50 6000000 0.050 0.100 7.50 0.50 0.200 40000000 39200000 P12M 3000000 694000 262797 3889000 400000 559481 18724000 16811000 1073000 840000 17223000 16623000 0.150 17348000 7000 100000 100000 3150000 2993000 0.05 0.080 0.180 2025-03-13 6.3171 2.7546 0.199 0.0499 0.180 157000 3695000 3150000 3000000 1000000 0.150 2024-08-21 4500000 285000 0.150 3793000 2108000 1419000 5000000 100000 0.120 0.150 2025-03-17 75000 1.25 94 7.10 50000 8.10 3000000 3000000 3000000 1 75000 7.10 2028-03-17 50000 8.10 2028-06-20 5.895 0.130 0.10 0.160 5640000 5523000 6000000 120000 0.125 0.155 2023-06-14 6000000 678000 0.125 0.155 2025-03-17 300000 1.25 375 8.10 3000 3000 3000000 2151000 15000000 3750000 0.125 2025-07-16 1650000 1350000 P5Y 2.4898 2.988 3908000 0.010 0.060 0.180 1 0.125 0.135 300000 5.895 0.10 1162000 13700000 0.165 29482000 12967000 <p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_zMpgvnxIulXb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_z1PtO8UME00b">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company’s lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date to determine the appropriate discount rate by multiple asset classes. Variable lease payments that are not based on an index or that result from changes to an index subsequent to the initial measurement of the corresponding lease liability are not included in the measurement of lease ROU assets or liabilities and instead are recognized in earnings in the period in which the obligation for those payments is incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. Rent expense was $<span id="xdx_90E_ecustom--OperatingLeasesRentExpense_pn3n3_c20240701__20240930_z1g7vZ3zfzW7" title="Rent expense">1,114</span> and $<span id="xdx_905_ecustom--OperatingLeasesRentExpense_pn3n3_c20230701__20230930_z9nWexVGaucg" title="Rent expense">892</span> for the three months ended September 30, 2024 and 2023, respectively. Rent expense was $<span id="xdx_903_ecustom--OperatingLeasesRentExpense_pn3n3_c20240101__20240930_zTJCcOyZ5Urk" title="Rent expense">3,333</span> and $<span id="xdx_90E_ecustom--OperatingLeasesRentExpense_pn3n3_c20230101__20230930_z7qj2viXeC51" title="Rent expense">2,687</span> for the nine months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2019, Legacy Celularity entered into a lease agreement for a <span id="xdx_901_ecustom--AreaOfBuilding_usqft_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zo0aQHYgDl5h" title="Area of building">147,215</span> square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in <span id="xdx_904_ecustom--OperatingLeaseExpiryYear_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zzvRso5gH75k" title="Area of building">2036</span>. The Company has the option to renew the term of the lease for two additional <span id="xdx_909_ecustom--OptionToRenewLeaseTermPeriod_dxL_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zJ8h0vEUmA7j" title="Option to renew lease term period.::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl4883">five-year</span></span> terms so long as the lease is then in full force and effect. The lease term commenced on <span id="xdx_907_ecustom--OperatingLeaseCommencementDate_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zXBGe1i3F7W5" title="Option to renew lease term period.">March 1, 2020</span> subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly base rent is approximately $<span id="xdx_905_ecustom--InitialMonthlyBaseRent_pn3n3_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zAvm8vwXoTM6" title="Initial monthly base rent.">230</span> and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $<span id="xdx_902_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_ztIh4nAMQIEa" title="Restricted cash"><span id="xdx_902_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zWHmBbxwP9Qf" title="Restricted cash">14,722</span></span>. The lease agreement allows for a landlord provided tenant improvement allowance of $<span id="xdx_90F_eus-gaap--TenantImprovements_iI_pn3n3_c20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zT0nNvzaUFQa" title="Tenant improvement allowance">14,722</span> to be applied to the costs of the construction of the leasehold improvements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2023, the Company entered into a lease amendment on the Company’s Florham Park, New Jersey facility to reduce the letter of credit by approximately $<span id="xdx_90F_ecustom--ReductionInLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zJNQuuLg2HQ5" title="Reduction in line of credit">4,900</span> for a new letter of credit in the amount of $<span id="xdx_905_ecustom--NewLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_z19WldVmigx5" title="New line of credit">9,883</span> in exchange for higher base rental payments of approximately $<span id="xdx_909_ecustom--BaseRentalPayments_pn3n3_c20230914__20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zBh3pDN1gO0k" title="Base rental payments">400</span> per year, effective October 1, 2023. The letter of credit, inclusive of interest earned on the account, is classified as restricted cash (non-current) on the condensed consolidated balance sheets. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. The Company accounted for the lease amendment as a modification since the change in lease payments did not represent additional ROU assets. The Company reassessed the IBR, remeasured the lease liability and ROU asset on the modification date of September 14, 2023. As a result, the Company recorded a decrease to the ROU asset and related lease liability in the amount of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zLrvANjavCuc" title="Operating lease liability">2,083</span> on the condensed consolidated balance sheets reflecting a higher IBR due to lower Company credit rating.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zCvdhhc3P4Nl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s lease costs are classified on its condensed consolidated statements of operations and comprehensive loss as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zcr26ow02uVl" style="display: none">Schedule of Lease Costs</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240701__20240930_zLveHKf2ge28" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230701__20230930_z7XXgBu8oTpj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20240930_zHuHK5NsfJp1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20230930_zTnrzij1hQl9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseCost_zJ2aHKULChFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">978</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">759</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,933</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,278</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--VariableLeaseCost_zAx4ShdLbmBc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">348</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">320</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">911</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_zALXGjmfXhv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,079</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zwTqGI4uIRCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zyI6JyPjUxai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below shows the cash and non-cash activity related to the Company’s lease liabilities during the period:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zpaI9j3t5D5i" style="display: none">Schedule of Cash and Non-cash Activity Related to the lease Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930_zegBnMriIkn5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zigBMDBerwJ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash paid related to lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_z90MJNgA8EYj" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,534</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,168</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zlYxv4pC2Pa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z1QJ3wEm59G" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the maturities of the Company’s operating lease liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zypwtCZ6ib9b" style="display: none">Schedule of Future Minimum Payments under Non-Cancelable Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20240930_zyzbUWkDZAPj" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzkGC_zZrSsyCbcqnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 82%">2024 (remaining three months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">845</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzkGC_z0MLPhWJ3jGd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining year</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">845</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzkGC_zwXmFQTULMeg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzkGC_zkX8RIkSOp0c" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year one</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzkGC_zadVOxOMtOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzkGC_zNrtRthrnin9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzkGC_zEO8atKxt4V9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzkGC_z09Zyh07x052" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzkGC_ztw6ypbMspXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzkGC_zVZmrJtiUIa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maLOLLPzkGC_z9Hig6Mx0fW9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maLOLLPzkGC_z0V8P2hVQcf3" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Year four Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzkGC_zeBnHVQM2N7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">99,663</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zIYFFu84wpq8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(73,212</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zbIymUMPIp87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,451</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z0ukmhfkK0q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the weighted average remaining lease term of the Company’s operating lease was <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240930_zdAkmYaRRgPc" title="Weighted average remaining lease term">21.5</span> years, and the weighted average discount rate used to determine the lease liability for the operating lease was <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20240930_zsmtG8SCNt31" title="Weighted average discount rate">14.24</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1114000 892000 3333000 2687000 147215 2036 2020-03-01 230000 14722000 14722000 14722000 4900000 9883000 400000 2083000 <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zCvdhhc3P4Nl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s lease costs are classified on its condensed consolidated statements of operations and comprehensive loss as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zcr26ow02uVl" style="display: none">Schedule of Lease Costs</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240701__20240930_zLveHKf2ge28" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230701__20230930_z7XXgBu8oTpj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20240930_zHuHK5NsfJp1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20230930_zTnrzij1hQl9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseCost_zJ2aHKULChFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">978</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">759</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,933</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,278</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--VariableLeaseCost_zAx4ShdLbmBc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">348</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">320</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,026</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">911</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_zALXGjmfXhv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,326</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,079</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,959</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 978000 759000 2933000 2278000 348000 320000 1026000 911000 1326000 1079000 3959000 3189000 <p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zyI6JyPjUxai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below shows the cash and non-cash activity related to the Company’s lease liabilities during the period:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zpaI9j3t5D5i" style="display: none">Schedule of Cash and Non-cash Activity Related to the lease Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930_zegBnMriIkn5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zigBMDBerwJ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash paid related to lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_z90MJNgA8EYj" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,534</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,168</td><td style="width: 1%; text-align: left"> </td></tr> </table> 2534000 2168000 <p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z1QJ3wEm59G" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the maturities of the Company’s operating lease liabilities were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zypwtCZ6ib9b" style="display: none">Schedule of Future Minimum Payments under Non-Cancelable Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20240930_zyzbUWkDZAPj" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzkGC_zZrSsyCbcqnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 82%">2024 (remaining three months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">845</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzkGC_z0MLPhWJ3jGd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining year</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">845</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzkGC_zwXmFQTULMeg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzkGC_zkX8RIkSOp0c" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year one</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,452</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzkGC_zadVOxOMtOHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzkGC_zNrtRthrnin9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year two</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzkGC_zEO8atKxt4V9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzkGC_z09Zyh07x052" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Year three</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,599</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzkGC_ztw6ypbMspXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzkGC_zVZmrJtiUIa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Year four</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maLOLLPzkGC_z9Hig6Mx0fW9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maLOLLPzkGC_z0V8P2hVQcf3" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Year four Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,568</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzkGC_zeBnHVQM2N7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">99,663</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zIYFFu84wpq8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(73,212</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zbIymUMPIp87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,451</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 845000 845000 3452000 3452000 3526000 3526000 3599000 3599000 3673000 3673000 84568000 84568000 99663000 73212000 26451000 P21Y6M 0.1424 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zdtF8RM8Wsx9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zSGf2n7MLSec">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingent Consideration Related to Business Combinations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with Legacy Celularity’s acquisition in 2017 of HLI Cellular Therapeutics, LLC and Anthrogenesis, the Company has agreed to pay future consideration to the sellers upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $<span id="xdx_90F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember__us-gaap--RelatedPartyTransactionAxis__custom--LLCAndAnthrogenesisMember_zY7sCvFl9Ipl" title="Contingent consideration"><span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember__us-gaap--RelatedPartyTransactionAxis__custom--LLCAndAnthrogenesisMember_z8UoKJrDcmrf" title="Contingent consideration">1,606</span></span> as contingent consideration as of September 30, 2024 and December 31, 2023. During 2023, the Company discontinued its unmodified NK cell and AML Cell Therapy clinical trials subject to the contingent consideration agreement under the Anthrogenesis acquisition and, as a result, the fair value of the contingent consideration obligation decreased significantly in 2023 and remains unchanged as of September 30, 2024. Due to the contingent nature of these milestone and royalty payments, there is a high degree of judgment in the management estimates that determine the fair value of the contingent consideration. See Note 3 for further discussion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Indemnification Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September 30, 2024 or December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Agreement with Palantir Technologies Inc.</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2021, Legacy Celularity executed a Master Subscription Agreement (the “Palantir MSA”) with Palantir under which it agreed to pay $<span id="xdx_90D_ecustom--PaymentsForMasterSubscriptionAgreement_pn3n3_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zSkCXwOYcz9l" title="Payments for master subscription agreement">40,000</span> over <span id="xdx_90E_ecustom--PaymentSubscriptionPeriod_dc_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_z5o7mgzX4q4d" title="Payment subscription period">five years</span> for access to Palantir’s Foundry platform along with certain professional services. The Company intended to utilize Palantir’s Foundry platform to secure deeper insights into data obtained from the Company’s discovery and process development, as well as manufacturing and biorepository operations. In January 2023, the Company ceased use of the software and provided a notice of dispute to Palantir on the basis that the software had not performed as promised and that Palantir had failed to provide the Company with the professional services necessary to successfully implement, integrate and enable the Foundry platform. As a result, in accordance with ASC 420, <i>Exit or Disposal Costs</i>, during the nine months ended September 30, 2023, the Company recognized the remaining related cease-use costs liability estimated based on the discounted future cash flows of contract payments for $<span id="xdx_907_eus-gaap--BusinessExitCosts1_pn3n3_c20230101__20230930__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--IncomeStatementLocationAxis__custom--SoftwareCeaseUseCostsMember_z4yiftAtc2Sh" title="Exit or disposal costs">24,161</span> which was included as software cease-use costs in the condensed consolidated statements of operations and comprehensive loss. On December 21, 2023, the Company entered into a settlement and release agreement with Palantir (the “Palantir Settlement Agreement”), which was subsequently amended on January 10, 2024 and May 6, 2024, whereupon the parties agreed that if the Company paid Palantir the settlement fees of $<span id="xdx_908_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240506__20240506__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zjzpNkYvaqSf" title="Agreed to pay settlement payment">3,500</span>, less any amounts previously paid, and issued shares as discussed in the <i>Arbitration Demand</i> section below no later than June 3, 2024, the parties would cease the arbitration and deem the original Palantir MSA terminated. The Company made the required payments prior to June 3, 2024, and on June 4, 2024, the parties dismissed all claims and counterclaims. Accordingly, at December 31, 2023, the Company reversed previously recognized costs in excess of the final settlement amount. The Company has <span id="xdx_903_ecustom--AccruedResearchAndDevelopmentSoftware_iI_dxL_c20240930_zdBM1SWwZhue" title="Accrued research and development software::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl4975">no</span></span> liability as of September 30, 2024 and a current liability of $<span id="xdx_906_ecustom--AccruedResearchAndDevelopmentSoftware_iI_pn3n3_c20231231_zfJkQAQGxaV1" title="Accrued research and development software">3,500</span> as of December 31, 2023, respectively, for accrued R&amp;D software on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sirion License Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, the Company entered into a license agreement (“Sirion License”) with Sirion Biotech GmbH (“Sirion”). Under the Sirion License, Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (“Licensed Product”). As part of the Sirion License, the Company paid Sirion $<span id="xdx_90A_ecustom--UpfrontFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zfmm7WKwuAP3" title="Upfront fee">136</span> as an upfront fee, a $<span id="xdx_900_ecustom--AnnualMaintenanceFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zc4aXbSMd1m9" title="Annual maintenance fee">113</span> annual maintenance fee and may owe up to $<span id="xdx_90B_ecustom--ClinicalAndRegulatoryMilestones_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zEI2PXNETASg" title="Clinical and regulatory milestones">5,099</span> related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration of the last to expire valid claim of the patents covering such Licensed Product, and (ii) <span id="xdx_900_eus-gaap--LongtermPurchaseCommitmentPeriod_dtY_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zGocNTqNKhMk" title="License agreement period">10</span> years after first Commercial Sale of a Licensed Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company for convenience upon <span id="xdx_90A_ecustom--LicenseAgreementNoticePeriod_dtD_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zAVhqpi1Ccwd" title="License agreement period">30</span> days written notice. During the nine months ended September 30, 2024 and 2023, no milestones have been achieved and no royalties have been earned.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Proceedings</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Civil Investigative Demand</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received a Civil Investigative Demand (the “Demand”) under the False Claims Act, 31 U.S.C. § 3729, dated August 14, 2022, from the U.S. Attorney’s Office for the Eastern District of Pennsylvania. The Demand requests documents and information relating to claims submitted to Medicare, Medicaid, or other federal insurers for services or procedures involving injectable human tissue therapy products derived from amniotic fluid or birth tissue and includes Interfyl, a biomaterials product. The Company is cooperating with the request and is engaged in an ongoing dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in preliminary stages and there is uncertainty as to whether the Demand will result in any liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arbitration Demand from Palantir Technologies Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 20, 2023, Palantir commenced an arbitration with JAMS Arbitration asserting claims for declaratory relief and breach of contract relating to the Palantir MSA, seeking damages in an amount equal to the full value of the contract. The Company responded to the arbitration demand and asserted counterclaims for breach of contract, breach of warranty, fraudulent inducement, violation of California’s Unfair Competition Law, amongst others, in relation to the Palantir MSA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 21, 2023, the Company and Palantir entered into the Palantir Settlement Agreement to resolve the JAMS Arbitration. The Palantir Settlement Agreement was subsequently amended on January 10, 2024 and May 6, 2024. Both parties agreed to dismiss the arbitration proceeding and dispute and provide for mutual releases upon the Company’s satisfaction of a settlement payment obligation. Through June 3, 2024, the Company made total settlement payments of $<span id="xdx_90F_eus-gaap--PaymentsForLegalSettlements_pn5n6_c20231221__20240603__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zdSXwPtvh6o5" title="Settlement payment">3,500</span> and issued Palantir an aggregate of <span id="xdx_90C_ecustom--NumberOfSharesIssuedForPiggybackRegistrationRights_pid_c20231221__20240603__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_z8uP0lnMdWw5" title="Shares issued for piggyback registration rights">60,584</span> shares of the Company’s Class A common stock as consideration for further amendments to the Palantir Settlement Agreement. On June 4, 2024, the parties dismissed all claims and counterclaims. The Palantir MSA is now fully terminated and neither party has any further rights or obligations thereunder. The shares of the Company’s Class A common stock issued to Palantir were issued with piggyback registration rights. Resale of such shares by Palantir shall be included on any future registration statement filed by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Celularity Inc. v. Evolution Biologyx, LLC, et al.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 17, 2023, the Company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively, “Evolution”) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for the sale of its biomaterial products in the amount of approximately $<span id="xdx_90E_ecustom--SaleOfBiomaterialProductsAmount_pn3n3_c20230417__20230417__srt--LitigationCaseAxis__custom--EvolutionMember_zlXNg8Bh1qU9" title="Sale of biomaterial products amount">2,350</span>, plus interest. In September 2021, the Company executed a distribution agreement with Evolution, whereupon Evolution purchased biomaterial products from the Company for sale through Evolution’s distribution channels. The Company fulfilled Evolution’s orders and otherwise performed each of its obligations under the distribution agreement. Despite attempts to recover the outstanding invoices and Evolution’s promise to pay, Evolution has refused to pay any of the invoices and has materially breached its obligations under the distribution agreement. The Company’s complaint asserts claims of breach of contract and fraudulent inducement, amongst others. The Company intends to vigorously pursue the matter to recover the outstanding payments owed by Evolution, as well as interest and reasonable attorney’s fees, but there can be no assurance as to the outcome of the litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TargetCW v. Celularity Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2024, WMBE Payrolling, Inc., dba TCWGlobal, filed a complaint in the United States District Court for the Southern District of California alleging a breach of contract and account stated claims relating to a Master Services Agreement dated May 4, 2020, or the TCWGlobal MSA, for the provision of certain leased workers to perform services on our behalf. The complaint alleges that the Company breached the TCWGlobal MSA by failing to make payments on certain invoices for the services of the leased workers. On May 7, 2024, the Company entered into a settlement agreement and mutual release with TCWGlobal whereupon the Company agreed to pay $<span id="xdx_909_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240507__20240507__srt--LitigationCaseAxis__custom--EvolutionMember_z2nWJRhWxXbi" title="Litigation settlement, amount awarded to other party">500</span> in tiered monthly installments, with the last payment due and payable on May 1, 2025, in exchange for a dismissal of the complaint and full release of all claims.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> 1606000 1606000 40000000 P5Y 24161000 3500000 3500000 136000 113000 5099000 P10Y P30D 3500000000 60584 2350000 500000 <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z8OTmpsQc5ve" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_z7DxyCfhGuc8">Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024 and December 31, 2023, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zAjkBBsAC2Gi" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zArtVKS9UQUe" title="Common stock, shares authorized">730,000,000</span></span> shares of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKI0iFCf3bp6" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z3PfLUwOrNa5" title="Common stock, par value">0.0001</span></span> par value Class A common stock. As of September 30, 2024 and December 31, 2023, shares of Class A common stock issued and outstanding were <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKuUizl5c7f" title="Common stock shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_ziZTf8g5GjLl" title="Common stock shares outstanding">21,984,614</span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJabX634xywc" title="Common stock shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzEzao2kyAa" title="Common stock shares outstanding">19,378,192</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Power</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company’s directors and all other matters requiring stockholder action. Holders of <span id="xdx_90E_eus-gaap--CommonStockVotingRights_c20240101__20240930_zVOgwrUe3pQ1" title="Common stock, voting rights">common stock are entitled to one vote per share</span> on matters to be voted on by stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of Class A common stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company’s board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation, Dissolution and Winding Up</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preemptive or Other Rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Election of Directors</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class serving a three-year term, except with respect to the election of directors at the special meeting held in connection with the merger with GX, Class I directors are elected to an initial one-year term (and three-year terms subsequently), the Class II directors are elected to an initial two-year term (and three-year terms subsequently) and the Class III directors are elected to an initial three-year term (and three-year terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the holders of more than <span id="xdx_90B_ecustom--PercentageOfSharesRequiredForVoting_dp_uPure_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zLqp8QgrBRH4" title="Percentage of shares required for voting">50.0</span>% of the shares voted for the election of directors can elect all of the directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Certificate of Incorporation authorized <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930_zl1SIBqUHFQ7" title="Preferred stock, shares authorized">10,000,000 </span>shares of preferred stock and provides that shares of preferred stock may be issued from time to time in one or more series. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series of preferred stock. The Company’s board of directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock and could have anti-takeover effects. The ability of the Company’s board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management. As of September 30, 2024 and December 31, 2023, the Company does <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20240930_zTLRJX1dUSR8" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zuuSkmbOa581" title="Preferred stock, shares outstanding">no</span></span>t have any outstanding preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ATM Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2022, the Company entered into an At-the-Market Sales Agreement (the “ATM Agreement”) with BTIG, LLC, Oppenheimer &amp; Co. Inc. and B. Riley Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, having an aggregate offering price of up to $<span id="xdx_909_ecustom--AggregateOfferingPrice_pn3n3_c20220908__20220908__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zsn5xz5ezjKd" title="Aggregate offering price">150,000</span>, subject to certain limitations as set forth in the ATM Agreement. The Company is not obligated to make any sales of shares under the ATM Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any shares offered and sold in the at-the-market offering will be issued pursuant to the Company’s shelf registration statement on Form S-3 and the related prospectus supplement. Under the ATM Agreement, the sales agents may sell shares of common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933. The Company will pay the sales agents a commission rate of up to <span id="xdx_902_ecustom--MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_pid_dp_uPure_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_zKp5WNqA6TB8" title="Sales agents commission rate">3.0</span>% of the gross sales proceeds of any shares sold and has agreed to provide the sales agents with customary indemnification, contribution and reimbursement rights. The ATM Agreement contains customary representations and warranties and conditions to the placements of the shares pursuant thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company received gross and net proceeds of $<span id="xdx_90F_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_zXpN4oP9oFd5" title="Gross proceeds from issuance of common stock">141</span> and $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_zEB20ytfMzg6" title="Net proceeds from sale of common stock">136</span>, respectively, from the sale of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z9vRsrIAzic9" title="Purchase and sale of shares">13,296</span> shares of its common stock at an average price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFNHk1GWlAyk" title="Average price per share">10.60</span> per share under the ATM Agreement. No shares were issued under the ATM Agreement during the nine months ended September 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>March 2023 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert Hariri, providing for the private placement of (i) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230320__20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zTjA8mYJvHA2" title="Purchase and sale of shares">938,184</span> shares of its Class A common stock, and (ii) accompanying warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z5rmtYr60qCe" title="Warrants to purchase aggregate shares">938,183</span> shares of Class A common stock (the “March 2023 PIPE Warrants”), for $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320_z02zRi93mZwj" title="Purchase price of per share">8.34</span> per share and $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zaJ3zM868LQ7" title="Purchase price of per share">1.25</span> per accompanying March 2023 PIPE Warrant, for an aggregate purchase price of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zDmqNPOx1D5b" title="Proceeds from PIPE financings">9,000</span> (of which Dr. Hariri subscribed for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpc57FtZ5aT5" title="Proceeds from PIPE financings">2,000</span>). The closing of the private placement occurred on March 27, 2023. Each March 2023 PIPE Warrant had an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zL0MvrUDFHy1" title="Exercise price">30.00</span> per share, is immediately exercisable, will expire on March 27, 2028 (<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z9CkFMLrwMGb" title="Term (years)">five years</span> from the date of issuance), and is subject to customary adjustments for certain transactions affecting the Company’s capitalization. The March 2023 PIPE Warrants may not be exercised if the aggregate number of shares of Class A common stock beneficially owned by the holder thereof (together with its affiliates) would exceed the specified percentage cap provided therein (which may be adjusted upon <span id="xdx_90B_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zJjBV1ekXTzg" title="Adjusted advance notice period">61</span> days advance notice) immediately after exercise thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the March 2023 PIPE Warrants and common stock as a single non-arm’s length transaction. The Company applied the guidance for this transaction in accordance with ASU 2020-06, <i>(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC 815 Derivatives and Hedging, </i>and <i>ASC 480 Distinguishing Liabilities from Equity</i>. Accordingly, the net proceeds were allocated between common stock and the March 2023 PIPE warrants at their respective fair value, which resulted in a net premium of $<span id="xdx_90C_ecustom--PremiumPaidForPrivatePlacementPurchase_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z4CHy1BcNNPe" title="Premium paid for private placement purchase">1,650</span> based on the difference between the proceeds and fair value of the common stock and March 2023 PIPE warrants, which was recorded as additional paid-in capital within stockholders’ equity on the condensed consolidated balance sheets. The fair value of the March 2023 PIPE Warrants was determined using a Black-Scholes option pricing model and the common stock based on closing date share price. The Company evaluated the March 2023 PIPE warrants under ASC 815 and determined that they did not require liability classification and met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. The warrants were recorded in additional paid-in capital within stockholders’ equity on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 14, 2023, the Company entered into a warrant amendment on the March 2023 PIPE Warrants with the unaffiliated investor to reduce the exercise price from $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z42T8HwZzpxg" title="Purchase price of per share">30.00</span> per share to $<span id="xdx_90F_ecustom--ReducedExercisePrice_pid_c20230314__20230314__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zXAjQgBarNv7" title="Reduced exercise price">10.00</span> per share for warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zLFbHooob5a3" title="Warrants to purchase aggregate shares">729,698</span> shares of Class A common stock. The warrant amendment was executed as consideration for professional services rendered to the Company. As a result, the Company accounted for the transaction in accordance with ASC 718, <i>Stock-Based Compensation,</i> and based on the calculated incremental fair value attributable to the modified warrant compared to the original warrant immediately prior to the modification, recognized an expense of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn3n3_c20240101__20240930_z0e4ixxvT6I1" title="Fair value of modified warrant, incremental expense">402</span> within selling, general and administrative on the condensed consolidated statements of operations for the three and nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Registered Direct Offerings</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 10, 2023, the Company closed on a registered direct offering of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230410__20230410_zW8Y6bfXOmg2" title="Purchase and sale of shares">923,077</span> shares of its Class A common stock together with warrants (“Registered Direct Warrants”) to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z40fWcTuB23h" title="Warrants to purchase aggregate shares">923,076</span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsUUWbKlMR5l" title="Purchase price of per share">6.50</span> per share and accompanying warrant, resulting in total gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230410__20230410_zLWQSzM49i1h" title="Proceeds from the exercise of warrants">6,000</span> before deducting placement agent commissions and other estimated offering expenses. The Registered Direct Warrants had an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230410_zpGo56Ilm8mk" title="Exercise price">7.50</span>, became exercisable beginning six months after the date of issuance and will expire <span id="xdx_909_ecustom--WarrantExpirationTerm_dc_c20230410__20230410_zhXGyPnaGmn1" title="Warrant term">five years</span> thereafter. The Company used the $<span id="xdx_909_ecustom--DebtInstrumentPayment_pn3n3_c20230410__20230410_zJ3L6juVB2rj" title="Debt instrument payment">5,505</span> net proceeds from the offering to repay its obligations to Yorkville under the PPA. The Company considered the appropriate accounting guidance and concluded that the Registered Direct Warrants qualified for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_902_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230410_z5qZ0kA0bd42" title="Fair value of the warrant liability">4,280</span> which was based on a Black-Scholes option pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded as a component of equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the closing of the registered direct offering on April 10, 2023, the Company amended the existing May 2022 PIPE Warrants, to reduce the exercise price from $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z46TPac6LuXi" title="Shares issued price per share">82.50</span> to $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zb4jfBELmFBj" title="Shares issued price per share">7.50</span> per share and extended the expiration <span id="xdx_901_ecustom--AmendedTerminationDateDescription_c20230410__20230410__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_zlrgoP98prLh" title="Amended termination date description">date to five and one-half years following the closing of the offering</span> or October 10, 2028. The modification resulted in the recognition of additional warrant liability of $<span id="xdx_90C_ecustom--AdditionalWarrantLiability_iI_pn3n3_c20230410_zqxbox2YFH81" title="Additional warrant liability">1,389</span> based on the Black-Scholes option pricing model as of the modification date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2023, the Company closed on a registered direct offering of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230731__20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zIv4Np7NnUNi" title="Purchase and sale of shares">857,143</span> shares of its Class A common stock together with warrants (“July 2023 Registered Direct Warrants”) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zVVWPjaEDjme" title="Warrants to purchase aggregate shares">857,142</span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230731_zvZyqBt7vjU9" title="Purchase price of per share">3.50</span> per share and accompanying warrant, resulting in total gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230731__20230731_zQo9fXqD0H1k" title="Proceeds from the exercise of warrants">3,000</span> before deducting placement agent commissions and other estimated offering expenses. The July 2023 Registered Direct Warrants have an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731__srt--RangeAxis__srt--MinimumMember_zmzCTLiQfRsk" title="Exercise price">3.50</span>, will be exercisable beginning six months after the date of issuance and will expire <span id="xdx_905_ecustom--WarrantExpirationTerm_dc_c20230731__20230731_zPN1iKAcOSRb" title="Warrant term">five years</span> thereafter. The Company used the $<span id="xdx_90F_ecustom--DebtInstrumentPayment_pn3n3_c20230731__20230731_zTeaJjKrODac" title="Debt instrument payment">2,740</span> net proceeds for working capital and general corporate purposes. The Company considered the appropriate accounting guidance and concluded that the July 2023 Registered Direct Warrants qualified for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_90B_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230731_zoJUePlVSKQc" title="Fair value of the warrant liability">2,645</span> which was based on a Black-Scholes option pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded as a component of equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the July 31, 2023 registered direct offering described above, the Company also entered into an amendment to certain existing warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731_zUQtWV62y0rf" title="Warrants to purchase Class A common stock">892,856</span> shares at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731__srt--RangeAxis__srt--MaximumMember_zNhCntP1By26" title="Exercise price">7.50</span> (consisting of all the May 2022 PIPE Warrants and a portion of the Registered Direct Warrants issued in April 2023), and such amended warrants have a reduced exercise price of $<span id="xdx_908_ecustom--ReducedExercisePrice_pid_c20230731__20230731_zpg8WmMWFcV7" title="Reduced exercise price">3.50</span> per share. As noted above, the modification resulted in an increase to the warrant liability of $<span id="xdx_904_ecustom--WarrantLiability_iI_pn3n3_c20230731_zw01qX4yIJoj" title="Warrant liabilities">511</span> based on the Black-Scholes option pricing model as of the July 31, 2023 modification date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>May 2023 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2023, the Company closed on a securities purchase agreement with a group of accredited investors, providing for the private placement of an aggregate (i) <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230518__20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantMember_zbIIOYBLLQCl" title="Purchase and sale of shares">581,395</span> shares of its Class A common stock and (ii) accompanying warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zoQ4DquAIeXf" title="Warrants to purchase aggregate shares">581,394</span> shares of Class A common stock (the “May 2023 PIPE Warrants”), for $5.20 per share and $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLOfpS7gWBx4" title="Purchase price of per share">1.25</span> per accompanying May 2023 PIPE Warrant, for an aggregate gross purchase price of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zhzUBqZBW4Gf" title="Proceeds from PIPE financings">3,750</span>. Each May 2023 PIPE Warrant has an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zNPiT2oWbEX4" title="Exercise price">10.00</span> per share, is immediately exercisable, will expire on <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zXnCj1VCrftf" title="Warrants and rights outstanding, expire date">May 17, 2028</span>, and is subject to customary adjustments for certain transactions affecting the Company’s capitalization. The May 2023 PIPE Warrants may not be exercised if the aggregate number of shares of Class A common stock beneficially owned by the holder thereof (together with its affiliates) would exceed the specified percentage cap provided therein (which may be adjusted upon <span id="xdx_900_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zWaUJx2nPxCa" title="Adjusted advance notice period">61</span> days advance notice) immediately after exercise thereof. The Company evaluated the May 2023 PIPE Warrants under ASC 815 and determined that they did not require liability classification and met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. Accordingly, the proceeds were allocated between common stock and the May 2023 PIPE Warrants at their respective relative fair value basis to stockholders’ equity on the condensed consolidated balance sheets. The fair value of the May 2023 PIPE Warrants was determined using a Black-Scholes option pricing model and the common stock based on the closing date share price and were recorded in additional paid-in capital within stockholders’ equity on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>January 2024 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, the Company entered into a securities purchase agreement with an existing investor, Dragasac Limited (“Dragasac”), providing for the private placement of (i) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zfwa0MvVZoz" title="Purchase and sale of shares">2,141,098</span> shares of its Class A common stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zhYc5Y6h1yif" title="Common stock, par value">0.0001</span> per share, or the Class A common stock, and (ii) accompanying warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember__srt--RangeAxis__srt--MaximumMember_z43ZVpbEGx35" title="Warrants to purchase aggregate shares">535,274</span> shares of Class A common stock (“January 2024 PIPE Warrant”), for $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zpG2wIuGItx5" title="Exercise price">2.4898</span> per share and $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zSVBhXbeEnsf" title="Purchase price of per share">1.25</span> per accompanying January 2024 PIPE Warrant, for an aggregate purchase price of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240112__20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zeP8neEmFUF6" title="Aggregate purchase price">6,000</span>. The closing of the private placement occurred on <span id="xdx_90F_ecustom--WarrantsAndRightsIssuedClosingDate_dd_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zFiBcv2v8Oih" title="Warrants and rights issued closing date">January 16, 2024</span>. The securities were issued pursuant to an exemption from registration provided under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The offer and sale of the shares and January 2024 PIPE Warrant (including the shares underlying the January 2024 PIPE Warrant) has not been registered under the Act or any state securities laws. The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Each January 2024 PIPE Warrant has an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zwgiSlcDRlC" title="Exercise price">2.4898</span> per share, is immediately exercisable, and will expire on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z8aIATDUpu6c" title="Warrants and rights outstanding, expire date">January 16, 2029 </span>(<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zuqu7bvZHSm6" title="Term (years)">five years</span> from the date of issuance).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the January 2024 PIPE Warrant and common stock as a single non-arm’s length transaction recognized in equity. The Company applied the guidance for this transaction in accordance with ASU 2020-06, <i>(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC 815 Derivatives and Hedging, </i>and <i>ASC 480 Distinguishing Liabilities from Equity</i>. Accordingly, the net proceeds were allocated between common stock and the January 2024 PIPE Warrant at their respective fair values, which resulted in proceeds of $<span id="xdx_90D_ecustom--ProceedsFromPrivatePlacements_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z3HfYegjCn2d" title="Proceeds from private placements">909</span> allocated to the January 2024 PIPE Warrant and the balance of the proceeds allocated to the common stock. The fair value of the January 2024 PIPE Warrant was determined using a Black-Scholes option pricing model and the common stock based on closing date share price. The Company evaluated the January 2024 PIPE warrant under ASC 815 and determined that it did not require liability classification and met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity’s own stock and classified in stockholders’ equity. The warrants were recorded in additional paid-in capital within stockholders’ equity on the condensed consolidated balance sheets. Also in connection with the January 2024 PIPE transaction, the Company repriced legacy warrants held by Dragasac to purchase <span id="xdx_902_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z2uIjlDgDxm7" title="Number Of warrants repriced">652,981</span> shares of common stock with a previous exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zv7mp3C3P8R2" title="Exercise price">67.70</span> per share to a new exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zhPjBc5q9RS5" title="Exercise price">2.4898</span> per share. The modification of warrants resulted in incremental fair value of $<span id="xdx_90A_ecustom--FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zcfbiZEaQzn2" title="Fair value of warrant modification">524</span>, which has been recognized as an equity issuance cost and had no net impact on stockholders’ equity as the warrants remain equity-classified after the modification.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the execution of the securities purchase agreement, the Company also entered into an investor rights agreement with Dragasac dated as of January 12, 2024. The investor rights agreement provides Dragasac certain information and audit rights, as well as registration rights with respect to the shares (and shares underlying the January 2024 PIPE Warrant), including both the undertaking to file a registration statement within 45 days of filing of the 2023 Form 10-K, “piggyback” registration rights, as well as the right to request up to three demand rights for underwritten offerings per year; in each case subject to customary “underwriter cutback” language as well as any objections raised by the SEC to inclusion of securities. If the initial registration statement was not filed on or prior to May 15, 2024, the investor rights agreement provides for partial liquidating damages equal to <span id="xdx_908_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zGgrP8vo53y1" title="Percentage of partial liquidating damages">1.0</span>% of the subscription amount each month, up to a maximum of <span id="xdx_904_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zctWOl4ykTzg" title="Percentage of partial liquidating damages">6.0</span>%, plus interest thereon accruing daily at a rate of <span id="xdx_90C_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112_zcGNltiqq1qf" title="Daily interest accruing rate">18.0</span>% per annum. The Company began to accrue partial liquidating damages and interest as of May 22, 2024. As a condition to closing, the Company entered into an amendment to an amended and restated distribution and manufacturing agreement with an affiliate of Dragasac to add cell therapy products in clinical development, investigational stage and/or in near-term commercial use to the list of products under the scope of the exclusive distribution and manufacturing licenses (including unmodified natural killer cells (such as CYNK-001) for aging and other non-oncology indications, PSC-100, PDA-001, PDA-002, pEXO and APPL-001 for regenerative indications).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective February 16, 2024, in order to comply with Section 4.15(a) of the securities purchase agreement, the Company entered into an amended employment agreement with its Chief Administrative Officer (“CAO”), whereby the CAO agreed to decrease his base salary from $<span id="xdx_909_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember_zoc4jc26sMm3" title="Base salary">500</span> to $<span id="xdx_90E_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zI1OvM3TQNsh" title="Base salary">425</span> per year through December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Modifications</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2024, in connection with the January 2024 PIPE, the Company agreed to amend the exercise price of legacy warrants held by Dragasac to purchase <span id="xdx_90E_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zEQdmyiaFqx5" title="Number of warrants repriced">652,981</span> shares of common stock, which expire <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zEZr37sKegil" title="Warrant expiration date">March 16, 2025</span>, from $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zl80AKP7W053" title="Exercise price">67.70</span> per share to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zBmcFSFjVbV3" title="Exercise price">2.4898</span> per share. On March 13, 2024, in connection with the RWI Forbearance Agreement (see Note 7), the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_908_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zQ8yqlBpoaLg" title="Number of warrants repriced">300,000</span> shares of common stock, which expires <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240313__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv84VTal9ZHc" title="Warrants and rights outstanding, expire date">June 20, 2028</span> and has an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_z4L74ihD6fc1" title="Exercise price">5.895</span> per share. Additionally, on March 13, 2024, in connection with the Starr Forbearance Agreement (see Note 7), the Company agreed to amend the exercise price of the <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_z9BOUkWwqefj" title="Warrants to purchase aggregate shares">75,000</span> March 2023 Loan Warrants expiring <span id="xdx_90B_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zvDqsHCzMWbl" title="Warrant expiration date">March 17, 2028</span> from $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240312__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zh5iH8FOjthg" title="Exercise price">7.10</span> per share to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zCRdMpS3Erjb" title="Exercise price">5.895</span> per share (the “Minimum Price” as determined pursuant to Nasdaq 5635(d) on March 13, 2024) and the <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zimaKBCMOvhd" title="Warrants to purchase aggregate shares">50,000</span> June 2023 Warrants expiring <span id="xdx_90F_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z8eY98YahJIk" title="Warrant expiration date">June 20, 2028</span> from $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zARb9c8iyJUc" title="Exercise price">8.10</span> per share to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zWutfEe0ODic" title="Exercise price">5.895</span> per share, each of which are held by C.V. Starr.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standby Equity Purchase Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2024, the Company and Yorkville entered into a SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $<span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_ztThzz1Cf6Yj" title="Common stock, shares authorized">10,000</span> of its Class A common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zj3ftdRfaUL7" title="Common stock, par value">0.0001</span> per share subject to certain limitations and conditions set forth in the SEPA, from time to time, over a 36-month period. Sales of the common stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company’s option, and the Company is under no obligation to sell any shares of common stock to Yorkville under the SEPA except in connection with notices that may be submitted by Yorkville, in certain circumstances as described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the satisfaction of the conditions precedent in the SEPA, which include having a resale shelf for shares of common stock issued to Yorkville declared effective, the Company has the right to direct Yorkville to purchase a specified number of shares of common stock by delivering written notice (“Advance”). An Advance may not exceed <span id="xdx_909_ecustom--SaleOfStockMaximumAverageDailyTradedAmountPercentage_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zlxdYptgbwO1" title="Sale of stock, maximum average daily traded amount (in percent)">100</span>% of the average of the daily trading volume of the common stock on Nasdaq, during the <span id="xdx_90B_ecustom--SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_pid_dc_uInteger_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zkb8BqSMzijl" title="Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days">five</span> consecutive trading days immediately preceding the written notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yorkville will generally purchase shares pursuant to an Advance at a price per share equal to <span id="xdx_905_ecustom--SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zkv58p8U9v32" title="Sale of stock, percentage based on volume weighted average price">97</span>% of the VWAP, on Nasdaq during the three consecutive trading days commencing on the date of the delivery of the written notice (unless the Company specifies a minimum acceptable price or there is no VWAP on the subject trading day).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The SEPA will automatically terminate on the earliest to occur of (i) the first day of the month next following the 36-month anniversary of the date of the SEPA or (ii) the date on which Yorkville shall have made payment for shares of common stock equal to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_z3hDnQGcVSji" title="Consideration shares of common stock">10,000</span>. The Company has the right to terminate the SEPA at no cost or penalty upon five trading days’ prior written notice to Yorkville, provided that there are no outstanding advances for which shares of common stock need to be issued and the Yorkville convertible promissory note (the “Initial Advance”) (see Note 7) has been paid in full. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As consideration for Yorkville’s commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville a $<span id="xdx_908_ecustom--SaleOfStockConsiderationCashDueDiligenceFee_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zK6TbpyE5t38" title="Cash due diligence fee">25</span> cash due diligence fee and a commitment fee equal to <span id="xdx_90B_ecustom--SaleOfStockConsiderationCommitmentFeeInShares_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zCp89TZHJ4Oa" title="Commitment fee in shares">16,964</span> shares of common stock. The Company recorded direct issuance costs of $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zruQ3B1SXPD1" title="Payments of stock issuance costs">125</span> inclusive of the commitment shares as other expense in the condensed consolidated statements of operations and other comprehensive loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the entry into the SEPA, on March 13, 2024, the Company entered into a registration rights agreement with Yorkville, pursuant to which the Company agreed to file with the SEC no later than May 3, 2024, a registration statement for the resale by Yorkville of the shares of common stock issued under the SEPA (including the commitment fee shares). The Company agreed to use commercially reasonable efforts to have such registration statement declared effective within 45 days of such filing and to maintain the effectiveness of such registration statement during the 36-month commitment period. The Company will not have the ability to request any Advances under the SEPA (nor may Yorkville convert the Initial Advance into common stock) until such resale registration statement is declared effective by the SEC. The Company has not yet filed a registration statement with the SEC for the resale by Yorkville of the shares of common stock issued under the SEPA, which is deemed an event of default under the SEPA and as a result, the interest rate on the on the Yorkville convertible promissory note (see Note 7) increased to <span id="xdx_908_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zB0i1cDqMuMl" title="Line of credit percentage">18.0</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the SEPA should be accounted for as a derivative measured at fair value, with changes in the fair value recognized in earnings. Because the Company has not yet filed a registration statement and no shares can currently be issued under the SEPA, the SEPA is deemed to have no value as of the issuance date and as of September 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the Company had <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zbPVtxP74LNc" title="Warrants to purchase aggregate shares">10,905,901</span> outstanding warrants to purchase Class A common stock. A summary of the warrants is as follows:</span></p> <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zmNxU2eCYcQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zpq2MrahqVq8" style="display: none">Summary of the Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration<br/> Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Dragasac Warrant⁽¹⁾</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zuwb3pQmgMDk" style="width: 14%; text-align: right" title="Number of shares">652,981</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zIHG2jbTixva" style="width: 14%; text-align: right" title="Exercise price">2.4898</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zssZhLQJl9Re" title="Expiration date">March 16, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Public Warrants⁽²⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zNGg4oabMLPl" style="text-align: right" title="Number of shares">1,437,447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zVwPoo2IMoj6" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zFOi46U9Wt7g" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Sponsor Warrants⁽²⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_z3LL6cVRM2Od" style="text-align: right" title="Number of shares">849,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zDNz4iYk0h2b" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zv2nU87BBC3b" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z7MRe4gv0iog" style="text-align: right" title="Number of shares">405,405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zp6JANu1XyDa" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zpouZQGe9O9l" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zq82u7oXtyaj" style="text-align: right" title="Number of shares">208,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zOBLNODoaC66" style="text-align: right" title="Exercise price">30.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z1N9o9VUVzOl" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">March 2023 PIPE Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zBoHd2wzpPj6" style="text-align: right" title="Number of shares">729,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zGVNs1KATxve" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zBnDQBNRIzG1" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 Loan Warrants⁽³⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zutQ1LWUQ2Bf" style="text-align: right" title="Number of shares">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zLHbXxLNzHh7" style="text-align: right" title="Exercise price">5.895</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zfUiiQ0Ndkz4" title="Expiration date">March 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zWUAqMUCvyad" style="text-align: right" title="Number of shares">435,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zuKnj2fqAfx9" style="text-align: right" title="Exercise price">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zLAq03SlA3m3" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2023 Registered Direct Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zfZUDvGCXiv1" style="text-align: right" title="Number of shares">487,451</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zS0Kn0BdJokf" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zszwgzuOAVy5" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zEfZ1zzDKvx8" style="text-align: right" title="Number of shares">581,394</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zPytoDmwVKH8" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zSds0ovTEhha" title="Expiration date">May 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 2023 Warrants⁽³⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zUmKRaWZSDmi" style="text-align: right" title="Number of shares">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zIqaszVlKSF3" style="text-align: right" title="Exercise price">5.895</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zypGCz4edhVe" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>June 2023 Loan Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zIWJS87jInQg" style="text-align: right" title="Number of shares">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zAZVAAmtibJd" style="text-align: right" title="Exercise price">8.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zB8UPrN4NSRd" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zd7u0aqVUfe9" style="text-align: right" title="Number of shares">857,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zL94Vzw3lZw1" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zp65hzXg6l9h" title="Expiration date">January 31, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>January 2024 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zAQzo0NlrXW" style="text-align: right" title="Number of shares">535,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zekbOdTMlAya" style="text-align: right" title="Exercise price">2.4898</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zlGmstSXjrg4" title="Expiration date">January 16, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">January 2024 Bridge Loan - Tranche #1 Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zxeaT6uTRn52" style="text-align: right" title="Number of shares">1,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zd5y1nm8dCO1" style="text-align: right" title="Exercise price">2.4898</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_z1P8A4OeMpHl" title="Expiration date">January 16, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">January 2024 Bridge Loan - Tranche #2 Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_znQI59JszYd2" style="text-align: right" title="Number of shares">1,350,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zXb7Y4dBYOx9" style="text-align: right" title="Exercise price">2.988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zmDHM2QPoRJh" title="Expiration date">July 15, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">March 2024 RWI Forbearance Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_z3WUDZvmVvjl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares">300,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zIPW8Rsj5fEc" style="padding-bottom: 1pt; text-align: right" title="Exercise price">5.895</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zLbv7yre1jL9" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930_zOs4qSKRobG9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of shares">10,905,901</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F01_zFQh89dDxu7">(1)</i></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F11_zN4tqwEp5FJi">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zkZlp81iQHOh" title="Number of warrants repriced">652,981</span> legacy warrants held by Dragasac with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_z0ZOGTQ6eThc" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zaViqZL32Shh" title="Exercise price">2.4898</span>. The term of the warrants was unchanged.</i></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0C_zzgox16ssaNl">(2)</i></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1E_zRtOMCCtPcG2">The number of Public Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--WarrantsOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zeoZzFNDYXB6" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_ecustom--WarrantsOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zeP2EFVMz4Gc" title="Warrants outstanding">8,499,999</span> Sponsor Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zk3dxVEb3Cfj" title="Exercise per share price (in Dollars per share)">115.00</span> as a result of the split.</i></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zff5GFYDHv9c">(3)</i></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1A_zdTRMr5Rh8ph">In connection with the execution of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 7, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zqb3IaidI0Wh" title="Number of warrants repriced">75,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zaE6mZajS9d4" title="Exercise price">7.10</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zJs5iw4oRek2" title="Number Of warrants repriced">50,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_z4tQjHouhege" title="Exercise price">8.10</span> held by C.V. Starr to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_ziDMUl6v7eyb" title="Exercise price">5.895</span>. The term of the warrants was unchanged.</i></span></td></tr> </table> <p id="xdx_8A6_zVPvzvpxUPKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 730000000 730000000 0.0001 0.0001 21984614 21984614 19378192 19378192 common stock are entitled to one vote per share 0.500 10000000 0 0 150000000 0.030 141000 136000 13296 10.60 938184 938183 8.34 1.25 9000000 2000000 30.00 P5Y P61D 1650000 30.00 10.00 729698 402000 923077 923076 6.50 6000000 7.50 P5Y 5505000 4280000 82.50 7.50 date to five and one-half years following the closing of the offering 1389000 857143 857142 3.50 3000000 3.50 P5Y 2740000 2645000 892856 7.50 3.50 511000 581395 581394 1.25 3750000 10.00 2028-05-17 P61D 2141098 0.0001 535274 2.4898 1.25 6000000 2024-01-16 2.4898 2029-01-16 P5Y 909000 652981 67.70 2.4898 524000 0.010 0.060 0.180 500000 425000 652981 2025-03-16 67.70 2.4898 300000 2028-06-20 5.895 2028-03-17 7.10 5.895 2028-06-20 8.10 5.895 10000 0.0001 1 5 0.97 10000000 25000 16964 125000 0.180 10905901 <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zmNxU2eCYcQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zpq2MrahqVq8" style="display: none">Summary of the Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration<br/> Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Dragasac Warrant⁽¹⁾</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zuwb3pQmgMDk" style="width: 14%; text-align: right" title="Number of shares">652,981</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zIHG2jbTixva" style="width: 14%; text-align: right" title="Exercise price">2.4898</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEp_zssZhLQJl9Re" title="Expiration date">March 16, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Public Warrants⁽²⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zNGg4oabMLPl" style="text-align: right" title="Number of shares">1,437,447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zVwPoo2IMoj6" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zFOi46U9Wt7g" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Sponsor Warrants⁽²⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_z3LL6cVRM2Od" style="text-align: right" title="Number of shares">849,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zDNz4iYk0h2b" style="text-align: right" title="Exercise price">115.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zv2nU87BBC3b" title="Expiration date">July 16, 2026</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2022 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z7MRe4gv0iog" style="text-align: right" title="Number of shares">405,405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zp6JANu1XyDa" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zpouZQGe9O9l" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zq82u7oXtyaj" style="text-align: right" title="Number of shares">208,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zOBLNODoaC66" style="text-align: right" title="Exercise price">30.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z1N9o9VUVzOl" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">March 2023 PIPE Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zBoHd2wzpPj6" style="text-align: right" title="Number of shares">729,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zGVNs1KATxve" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zBnDQBNRIzG1" title="Expiration date">March 27, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2023 Loan Warrants⁽³⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zutQ1LWUQ2Bf" style="text-align: right" title="Number of shares">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zLHbXxLNzHh7" style="text-align: right" title="Exercise price">5.895</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zfUiiQ0Ndkz4" title="Expiration date">March 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zWUAqMUCvyad" style="text-align: right" title="Number of shares">435,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zuKnj2fqAfx9" style="text-align: right" title="Exercise price">7.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zLAq03SlA3m3" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2023 Registered Direct Warrants (modified)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zfZUDvGCXiv1" style="text-align: right" title="Number of shares">487,451</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zS0Kn0BdJokf" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zszwgzuOAVy5" title="Expiration date">October 10, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2023 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zEfZ1zzDKvx8" style="text-align: right" title="Number of shares">581,394</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zPytoDmwVKH8" style="text-align: right" title="Exercise price">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zSds0ovTEhha" title="Expiration date">May 17, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 2023 Warrants⁽³⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zUmKRaWZSDmi" style="text-align: right" title="Number of shares">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zIqaszVlKSF3" style="text-align: right" title="Exercise price">5.895</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zypGCz4edhVe" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>June 2023 Loan Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zIWJS87jInQg" style="text-align: right" title="Number of shares">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zAZVAAmtibJd" style="text-align: right" title="Exercise price">8.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zB8UPrN4NSRd" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">July 2023 Registered Direct Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zd7u0aqVUfe9" style="text-align: right" title="Number of shares">857,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zL94Vzw3lZw1" style="text-align: right" title="Exercise price">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zp65hzXg6l9h" title="Expiration date">January 31, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>January 2024 PIPE Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zAQzo0NlrXW" style="text-align: right" title="Number of shares">535,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zekbOdTMlAya" style="text-align: right" title="Exercise price">2.4898</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zlGmstSXjrg4" title="Expiration date">January 16, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">January 2024 Bridge Loan - Tranche #1 Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zxeaT6uTRn52" style="text-align: right" title="Number of shares">1,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zd5y1nm8dCO1" style="text-align: right" title="Exercise price">2.4898</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_z1P8A4OeMpHl" title="Expiration date">January 16, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">January 2024 Bridge Loan - Tranche #2 Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_znQI59JszYd2" style="text-align: right" title="Number of shares">1,350,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zXb7Y4dBYOx9" style="text-align: right" title="Exercise price">2.988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zmDHM2QPoRJh" title="Expiration date">July 15, 2029</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">March 2024 RWI Forbearance Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_z3WUDZvmVvjl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares">300,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zIPW8Rsj5fEc" style="padding-bottom: 1pt; text-align: right" title="Exercise price">5.895</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zLbv7yre1jL9" title="Expiration date">June 20, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930_zOs4qSKRobG9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of shares">10,905,901</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F01_zFQh89dDxu7">(1)</i></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F11_zN4tqwEp5FJi">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zkZlp81iQHOh" title="Number of warrants repriced">652,981</span> legacy warrants held by Dragasac with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_z0ZOGTQ6eThc" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zaViqZL32Shh" title="Exercise price">2.4898</span>. The term of the warrants was unchanged.</i></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0C_zzgox16ssaNl">(2)</i></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1E_zRtOMCCtPcG2">The number of Public Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--WarrantsOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zeoZzFNDYXB6" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_ecustom--WarrantsOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zeP2EFVMz4Gc" title="Warrants outstanding">8,499,999</span> Sponsor Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zk3dxVEb3Cfj" title="Exercise per share price (in Dollars per share)">115.00</span> as a result of the split.</i></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F02_zff5GFYDHv9c">(3)</i></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1A_zdTRMr5Rh8ph">In connection with the execution of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 7, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zqb3IaidI0Wh" title="Number of warrants repriced">75,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zaE6mZajS9d4" title="Exercise price">7.10</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zJs5iw4oRek2" title="Number Of warrants repriced">50,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_z4tQjHouhege" title="Exercise price">8.10</span> held by C.V. Starr to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_ziDMUl6v7eyb" title="Exercise price">5.895</span>. The term of the warrants was unchanged.</i></span></td></tr> </table> 652981 2.4898 2025-03-16 1437447 115.00 2026-07-16 849999 115.00 2026-07-16 405405 3.50 2028-10-10 208485 30.00 2028-03-27 729698 10.00 2028-03-27 75000 5.895 2028-03-17 435625 7.50 2028-10-10 487451 3.50 2028-10-10 581394 10.00 2028-05-17 50000 5.895 2028-06-20 300000 8.10 2028-06-20 857142 3.50 2029-01-31 535274 2.4898 2029-01-16 1650000 2.4898 2029-01-16 1350000 2.988 2029-07-15 300000 5.895 2028-06-20 10905901 652981 67.70 2.4898 14374478 8499999 115.00 75000 7.10 50000 8.10 5.895 <p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zun1hlxVZrdg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zAlzvDka3uJ9">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021 Equity Incentive Plan</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, the Company’s board of directors adopted, and the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares of Class A Common Stock initially reserved for issuance under the 2021 Plan is <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210731__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQAOQidtE132" title="Number of shares reserved for issuance">2,091,528</span>. As of September 30, 2024, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zI1Iix50UEdl" title="Number of shares remaining available for future grant">1,254,803</span> shares remain available for future grant under the 2021 Plan. The number of shares reserved for issuance will automatically increase on January 1 of each year, for a period of <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zWiF3BoiIqva" title="Number of shares issued for future issuance automatic increase period">10</span> years, from January 1, 2022 through January 1, 2031, by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zWPzpZPCzQZ3" title="Percentage of shares issued from outstanding capital stock, maximum">4.0</span>% of the total number of shares of Celularity common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company’s board of directors. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021 Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2021 Plan is administered by the Company’s board of directors. The Company’s board of directors, or a duly authorized committee thereof, may delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of the Company’s stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2017 Equity Incentive Plan</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2017 Equity Incentive Plan (the “2017 Plan”) adopted by Legacy Celularity’s board of directors and approved by Legacy Celularity’s stockholders provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with the closing of the merger and effectiveness of the 2021 Plan, no further grants will be made under the 2017 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of stock options that could have been issued under the 2017 Plan was <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_zmpMCSy1lKTc" title="Number of shares remaining available for future grant">3,234,204</span>. Shares that expired, forfeited, canceled or otherwise terminated without having been fully exercised were available for future grant under the 2017 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2017 Plan is administered by the Company’s board of directors or, at the discretion of the Company’s board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy Celularity’s board of directors, or its committee if so delegated, except that the exercise price per share of stock options could not be less than <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_zXt5Ckkkqprh" title="Percentage of fair market value">100</span>% of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zFuPxydodAv1" title="Stock option, expiration period">ten years</span>. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zS9bW09mjMdk" title="Options vesting period::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl5362">three</span></span> or <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zbSSKXNlRweh" title="Options vesting period::XDX::P4Y"><span style="-sec-ix-hidden: xdx2ixbrl5364">four</span></span> year period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Option Valuation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Awards with Service Conditions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected term of employee stock options with service-based vesting is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term or its estimated term based on the underlying agreement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected stock price volatility is based on historical volatilities of comparable public entities within the Company’s industry.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the respective expected term or contractual term.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected dividend yield is <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dpxL_uPure_c20230101__20231231_zuHyKWLaT5fk" title="Expected dividend yield::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl5366">0</span></span>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zpuF55fF3iS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the nine months ended September 30, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_8B8_zlDVLixgWKc7">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930_z2s2osZmei41" title="Risk-free interest rate">4.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930_zPNI2Dr5q8Jc" title="Risk-free interest rate">4.1</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930_zPZCc0c1nZa2" title="Expected term (in years)">5.5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zJULine8xqw5" title="Expected term (in years)">5.6</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930_zADXBxhNRXSi" title="Expected volatility">110.8</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930_z5b6kRfIrzQ1" title="Expected volatility">86.5</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930_ziaocXcS8J4h" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_z9g4VtYDC8y1" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A5_z29bNnPYEgyl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant-date fair value per share of stock options granted during the nine months ended September 30, 2024 and 2023 was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930_zZu9CzP14kD" title="Weighted average grant-date fair value of stock options granted">3.10</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930_zaJZwfLHnUH9" title="Weighted average grant-date fair value of stock options granted">0.39</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKr4MEdfYq31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zEp0XrgLkHOf">Schedule of Stock Option Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Contract Term<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zGV27q8pj1rc" style="width: 12%; text-align: right" title="Options beginning balance">2,820,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zpqYsncOhMVb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, beginning balance">40.16</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zumK1aX7Y6h" style="width: 12%; text-align: right" title="Weighted Average Contract Term">5.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zdwlw2sKBXwa" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl5398">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zBI6jv9fU4zf" style="text-align: right" title="Options Granted">879,664</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zLmsKdxyz4xk" style="text-align: right" title="Weighted Average Exercise Price, Granted">3.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z1NgqdeURIHg" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl5404">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zrrcInoc8MQk" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl5406">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zza4x3evYWlf" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited/Expired">(289,802</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHbLbdnon9l7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired">31.47</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zQArQzRLVVza" style="border-bottom: Black 2.5pt double; text-align: right" title="Options ending balance">3,410,049</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zzRtF5QGV6o5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance">31.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zMeBW3DjSjv2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term">6.0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zS733skyD9Pe" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value">115</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zH7vldle2r3f" style="text-align: right" title="Options Vested and expected to vest">3,410,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zAPJF9XfHMna" style="text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest">31.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zkSiK795KGf3" style="text-align: right" title="Weighted Average Contract Term, Vested and expected to vest">6.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zlEpyqRmX01a" style="text-align: right" title="Aggregate Intrinsic Value Vested and expected to vest">115</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHxjQt3kp4hi" style="text-align: right" title="Options Exercisable">2,513,584</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zIUFQ3lRkqZf" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">38.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zos8dyYn347j" style="text-align: right" title="Weighted Average Contract Term Exercisable">4.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zkLdqYqi5IUk" style="text-align: right" title="Aggregate Intrinsic Value Exercisable">113</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F01_zuxWqIYWhwEk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F14_z25Gyov4CBdh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding at September 30, 2024 under the 2021 Plan and 2017 Plan were <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwentyTwentyOneAndTwoThousandSeventeenPlanMember_z7jdvAnO0Oj2" title="Options outstanding">1,979,953</span> and <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--TwentyTwentyOneAndTwoThousandSeventeenPlanMember_zl8GJ3woTLbh" title="Options outstanding">1,475,096</span>, respectively. Options outstanding at September 30, 2024 under the 2021 Plan include <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwentyTwentyOnePlanMember_zb6gapIZQ6G2" title="Options outstanding including awards">45,000</span> awards with performance conditions (see below).</span></td> </tr></table> <p id="xdx_8AC_zYTJKmu46IJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those options that had exercise prices lower than the fair value of Class A common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense relating to option awards with service conditions of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlcqQloqrZff" title="Stock-based compensation expense">2,077</span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrnKUWcB33s" title="Stock-based compensation expense">6,306</span> for the three and nine months ended September 30, 2024, respectively. The Company recorded stock-based compensation expense relating to option awards with service conditions of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGTHJy4y8Sri" title="Stock-based compensation expense">2,255</span> and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrnVspYktIke" title="Stock-based compensation expense">6,952</span> for the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, unrecognized compensation cost for options issued with service conditions was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvljF2eIXS11" title="Unrecognized compensation cost for options issued">8,370</span> and will be recognized over an estimated weighted-average amortization period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhIAMKr4AWa8" title="Estimated weighted-average amortization period">2.62</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Awards with Performance Conditions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the advisory agreement signed with Robin L. Smith, MD (see Note 15), the Company awarded options under the 2021 Plan to acquire a total of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_z5aViHinLpDa" title="Vested options to acquire shares">105,000</span> shares with an exercise price of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zUnhuz2ajpZd" title="Vested options to acquire shares">29.90</span> to Dr. Smith, a former member of the Company’s board of directors. The initial tranche of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--InitialTrancheMember_zBpWSSER75J1" title="Vested options to acquire shares">25,000</span> stock options vested upon execution of the advisory agreement on August 16, 2022. The remaining <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zlzZAlhQ0W0d" title="Stock option vesting">80,000</span> stock options are subject to vesting upon achievement of certain predefined milestones in relation to the expansion of the degenerative disease business. On November 1, 2022, the second tranche of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--SecondTrancheMember_z4PxHWY72R65" title="Stock option vesting">20,000</span> stock options vested upon achievement of the first milestone. The fair value of the award was determined based on a Black-Scholes option-pricing model. The Company’s grant date fair value assumptions were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zobnIE9MuOs8" title="Expected volatility">79.9</span>% expected volatility, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zRc5q9wavIvk" title="Risk-free interest rate">2.95</span>% risk-free interest rate, <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20240930__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_ztnhMgLOpEAb" title="Expected term (in years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl5469">five</span></span>-year expected term, and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_z9sGBPK8e6rj" title="Expected dividend yield">0</span>% expected dividend yield. The remaining <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230816__20230816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zHt9BttN0Vqk" title="Number of shares remaining stock options forfeited">60,000</span> stock options were forfeited on August 16, 2023 upon termination of the advisory agreement. There were no milestones achieved or probable of being achieved and accordingly there was <span id="xdx_907_eus-gaap--ShareBasedCompensation_do_c20230701__20230930_zA2XLo93Szsb" title="Share based compensation"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_do_c20230101__20230930_zYf6IJh3pi4b" title="Share based compensation">no</span></span> stock-based compensation recorded during the three and nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Awards with Market Conditions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, the Company awarded options to acquire a total of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210901__20210930__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_z2x5EhYrlUN9" title="Vested options to acquire shares">246,928</span> shares with an exercise price of $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20210901__20210930__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_zFOSfUsOlQNf" title="Vested options to acquire per share">63.20</span> to the Company’s former President in connection with the commencement of his employment. The grant was comprised of four equal tranches, and would <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20240101__20240930__us-gaap--AwardTypeAxis__custom--AwardsWithMarketConditionsMember_ztWVue03eNSd" title="Vesting description">vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date</span>, subject to his continued employment with the Company. The Company’s President resigned effective August 31, 2022, and the entirety of the President’s award was terminated at such time, all previously recognized stock-based compensation expense was reversed, and a consulting agreement was signed thereafter, refer to Note 15 for further details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issues restricted stock units (“RSUs”) to employees that generally vest over a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDfHOZ7njBO9" title="Options vesting period::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl5485">four-year</span></span> period, with <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zBFXsBlTxCee" title="Vesting percentage">25.0</span>% vesting on the anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that the RSUs are vested in full on the four-year anniversary of the grant date. At times, the board of directors may approve exceptions to the standard RSU vesting terms. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company’s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period. There are no RSUs outstanding under the 2017 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zJz9gKYFuMse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activity related to RSU stock-based payment awards under the 2021 Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zOmi3iQY4z24">Schedule of Activity Related to RSU Stock-Based Payment Awards</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwRIXj2Uz0Lg" style="width: 12%; text-align: right" title="Number of Shares opening balance">823,332</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOXlUgOROU13" style="width: 12%; text-align: right" title="Weighted Average Grant Date Fair Value, beginning balance">13.77</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeqiddHBd0Ce" style="text-align: right" title="Number of Shares Granted"><span style="-sec-ix-hidden: xdx2ixbrl5495">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyzKhwj95KTj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl5497">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWJTYFrQcGKf" style="text-align: right" title="Number of Shares Released">(395,996</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoz6M8nAxpea" style="text-align: right" title="Weighted Average Grant Date Fair Value, Released">11.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpxWZmtbokak" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Forfeited">(99,977</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrXQLYn77iad" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">13.24</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzzOhbmUxcIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares ending balance">327,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDc4lEizqdae" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance">16.68</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_z1HD7jQbKfsb" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense of $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDWjrseLt9eh" title="Stock-based compensation expense">595</span> and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmXYO7vKr6Lb" title="Stock-based compensation expense">2,322</span> for the three and nine months ended September 30, 2024, respectively, related to RSUs. The Company recorded stock-based compensation expense of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4CCs1JQoFXe" title="Stock-based compensation expense">1,343</span> and $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8X5TtZ5vfF4" title="Stock-based compensation expense">4,490</span> for the three and nine months ended September 30, 2023, respectively, related to RSUs. As of September 30, 2024, the total unrecognized expense related to all RSUs was $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUML9x2nHqEc" title="Stock-based compensation expense">4,086</span>, which the Company expects to recognize over a weighted-average period of <span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbzbDiTwfcxg" title="Estimated weighted-average amortization period">2.20</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Units with Market Condition Vesting</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2023, the Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zAreagXaZR6g" title="Number of Shares Granted">174,500</span> market condition stock unit awards (“MCUs”) under the 2021 Plan to certain members of management. The awards are scheduled to vest over a period of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MinimumMember_zRkTFOuquCLa" title="Options vesting period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl5525">one</span></span> to <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MaximumMember_z5dfRylY5X8c" title="Options vesting period">three years</span> from the grant date based on continuous employment and specified market conditions based on the Company’s stock price at the time of vest. As of September 30, 2024, <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20240930__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zLFCs908PSi6" title="Estimated weighted-average amortization period">145,833</span> of the MCUs were forfeited as a result of the participant’s termination of continuous service. Stock-based compensation expense for the remaining <span id="xdx_901_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_z0LBElUt3yL5" title="Stock based compensation">28,667</span> MCUs is being recognized over the requisite service period based on the award’s fair value on the grant date, which was determined based on the Company’s closing stock price on the date of grant of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zD4uteepY6Qi" title="Weighted Average Grant Date Fair Value, Granted">5.00</span>, further discounted to reflect the effects of the market condition of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation Expense</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zQ3TK9uwDW6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zKb4EHyFvQce">Schedule of Stock-based Compensation Expense </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930_zjb7FLDVsc25" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230701__20230930_zOC1rIhjk5jg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930_zJlCUUOAVXR2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20230930_zuFZyAHP79l1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zaE1FEbyrE7e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Cost of revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">166</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">285</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">462</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI8QSGPhRKfk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,384</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z3EsYHhGBxte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,053</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,440</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,596</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zVaM8Y5B7Bb7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,672</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,442</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zmQVISKE4CD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2091528 1254803 P10Y 0.040 3234204 1 P10Y <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zpuF55fF3iS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the nine months ended September 30, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_8B8_zlDVLixgWKc7">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930_z2s2osZmei41" title="Risk-free interest rate">4.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930_zPNI2Dr5q8Jc" title="Risk-free interest rate">4.1</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930_zPZCc0c1nZa2" title="Expected term (in years)">5.5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_zJULine8xqw5" title="Expected term (in years)">5.6</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930_zADXBxhNRXSi" title="Expected volatility">110.8</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930_z5b6kRfIrzQ1" title="Expected volatility">86.5</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930_ziaocXcS8J4h" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_z9g4VtYDC8y1" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr> </table> 0.045 0.041 P5Y6M P5Y7M6D 1.108 0.865 0 0 3.10 0.39 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKr4MEdfYq31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zEp0XrgLkHOf">Schedule of Stock Option Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Contract Term<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zGV27q8pj1rc" style="width: 12%; text-align: right" title="Options beginning balance">2,820,187</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zpqYsncOhMVb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, beginning balance">40.16</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zumK1aX7Y6h" style="width: 12%; text-align: right" title="Weighted Average Contract Term">5.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zdwlw2sKBXwa" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl5398">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zBI6jv9fU4zf" style="text-align: right" title="Options Granted">879,664</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zLmsKdxyz4xk" style="text-align: right" title="Weighted Average Exercise Price, Granted">3.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z1NgqdeURIHg" style="text-align: right" title="Options Exercised"><span style="-sec-ix-hidden: xdx2ixbrl5404">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zrrcInoc8MQk" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl5406">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zza4x3evYWlf" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited/Expired">(289,802</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHbLbdnon9l7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired">31.47</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zQArQzRLVVza" style="border-bottom: Black 2.5pt double; text-align: right" title="Options ending balance">3,410,049</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zzRtF5QGV6o5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance">31.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zMeBW3DjSjv2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term">6.0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zS733skyD9Pe" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value">115</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zH7vldle2r3f" style="text-align: right" title="Options Vested and expected to vest">3,410,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zAPJF9XfHMna" style="text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest">31.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zkSiK795KGf3" style="text-align: right" title="Weighted Average Contract Term, Vested and expected to vest">6.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zlEpyqRmX01a" style="text-align: right" title="Aggregate Intrinsic Value Vested and expected to vest">115</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHxjQt3kp4hi" style="text-align: right" title="Options Exercisable">2,513,584</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zIUFQ3lRkqZf" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">38.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zos8dyYn347j" style="text-align: right" title="Weighted Average Contract Term Exercisable">4.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zkLdqYqi5IUk" style="text-align: right" title="Aggregate Intrinsic Value Exercisable">113</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F01_zuxWqIYWhwEk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F14_z25Gyov4CBdh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding at September 30, 2024 under the 2021 Plan and 2017 Plan were <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwentyTwentyOneAndTwoThousandSeventeenPlanMember_z7jdvAnO0Oj2" title="Options outstanding">1,979,953</span> and <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--TwentyTwentyOneAndTwoThousandSeventeenPlanMember_zl8GJ3woTLbh" title="Options outstanding">1,475,096</span>, respectively. Options outstanding at September 30, 2024 under the 2021 Plan include <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwentyTwentyOnePlanMember_zb6gapIZQ6G2" title="Options outstanding including awards">45,000</span> awards with performance conditions (see below).</span></td> </tr></table> 2820187 40.16 P5Y7M6D 879664 3.76 289802 31.47 3410049 31.51 P6Y 115000 3410049 31.51 P6Y 115000 2513584 38.00 P4Y10M24D 113000 1979953 1475096 45000 2077000 6306000 2255000 6952000 8370000 P2Y7M13D 105000 29.90 25000 80000 20000 0.799 0.0295 0 60000 0 0 246928 63.20 vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date 0.250 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zJz9gKYFuMse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activity related to RSU stock-based payment awards under the 2021 Plan:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zOmi3iQY4z24">Schedule of Activity Related to RSU Stock-Based Payment Awards</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwRIXj2Uz0Lg" style="width: 12%; text-align: right" title="Number of Shares opening balance">823,332</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOXlUgOROU13" style="width: 12%; text-align: right" title="Weighted Average Grant Date Fair Value, beginning balance">13.77</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeqiddHBd0Ce" style="text-align: right" title="Number of Shares Granted"><span style="-sec-ix-hidden: xdx2ixbrl5495">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyzKhwj95KTj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl5497">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWJTYFrQcGKf" style="text-align: right" title="Number of Shares Released">(395,996</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoz6M8nAxpea" style="text-align: right" title="Weighted Average Grant Date Fair Value, Released">11.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpxWZmtbokak" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Forfeited">(99,977</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrXQLYn77iad" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">13.24</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzzOhbmUxcIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares ending balance">327,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDc4lEizqdae" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, ending balance">16.68</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 823332 13.77 395996 11.50 99977 13.24 327359 16.68 595000 2322000 1343000 4490000 4086000 P2Y2M12D 174500 P3Y 145833000 28667000 5.00 <p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zQ3TK9uwDW6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zKb4EHyFvQce">Schedule of Stock-based Compensation Expense </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930_zjb7FLDVsc25" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230701__20230930_zOC1rIhjk5jg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930_zJlCUUOAVXR2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20230930_zuFZyAHP79l1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zaE1FEbyrE7e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Cost of revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">166</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">285</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">462</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zI8QSGPhRKfk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">379</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,384</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z3EsYHhGBxte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,053</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,440</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,596</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zVaM8Y5B7Bb7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,672</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,442</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 90000 166000 285000 462000 182000 379000 903000 1384000 2400000 3053000 7440000 9596000 2672000 3598000 8628000 11442000 <p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_zOXl0FOexGni" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zGvKLFCN9z8d">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zY2W10kABijl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides information about disaggregated revenue by product and services:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zStnZe7EP95h">Schedule of Disaggregated Revenue by Product And Services</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240701__20240930_zYlbAbdW5s1f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230701__20230930_zI6kTMgroIN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20240930_zoIBqsqZ5Pa3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20230930_zGAzfepF7yI1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_z33lNVIc2hN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,393</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,684</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">26,199</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,633</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zne6vsVLyMBe" style="vertical-align: bottom; background-color: White"> <td>Services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,857</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,062</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zPviizY8L9ci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,611</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">675</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,032</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,964</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zkVMQMGXs4S" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,296</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zCLPCu0Phq38" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net revenues include: (i) sales of biomaterial products, including Biovance, Biovance 3L, Rebound^TM, Interfyl, and CentaFlex, of which our direct sales are included in Product Sales while sales through our network of distribution partners are included in License, royalty and other; and (ii) the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zCqP6cvgRSrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides changes in deferred revenue from contract liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z7ayttro3NW8">Schedule of Changes in Deferred Revenue from Contract Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20240930_ziOROagolSv9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20230930_z4oHRUjdpq71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zW4pRP3QFrNl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,020</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,492</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_z3N0TDZceDik" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,492</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_zYW8NNSNUbwa" style="vertical-align: bottom; background-color: White"> <td>Deferral of revenue<sup id="xdx_F4F_zQ2P6I2Zjo0i">(1)</sup></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,579</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_z8DMj4k4TmU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Recognition of unearned revenue<sup id="xdx_F49_zSVhFWIypT16">(2)</sup></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,619</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,514</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zyHE0tQ9e9N1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,557</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_z8DzDR3c1XB3" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,557</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span id="xdx_F09_zZV0tFKRPYIe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span id="xdx_F17_zzT6iLSvNLqi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferral of revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DeferredRevenue_iI_pn3n3_c20240930_zHwsPWL3OnHj" title="Deferred revenue">3,736</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--DeferredRevenue_iI_pn3n3_c20230930_z6sc7uIjnbVj" title="Deferred revenue">3,818 </span>in 2024 and 2023, respectively, resulting from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span id="xdx_F00_zn3WTkqYFeYk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span id="xdx_F1E_z7YOSGDHHXx7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of unearned revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_ecustom--UnearnedRevenue_iI_pn3n3_c20240930_zZeEGV4bwxB1" title="Unearned revenue">2,271</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_ecustom--UnearnedRevenue_iI_pn3n3_c20230930_znqxp5ldkG78" title="Unearned revenue">2,274</span> that was included in the beginning deferred revenue balance at January 1, 2024 and 2023, respectively.</span></td></tr> </table> <p id="xdx_8A9_zAFHRAuCRDLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zY2W10kABijl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides information about disaggregated revenue by product and services:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zStnZe7EP95h">Schedule of Disaggregated Revenue by Product And Services</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240701__20240930_zYlbAbdW5s1f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230701__20230930_zI6kTMgroIN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20240930_zoIBqsqZ5Pa3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20230930_zGAzfepF7yI1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_z33lNVIc2hN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,393</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,684</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">26,199</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,633</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zne6vsVLyMBe" style="vertical-align: bottom; background-color: White"> <td>Services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,857</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,062</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zPviizY8L9ci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,611</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">675</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,032</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,964</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zkVMQMGXs4S" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,296</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3393000 1684000 26199000 3633000 1292000 1427000 3857000 4062000 4611000 675000 6032000 2964000 9296000 3786000 36088000 10659000 <p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zCqP6cvgRSrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides changes in deferred revenue from contract liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_z7ayttro3NW8">Schedule of Changes in Deferred Revenue from Contract Liabilities</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20240930_ziOROagolSv9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20230930_z4oHRUjdpq71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zW4pRP3QFrNl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,020</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,492</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_z3N0TDZceDik" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,492</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_zYW8NNSNUbwa" style="vertical-align: bottom; background-color: White"> <td>Deferral of revenue<sup id="xdx_F4F_zQ2P6I2Zjo0i">(1)</sup></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,579</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_z8DMj4k4TmU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Recognition of unearned revenue<sup id="xdx_F49_zSVhFWIypT16">(2)</sup></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,619</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,514</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zyHE0tQ9e9N1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,557</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_z8DzDR3c1XB3" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,557</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span id="xdx_F09_zZV0tFKRPYIe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span id="xdx_F17_zzT6iLSvNLqi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferral of revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DeferredRevenue_iI_pn3n3_c20240930_zHwsPWL3OnHj" title="Deferred revenue">3,736</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--DeferredRevenue_iI_pn3n3_c20230930_z6sc7uIjnbVj" title="Deferred revenue">3,818 </span>in 2024 and 2023, respectively, resulting from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span id="xdx_F00_zn3WTkqYFeYk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span id="xdx_F1E_z7YOSGDHHXx7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of unearned revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_ecustom--UnearnedRevenue_iI_pn3n3_c20240930_zZeEGV4bwxB1" title="Unearned revenue">2,271</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_ecustom--UnearnedRevenue_iI_pn3n3_c20230930_znqxp5ldkG78" title="Unearned revenue">2,274</span> that was included in the beginning deferred revenue balance at January 1, 2024 and 2023, respectively.</span></td></tr> </table> 6020000 4492000 6020000 4492000 3931000 4579000 -3619000 -3514000 6332000 5557000 6332000 5557000 3736000 3818000 2271000 2274000 <p id="xdx_806_ecustom--LicenseAndDistributionAgreementsTextBlock_zcsEjTndV4Ie" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zQuyQZ49ZsHi">License and Distribution Agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sequence LifeScience, Inc. Independent Distribution Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 23, 2024, the Company entered into an Independent Distributor Agreement (the “Distribution Agreement”) with Sequence LifeScience, Inc. (“Sequence”), which provides the Company exclusive rights to market, sell and distribute Rebound^TM, a full thickness placental-derived allograft matrix product, in the U.S. for a period of ninety (90) days. Under the terms of the Distribution Agreement, Sequence will make Rebound available for purchase to the Company at a fixed price consistent with market terms. The Distribution Agreement is intended to be a bridge to allow the parties to cooperatively market the product prior to consummating the Asset Purchase Agreement. The Company acquired Rebound on October 9, 2024, through an asset purchase agreement with Sequence. For more information about the Rebound asset purchase agreement see Note 16, “Subsequent Events.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regeneron Research Collaboration Services Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 25, 2023, the Company entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”), pursuant to which the Company will support the research effort of Regeneron’s allogeneic cell therapy candidates (the “Regeneron Services Agreement”). The Regeneron Services Agreement’s initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. Payments to the Company under the Regeneron Services Agreement included a non-refundable up-front payment and payments based upon the achievement of defined milestones according to written statements of work. The Regeneron Services Agreement will expire <span id="xdx_904_ecustom--ServiceAgreementTerm_dc_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zVUSthjxChnj" title="Service agreement term">five years</span> from the effective date and may be terminated immediately by either party for the uncured material breach, bankruptcy, or insolvency of the other party. Regeneron may also terminate for convenience upon <span id="xdx_901_ecustom--LicenseAgreementNoticePeriod_dtD_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_z9muabzPRB8a" title="License agreement notice period">30</span> days’ written notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Regeneron Services Agreement grants Regeneron a royalty-free, fully-paid up, worldwide, non-exclusive license, with the right to grant sublicenses, to the Company’s intellectual property (“IP”) to the extent that any such license is necessary for Regeneron to fully use the Company’s research services. The Company determined that the (1) research licenses and (2) the research activities performed by the Company represent a single combined performance obligation under the Regeneron Services Agreement. The Company determined that Regeneron cannot benefit from the licenses separately from the research activities because these services are specialized and rely on the Company’s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The upfront payment of $<span id="xdx_900_eus-gaap--DeferredRevenue_iI_pn3n3_c20240930__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zxe0LGUOoyA9" title="Deferred revenue">750</span> was recorded as deferred revenue as of September 30, 2024, and will be recognized as revenue as the combined performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December 31, 2023, the potential research milestone payments that the Company is eligible to receive and have not been achieved, and were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sorrento Therapeutics, Inc. License and Transfer Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and Sorrento Therapeutics, Inc. (“Sorrento”), a related party through September 30, 2023, are party to a License and Transfer Agreement for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder (the “2020 Sorrento License Agreement”). The Company retains the right to sublicense the rights granted under the agreement with Sorrento’s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until terminated by either the Company or Sorrento for uncured material breach upon 90 days written notice or, after the first anniversary of the effective date of the 2020 Sorrento License Agreement, by the Company for convenience upon six months’ written notice to Sorrento. On October 19, 2023, Sorrento filed a Plan of Reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas which plan contemplates a liquidation of the debtor. If the Plan is confirmed by the Bankruptcy Court, the Company believes that Sorrento will not be able to perform under the license and that any rights the Company might have under the license would be unenforceable. After assessing the status of the IND to determine an optional path forward for the program, the Company elected to terminate development of CYCART-19 for B-cell malignancies during the third quarter of 2023. The Company may continue pre-clinical development of other T-cell candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Genting Innovation PTE LTD Distribution Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 4, 2018, concurrently with Dragasac’s equity investment in Legacy Celularity, Legacy Celularity entered into a distribution agreement with Genting Innovation pursuant to which Genting Innovation was granted supply and distribution rights to certain Company products in select Asia markets (the “Genting Agreement”). The Genting Agreement grants Genting Innovation limited distribution rights to the Company’s then-current portfolio of degenerative disease products and provides for the automatic rights to future products developed by or on behalf of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of the Genting Agreement was renewed on January 31, 2023, and automatically renews for successive 12 month terms unless: Genting provides written notice of its intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party for cause.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genting Innovation and Dragasac are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 14, 2023, the Genting Agreement was amended and restated to include manufacturing rights in the territories covered under the agreement, expanded to include two new countries, and a commitment by the Company to provide technology transfer pursuant to the plan established by a Joint Steering Committee. On January 17, 2024, the Company further amended the Genting Agreement to include distribution and manufacturing rights to certain of the Company’s cell therapy products, including PSC-100, PDA-001, PDA-002, pEXO-001, APPL-001 and CYNK-001. As of September 30, 2024, the Company has not recognized any revenue under the Genting Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Celgene Corporation License Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is party to a license agreement with Celgene (the “Celgene Agreement”) pursuant to which the Company granted Celgene two separate licenses to certain intellectual property. The Celgene Agreement grants Celgene a royalty-free, fully-paid up, worldwide, non-exclusive license to the certain intellectual property (“IP”) for pre-clinical research purposes in all fields and a royalty-free, fully-paid up, worldwide license, with the right to grant sublicenses, for the development, manufacture, commercialization and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte or NK cell to express such a CAR, and/or the use of such CARs or T-lymphocytes or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic uses thereof. The Celgene Agreement will remain in effect until its termination by either party for cause.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pulthera, LLC Binding Term Sheet</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with the entry into the securities purchase agreement for the private placement described in Note 7 above, the Company executed a binding term sheet to negotiate and enter into a sublicense agreement of certain assets from an affiliate of Pulthera, LLC (the “sublicensor”). Pursuant to the binding term sheet, the Company paid sublicensor $<span id="xdx_906_ecustom--PaymentOfOptionFeeInCash_pn3n3_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember_zY76BH63JHv1" title="Payment of option fee in cash">3,000</span> option fee in cash and issued $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl7iB675kigg" title="Issuance of common stock">1,000</span> of shares of its Class A common stock (<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJscGhasJudg" title="Purchase and sale of shares">169,492</span> shares based on the closing price on March 17, 2023) as consideration for stem-cells inventory to be used in research and development. The option fee paid by the Company will be applied towards an initial license fee as outlined in the sublicense agreement. The Company is required to use diligent and reasonable efforts to develop and obtain regulatory approval to market at least one licensed product contingent upon a firm written commitment to provide further financing to the Company. The $<span id="xdx_90F_ecustom--OptionFeeExpense_pn3n3_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLlcBindingTermSheetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbHV3Qbzjgp6" title="Option fee expense">3,000</span> option fee was recorded as acquired IPR&amp;D expense included in research and development expense on the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023, as the acquired IPR&amp;D had no alternative future use.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License Agreement with BioCellgraft, Inc.</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2023, the Company and BioCellgraft, Inc. (“BioCellgraft”) entered into a license agreement whereby the Company granted an exclusive license to BioCellgraft, with the right to sublicense, to develop and commercialize certain licensed products to the dental market in the United States over an initial <span id="xdx_90A_ecustom--CommercialLicenseToDentalProductsAgreementPeriod_dxL_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zIHa8kCh7Abl" title="Option fee expense::XDX::P4Y"><span style="-sec-ix-hidden: xdx2ixbrl5627">four</span></span> year term and will automatically renew for an additional <span id="xdx_90C_ecustom--CommercialLicenseToDentalProductsAgreementRenewalTerm_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zqwTdg9hZCP" title="Commercial license to dental products agreement renewal term">two years</span> unless either party provides written notice of termination. BioCellgraft will pay to the Company total license fees of $<span id="xdx_90F_ecustom--LicenseFeeExpense_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zXckfGNfrrX2" title="License fee expense">5,000</span> over a <span id="xdx_907_ecustom--LicenseFeesPaymentPeriod_dxL_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z2t6vz92FUn9" title="License fees payment period::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl5633">two</span></span> year period, as defined. Upon execution of the agreement, the Company received a $<span id="xdx_902_ecustom--LicenseFeePayment_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zFqUqUisMLJ1" title="License fee payment">300</span> payment towards the first year payment. To date, the Company has not received any additional consideration beyond the $<span id="xdx_906_ecustom--LicenseFeePayment_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zf0LYVgnYZq8" title="License fee payment">300</span> license payment under the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> P5Y P30D 750000 3000000 1000000 169492 3000000 P2Y 5000000 300000 300000 <p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_z9xJWZ9yUy6k" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zQxWj1B9UiI7">Segment Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The Company manages its operations through an evaluation of <span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20240930_zhXn3TEHf5Uj" title="Number of operating segments">three</span> distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. The chief operating decision maker uses the revenues and earnings (losses) of the operating segments, among other factors, for performance evaluation and resource allocation among these segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. BioBanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information or related income statement effects by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were $<span id="xdx_90B_eus-gaap--Assets_iI_pn3n3_c20240930_z0Ws97HX67Si" title="Total assets">128,840</span> and $<span id="xdx_902_eus-gaap--Assets_iI_pn3n3_c20231231_zZK5EoYA4uK6" title="Total assets">143,889</span> as of September 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZgHmjoBs0Wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial information by segment for the three months ended September 30, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z8u7fJiPJoqd">Schedule of Financial Information by Segment </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zo3laUMWF4xb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zRNwuHOk90Ii" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_ziYGoQmjxX37" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zvmqd3EknPx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240701__20240930_zPOZqn4Y07b5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zXKL8rjb5CZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5649">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5652">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,296</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zsKWf9BUBOra" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5655">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,645</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5658">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,883</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zHa3lQbvzd7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,496</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">353</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,187</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,529</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,565</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zgkjGS89Zk51" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,496</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,529</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,152</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zZndSh82gf7f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(a)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z1FkSxrKgCAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,527</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(a) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AdjustmentForAmortization_pn3n3_zlDTkOcdfFJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_z4K38osGF3T8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zd2pj5vek685" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zGLdcuHRT9x1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zrTlA3LoSohb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zHI5NKixN9Sh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230701__20230930_zAZOXQ2Naw66" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zfJJXTa8FVS5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5697">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,427</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,359</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5700">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,786</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z3slH5wvnqX9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5703">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5706">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,602</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zLlcTkhCxt7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,887</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,901</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,074</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,212</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zUEyf3QDP7Yj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,887</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,746</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,074</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(16,028</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zEZCmPwrQqVg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">83,228</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(b)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">83,228</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zDzAYJMSfLr1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(99,256</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(b) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zarJcHsvAVJd" style="text-align: right" title="Change in fair value of contingent consideration liability">(39</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zqXK4wJb81M2" style="text-align: right" title="Goodwill impairment">82,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AdjustmentForAmortization_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zM6DQkKPXjpk" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">553</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zlC95TUtGda" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">83,228</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial information by segment for the nine months ended September 30, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zSw9bJ3GZaP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zAhcfd3gYkCc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zKtWND7qVBRd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zsUPgQsdvWk3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930_zMYJNJZflHtl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zTFk9dKJefVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5741">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,857</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,231</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5744">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,088</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zJGMZibkcCv7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5747">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">952</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,694</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5750">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,646</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_z02BXOxGwCnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,383</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,216</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,159</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">56,143</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zzWpvR10DX3a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,383</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,689</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,159</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(27,701</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zXxZd7TNzG4l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">1,377</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(a)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,377</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zFH7sDOT0ZJg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(29,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(a) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AdjustmentForAmortization_pn3n3_zau8Ab2kX4Il" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,377</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zZQqDIJlNArf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_ziNKZ2ohyYCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zAkORkd1OLql" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zboCcD5QQfS4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zI5kkpxa9mR2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20230930_zAI7ij57ZpOb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">``Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zzsQPidXJtkk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5789">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,597</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5792">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,659</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z7wW72dQGedd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5795">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,355</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,052</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5798">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,407</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zRyRKns6WDH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">53,505</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">780</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,799</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,481</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">92,565</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zOLOX6zqHu77" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(53,505</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,927</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,254</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(31,481</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(88,313</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zGPjL5jHcEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">117,289</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(b)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">117,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z0hsdxX2Mdok" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(205,602</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(b) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of contingent consideration liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zCQpV1hS1Q85" style="text-align: right" title="Change in fair value of contingent consideration liability">(104,339</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ChangeInFairValueOfContingentStockConsideration_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zkwXMWrw8Coa" style="text-align: right" title="Change in fair value of contingent stock consideration">(159</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zEIIHPW3Qbh7" style="text-align: right" title="Goodwill impairment">112,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">IPR&amp;D impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zD9sXxnTbUd8" style="text-align: right" title="IPR&amp;D impairment">107,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AdjustmentForAmortization_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zpVfrUnc7Laa" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">1,640</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zfilejYwuLk6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">117,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zWTyb53vYwji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3 128840000 143889000 <p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZgHmjoBs0Wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial information by segment for the three months ended September 30, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z8u7fJiPJoqd">Schedule of Financial Information by Segment </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zo3laUMWF4xb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zRNwuHOk90Ii" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_ziYGoQmjxX37" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zvmqd3EknPx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240701__20240930_zPOZqn4Y07b5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zXKL8rjb5CZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5649">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5652">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,296</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zsKWf9BUBOra" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5655">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,645</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5658">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,883</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zHa3lQbvzd7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,496</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">353</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,187</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8,529</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,565</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zgkjGS89Zk51" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,496</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">172</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,529</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,152</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zZndSh82gf7f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(a)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z1FkSxrKgCAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,527</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(a) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AdjustmentForAmortization_pn3n3_zlDTkOcdfFJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_z4K38osGF3T8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zd2pj5vek685" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zGLdcuHRT9x1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zrTlA3LoSohb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zHI5NKixN9Sh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230701__20230930_zAZOXQ2Naw66" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zfJJXTa8FVS5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5697">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,427</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,359</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5700">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,786</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z3slH5wvnqX9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5703">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,204</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5706">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,602</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zLlcTkhCxt7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,887</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,901</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,074</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,212</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zUEyf3QDP7Yj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,887</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,746</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,074</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(16,028</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zEZCmPwrQqVg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">83,228</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(b)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">83,228</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zDzAYJMSfLr1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(99,256</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(b) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zarJcHsvAVJd" style="text-align: right" title="Change in fair value of contingent consideration liability">(39</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zqXK4wJb81M2" style="text-align: right" title="Goodwill impairment">82,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AdjustmentForAmortization_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zM6DQkKPXjpk" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">553</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zlC95TUtGda" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">83,228</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial information by segment for the nine months ended September 30, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zSw9bJ3GZaP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zAhcfd3gYkCc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zKtWND7qVBRd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zsUPgQsdvWk3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930_zMYJNJZflHtl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zTFk9dKJefVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5741">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,857</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,231</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5744">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,088</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zJGMZibkcCv7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5747">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">952</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,694</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5750">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,646</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_z02BXOxGwCnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,383</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,216</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,159</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">56,143</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zzWpvR10DX3a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,383</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,689</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,159</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(27,701</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zXxZd7TNzG4l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">1,377</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(a)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,377</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zFH7sDOT0ZJg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(29,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(a) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AdjustmentForAmortization_pn3n3_zau8Ab2kX4Il" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,377</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zZQqDIJlNArf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_ziNKZ2ohyYCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zAkORkd1OLql" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zboCcD5QQfS4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zI5kkpxa9mR2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20230930_zAI7ij57ZpOb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">``Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cell<br/> Therapy</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative<br/> Disease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zzsQPidXJtkk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5789">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,597</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5792">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,659</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z7wW72dQGedd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5795">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,355</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,052</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl5798">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,407</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zRyRKns6WDH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">53,505</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">780</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,799</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,481</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">92,565</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zOLOX6zqHu77" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(53,505</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,927</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,254</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(31,481</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(88,313</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zGPjL5jHcEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Indirect expenses</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">117,289</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="text-align: left; padding-bottom: 1pt">(b)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">117,289</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z0hsdxX2Mdok" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(205,602</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: left">(b) Components of other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of contingent consideration liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ChangeInFairValueOfContingentConsiderationLiability_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zCQpV1hS1Q85" style="text-align: right" title="Change in fair value of contingent consideration liability">(104,339</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of contingent stock consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ChangeInFairValueOfContingentStockConsideration_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zkwXMWrw8Coa" style="text-align: right" title="Change in fair value of contingent stock consideration">(159</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goodwill impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zEIIHPW3Qbh7" style="text-align: right" title="Goodwill impairment">112,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">IPR&amp;D impairment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zD9sXxnTbUd8" style="text-align: right" title="IPR&amp;D impairment">107,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AdjustmentForAmortization_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zpVfrUnc7Laa" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">1,640</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_c20230101__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zfilejYwuLk6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total other">117,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1292000 8004000 9296000 238000 3645000 3883000 3496000 353000 4187000 8529000 16565000 -3496000 701000 172000 -8529000 -11152000 375000 375000 -11527000 375000 375000 1427000 2359000 3786000 398000 3204000 3602000 4887000 350000 1901000 9074000 16212000 -4887000 679000 -2746000 -9074000 -16028000 83228000 83228000 -99256000 -39000 82714000 553000 83228000 3857000 32231000 36088000 952000 6694000 7646000 12383000 1216000 14385000 28159000 56143000 -12383000 1689000 11152000 -28159000 -27701000 1377000 1377000 -29078000 1377000 1377000 4062000 6597000 10659000 1355000 5052000 6407000 53505000 780000 6799000 31481000 92565000 -53505000 1927000 -5254000 -31481000 -88313000 117289000 117289000 -205602000 -104339000 -159000 112347000 107800000 1640000 117289000 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHG7UJWOwejg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zYhtPdueFnNa">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amended and Restated Employment Agreement with Dr. Robert Hariri</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 25, 2023, in order to address the Company’s current working capital requirements, Robert Hariri, M.D., Ph.D., the Company’s Chairman and Chief Executive Officer, agreed to temporarily reduce payment of his salary pursuant to his employment agreement to minimum wage level with the remaining salary deferred until December 31, 2023. As of September 30, 2024, $<span id="xdx_90C_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20240930__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zwd8ZVMaX9x9" title="Accrued expenses">1,432</span> was recorded to accrued expenses on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to comply with the Securities Purchase Agreement dated <span id="xdx_90E_ecustom--SecuritiesPurchaseAgreementDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zyYK9LGApoAh" title="Securities purchase agreement date">January 12, 2024</span> with Dragasac Limited that Dr. Hariri not be paid the $<span id="xdx_901_ecustom--UnpaidBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWNNL2AuLtR5" title="Unpaid base salary">1,088</span> in base salary that was otherwise due to him for the 2023 calendar year unless the Company raises additional cash through offerings of equity securities with aggregate net proceeds equal or greater to $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9F6yAzQEde6" title="Net proceeds from offerings of equity securities">21,000</span> at a valuation at least equal to the valuation, cost per security or exercise/conversion price, as applicable, of the Class A common stock and January 2024 PIPE Warrant purchased by Dragasac Limited in January 2024. In compliance with the requirements of Internal Revenue Code Section 409A, the compensation committee of the Company’s board of directors approved a cash bonus program, or bonus program, effective February 16, 2024, pursuant to which Dr. Hariri will be paid <span id="xdx_90B_ecustom--PercentageOfUnpaidBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZOp9mBqdslj" title="Percentage of unpaid base salary">125</span>% of his unpaid base salary upon the satisfaction of the foregoing performance conditions. Accordingly, the Company entered into a second amendment to Dr. Hariri’s employment agreement implementing the <span id="xdx_903_ecustom--PercentageOfBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHiOAKLEBqHj" title="Percentage of base salary">85</span>% base salary reduction effective as of <span id="xdx_90F_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzuRv3ehUGe7" title="Bonus program effective date">February 16, 2024</span> and documenting the bonus program. As a result of the reduction, Dr. Hariri’s annual rate of base salary for the 2024 year will be $<span id="xdx_90C_ecustom--AnnualRateOfBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPrlXblQvat4" title="Annual rate of base salary">180</span>. Payment of Dr. Hariri’s base salary at the rate in effect prior to the reduction will resume on <span id="xdx_90D_ecustom--BaseSalaryEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zCuUtdcmGKAd" title="Bonus program effective date">January 1, 2025</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>March 2023 PIPE</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert Hariri, for an aggregate purchase price of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DrRobertHaririMember_zJsF77X7aw9d" title="Proceeds from PIPE financings">9,000</span> (of which Dr. Hariri subscribed for $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--DrHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRUllZsOt3g7" title="Proceeds from PIPE financings">2,000</span>). See Note 10, Equity under March 2023 PIPE caption for further details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan Agreement with Dr. Robert Hariri</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2023, the Company entered into a $<span id="xdx_908_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z0VDOqQJCDKe" title="Debt instrument contribution amount">1,000</span> loan agreement with Dr. Robert Hariri, M.D., Ph.D., the Company’s Chairman and Chief Executive Officer, which bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zUI0gpTLRuEi" title="Loan interest rate">15</span>% per year, with the first year of interest being paid in kind on the last day of each month and was schedule to mature on August 21, 2024. The loan maturity date was subsequently extended to December 31, 2024. On September 30, 2024, Dr. Hariri assumed the loans of two unaffiliated lenders who were parties to an August 21, 2023 loan agreement. See Note 7, Short-Term Debt - Other and CEO Promissory Note for more information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 12, 2023, in order to further address the Company’s immediate working capital requirements, Robert Hariri, M.D., Ph.D., the Company’s Chairman and Chief Executive Officer, and the Company signed a promissory note for $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zd6ARE2hESxc" title="Principal amont">285</span> which bears interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z2XfMqu46CV2" title="Interest rate">15.0</span>% per year (see Note 7).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting &amp; Advisory Agreements with Dr. Andrew Pecora</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--RelatedPartyTransactionTermsAndMannerOfSettlement_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zmXs0EvfNg3f" title="Related party description">On August 31, 2022, Dr. Pecora resigned as the Company’s President, and subsequently entered into a consulting agreement with the Company dated September 21, 2022, to receive a $<span id="xdx_905_ecustom--ReceiveForMonth_pn3n3_c20220901__20220921__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zpyV01Vvjoq8" title="Receive for month">10</span> monthly fee for an initial six-month term and will be automatically renewed for one additional six- month term if either party does not provide notice of non-renewal.</span> Simultaneously, the Company entered into a scientific and clinical advisor agreement (the “SAB Agreement”), effective as of September 1, 2022, whereby Dr. Pecora agreed to serve as co-chair of the Company’s scientific and clinical advisory board for a $<span id="xdx_908_ecustom--ReceiveForMonth_pn3n3_c20220901__20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_z9TdqRHu8ED7" title="Receive for month">10</span> monthly fee and a one-time grant of RSUs having a value of $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zosxXPzgFm1g" title="RSUs one-time grant value">125</span> on the grant date and will vest equally over <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220901__20220901__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_z7LLqyGQ5Xke" title="Options vesting period">four years</span>. The SAB Agreement has a one-year term and may be renewed for successive one-year terms upon mutual agreement of both parties. The consulting agreement was early terminated effective January 14, 2023. As of August 8, 2024, Dr. Pecora no longer serves on the Company’s scientific and clinical advisory board.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advisory Agreement with Robin L. Smith MD</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 16, 2022, the Company entered into an advisory agreement with Robin L. Smith, MD, a then member of the Company’s board of directors, to receive $<span id="xdx_90D_ecustom--ReceiveForMonth_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zU35hqD0yDA5" title="Receive for month">20</span> per month for advisory fees, an equity grant for a total amount of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zhjjW2959w44" title="Vested options to acquire shares">105,000</span> stock options with the initial tranche of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__custom--InitialTrancheMember_zSIFKAiPr4g6" title="Vested options to acquire shares">25,000</span> stock options vesting upon execution of the advisory agreement and the remaining shares subject to vesting upon achievement of certain predefined milestones. On November 1, 2022, the second tranche of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zifuC55OWcrc" title="Vested options to acquire shares">20,000</span> stock options vested upon achievement of the milestone. The agreement also provides for a one-time cash bonus of $<span id="xdx_901_ecustom--RelatedPartyCashBonus_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zB8auvbAJKBl" title="One-time cash bonus">1,500</span> upon the successful achievement of the trigger event, as defined in the agreement. The Company paid advisory fees of $<span id="xdx_903_ecustom--PaymentsToRelatedParty_pn3n3_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zPXfx9GtrDDl" title="Amount paid">0</span> and $<span id="xdx_90A_ecustom--PaymentsToRelatedParty_pn3n3_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zyDL6K68dGX6" title="Amount paid">20</span> for the nine months ended September 30, 2024 and 2023, respectively. The advisory agreement expired pursuant to the terms of the agreement on August 16, 2023 and was not renewed for an additional term. Dr. Smith resigned from the Company’s board effective December 24, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COTA, Inc</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2020, Legacy Celularity and COTA, Inc. (“COTA”) entered into an Order Schedule (the “Order Schedule No. 2”), to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide the licensed data in connection with AML patients. The COTA Order Schedule No. 2 will terminate on the one-year anniversary following the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity’s former President, is the Founder and Chairman of the Board of COTA and Dr. Robin L. Smith, a former member of the Company’s board of directors, is an investor in COTA. The Company did <span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zTNhgwNhHBga" title="Contribution made"><span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zQV7CEJRD4e6" title="Contribution made">no</span></span>t make any payments to COTA during the nine months ended September 30, 2024 and 2023. As of August 8, 2024, Dr. Pecora no longer serves on the Company’s scientific and clinical advisory board and therefore, COTA is no longer a related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cryoport Systems, Inc</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2024 and 2023, the Company made payments totaling $<span id="xdx_903_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_zdLEA8wMhPY9" title="Contribution made">2</span> and $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_zxwivWlHs3vg" title="Contribution made">33</span>, respectively to Cryoport Systems, Inc (“Cryoport”) for transportation of cryopreserved materials. The Company’s Chief Executive Officer and director, Dr. Robert Hariri, M.D, Ph.D., has served on Cryoport’s board of directors since September 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>C.V. Starr Loan</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 17, 2023 the Company entered into a $<span id="xdx_909_ecustom--LoanAgreement_iI_pn3n3_c20230317__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember_zX1sZ1KWE9k2" title="Loan agreement">5,000</span> loan agreement with C.V. Starr. C.V. Starr is an investor in the Company, holding <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__custom--StatementEquityComponentsAxis.Axis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zIDJymONNmx4" title="Warrants to purchase Class A common stock">125,000</span> warrants to purchase Class A common stock and <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zr4T11NyAJHf" title="Warrants to purchase common stock">1,528,138</span> shares of Class A common stock as of September 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment of an Immediate Family Member</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and Chief Executive Officer, is employed by Celularity as an Executive Director, Corporate Strategy &amp; Business Development. Ms. Hariri’s annual base salary for 2024 and 2023 was $<span id="xdx_90C_ecustom--RelatedPartyBaseSalary_pn3n3_c20240101__20240930__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_z1CJsr2mIGYg" title="Base salary"><span id="xdx_901_ecustom--RelatedPartyBaseSalary_pn3n3_c20230101__20230930__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_zXrjXfCUYuB3" title="Base salary">265</span></span>. Ms. Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and conditions as applicable to unrelated employees in similar positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fountain Life Management LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 7, 2024, the Company entered into a Technology Services Agreement with Fountain Life Management LLC (“Fountain Life”) under which the Company agreed to process and store mononuclear cells isolated from blood samples collected by Fountain Life or its authorized representatives in accordance with the Company’s adult banking enrollment processes. In consideration of the services, Fountain Life will pay the Company a one-time fee of two thousand five hundred dollars per sample collected and stored. The initial term of the agreement is one year and automatically extends for one-year periods unless earlier terminated by either party. The Company’s Chairman and Chief Executive Officer, Dr. Robert Hariri, M.D, Ph.D., and director, Peter Diamandis, M.D., are founding partners of Fountain Life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1432 2024-01-12 1088000 21000000 1.25 0.85 2024-02-16 180000 2025-01-01 9000000 2000000 1000000 0.15 285000 0.150 On August 31, 2022, Dr. Pecora resigned as the Company’s President, and subsequently entered into a consulting agreement with the Company dated September 21, 2022, to receive a $10 monthly fee for an initial six-month term and will be automatically renewed for one additional six- month term if either party does not provide notice of non-renewal. 10000 10000 125000 P4Y 20000 105000 25000 20000 1500000 0 20000 0 0 2000 33000 5000000 125000 1528138 265000 265000 <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_z0ljuq9WNHc7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zMfTC6PwQbO9">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rebound^TMAsset Purchase Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 9, 2024, the Company entered into an asset purchase agreement with Sequence LifeScience, Inc. (“Sequence”) to acquire Sequence’s Rebound™ full thickness placental-derived allograft matrix product and certain related assets. The aggregate consideration paid for the assets was $<span id="xdx_90D_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9i4VoECezfd" title="Consideration paid for assets">5,500</span>, which consisted of (i) an upfront cash payment of $<span id="xdx_901_ecustom--UpfrontPayment_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGnXNh4HcHW6" title="Upfront payment">1,000</span> (ii) an aggregate of up to $<span id="xdx_906_ecustom--MonthlyMilestonePayments_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTrtEPzUtQA7" title="Monthly milestone payments">4,000</span> in monthly milestone payments, and (iii) a credit of $<span id="xdx_903_ecustom--PriorPaymentToRelatedParty_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7mvcVbrO071" title="Prior payment to related party">500</span> for previous payments made by Celularity to Sequence pursuant to a letter of intent between Celularity and Sequence dated August 16, 2024. Pursuant to the terms of the asset purchase agreement, the milestone payments are calculated based on <span id="xdx_90E_ecustom--NetSalesPercentage_pid_dp_uPure_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzdfNEeYkJT7" title="Net sales percentage">20</span>% of net sales collected by Celularity from its customers during the preceding calendar month, commencing the first full month after the closing of the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the execution of the asset purchase agreement, the Company entered into an exclusive supply agreement with Sequence for the manufacture and supply of Rebound for a minimum period of six months. Celularity retains the right to manufacture Rebound internally and intends to commence a technology transfer as soon as practicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unsecured Senior Convertible Notes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 25, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated thereunder, pursuant to which the Company agreed to sell and issue, in one or more closings, to the investor and other purchasers (the “Purchasers”) in a private placement transaction, unsecured senior convertible notes (the “Notes”) and warrants (the “Purchaser Warrants”) for an aggregate original principal amount of up to $<span id="xdx_903_ecustom--NotesAndPurchaserWarrantsPrincipalAmount_iI_pn3n3_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zZPUzZlIqRqj" title="Notes and purchaser warrants principal amount">1,000</span>. As of the date of this filing, the Company issued and sold $<span id="xdx_909_ecustom--ProceedsFromNotesAndPurchaserWarrants_pn3n3_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZqPry4LNXCb" title="Proceeds from notes and purchaser warrants">750</span> Notes and Purchaser Warrants pursuant to the Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Notes bear interest at an annual rate of <span id="xdx_900_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm8U10xtRPCj" title="Bearing interest">8</span>% (increasing to <span id="xdx_908_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGHdJ9QVhO92" title="Increase in bearing interest">10</span>% in the event of default as defined in the Purchase Agreement) and have a maturity date of one year from the date of issuance. Upon an event of default, the Notes are convertible at the Purchasers’ option into shares of the Company’s Class A common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zn0onvkECyF" title="Common stock par value">0.0001</span> per share (the “Common Stock”), at a price per share equal to (i) $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYisVhZZodS3" title="Stock price per share">2.85</span> (adjusted for stock splits, reverse stock splits, stock dividends, or similar transactions); or (ii) the offering price of a subsequent financing transaction with gross proceeds of $<span id="xdx_900_ecustom--MinimumGrossProceeds_pn3n3_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqGtCftGiRW8" title="Gross proceeds">2,500</span> or more (a “Subsequent Financing”), subject to a floor price of $<span id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcKjpEjDcpzd" title="Floor price">1.00</span> per share. The Notes include customary negative covenants restricting the Company’s ability to incur other indebtedness other than as permitted, pay dividends to stockholders, grant or suffer to exist a security interest in any of the Company’s assets, other than as permitted, amongst others. In addition, the Notes include customary events of default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Purchaser Warrants entitle the Purchasers to purchase shares of Common Stock equal to each Purchaser’s subscription amount divided by the exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzjXmQXID4N" title="Exercise price">2.85</span> per share. The exercise price, and the number of shares of Common Stock issuable under the Purchaser Warrants, are subject to a one-time reset upon the completion of a Subsequent Financing, subject to a floor price of $<span id="xdx_90A_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zG6u0QcaOiJj" title="Floor price">1.00</span> per share. The Purchaser Warrants are immediately exercisable and have a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8hZkAhiusGi" title="Warrant outstanding term">5</span>-year term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the transaction, the Company paid a cash fee equal to <span id="xdx_900_ecustom--PercentageOfCashFeeEqualToAggregateProceeds_pid_dp_uPure_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmECclc64L2d" title="Percentage of cash fee equal to aggregate proceeds">7</span>% of the aggregate proceeds, a non-accountable expense fee of <span id="xdx_90B_ecustom--PercentageOfNonAccountableExpenseFee_pid_dp_uPure_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0r8tP534qee" title="Percentage of non-accountable expense fee">1</span>% of the aggregate proceeds, and an initial retainer fee of $<span id="xdx_90D_ecustom--InitialRetainerFee_pn3n3_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuHDmqZZXgw1" title="Initial retainer fee">25</span>, and a reimbursement of legal expenses up to $<span id="xdx_90E_ecustom--ReimbursementOfLegalExpenses_pn3n3_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1lJVv0rOVoa" title="Reimbursement of legal expenses">75</span>. In addition, the Company agreed to issue a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUoOCKWgb2W8" title="Warrant outstanding term">5</span>-year warrant to purchase a number of shares of Common Stock equal to <span id="xdx_907_ecustom--PercentageOfCashFeeEqualToAggregateProceeds_pid_dp_uPure_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMesokxJHfg6" title="Percentage of cash fee equal to aggregate proceeds">7</span>% of the proceeds of the transaction (the “Placement Agent Warrants”), at an exercise price equal to <span id="xdx_900_ecustom--PercentageOfExercisePriceEqualToOfferingPrice_pid_dp_uPure_c20241125__20241125__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEJG1uJTiA9c" title="Percentage of exercise price equal to offering price">125</span>% of the offering price. The Placement Agent Warrants are subject to the same one-time exercise price adjustment provision as the Purchaser Warrants in connection with a Subsequent Financing. The Company intends to use the net proceeds from the Notes and the Purchaser Warrants for working capital and general corporate purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no additional items that have not previously been mentioned elsewhere (see Note 1) requiring disclosure.</span></p> 5500000 1000000 4000000 500000 0.20 1000000 750000 0.08 0.10 0.0001 2.85 2500000 1.00 2.85 1.00 P5Y 0.07 0.01 25000 75000 P5Y 0.07 1.25 The exercise price is the lesser of $67.70 per share or 80% of either (i) the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii) the price at which one share of common stock is sold to the public market in an initial public offering. The number of Public Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are 14,374,478 Public Warrants and 8,499,999 Sponsor Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $115.00 as a result of the split. Deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed. Also includes up-front payment incurred in connection with signing of the Regeneron Services Agreement in August 2023 (see Note 15 below). As discussed further in Note 7, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July 15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the Company’s own stock. As such, the warrants were marked to fair value as of the initial exercise date and then reclassified from liability classified to equity classified. In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice 652,981 legacy warrants held by Dragasac with a previous exercise price of $67.70 to a new exercise price of $2.4898. The term of the warrants was unchanged. The number of Public Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are 14,374,478 Public Warrants and 8,499,999 Sponsor Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $115.00 as a result of the split. In connection with the execution of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 7, the Company agreed to reprice 75,000 warrants with a previous exercise price of $7.10 and 50,000 warrants with a previous exercise price of $8.10 held by C.V. Starr to a new exercise price of $5.895. The term of the warrants was unchanged. Options outstanding at September 30, 2024 under the 2021 Plan and 2017 Plan were 1,979,953 and 1,475,096, respectively. Options outstanding at September 30, 2024 under the 2021 Plan include 45,000 awards with performance conditions (see below). Deferral of revenue includes $3,736 and $3,818 in 2024 and 2023, respectively, resulting from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed. Recognition of unearned revenue includes $2,271 and $2,274 that was included in the beginning deferred revenue balance at January 1, 2024 and 2023, respectively.